var images_info;if (!images_info) images_info =[]; images_info["90"]={"90002":{"type":"graphic_movie","displayName":"Abduction adduction exercise for frozen shoulder PI","title":"Abduction adduction exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Abduction adduction exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PI/90002_AbdaddfrozshoulPIvideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:468px; height:261px;\" src=\"images/PI/90002_AbdaddfrozshoulPIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After your mobility has started to improve, do this exercise to build strength and increase your range. If it causes undue pain, do not do the exercise.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 90002 Version 1.0</div></div></div>"},"90003":{"type":"graphic_movie","displayName":"Active flexion extension exercise for frozen shoulder PI","title":"Active flexion extension exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Active flexion extension exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PI/90003_ActflexextfrozPIvideo.mp4\" style=\"width:288px;height:528px\"></div><img style=\"width:285px; height:465px;\" src=\"images/PI/90003_ActflexextfrozPIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After your mobility has started to improve, do this exercise to build strength and increase your range. If it causes undue pain, do not do the exercise.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 90003 Version 1.0</div></div></div>"},"90004":{"type":"graphic_movie","displayName":"Seated external rotation exercise for frozen shoulder PI","title":"Seated external rotation exercise for frozen shoulder","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Seated external rotation exercise for frozen shoulder</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PI/90004_SeatedextrotfroPIvideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:459px; height:333px;\" src=\"images/PI/90004_SeatedextrotfroPIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After your mobility has started to improve, do this exercise. If it causes undue pain, do not do the exercise.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 90004 Version 1.0</div></div></div>"},"90005":{"type":"graphic_table","displayName":"Gene expression assays US stage II colon cancer","title":"Gene expression assays available in the United States for clinical use in stage II colon cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gene expression assays available in the United States for clinical use in stage II colon cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assay</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">Gene signature</td> <td class=\"subtitle1\">Specimen used</td> </tr> <tr> <td>ColoPrint colon cancer recurrence assay*</td> <td>Agendia, Inc</td> <td>18 gene expression profile (using agilent microarray)</td> <td>Fresh tissue or fresh, frozen tissue</td> </tr> <tr> <td>ColonPRS<sup>&#182;</sup></td> <td>Signal Genetics, LLC</td> <td>163 genes</td> <td>Fresh, frozen biopsies</td> </tr> <tr> <td>GeneFx colon </td> <td>Licensed by Precision Therapeutics (originally developed by Almac Diagnostics as the ColDX assay)</td> <td>634 probe-set signature</td> <td>Formalin-fixed paraffin embedded tissue</td> </tr> <tr> <td>OncoDefender-CRC (colon and rectal cancer)</td> <td>Everist Genomics</td> <td>5 genes</td> <td>Formalin-fixed paraffin embedded tissue</td> </tr> <tr> <td>Oncotype DX colon cancer assay</td> <td>Genomic Health, Inc</td> <td>12 genes (seven prognostic and five reference genes)</td> <td>Formalin-fixed paraffin embedded tissue</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* May also be available for use through PARSC clinical trial.<br />&para; Currently available for nondiagnostic or research use only.</div><div class=\"graphic_reference\">Reproduced from: Black ER, Falzon L, Aronson N. Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer. Technical Brief. No. 13. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-0058-I.) Rockville, MD: Agency for Healthcare Research and Quality. December 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.</div><div id=\"graphicVersion\">Graphic 90005 Version 4.0</div></div></div>"},"90006":{"type":"graphic_picture","displayName":"Lichen planopilaris vertex","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:380px; height:504px;\" src=\"images/DERM/90006_Lichen_planopilaris_vertex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patch of lichen planopilaris with moderate scarring on the vertex of the scalp.</div><div id=\"graphicVersion\">Graphic 90006 Version 2.0</div></div></div>"},"90007":{"type":"graphic_figure","displayName":"Schistosomiasis life cycle","title":"Life cycle of schistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Life cycle of schistosomiasis</div><div class=\"cntnt\"><img style=\"width:548px; height:430px;\" src=\"images/ID/90007_Schistosomiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Life cycle:</strong> Eggs are eliminated with feces or urine <strong>(1)</strong>. Under optimal conditions, the eggs hatch and release miracidia <strong>(2)</strong>, which swim and penetrate specific snail intermediate hosts <strong>(3)</strong>. The stages in the snail include two generations of sporocysts <strong>(4)</strong> and the production of cercariae <strong>(5)</strong>. Upon release from the snail, the infective cercariae swim, penetrate the skin of the human host <strong>(6)</strong>, and shed their forked tail, becoming schistosomulae <strong>(7)</strong>. The schistosomulae migrate through several tissues and stages to their residence in the veins <strong>(8,9)</strong>. Adult worms in humans reside in the mesenteric venules in various locations, which at times seem to be specific for each species <strong>(10)</strong>. For instance, <em>S. japonicum</em> is more frequently found in the superior mesenteric veins draining the small intestine <strong>(A)</strong>, and <em>S. mansoni</em> occurs more often in the superior mesenteric veins draining the large intestine <strong>(B)</strong>. However, both species can occupy either location, and they are capable of moving between sites, so it is not possible to state unequivocally that one species only occurs in one location. <em>S. haematobium</em> most often occurs in the venous plexus of bladder <strong>(C)</strong>, but it can also be found in the rectal venules. The females (size 7 to 20 mm; males slightly smaller) deposit eggs in the small venules of the portal and perivesical systems. The eggs are moved progressively toward the lumen of the intestine (<em>S. mansoni</em> and <em>S. japonicum</em>) and of the bladder and ureters (<em>S. haematobium</em>), and are eliminated with feces or urine, respectively <strong>(1)</strong>. Pathology of <em>S. mansoni</em> and <em>S. japonicum</em> schistosomiasis includes: Katayama fever, hepatic perisinusoidal egg granulomas, Symmers' pipe stem periportal fibrosis, portal hypertension, and occasional embolic egg granulomas in brain or spinal cord. Pathology of <em>S. haematobium</em> schistosomiasis includes: hematuria, scarring, calcification, squamous cell carcinoma, and occasional embolic egg granulomas in brain or spinal cord.<br />Human contact with water is thus necessary for infection by schistosomes. Various animals, such as dogs, cats, rodents, pigs, horses, and goats, serve as reservoirs for <em>S. japonicum</em>, and dogs for <em>S. mekongi</em>.<br /><strong>Geographic distribution:</strong> <em>Schistosoma mansoni</em> is found in parts of South America and the Caribbean, Africa, and the Middle East; <em>S. haematobium</em> in Africa and the Middle East; and <em>S. japonicum</em> in the Far East. <em>Schistosoma mekongi</em> and <em>S. intercalatum</em> are found focally in Southeast Asia and central West Africa, respectively.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Schistosomiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/schistosomiasis/\">http://www.cdc.gov/dpdx/schistosomiasis/</A>.</div><div id=\"graphicVersion\">Graphic 90007 Version 2.0</div></div></div>"},"90008":{"type":"graphic_picture","displayName":"Lichen planopilaris extensive","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:521px; height:590px;\" src=\"images/DERM/90008_Lichen_planopilaris_extens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic lichen planopilaris. Large patch of scarring alopecia on the scalp in a patient with stable disease. Signs of active inflammation are absent.</div><div id=\"graphicVersion\">Graphic 90008 Version 1.0</div></div></div>"},"90009":{"type":"graphic_picture","displayName":"Lichen planopilaris reticulated","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:563px; height:590px;\" src=\"images/DERM/90009_Lichen_planopilaris_reticul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active classic lichen planopilaris. Coalescence of small patches of alopecia led to a reticulated pattern of hair loss. Erythema is present perifollicularly and at the periphery of patches of alopecia.</div><div id=\"graphicVersion\">Graphic 90009 Version 1.0</div></div></div>"},"90010":{"type":"graphic_picture","displayName":"Frontal fibrosing alopecia","title":"Frontal fibrosing alopecia","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Frontal fibrosing alopecia</div><div class=\"cntnt\"><img style=\"width:590px; height:335px;\" src=\"images/DERM/90010_Frontal_fibrosing_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Band-like distribution of alopecia affecting the frontotemporal scalp. A few isolated hairs remain within the band of alopecia, consistent with the \"lonely hair sign.\"</div><div id=\"graphicVersion\">Graphic 90010 Version 1.0</div></div></div>"},"90011":{"type":"graphic_picture","displayName":"Frontal fibrosing alopecia extensive","title":"Frontal fibrosing alopecia extending beyond the frontotemporal scalp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal fibrosing alopecia extending beyond the frontotemporal scalp</div><div class=\"cntnt\"><img style=\"width:402px; height:504px;\" src=\"images/DERM/90011_Front_fibros_alopecia_exten.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with frontal fibrosing alopecia extending to the occipital scalp. This patient also had findings consistent with classic lichen planopilaris.</div><div id=\"graphicVersion\">Graphic 90011 Version 2.0</div></div></div>"},"90012":{"type":"graphic_picture","displayName":"Lichen planopilaris histopathology","title":"Lichen planopilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planopilaris</div><div class=\"cntnt\"><img style=\"width:402px; height:504px;\" src=\"images/DERM/90012_Lichenplanopilarihisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planopilaris. Follicular plugging, hypergranulosis, and dense, band-like perifollicular lymphocytic infiltrate that obscures the infundibular epithelium.</div><div class=\"graphic_reference\">Reproduced with permission from: Mobini N, Caire ST, Hu S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In: Lever's Histopathology of the Skin, 11th ed, Elder D (Ed), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90012 Version 5.0</div></div></div>"},"90018":{"type":"graphic_table","displayName":"Renal syndromes associated with NSAID use","title":"Renal syndromes associated with NSAID use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal syndromes associated with NSAID use</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acute kidney injury (hemodynamically-mediated or acute tubular necrosis)</td> </tr> <tr> <td>Acute interstitial nephritis</td> </tr> <tr> <td>Nephrotic syndrome (minimal change disease or membranous nephropathy)</td> </tr> <tr> <td>Hyponatremia</td> </tr> <tr> <td>Hyperkalemia/type 4 renal tubular acidosis</td> </tr> <tr> <td>Hypertension/edema</td> </tr> <tr> <td>Acute papillary necrosis</td> </tr> <tr> <td>Chronic tubulointerstitial nephritis/analgesic nephropathy</td> </tr> <tr> <td>Uroepithelial malignancy</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.</div><div id=\"graphicVersion\">Graphic 90018 Version 1.0</div></div></div>"},"90019":{"type":"graphic_table","displayName":"Conditions associated with NSAID-induced AKI","title":"Conditions associated with NSAID-induced acute kidney injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with NSAID-induced acute kidney injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Volume depletion: emesis, diarrhea, sepsis, hemorrhage</td> </tr> <tr> <td>Medications: diuretics, ACE-I, ARB, calcineurin inhibitors</td> </tr> <tr> <td>Cirrhosis</td> </tr> <tr> <td>Congestive heart failure</td> </tr> <tr> <td>Nephrotic syndrome</td> </tr> <tr> <td>Hypercalcemia (severe)</td> </tr> <tr> <td>Chronic kidney disease</td> </tr> <tr> <td>Renal artery stenosis</td> </tr> <tr> <td>Older age</td> </tr> <tr> <td>Angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Randy Luciano, MD, PhD, and Mark A Perazella, MD, FACP.</div><div id=\"graphicVersion\">Graphic 90019 Version 1.0</div></div></div>"},"90021":{"type":"graphic_picture","displayName":"Exogenous ochronosis","title":"Exogenous ochronosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Exogenous ochronosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90021_Exogenous_ochronosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-gray discoloration of the skin with characteristic pin-point, caviar-like papules in a patient with exogenous ochronosis associated with a prolonged use of topical hydroquinone.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90021 Version 1.0</div></div></div>"},"90023":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray C gattii","title":"Pulmonary cryptococcoma caused by<EM> Cryptococcus gattii</EM>","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Pulmonary cryptococcoma caused by<EM> Cryptococcus gattii</EM></div><div class=\"cntnt\"><img style=\"width:467px; height:574px;\" src=\"images/ID/90023_Chest_x-ray_C_gattii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of an immunocompetent patient showing a right lower lobe mass lesion from which <EM>C. gattii </EM>was isolated on percutaneous needle biopsy.</div><div class=\"graphic_reference\">Courtesy of Sharon Chen, MD, and Tania Sorrell, MD.</div><div id=\"graphicVersion\">Graphic 90023 Version 2.0</div></div></div>"},"90024":{"type":"graphic_table","displayName":"Cryptococcus gattii genotypes","title":"<em>Cryptococcus gattii</em> genotypes by geographic location","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\"><em>Cryptococcus gattii</em> genotypes by geographic location</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Genotypes</td> </tr> <tr> <td>Australia</td> <td>VGI&#62;&#62;VGII</td> </tr> <tr> <td>Papua New Guinea</td> <td>VGI</td> </tr> <tr> <td>British Columbia, Canada</td> <td>VGIIa&#62;VGIIb</td> </tr> <tr> <td>Pacific Northwest, United States</td> <td>VGIIa&#62;VGIIc&#62;VGIIb</td> </tr> <tr> <td>Southern California, United States</td> <td>VGIII, VGI, VGII</td> </tr> <tr> <td>Asia</td> <td>VGI, VGII, VGIII, VGIV</td> </tr> <tr> <td>Africa</td> <td>VGIV</td> </tr> <tr> <td>South America</td> <td>VGII, VGI, VGIII, VGIV</td> </tr> <tr> <td>Mexico</td> <td>VGI, VGII, VGIII, VGIV</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Harris J, Lockhart S, Chiller T. Cryptococcus gattii: Where do we go from here? Med Mycol 2012; 50:113.</li>&#xD;&#xA;    <li>Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: An atlas of the molecular types. Scientifica 2013. <a href=\"http://www.hindawi.com/journals/scientifica/2013/675213/\" target=\"_blank\">http://www.hindawi.com/journals/scientifica/2013/675213/</a> (Accessed on September 4, 2013).</li>&#xD;&#xA;    <li>Byrnes EJ, Li W, Lewit Y, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 2010; 6:e1000850.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90024 Version 4.0</div></div></div>"},"90032":{"type":"graphic_table","displayName":"ATRIA stroke risk model point scoring system","title":"ATRIA stroke risk model point scoring system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ATRIA stroke risk model point scoring system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Points without prior stroke</td> <td class=\"subtitle1\">Points with prior stroke</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Age, y</td> </tr> <tr> <td class=\"indent1\">&#8805;85</td> <td class=\"centered\">6</td> <td class=\"centered\">9</td> </tr> <tr> <td class=\"indent1\">75 to 84</td> <td class=\"centered\">5</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">65 to 74</td> <td class=\"centered\">3</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"indent1\">&#60;65</td> <td class=\"centered\">0</td> <td class=\"centered\">8</td> </tr> <tr> <td>Female</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>Diabetes</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>CHF</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>Hypertension</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>Proteinuria</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td>eGFR &#60;45 or ESRD</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Possible point scores range from 0 to 12 for those without a prior stroke and from 7 to 15 for those with a prior stroke.</div><div class=\"graphic_footnotes\">ATRIA: Anticoagulation and Risk Factors in Atrial Fibrillation; CHF: congestive heart failure; eGFR: estimated glomerular filtration rate; ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reprinted with permission. J Am Heart Assoc 2013; 2:e000250. Copyright &copy; 2013 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 90032 Version 1.0</div></div></div>"},"90034":{"type":"graphic_figure","displayName":"Hook of hamate pull test","title":"Hook of hamate pull test","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Hook of hamate pull test</div><div class=\"cntnt\"><img style=\"width:530px; height:177px;\" src=\"images/EM/90034_Hook_hamate_pull_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hook of hamate pull test. The patient's hand is placed palm up on an examination table with the wrist in full active ulnar deviation, and the ring and little fingers flexed. The examiner then resists the patient's active flexion (of the digitorum profundus) in these two fingers. During the maneuver, pain focused at the hook of the hamate region (and sometimes radiating into the palm or wrist) suggests fracture of the hamulus.<br />(A) Anatomical drawing showing position of tendons and hook of hamate during test. Inset shows direction of displacement of force.<br />(B) Photograph of a hand in same position. The tendons and hook of hamate are drawn on the fingers, palm, and wrist. The hook of hamate is indicated by the red spot and the direction of force displacement is indicated by the arrow.</div><div class=\"graphic_reference\">Reproduced from: Wright TW, Moser MW, Sahajpal DT. Hook of Hamate Pull Test. J Hand Surg Am 2010; 35:1887. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90034 Version 1.0</div></div></div>"},"90035":{"type":"graphic_table","displayName":"Expert group definitions of high risk stage II colon cancer","title":"Definitions of \"high risk\" stage II colon cancer from expert groups*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of \"high risk\" stage II colon cancer from expert groups*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">ASCO (2004)</td> <td class=\"subtitle1\">NCCN (2014)</td> <td class=\"subtitle1\">ESMO (2012)</td> </tr> <tr> <td><strong>T4 primary tumor</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Inadequately sampled nodes</strong></td> <td class=\"centered\">+<br /> (&#60;13)</td> <td class=\"centered\">+<br /> (&#60;12)</td> <td class=\"centered\">+<br /> (&#60;12)</td> </tr> <tr> <td><strong>Poorly differentiated tumor</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Perforation</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">+<br /> (localized)</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Obstruction</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>LVI</strong></td> <td class=\"centered\">+&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>PNI</strong></td> <td class=\"centered\">+&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Close/indeterminate or positive margins</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>High preoperative levels of serum CEA</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVI: lymphovascular invasion; PNI: perineural invasion; CEA: carcinoembryonic antigen.<br />* Ie, the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the European Society for Medical Oncology (ESMO).</div><div id=\"graphicVersion\">Graphic 90035 Version 6.0</div></div></div>"},"90036":{"type":"graphic_picture","displayName":"Nevus sebaceous adolescent","title":"Nevus sebaceous of Jadassohn","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous of Jadassohn</div><div class=\"cntnt\"><img style=\"width:576px; height:380px;\" src=\"images/DERM/90036_Nevus_sebaceous_adolescent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus sebaceous with multiple nodular areas in a 17-year-old boy.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <a href=\"http://www.dermis.net/\">www.dermis.net</a>. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90036 Version 2.0</div></div></div>"},"90037":{"type":"graphic_picture","displayName":"Nevus sebaceous adult","title":"Nevus sebaceous of Jadassohn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous of Jadassohn</div><div class=\"cntnt\"><img style=\"width:380px; height:576px;\" src=\"images/DERM/90037_Nevus_sebaceous_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus sebaceous presenting as a large, nodular plaque in a 48-year-old woman.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <a href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</a>. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90037 Version 2.0</div></div></div>"},"90038":{"type":"graphic_table","displayName":"Muscles of scalp and face","title":"Muscles of scalp and face","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscles of scalp and face</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Muscle*</td> <td class=\"subtitle1\">Origin</td> <td class=\"subtitle1\">Insertion</td> <td class=\"subtitle1\">Main action(s)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Occipitofrontalis</td> </tr> <tr> <td class=\"indent1\">Front belly<sup>2</sup></td> <td>Epicranial aponeurosis</td> <td>Skin and subcutaneous tissue of eyebrows and forehead</td> <td>Elevates eyebrows and wrinkles skin of forehead; protracts scalp (indicating surprise or curiosity)</td> </tr> <tr> <td class=\"indent1\">Occipital belly<sup>1</sup></td> <td>Lateral two thirds of superior nuchal line</td> <td>Epicranial aponeurosis</td> <td>Retracts scalp; increasing effectiveness of frontal belly</td> </tr> <tr> <td>Orbicularis oculi (orbital sphincter)<sup>2,3</sup></td> <td>Medial orbital margin; medial palpebral ligament; lacrimal bone</td> <td>Skin around margin of orbit; superior and inferior tarsal plates</td> <td>Closes eyelids: palpebral part does so gently; orbital part tightly (winking)</td> </tr> <tr> <td>Corrugator supercilii<sup>2</sup></td> <td>Medial end of superciliary arch</td> <td>Skin superior to middle of supraorbital margin and superciliary arch</td> <td>Draws eyebrow medially and inferiorly, creating vertical wrinkles above nose (demonstrating concern or worry)</td> </tr> <tr> <td>Procerus plus transverse part of nasalis<sup>4</sup></td> <td>Fascia aponeurosis covering nasal bone and lateral nasal cartilage</td> <td>Skin of inferior forehead, between eyebrows</td> <td>Depresses medial end of eyebrow; wrinkles skin over dorsum of nose (conveying disdain or dislike)</td> </tr> <tr> <td>Alar part of nasalis plus levator labii superioris alaeque nasii<sup>4</sup></td> <td>Frontal process of maxilla (inferomedial margin of orbit)</td> <td>Major alar cartilage</td> <td>Depresses ala laterally, dilating anterior nasal aperture (ie, \"flaring nostrils,\" as during anger or exertion)</td> </tr> <tr> <td>Orbicularis oris (oral sphincter)<sup>4</sup></td> <td>Medial maxilla and mandible; deep surface of peri-oral skin; angle of mouth (modiolus)</td> <td>Mucous membrane of lips</td> <td>Tonus closes oral fissure; phasic contraction compresses and protrudes lips (kissing) or resists distension (when blowing)</td> </tr> <tr> <td>Levator labii superioris<sup>4</sup></td> <td>Infra-orbital margin (maxilla)</td> <td rowspan=\"2\">Skin of upper lip</td> <td rowspan=\"2\">Part of dilators of mouth; retract (elevate) and/or evert upper lip; deepen nasolabial sulcus (showing sadness)</td> </tr> <tr> <td>Zygomaticus minor<sup>4</sup></td> <td>Anterior aspect, zygomatic bone</td> </tr> <tr> <td>Buccinator (cheek muscle)<sup>4</sup></td> <td>Mandible, alveolar processes of maxilla and mandible, pterygomandibular raphe</td> <td>Angle of mouth (modiolus); orbicularis oris</td> <td>Presses cheek against molar teeth; works with tongue to keep food between occlusal surfaces and out of oral vestibule; resists distension (when blowing)</td> </tr> <tr> <td>Zygomaticus major<sup>4</sup></td> <td>Lateral aspect of zygomatic bone</td> <td rowspan=\"4\">Angle of mouth (modiolus)</td> <td>Part of dilators of mouth; elevate labial commissure&#8212;bilaterally to smile (happiness); unilaterally to sneer (disdain)</td> </tr> <tr> <td>Levator anguli oris<sup>4</sup></td> <td>Infra-orbital maxilla (canine fossa)</td> <td>Part of dilators of mouth; widens oral fissure, as when grinning or grimacing</td> </tr> <tr> <td>Risorius<sup>4</sup></td> <td>Parotid fascia and buccal skin (highly variable)</td> <td rowspan=\"2\">Part of dilators of mouth; depresses labial commissure bilaterally to frown (sadness)</td> </tr> <tr> <td>Depressor anguli oris<sup>5</sup></td> <td>Anterolateral base of mandible</td> </tr> <tr> <td>Depressor labii inferioris<sup>5</sup></td> <td>Platysma and anterolateral body of mandible</td> <td>Skin of lower lip</td> <td>Part of dilators of mouth; retracts (depresses) and/or everts lower lip (pouting, sadness)</td> </tr> <tr> <td>Mentalis<sup>5</sup></td> <td>Body of mandible (anterior to roots of inferior incisors)</td> <td>Skin of chin (mentolabial sulcus)</td> <td>Elevates and protrudes lower lip; elevates skin of chin (showing doubt)</td> </tr> <tr> <td>Platysma<sup>6</sup></td> <td>Subcutaneous tissue of infraclavicular and supraclavicular regions</td> <td>Base of mandible; skin of cheek and lower lip; angle of mouth (modiolus); orbicularis oris</td> <td>Depresses mandible (against resistance); tenses skin of inferior face and neck (conveying tension and stress)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All facial muscles are innervated by the facial nerve (CN VII) via its posterior auricular branch (1) or via the temporal (2), zygomatic (3), buccal (4), marginal mandibular (5), or cervical (6) branches of the parotid plexus.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 90038 Version 3.0</div></div></div>"},"90039":{"type":"graphic_table","displayName":"ICD-10 diagnostic criteria Asperger syndrome","title":"ICD-10 diagnostic criteria for Asperger syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ICD-10 diagnostic criteria for Asperger syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical description</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A disorder of uncertain nosological validity, characterized by the same kind of qualitative abnormalities of reciprocal social interaction that typify autism, together with a restricted, stereotyped, repetitive repertoire of interests and activities. The disorder differs from autism primarily in that there is no general delay or retardation in language or in cognitive development. Most individuals are of normal general intelligence but it is common for them to be markedly clumsy; the condition occurs predominantly in boys (in a ratio of about eight boys to one girl). It seems highly likely that at least some cases represent mild varieties of autism, but it is uncertain whether or not that is so for all. There is a strong tendency for the abnormalities to persist into adolescence and adult life and it seems that they represent individual characteristics that are not greatly affected by environmental influences. Psychotic episodes occasionally occur in early adult life.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic guidelines</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diagnosis is based on the combination of a lack of any clinically significant general delay in language or cognitive development plus, as with autism, the presence of qualitative deficiencies in reciprocal social interaction and restricted, repetitive, stereotyped patterns of behavior, interests, and activities. There may or may not be problems in communication similar to those associated with autism, but significant language retardation would rule out the diagnosis.</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic criteria (for research)</td> </tr> <tr> <td class=\"indent1\">A. A lack of any clinically significant general delay in spoken or receptive language or cognitive development. Diagnosis requires that single words should have developed by two years of age or earlier and that communicative phrases be used by three years of age or earlier. Self-help skills, adaptive behaviour and curiosity about the environment during the first three years should be at a level consistent with normal intellectual development. However, motor milestones may be somewhat delayed and motor clumsiness is usual (although not a necessary diagnostic feature). Isolated special skills, often related to abnormal preoccupations, are common, but are not required for diagnosis.</td> </tr> <tr> <td class=\"indent1\">B. Qualitative abnormalities in reciprocal social interaction (criteria as for autism).</td> </tr> <tr> <td class=\"indent1\">C. An unusually intense circumscribed interest or restricted, repetitive, and stereotyped patterns of behavior, interests and activities (criteria as for autism; however it would be less usual for these to include either motor mannerisms or preoccupations with part-objects or non-functional elements of play materials).</td> </tr> <tr> <td class=\"indent1\">D. The disorder is not attributable to the other varieties of pervasive developmental disorder; schizotypal disorder; simple schizophrenia; reactive and disinhibited attachment disorder of childhood; obsessional personality disorder; obsessive-compulsive disorder.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. <a href=\"http://www.who.int/classifications/icd/en/bluebook.pdf\" target=\"_blank\">www.who.int/classifications/icd/en/bluebook.pdf</a> (Accessed on June 4, 2013).</li>&#xD;&#xA;    <li>World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research. <a href=\"http://www.who.int/classifications/icd/en/GRNBOOK.pdf\" target=\"_blank\">www.who.int/classifications/icd/en/GRNBOOK.pdf</a> (Accessed on June 11, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90039 Version 2.0</div></div></div>"},"90040":{"type":"graphic_table","displayName":"Signaling molecules in appetite regulation","title":"Signaling molecules that influence appetite regulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signaling molecules that influence appetite regulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Positive effect</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Dopamine</td> </tr> <tr> <td class=\"indent1\">Ghrelin</td> </tr> <tr> <td class=\"indent1\">Orexin A and B</td> </tr> <tr> <td class=\"indent1\">Endocannabinoids</td> </tr> <tr> <td class=\"indent1\">Neuropeptide Y</td> </tr> <tr> <td class=\"subtitle1_single\">Negative effect</td> </tr> <tr> <td class=\"indent1\">Alpha-melanocyte-stimulating hormone</td> </tr> <tr> <td class=\"indent1\">Serotonin</td> </tr> <tr> <td class=\"indent1\">Leptin</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor alpha</td> </tr> <tr> <td class=\"indent1\">Pro-opiomelanocortin</td> </tr> <tr> <td class=\"indent1\">Thyrotropin-releasing hormone</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Baracos VE, Parsons HA. Metabolism and physiology. In: Nutrition and the Cancer Patient, Del Fabbro E, Baracos V, Denmark-Wahnefried W, et al (Eds), Oxford University Press 2010.</div><div id=\"graphicVersion\">Graphic 90040 Version 1.0</div></div></div>"},"90041":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray ring around the artery sign ","title":"Pneumomediastinum with ring around the artery sign on chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Pneumomediastinum with ring around the artery sign on chest x-ray</div><div class=\"cntnt\"><img style=\"width:599px; height:574px;\" src=\"images/RADIOL/90041_Chst_x_ring_arter_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain chest radiographs of a 22-year-old-woman who presented to the Emergency Department with 10 days of sore throat and cough. Image A is a radiograph of the chest in the PA projection and reveals linear lucencies overlying the upper chest and neck (arrows) consistent with pneumomediastinum. Image B is a radiograph of the chest in the lateral projection and reveals the \"ring around the artery\" sign (arrow), a finding seen in pneumomediastinum. Image C is a magnified view of the \"ring around the artery\" sign (arrow).</div><div class=\"graphic_reference\">Courtesy of Anna Ellermeier, MD.</div><div id=\"graphicVersion\">Graphic 90041 Version 1.0</div></div></div>"},"90042":{"type":"graphic_diagnosticimage","displayName":"CT splenosis and SBO","title":"Splenosis causing small bowel obstruction on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Splenosis causing small bowel obstruction on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:276px;\" src=\"images/RADIOL/90042_CT_splenosis_SBO.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan reformatted in the coronal plane (A) shows an empty splenic bed (short arrow), multiple peritoneal nodules (arrowheads), and dilated small bowel (dashed arrow). An axial image through the abdomen (B) shows multiple splenic peritoneal implants (arrowheads), dilated upstream small bowel (dashed arrow), and decompressed distal small bowel (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; SBO: small bowel obstruction.</div><div id=\"graphicVersion\">Graphic 90042 Version 2.0</div></div></div>"},"90044":{"type":"graphic_picture","displayName":"Jacquet erosive diaper dermatitis","title":"Jacquet's erosive diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jacquet's erosive diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/90044_Jacqueterosivediaperderm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated nodules with superficial ulcerations in an infant with Jacquet's erosive diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90044 Version 2.0</div></div></div>"},"90045":{"type":"graphic_picture","displayName":"Granuloma gluteale infantum","title":"Granuloma gluteale infantum","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Granuloma gluteale infantum</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/90045_Granulomaglutealeinfantum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reddish-purple nodules on the inguinal folds of an infant with granuloma gluteale infantum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90045 Version 2.0</div></div></div>"},"90046":{"type":"graphic_picture","displayName":"Diaper dermatitis irritant","title":"Irritant diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/90046_Diaper_dermatitis_irritant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intense erythema and scaling with sparing of the skin fold are characteristic of irritant diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90046 Version 1.0</div></div></div>"},"90050":{"type":"graphic_table","displayName":"EDD questions to determine antidepressant treatment resistance","title":"Efficacy, duration, and dose (EDD) questions to ask to determine treatment resistance for each antidepressant used","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Efficacy, duration, and dose (EDD) questions to ask to determine treatment resistance for each antidepressant used</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Efficacy</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Did the medication help at all? <ul> <li>If no, then this is a clear nonresponse.</li> <li>If yes, ask the following:</li> </ul> </li> <li>Did it help a lot, say, made you feel more than 50% better? <ul> <li>If yes, this is a response.</li> </ul> </li> <li>Did it help a little, say, made you feel somewhere between 25 and 50% better? <ul> <li>If yes, this is a partial response; if no, this is a nonresponse.</li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Duration</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>For how long did you take the medication? <ul> <li>If the patient isn't sure, prompt as follows:</li> </ul> </li> <li>Would you say you were on it for at least a month?</li> <li>What about longer than that, say, at least 2 months?</li> <li>Longer than that? <ul> <li>This should give a good estimate of the adequacy of the treatment period.)</li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Dose</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Do you remember what dose you took? <ul> <li>If the patient isn't sure, prompt as follows:</li> </ul> </li> <li>Were you on a single pill per day?</li> <li>Was you dose increased at any time? <ul> <li>This should give an idea of whether the patient stayed on a starting dose or received a higher dose.)</li> </ul> </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Desseilles M, Witte J, Chang TE, et al, Assessing the adequacy of past antidepressant trials: A clinician's guide to the antidepressant treatment response questionnaire, The Journal of Clinical Psychiatry. Volume 72, Pages 1152-54, 2011. Copyright &copy; 2011, Physician Postgraduate Press. Reprinted by permission.</div><div id=\"graphicVersion\">Graphic 90050 Version 1.0</div></div></div>"},"90055":{"type":"graphic_picture","displayName":"Scombroid poisoning rash","title":"Scombroid poisoning rash","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Scombroid poisoning rash</div><div class=\"cntnt\"><img style=\"width:730px; height:277px;\" src=\"images/EM/90055_Scombroid_poison_rsh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This erythematous rash developed shortly after the patient consumed contaminated tuna.</div><div class=\"graphic_reference\">Reproduced with permission from: Oakley A. Scombroid fish poisoning. DermNet NZ; 2004. Copyright &copy; 2015 DermNet New Zealand Trust.</div><div id=\"graphicVersion\">Graphic 90055 Version 1.0</div></div></div>"},"90060":{"type":"graphic_picture","displayName":"Dohle bodies","title":"Multiple Döhle bodies in a mature neutrophil in a patient with bacterial sepsis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Multiple Döhle bodies in a mature neutrophil in a patient with bacterial sepsis</div><div class=\"cntnt\"><img style=\"width:504px; height:426px;\" src=\"images/GAST/90060_Dohle_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This high power photomicrograph of a peripheral blood smear in a patient with bacterial sepsis shows a mature neutrophil containing multiple D&ouml;hle bodies (arrows).</div><div class=\"graphic_reference\">Kindly provided by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 90060 Version 1.0</div></div></div>"},"90069":{"type":"graphic_figure","displayName":"Gambee suture","title":"Gambee suture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gambee suture</div><div class=\"cntnt\"><img style=\"width:428px; height:557px;\" src=\"images/SURG/90069_Gambee_suture.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90069 Version 1.0</div></div></div>"},"90070":{"type":"graphic_table","displayName":"EDS classification and gene defects","title":"Classification and genetics of Ehlers-Danlos syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification and genetics of Ehlers-Danlos syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Inheritance pattern</td> <td class=\"subtitle1\">Gene (enzyme)</td> </tr> <tr> <td>Classic (EDS I, EDS II)</td> <td>Autosomal dominant</td> <td><em>COL5A1</em>, <em>COL5A2</em></td> </tr> <tr> <td rowspan=\"2\">Hypermobility (EDS III)</td> <td>Autosomal dominant</td> <td>Unknown</td> </tr> <tr> <td>Autosomal recessive</td> <td><em>TNXB</em></td> </tr> <tr> <td>Vascular (EDS IV)</td> <td>Autosomal dominant</td> <td><em>COL3A1</em></td> </tr> <tr> <td>Kyphoscoliosis (EDS VI)</td> <td>Autosomal recessive</td> <td><em>PLOD1</em> (lysyl hydoxylase)</td> </tr> <tr> <td>Arthrochalasia (EDS VIIA, EDS VIIB)</td> <td>Autosomal dominant</td> <td><em>COL1A1</em>, <em>COL1A2</em></td> </tr> <tr> <td>Dermatosparaxis (EDS VIIC)</td> <td>Autosomal recessive</td> <td><em>ADAMTS2</em> (procollagen peptidase)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDS: Ehlers-Danlos syndrome.</div><div class=\"graphic_reference\">Courtesy of Susan P Pauker, MD, FACMG, and Joan Stoler, MD.</div><div id=\"graphicVersion\">Graphic 90070 Version 2.0</div></div></div>"},"90071":{"type":"graphic_diagnosticimage","displayName":"MRI C gattii thigh","title":"<EM>Cryptococcus gattii</EM> thigh abscess","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\"><EM>Cryptococcus gattii</EM> thigh abscess</div><div class=\"cntnt\"><img style=\"width:576px; height:555px;\" src=\"images/ID/90071_MRI_C_gattii_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging scan, showing a 5x4x4 cm mass in the inner mid right thigh involving the adductor magnus muscle. The mass had mild heterogeneous enhancement on T2 imaging and changes consistent with limited surrounding edema. Histopathology from a percutaneous biopsy demonstrated soft tissue necrosis and thick-walled, encapsulated organisms that stained with Gomori methenamine silver and mucicarmine. The mass was surgically resected and cultures grew <EM>Cryptococcus gattii</EM>.</div><div class=\"graphic_reference\">Reproduced from: Byrnes EJ III, Li W, Lewit Y, et al. First reported case of Cryptococcus gattii in the Southeastern USA: Implications for travel-associated acquisition of an emerging pathogen. PLoS ONE 2009; 4:e5851. Copyright © 2009 Byrnes, III et al, published by the Public Library of Science.</div><div id=\"graphicVersion\">Graphic 90071 Version 3.0</div></div></div>"},"90072":{"type":"graphic_diagnosticimage","displayName":"MRI C gattii brain","title":"Cerebral cryptococcomas caused by<EM> Cryptococcus gattii</EM>","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Cerebral cryptococcomas caused by<EM> Cryptococcus gattii</EM></div><div class=\"cntnt\"><img style=\"width:593px; height:572px;\" src=\"images/ID/90072_MRI_C_gattii_brain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A magnetic resonance imaging scan showing a large, enhancing mass in the left parietal lobe and a similar mass in the right cerebellar hemisphere (panels A and B). A biopsy of the parietal mass showed numerous yeast cells, and cultures grew <EM>Cryptococcus gattii</EM>. Repeat imaging 16 months later, while the patient was still receiving fluconazole, showed a significant reduction in the size of the cerebral cryptococcomas (panels C and D).</div><div class=\"graphic_reference\">Reproduced from: Byrnes EJ III, Li W, Lewit Y, et al. First reported case of Cryptococcus gattii in the Southeastern USA: Implications for travel-associated acquisition of an emerging pathogen. PLoS ONE 2009; 4:e5851. Copyright © 2009 Byrnes, III et al, published by the Public Library of Science.</div><div id=\"graphicVersion\">Graphic 90072 Version 2.0</div></div></div>"},"90074":{"type":"graphic_table","displayName":"Differential diagnosis of cerebellar ataxia","title":"Differential diagnosis of cerebellar ataxia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of cerebellar ataxia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Congenital disorders</td> </tr> <tr> <td class=\"indent1\">Arnold-Chiari malformation</td> </tr> <tr> <td class=\"indent1\">Congenital cerebellar hypoplasia/aplasia</td> </tr> <tr> <td class=\"indent1\">Dandy Walker cyst</td> </tr> <tr> <td class=\"indent1\">Gillespie syndrome</td> </tr> <tr> <td class=\"indent1\">Hydrocephalus</td> </tr> <tr> <td class=\"indent1\">Joubert syndrome (congenital absence of the cerebellar vermis)</td> </tr> <tr> <td class=\"indent1\">Pontocerebellar hypoplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders with dominant inheritance</td> </tr> <tr> <td class=\"indent1\">Adult onset leukodystrophy</td> </tr> <tr> <td class=\"indent1\">Dentatorubral pallidoluysian atrophy</td> </tr> <tr> <td class=\"indent1\">Episodic ataxias</td> </tr> <tr> <td class=\"indent1\">Myelocerebellar disorder (ataxia-pancytopenia syndrome)</td> </tr> <tr> <td class=\"indent1\">Spinocerebellar ataxias</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders with autosomal recessive inheritance</td> </tr> <tr> <td class=\"indent1\">Abetalipoproteinemia (Bassen-Kornzweig disease)</td> </tr> <tr> <td class=\"indent1\">Aceruloplasminemia</td> </tr> <tr> <td class=\"sublist2_start\">Aminoacidurias</td> </tr> <tr> <td class=\"indent2\">&#8226; Hartnup disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Isovaleric acidemia</td> </tr> <tr> <td class=\"indent2\">&#8226; Maple syrup urine disease</td> </tr> <tr> <td class=\"indent1\">Ataxia with hypogonadism (Holmes ataxia)</td> </tr> <tr> <td class=\"indent1\">Ataxia with isolated vitamin E deficiency</td> </tr> <tr> <td class=\"indent1\">Ataxia with oculomotor apraxia I</td> </tr> <tr> <td class=\"indent1\">Ataxia with oculomotor apraxia II</td> </tr> <tr> <td class=\"indent1\">Ataxia-telangiectasia</td> </tr> <tr> <td class=\"indent1\">Ataxia-telangiectasia-like disorder</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive cerebellar&nbsp;ataxia type 1</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive cerebellar&nbsp;ataxia type 2</td> </tr> <tr> <td class=\"indent1\">Autosomal recessive cerebellar&nbsp;ataxia type 3</td> </tr> <tr> <td class=\"indent1\">Cerebrotendinous xanthomatosis</td> </tr> <tr> <td class=\"indent1\">Cockayne syndrome</td> </tr> <tr> <td class=\"indent1\">Friedreich ataxia</td> </tr> <tr> <td class=\"sublist2_start\">Hyperammonemias</td> </tr> <tr> <td class=\"indent2\">&#8226; Biotin-responsive multiple carboxylase deficiency</td> </tr> <tr> <td class=\"indent2\">&#8226; Argininosuccinate lyase deficiency</td> </tr> <tr> <td class=\"indent2\">&#8226; Argininosuccinate synthetase deficiency</td> </tr> <tr> <td class=\"sublist2_start\">Leukodystrophies</td> </tr> <tr> <td class=\"indent2\">&#8226; Adrenoleukodystrophy</td> </tr> <tr> <td class=\"indent2\">&#8226; Krabbe disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Metachromic leukodystrophy</td> </tr> <tr> <td class=\"sublist2_start\">Lysosomal storage diseases</td> </tr> <tr> <td class=\"indent2\">&#8226; Niemann-Pick type C</td> </tr> <tr> <td class=\"indent2\">&#8226; Neuronal ceroid lipofuscinosis</td> </tr> <tr> <td class=\"indent2\">&#8226; Tay-Sachs disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Adult-onset hexosaminidase B deficiency</td> </tr> <tr> <td class=\"indent1\">Marinesco-Sj&#246;gren syndrome</td> </tr> <tr> <td class=\"indent1\">Nijmegen breakage syndrome</td> </tr> <tr> <td class=\"indent1\">Pantothenate kinase-associated neurodegeneration</td> </tr> <tr> <td class=\"indent1\">Refsum disease</td> </tr> <tr> <td class=\"indent1\">Spastic ataxia of Charlevoix-Saguenay</td> </tr> <tr> <td class=\"indent1\">Unverricht-Lundborg disease</td> </tr> <tr> <td class=\"indent1\">Wilson disease</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders with X-linked inheritance</td> </tr> <tr> <td class=\"indent1\">Adrenomyeloneuropathy</td> </tr> <tr> <td class=\"indent1\">Fragile X tremor ataxia syndrome</td> </tr> <tr> <td class=\"indent1\">Ornithine transcarbamylase defiance</td> </tr> <tr> <td class=\"indent1\">Pyruvate dehydrogenase deficiency</td> </tr> <tr> <td class=\"indent1\">X-linked adrenoleukodystrophy</td> </tr> <tr> <td class=\"indent1\">X-linked sideroblastic anemia with ataxia</td> </tr> <tr> <td class=\"subtitle1_single\">Mitochondrial disorders</td> </tr> <tr> <td class=\"indent1\">Nonsyndromic mitochondrial disorders</td> </tr> <tr> <td class=\"sublist2_start\">Syndromic mitochondrial disorders</td> </tr> <tr> <td class=\"indent2\">&#8226; Myoclonic epilepsy with ragged red fibers (MERRF)</td> </tr> <tr> <td class=\"indent2\">&#8226; Neurogenic weakness with ataxia and retinitis pigmentosa (NARP)</td> </tr> <tr> <td class=\"indent2\">&#8226; Maternally inherited Leigh syndrome (MILS)</td> </tr> <tr> <td class=\"indent2\">&#8226; Kearns-Sayre syndrome (KSS)</td> </tr> <tr> <td class=\"indent2\">&#8226; Leigh syndrome (LS)</td> </tr> <tr> <td class=\"indent2\">&#8226; Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO)</td> </tr> <tr> <td class=\"indent2\">&#8226; Spinocerebellar ataxia and epilepsy (SCAE)</td> </tr> <tr> <td class=\"indent2\">&#8226; Alpers-Huttenlocher disease (AHS)</td> </tr> <tr> <td class=\"indent2\">&#8226; Infantile-onset spinocerebellar ataxia (IOSCA)</td> </tr> <tr> <td class=\"indent2\">&#8226; Mitochondrial recessive ataxia syndrome (MIRAS)</td> </tr> <tr> <td class=\"indent2\">&#8226; Myoclonus, epilepsy, myopathy, and sensory ataxia (MEMSA)</td> </tr> <tr> <td class=\"indent2\">&#8226; Leukoencephalopathy with brainstem and spinal cord involvement and lactic acidosis (LBSL)</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic and metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Alcoholic cerebellar degeneration</td> </tr> <tr> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"indent1\">Drugs (eg, antiepileptic medications, chemotherapy; see table for details)</td> </tr> <tr> <td class=\"indent1\">Extra pontine myelinolysis</td> </tr> <tr> <td class=\"indent1\">Hepatocerebral degeneration</td> </tr> <tr> <td class=\"indent1\">Hyperthermia</td> </tr> <tr> <td class=\"indent1\">Hypomagnesemia</td> </tr> <tr> <td class=\"indent1\">Hypoparathyroidism</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Insecticides</td> </tr> <tr> <td class=\"indent1\">Portal-systemic encephalopathy</td> </tr> <tr> <td class=\"sublist2_start\">Toxins</td> </tr> <tr> <td class=\"indent2\">&#8226; Arsenic</td> </tr> <tr> <td class=\"indent2\">&#8226; Benzene</td> </tr> <tr> <td class=\"indent2\">&#8226; Carbon disulfide</td> </tr> <tr> <td class=\"indent2\">&#8226; Lead</td> </tr> <tr> <td class=\"indent2\">&#8226; Mercury</td> </tr> <tr> <td class=\"indent2\">&#8226; Thallium</td> </tr> <tr> <td class=\"indent2\">&#8226; Toluene</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious etiologies</td> </tr> <tr> <td class=\"indent1\">Cerebellar abscess</td> </tr> <tr> <td class=\"indent1\">Congenital rubella panencephalitis</td> </tr> <tr> <td class=\"indent1\">Fungal meningoencephalitis</td> </tr> <tr> <td class=\"indent1\">HIV encephalitis/AIDS</td> </tr> <tr> <td class=\"indent1\">HSV encephalitis</td> </tr> <tr> <td class=\"indent1\">Legionella</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Mycoplasma</td> </tr> <tr> <td class=\"indent1\">Neurocysticercosis (rarely)</td> </tr> <tr> <td class=\"sublist2_start\">Prion diseases</td> </tr> <tr> <td class=\"indent2\">&#8226; Creutzfeldt-Jacob disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Variant Creutzfeldt-Jacob disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Gerstmann-Str&#228;ussler-Scheinker syndrome</td> </tr> <tr> <td class=\"indent1\">Progressive multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Streptococcus pneumoniae</td> </tr> <tr> <td class=\"indent1\">Subacute sclerosing panencephalitis (classically measles, rubella)</td> </tr> <tr> <td class=\"indent1\">Syphilis (rare as only manifestation)</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis (rare as only manifestation)</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"sublist2_start\">Viral cerebellitis</td> </tr> <tr> <td class=\"indent2\">&#8226; Cytomegalovirus</td> </tr> <tr> <td class=\"indent2\">&#8226; Coxsackie A/B</td> </tr> <tr> <td class=\"indent2\">&#8226; Echovirus</td> </tr> <tr> <td class=\"indent2\">&#8226; Eastern equine encephalitis</td> </tr> <tr> <td class=\"indent2\">&#8226; Epstein-Barr virus</td> </tr> <tr> <td class=\"indent2\">&#8226; Mumps</td> </tr> <tr> <td class=\"indent2\">&#8226; Polio</td> </tr> <tr> <td class=\"indent2\">&#8226; St. Louis encephalitis</td> </tr> <tr> <td class=\"indent2\">&#8226; Varicella zoster virus</td> </tr> <tr> <td class=\"indent2\">&#8226; West Nile virus</td> </tr> <tr> <td class=\"indent1\">Whipple disease</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td class=\"indent1\">Cerebellar hemorrhage</td> </tr> <tr> <td class=\"indent1\">Cerebellar infarction</td> </tr> <tr> <td class=\"indent1\">Superficial siderosis</td> </tr> <tr> <td class=\"sublist2_start\">Vertebrobasilar insufficiency</td> </tr> <tr> <td class=\"indent2\">&#8226; Basilar artery stenosis</td> </tr> <tr> <td class=\"indent2\">&#8226; Subclavian steal phenomenon</td> </tr> <tr> <td class=\"indent2\">&#8226; Vertebral artery stenosis or dissection</td> </tr> <tr> <td class=\"subtitle1_single\">Vitamin deficiencies</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Vitamin E deficiency</td> </tr> <tr> <td class=\"indent1\">Wernicke encephalopathy, thiamine deficiency</td> </tr> <tr> <td class=\"indent1\">Zinc deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic processes</td> </tr> <tr> <td class=\"sublist2_start\">Benign tumors</td> </tr> <tr> <td class=\"indent2\">&#8226; Vestibular schwannoma</td> </tr> <tr> <td class=\"indent2\">&#8226; Meningioma</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic cerebellar degeneration </td> </tr> <tr> <td class=\"indent1\">PTEN hamartoma tumor syndrome, including Cowden syndrome</td> </tr> <tr> <td class=\"sublist2_start\">Metastatic cancer, most commonly in adults</td> </tr> <tr> <td class=\"indent2\">&#8226; Breast cancer</td> </tr> <tr> <td class=\"indent2\">&#8226; Colon cancer</td> </tr> <tr> <td class=\"indent2\">&#8226; Lung cancer</td> </tr> <tr> <td class=\"indent2\">&#8226; Melanoma</td> </tr> <tr> <td class=\"indent2\">&#8226; Renal cell carcinoma</td> </tr> <tr> <td class=\"sublist2_start\">Primary malignant tumors</td> </tr> <tr> <td class=\"indent2\">&#8226; Ependymoma</td> </tr> <tr> <td class=\"indent2\">&#8226; Glioma</td> </tr> <tr> <td class=\"indent2\">&#8226; Hemangioblastoma (associated with von Hippel-Lindau syndrome)</td> </tr> <tr> <td class=\"indent2\">&#8226; Medulloblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune diseases</td> </tr> <tr> <td class=\"indent1\">Acute disseminated encephalomyelitis</td> </tr> <tr> <td class=\"indent1\">Bickerstaff encephalitis</td> </tr> <tr> <td class=\"indent1\">Celiac disease (gluten enteropathy with ataxia)</td> </tr> <tr> <td class=\"indent1\">GAD antibody-associated ataxia</td> </tr> <tr> <td class=\"indent1\">Hashimoto thyroiditis/encephalopathy</td> </tr> <tr> <td class=\"indent1\">Histiocytosis X</td> </tr> <tr> <td class=\"indent1\">Miller Fisher variant of Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis (note overlap with postinfectious cerebellitis as initial presenting symptom)</td> </tr> <tr> <td class=\"indent1\">Neurosarcoidosis</td> </tr> <tr> <td class=\"indent1\">Postinfectious cerebellitis (eg, following varicella zoster virus or Epstein-Barr virus infections)</td> </tr> <tr> <td class=\"sublist2_start\">Vasculitis, including</td> </tr> <tr> <td class=\"indent2\">&#8226; Beh&#231;et disease</td> </tr> <tr> <td class=\"indent2\">&#8226; Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent2\">&#8226; Temporal arteritis</td> </tr> <tr> <td class=\"subtitle1_single\">Sporadic cerebellar neurodegenerative diseases</td> </tr> <tr> <td class=\"indent1\">Multiple system atrophy</td> </tr> <tr> <td class=\"indent1\">Neuroacanthocytosis</td> </tr> <tr> <td class=\"indent1\">Pantothenate kinase-associated neurodegeneration (sporadic form)</td> </tr> <tr> <td class=\"indent1\">Progressive supranuclear palsy</td> </tr> <tr> <td class=\"subtitle1_single\">Cerebellar ataxia mimics</td> </tr> <tr> <td class=\"indent1\">Large fiber sensory neuropathy</td> </tr> <tr> <td class=\"indent1\">Migraine headache with ataxia</td> </tr> <tr> <td class=\"indent1\">Normal pressure hydrocephalus</td> </tr> <tr> <td class=\"indent1\">Obstructive hydrocephalus</td> </tr> <tr> <td class=\"indent1\">Psychogenic ataxia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90074 Version 4.0</div></div></div>"},"90077":{"type":"graphic_table","displayName":"Drugs and toxins associated with cerebellar symptoms","title":"Drugs and toxins associated with cerebellar symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs and toxins associated with cerebellar symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Alcohol</td> </tr> <tr> <td>Amiodarone</td> </tr> <tr> <td>Antiepileptic drugs</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td>Bismuth</td> </tr> <tr> <td>Bromides</td> </tr> <tr> <td>Carbon tetrachloride</td> </tr> <tr> <td>Chemotherapeutic agents (particularly high-dose cytarabine, fluorouracil, and asparaginase)</td> </tr> <tr> <td>Cyclosporine</td> </tr> <tr> <td>Glucocorticoids (high-dose)</td> </tr> <tr> <td>Heavy metals (particularly mercury and manganese)</td> </tr> <tr> <td>Lithium</td> </tr> <tr> <td>Metronidazole</td> </tr> <tr> <td>Phencyclidine</td> </tr> <tr> <td>Piperazine</td> </tr> <tr> <td>Tacrolimus</td> </tr> <tr> <td>Thallium</td> </tr> <tr> <td>Toluene</td> </tr> <tr> <td>Zidovudine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90077 Version 1.0</div></div></div>"},"90078":{"type":"graphic_table","displayName":"Laboratory tests to consider for cerebellar ataxia","title":"Laboratory tests to consider for the patient with cerebellar ataxia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory tests to consider for the patient with cerebellar ataxia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Most patients should have:</td> </tr> <tr> <td class=\"indent1\">Complete blood count with peripheral smear</td> </tr> <tr> <td class=\"indent1\">Creatinine</td> </tr> <tr> <td class=\"indent1\">Electrolytes including calcium and magnesium</td> </tr> <tr> <td class=\"indent1\">Erythrocyte sedimentation rate</td> </tr> <tr> <td class=\"indent1\">C-reactive protein</td> </tr> <tr> <td class=\"indent1\">Liver function tests</td> </tr> <tr> <td class=\"indent1\">Thyroid function tests</td> </tr> <tr> <td class=\"indent1\">Vitamin B12, vitamin E, and serum copper levels (for vitamin deficiencies)</td> </tr> <tr> <td class=\"indent1\">Serum ceruloplasmin and 24-hour urine copper (for Wilson disease)</td> </tr> <tr> <td class=\"indent1\">Serum lactate and pyruvate (for mitochondrial disorders)</td> </tr> <tr> <td class=\"subtitle1_single\">Consider in selected patients:</td> </tr> <tr> <td class=\"indent1\">Lumbar puncture for CSF cell count, protein, glucose, cultures, oligoclonal bands, cytology, lactate, 14-3-3 protein, and cerebellar autoantibodies</td> </tr> <tr> <td class=\"indent1\">Genetic testing (see text)</td> </tr> <tr> <td class=\"indent1\">Serum thiamine*</td> </tr> <tr> <td class=\"indent1\">Anti-glutamic acid decarboxylase (GAD) antibodies (for GAD antibody-associated ataxia)</td> </tr> <tr> <td class=\"indent1\">Anti-gliadin, anti-tissue-transglutaminase and anti-endomysial antibodies (for celiac disease)</td> </tr> <tr> <td class=\"indent1\">HIV, RPR, and Lyme disease testing</td> </tr> <tr> <td class=\"indent1\">Alpha-fetoprotein (for AT, ATLD, and AOA type II)</td> </tr> <tr> <td class=\"indent1\">Lipids (for AOA type I and abetalipoproteinemia)</td> </tr> <tr> <td class=\"indent1\">ACE, ANA, Ro/SSA, La/SSB, C-ANCA, P-ANCA, and anticardiolipin antibodies (for systemic immune disorders)</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic antibodies</td> </tr> <tr> <td class=\"indent1\">Cholestanol (for cerebrotendinous xanthomatosis)</td> </tr> <tr> <td class=\"indent1\">Phytanic acid level (for Refsum disease)</td> </tr> <tr> <td class=\"indent1\">Urinary heavy metals (for toxic causes)</td> </tr> <tr> <td class=\"indent1\">Plasma amino acids, urine organic amino acids, and very long chain fatty acids (for various inherited metabolic disorders)</td> </tr> <tr> <td class=\"indent1\">Serum ammonia level (for urea cycle disorders)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibodies; AOA: ataxia with oculomotor apraxia; AT: ataxia-telangiectasia; ATLD: ataxia-telangiectasia-like disorder; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; RPR: rapid plasma reagin (for syphilis).<br />* When Wernicke encephalopathy is suspected, immediate thiamine replacement takes precedence over laboratory diagnosis.</div><div id=\"graphicVersion\">Graphic 90078 Version 6.0</div></div></div>"},"90082":{"type":"graphic_figure","displayName":"Central pancreatectomy","title":"Central pancreatectomy","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Central pancreatectomy</div><div class=\"cntnt\"><img style=\"width:489px; height:697px;\" src=\"images/SURG/90082_Central_pancreatectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90082 Version 1.0</div></div></div>"},"90102":{"type":"graphic_table","displayName":"Endometriosis conservative definitive surgery","title":"Conservative versus definitive surgery for endometriosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conservative versus definitive surgery for endometriosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Surgery</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" colspan=\"2\">Rate of reoperation (%)</td> </tr> <tr> <td class=\"subtitle2\">Two years</td> <td class=\"subtitle2\">Seven years</td> </tr> <tr> <td>Laparoscopy, both ovaries preserved</td> <td class=\"centered\">96</td> <td class=\"centered\">21</td> <td class=\"centered\">59</td> </tr> <tr> <td>Hysterectomy, both ovaries preserved</td> <td class=\"centered\">28</td> <td class=\"centered\">8</td> <td class=\"centered\">22</td> </tr> <tr> <td>Hysterectomy, one ovary removed</td> <td class=\"centered\">19</td> <td class=\"centered\">0</td> <td class=\"centered\">24</td> </tr> <tr> <td>Hysterectomy, both ovaries removed</td> <td class=\"centered\">50</td> <td class=\"centered\">4</td> <td class=\"centered\">8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008; 111:1285.</div><div id=\"graphicVersion\">Graphic 90102 Version 4.0</div></div></div>"},"90104":{"type":"graphic_table","displayName":"Adjuvant chemotherapy trials","title":"Adjuvant chemotherapy trials for non-small cell lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjuvant chemotherapy trials for non-small cell lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\"><span style=\"color: black;\">Study</span></td> <td class=\"subtitle1\" rowspan=\"2\"><span style=\"color: black;\">Stage</span></td> <td class=\"subtitle1\" rowspan=\"2\"><span style=\"color: black;\">Chemo</span></td> <td class=\"subtitle1\" rowspan=\"2\"><span style=\"color: black;\">RT</span></td> <td class=\"subtitle1\" rowspan=\"2\"><span style=\"color: black;\">Number of patients</span></td> <td class=\"subtitle1\" colspan=\"3\"><span style=\"color: black;\">5 year survival</span></td> </tr> <tr> <td class=\"subtitle2\"><span style=\"color: black;\">Chemo</span></td> <td class=\"subtitle2\"><span style=\"color: black;\">Observe</span></td> <td class=\"subtitle2\"><span style=\"color: black;\">P-value</span></td> </tr> <tr> <td><span style=\"color: black;\">ALPI*<sup>[1]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">I, II, IIIA</span></td> <td class=\"centered\"><span style=\"color: black;\">MVdP</span></td> <td class=\"centered\"><span style=\"color: black;\">&#177;</span></td> <td class=\"centered\"><span style=\"color: black;\">1088</span></td> <td class=\"centered\"><span style=\"color: black;\">+1 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">---</span></td> <td class=\"centered\"><span style=\"color: black;\">0.59</span></td> </tr> <tr> <td><span style=\"color: black;\">IALT*<sup>[2]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">I, II, III</span></td> <td class=\"centered\"><span style=\"color: black;\">PE, PN, PV</span></td> <td class=\"centered\"><span style=\"color: black;\">&#177;</span></td> <td class=\"centered\"><span style=\"color: black;\">1867</span></td> <td class=\"centered\"><span style=\"color: black;\">44 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">40 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">0.03</span></td> </tr> <tr> <td><span style=\"color: black;\">BLT*<sup>[3]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">I, II, III</span></td> <td class=\"centered\"><span style=\"color: black;\">MVP, MIP, PN, PVd</span></td> <td class=\"centered\"><span style=\"color: black;\">&#177;</span></td> <td class=\"centered\"><span style=\"color: black;\">381</span></td> <td class=\"centered\"><span style=\"color: black;\">58 percent<sup>&#182;</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">60 percent<sup>&#182;</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">0.90</span></td> </tr> <tr> <td><span style=\"color: black;\">JBR.10*<sup>[4]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">IB, II</span></td> <td class=\"centered\"><span style=\"color: black;\">PN</span></td> <td class=\"centered\"><span style=\"color: black;\">&ndash;</span></td> <td class=\"centered\"><span style=\"color: black;\">482</span></td> <td class=\"centered\"><span style=\"color: black;\">69 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">54 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">0.002</span></td> </tr> <tr> <td><span style=\"color: black;\">ANITA*<sup>[5]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">I, II, IIIA&nbsp;</span></td> <td class=\"centered\"><span style=\"color: black;\">PN&nbsp;</span></td> <td class=\"centered\"><span style=\"color: black;\">+/&ndash;</span></td> <td class=\"centered\"><span style=\"color: black;\">840&nbsp;</span></td> <td class=\"centered\"><span style=\"color: black;\">+8.6 percent&nbsp;</span></td> <td class=\"centered\"><span style=\"color: black;\">---&nbsp;</span></td> <td class=\"centered\"><span style=\"color: black;\">0.017&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">CALGB<sup>[6]</sup></span></td> <td class=\"centered\"><span style=\"color: black;\">IB</span></td> <td class=\"centered\"><span style=\"color: black;\">CT</span></td> <td class=\"centered\"><span style=\"color: black;\">&ndash;</span></td> <td class=\"centered\"><span style=\"color: black;\">344</span></td> <td class=\"centered\"><span style=\"color: black;\">60 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">58 percent</span></td> <td class=\"centered\"><span style=\"color: black;\">0.125</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">P: cisplatin; E: etoposide; N: vinorelbine; V: vinblastine; M: mitomycin; I: ifosfamide; C: carboplatin; Vd: vindesine; RT: radiation therapy.<br />* Included in LACE meta-analysis <SUP>[7]</SUP>.<br />¶&nbsp;2 year survival.</SPAN></div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453.</LI>&#xD;&#xA;<LI>Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28:35.</LI>&#xD;&#xA;<LI>Waller D, Gower N, Milroy MD, et al. The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting (abstract). Proc Am Soc Clin Oncol 2003; 22:639.</LI>&#xD;&#xA;<LI>Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28:29.</LI>&#xD;&#xA;<LI><FONT color=black>Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552.</FONT></LI></OL></div><div id=\"graphicVersion\">Graphic 90104 Version 5.0</div></div></div>"},"90106":{"type":"graphic_table","displayName":"Cachexia domains covered by malnutrition assessment tools","title":"Cachexia assessment domains covered by several malnutrition assessment tools","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cachexia assessment domains covered by several malnutrition assessment tools</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">PG-SGA</td> <td class=\"subtitle1\">MNA</td> <td class=\"subtitle1\">MST</td> <td class=\"subtitle1\">MUST</td> <td class=\"subtitle1\">NRS 02</td> </tr> <tr> <td><strong>Stores depletion</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Muscle mass and strength</strong></td> <td class=\"centered\">(X)*</td> <td class=\"centered\">X<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Anorexia or reduced food intake</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Catabolic drivers</strong></td> <td class=\"centered\">(X)<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td><strong>Functional and psychosocial effects</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PG-SGA: patient-generated subjective global assessment; MNA: mini nutritional assessment; MST: malnutrition-screening tool; MUST: malnutrition universal screening tool; NRS 02: nutritional risk screening-2002.<br />* Only physical examination.<br />¶ Only calf circumference.<br />Δ Only fever and corticosteroids.</div><div class=\"graphic_reference\">Reproduced with permission from: Blum D, Strasser F. Cachexia assessment tools. Curr Opin Support Palliat Care 2011; 5:350. DOI: <a href=\"http://journals.lww.com/co-supportiveandpalliativecare/pages/articleviewer.aspx?year=2011&amp;issue=12000&amp;article=00009&amp;type=abstract\" target=\"_blank\">10.1097/SPC.0b013e32834c4a05</a>. Copyright &copy; 2011 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90106 Version 8.0</div></div></div>"},"90107":{"type":"graphic_table","displayName":"Signs and symptoms in cachexia assessment","title":"Signs and symptoms in cachexia assessment including secondary nutrition impact symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms in cachexia assessment including secondary nutrition impact symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms related to the underlying disease</td> <td class=\"subtitle1\">Secondary nutrition impact symptoms that may impact caloric intake</td> <td class=\"subtitle1\">Symptoms that might be a consequence of cachexia</td> <td class=\"subtitle1\">Other contributory factors</td> </tr> <tr> <td> <p>Appetite loss</p> <p>Early satiety</p> Weakness or disability</td> <td> <p>Anxiety/depression</p> <p>Constipation or diarrhea</p> <p>Difficulty chewing/dysphagia</p> <p>Dysgeusia</p> <p>Dyspnea</p> <p>Fatigue</p> <p>Nausea/vomiting</p> <p>Pain (especially epigastric or abdominal)</p> <p>Stomatitis</p> <p>Thick saliva/secretions</p> Xerostomia</td> <td> <p>Body-image dissatisfaction</p> <p>Eating-related distress</p> Fatigue</td> <td> <p>Adrenal insufficiency</p> <p>Hypogonadism (in men)</p> <p>Hypothyroidism</p> Sarcopenia from cancer treatment (androgen deprivation therapy, sorafenib, bevacizumab)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Strasser F. Classification of cancer cachexia and secondary nutrition impact symptoms. In: Nutrition and the Cancer Patient, Del Fabbro E, Baracos V, Denmark-Wahnefried W, et al (Eds), Oxford University Press 2010.</div><div id=\"graphicVersion\">Graphic 90107 Version 2.0</div></div></div>"},"90109":{"type":"graphic_table","displayName":"Mimics of cutaneous lymphoproliferative disorders","title":"Histologic mimics of cutaneous lymphoproliferative disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic mimics of cutaneous lymphoproliferative disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mimickers of mycosis fungoides</td> <td class=\"subtitle1\">Features suggestive of reactive inflammatory process</td> </tr> <tr> <td>Drug-induced pseudolymphoma</td> <td>Primarily clinical</td> </tr> <tr> <td>Lichen sclerosis</td> <td>Location (genital), dense homogenized papillary dermal collagen</td> </tr> <tr> <td>Lichen striatus</td> <td>Spongiosis, perieccrine inflammation</td> </tr> <tr> <td>Lichenoid/lymphomatoid keratosis</td> <td>Wedge-shaped hypergranulosis, dyskeratotic keratinocytes, eosinophils, adjacent epithelial neoplasm (seborrheic keratosis, solar lentigo, etc)</td> </tr> <tr> <td>Lymphomatoid contact dermatitis</td> <td>Spongiosis, papillary dermal edema, flask-shaped intraepidermal abscesses</td> </tr> <tr> <td>Actinic reticuloid/chronic actinic dermatitis</td> <td>Spongiosis, epidermal acanthosis, CD8+ lymphocytes predominate</td> </tr> <tr> <td>Vitiligo (inflammatory stage)</td> <td>Primarily clinical</td> </tr> <tr> <td>Pigmented purpuric dermatitis</td> <td>Lack of cytologic atypia, lack of papillary dermal fibrosis</td> </tr> <tr> <td>Fungal infection</td> <td>Neutrophils in stratum corneum, positive Periodic Acid-Schiff (PAS) stain</td> </tr> <tr> <td>Arthropod assault</td> <td>Spongiosis, eosinophils, lymphoid follicles</td> </tr> <tr class=\"divider_bottom\"> <td>Secondary syphilis</td> <td>Plasma cells, endarteritis, basal vacuolar interface changes</td> </tr> <tr> <td class=\"subtitle1\">Mimickers of CD30+ lymphoproliferative disorders</td> <td class=\"subtitle1\">Features suggestive of reactive inflammatory process</td> </tr> <tr> <td>Viral infections (Orf, Milker's nodule, molluscum contagiosum, herpes simplex)</td> <td>Scattered CD30+ cells, viropathic changes</td> </tr> <tr class=\"divider_bottom\"> <td>Arthropod assault</td> <td>Scattered CD30+ cells, eosinophils, spongiosis</td> </tr> <tr> <td class=\"subtitle1\">Mimickers of primary cutaneous B-cell lymphoma</td> <td class=\"subtitle1\">Features suggestive of reactive inflammatory process</td> </tr> <tr> <td>Lymphomatoid drug reaction</td> <td>Primarily clinical</td> </tr> <tr> <td>Persistent nodular arthropod bite reaction</td> <td>Epidermal spongiosis, eosinophils, endothelial swelling</td> </tr> <tr> <td>Lymphocytoma cutis</td> <td>Well-formed germinal centers, \"top-heavy\" infiltrate, tingible body macrophages</td> </tr> <tr> <td>Tattoo reaction</td> <td>Tattoo pigment</td> </tr> <tr> <td>Vaccine reaction</td> <td>Central vertical focus of degeneration and fibrosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pseudolymphomas of the skin. In: An Illustrated Guide to Skin Lymphoma, 2nd ed, Cerroni L, Gatter K, Kerl H (Eds), Blackwell Publishing, Malden, Massachusetts, 1998.</li>&#xD;&#xA;    <li>Reddy K, Bhawan J. Histologic mimickers of mycosis fungoides: a review. J Cutan Pathol 2007; 34:519.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90109 Version 2.0</div></div></div>"},"90110":{"type":"graphic_figure","displayName":"Prevalence of hepatitis C by birth year","title":"Estimated prevalence of hepatitis C in the United States by birth year","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Estimated prevalence of hepatitis C in the United States by birth year</div><div class=\"cntnt\"><img style=\"width:556px; height:322px;\" src=\"images/ID/90110_Prev_hepatitis_C_birth_yr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These data were derived from the National Health and Nutrition Examination Survey in the United States from 1988-1994 (dotted line) and 1999-2002 (solid line). The vertical bars represent 95% CIs.</div><div class=\"graphic_reference\">Reproduced with permission from: Armstrong GL, Wasley A, Simard EP, et al. The prevalence of Hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705. Copyright &copy; 2006 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 90110 Version 5.0</div></div></div>"},"90114":{"type":"graphic_figure","displayName":"Cardiovascular physiologic changes in obesity","title":"Cardiovascular physiologic changes in obesity","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Cardiovascular physiologic changes in obesity</div><div class=\"cntnt\"><img style=\"width:586px; height:760px;\" src=\"images/ANEST/90114_Cardiovas_phys_chng_obesity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed pathophysiology of obesity cardiomyopathy. This diagram shows the central hemodynamic alterations that result from excessive adipose accumulation in severely-obese patients and their subsequent effects on cardiac morphology and ventricular function. LV hypertrophy in severe obesity may be eccentric or concentric. Factors influencing LV remodeling and geometry include severity and duration of obesity, duration and severity of adverse LV loading conditions (particularly hypertension), and, possibly, neurohormonal and metabolic abnormalities, such as increased sympathetic nervous system tone, activation of the renin-angiotensin-aldosterone system, insulin resistance with hyperinsulinemia, leptin resistance with hyperleptinemia, adiponectin deficiency, lipotoxicity, and lipoapoptosis. These alterations may contribute to the development of LV failure. LV failure, facilitated by pulmonary arterial hypertension from sleep apnea/obesity hypoventilation, may subsequently lead to RV failure.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle.</div><div class=\"graphic_reference\">Reproduced from: Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Dis 2014; 56:391. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90114 Version 2.0</div></div></div>"},"90116":{"type":"graphic_table","displayName":"Immunohistochemical markers skin","title":"Common immunohistochemical markers for cutaneous lymphoproliferative disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common immunohistochemical markers for cutaneous lymphoproliferative disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Common antigens in lymphoproliferative disorders</td> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Comments/use</td> </tr> <tr> <td>CD2</td> <td>T cells</td> <td>Loss marker (ie, loss of expression is suggestive of malignancy)</td> </tr> <tr> <td>CD3</td> <td>T cells</td> <td>Pan T cell marker. Expression rarely lost.</td> </tr> <tr> <td>CD4</td> <td>T cells</td> <td>T-helper and T-regulatory cells. The majority of mycosis fungoides/S&#233;zary syndrome is CD4+.</td> </tr> <tr> <td>CD5</td> <td>Primarily T cells</td> <td>Loss marker. Expression in B cells suggestive of B-cell lymphoma/leukemia (B-CLL).</td> </tr> <tr> <td>CD7</td> <td>T cells</td> <td>Loss marker</td> </tr> <tr> <td>CD8</td> <td>T cells</td> <td>T-cytotoxic cells. Rare variants of mycosis fungoides and cytotoxic T cell lymphomas.</td> </tr> <tr> <td>CD10</td> <td>B cells</td> <td>Germinal center-derived B cells</td> </tr> <tr> <td>CD20</td> <td>B cells</td> <td>B cell marker. Does not highlight plasma cells. Target of rituximab therapy.</td> </tr> <tr> <td>CD21</td> <td>Follicular dendritic cells</td> <td>Highlights germinal centers</td> </tr> <tr> <td>CD23</td> <td>B cells and follicular dendritic cells</td> <td>Highlights germinal centers. Can be expressed in reactive B cells and B-CLL.</td> </tr> <tr> <td>CD25</td> <td>T cells</td> <td>Activated T cells and adult T cell leukemia/lymphoma (ATLL). Target of denileukin diftitox therapy.</td> </tr> <tr> <td>CD30</td> <td>T and B cells</td> <td>Activated T and B cells. CD30+ lymphoproliferative disorders.</td> </tr> <tr> <td>CD45</td> <td>All leukocytes</td> <td>Broad leukocyte marker</td> </tr> <tr> <td>CD79a</td> <td>B cells</td> <td>Broader range of B cell developmental stages than CD20 (pre-B cells and most plasma cells)</td> </tr> <tr> <td>CD138</td> <td>Plasma cells</td> <td>&nbsp;</td> </tr> <tr> <td>Ig light chain (lambda [&#955;]/kappa [&#922;])</td> <td>B cells</td> <td>Exclusive expression of either lambda or kappa light chain is suggestive of malignancy. Normal ratio is 3:1 kappa to lambda.</td> </tr> <tr> <td>BCL-2</td> <td>B and T cells</td> <td>Expressed by marginal zone B cells, T cells, and follicular lymphomas</td> </tr> <tr> <td>BCL-6</td> <td>B cells</td> <td>Germinal center-derived B cells</td> </tr> <tr> <td>PAX-5</td> <td>B cells</td> <td>Highlights B cells at all stages of development. Nuclear staining.</td> </tr> <tr> <td>LMO2</td> <td>B cells</td> <td>Germinal center-derived B cells</td> </tr> <tr> <td>MUM-1</td> <td>B cells</td> <td>Activated B cells. Large B cell lymphoma.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cerroni L, Kerl H. Diagnostic immunohistology: Cutaneous lymphomas and pseudolymphomas. Semin Cutan Med Surg 1999; 18:64.</li>&#xD;&#xA;    <li>Martin AW. Immunohistology of non-Hodgkin lymphoma. In: Diagnostic immunohistochemistry: Theranostic and genomic applications, 3rd ed, Dabbs DJ (ED), Elsevier, Philadelphia 2010.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90116 Version 2.0</div></div></div>"},"90117":{"type":"graphic_figure","displayName":"VDJ recombination","title":"Detection of clonal immunoglobulin and T cell receptor gene recombinations by polymerase chain reaction (PCR)-based methods","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Detection of clonal immunoglobulin and T cell receptor gene recombinations by polymerase chain reaction (PCR)-based methods</div><div class=\"cntnt\"><img style=\"width:428px; height:534px;\" src=\"images/DERM/90117_VDJ_recombination.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the TCR and Ig genes are comprised of multiple gene fragments divided into Variable (V), Diverse (D), Joining (J), and Constant (C) regions. During T and B cell maturation, the lymphocytes undergo a process known as somatic recombination in which individual V, D and J regions are combined to form unique TCR and Ig, respectively. Standard primers are designed to bind DNA sequences within V and J regions and allow for the detection of unique TCR and Ig. The finding of a preponderance of a single TCR or Ig within a population of lymphocytes suggests a clonal population of cells.</div><div id=\"graphicVersion\">Graphic 90117 Version 2.0</div></div></div>"},"90120":{"type":"graphic_table","displayName":"Shellfish and pufferfish poisoning syndromes","title":"Shellfish and pufferfish poisoning syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Shellfish and pufferfish poisoning syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Poisoning syndrome</td> <td class=\"subtitle1\">Affected seafood</td> <td class=\"subtitle1\">Common geographic distribution</td> <td class=\"subtitle1\">Primary toxin</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>Paralytic shellfish poisoning</td> <td>Bivalve mollusks* (Cockles, fresh- and salt-water mussels, little neck clams)</td> <td>Worldwide, especially USA (Northeast, Pacific Northwest, and Alaska)</td> <td>Saxitoxin</td> <td> <p>Perioral tingling</p> <p>Paresthesias</p> <p>Difficulty swallowing</p> <p>Dizziness</p> <p>Ataxia</p> Paralysis</td> <td> <p>Supportive care</p> Mechanical ventilation for respiratory failure</td> </tr> <tr class=\"divider_bottom\"> <td>Neurotoxic shellfish poisoning</td> <td>Bivalve mollusks (eg, mussels or clams)</td> <td> <p>Southeast USA</p> <p>Mexico</p> <p>Caribbean</p> New Zealand</td> <td>Brevetoxin</td> <td>Ingestion: <ul> <li>Nausea </li> <li>Vomiting </li> <li>Diarrhea </li> <li>Abdominal pain </li> <li>Paresthesias </li> <li>Dizziness </li> <li>Ataxia </li> <li>Temperature-related dysesthesia </li> <li>Paralysis (rare) </li> <li>Coma (rare) </li> <li>Seizures (rare) </li> </ul> <br /> Inhalation: <ul> <li>Rhinorrhea </li> <li>Bronchoconstriction </li> </ul> </td> <td> <p>Supportive care</p> Ingestion: <ul> <li>Activated charcoal </li> <li>Antiemetics (eg, ondansetron) </li> <li>Fluid repletion </li> <li>Treat seizures with benzodiazepines (eg, lorazepam) </li> <li>Mechanical ventilation for respiratory failure </li> </ul> <br /> Inhalation: <ul> <li>Inhaled bronchodilators (eg, albuterol) for bronchospasm </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Diarrhetic shellfish poisoning</td> <td>Mussels</td> <td> <p>Japan</p> <p>Scandinavia</p> <p>France</p> <p>Belgium</p> <p>Spain</p> <p>Chile</p> <p>Uruguay</p> <p>Ireland</p> Canada</td> <td>Okadaic acid</td> <td> <p>Nausea</p> <p>Vomiting</p> <p>Diarrhea</p> Abdominal pain</td> <td> <p>Supportive care</p> <p>Antiemetics (eg, ondansetron)</p> Fluid repletion</td> </tr> <tr class=\"divider_bottom\"> <td>Amnestic shellfish poisoning</td> <td> <p>Mussels</p> <p>Razor clams</p> Crustaceans</td> <td> <p>Canada</p> <p>Spain</p> <p>Portugal</p> <p>France</p> <p>United Kingdom</p> <p>Australia</p> New Zealand</td> <td>Domoic acid</td> <td> <p>Diarrhea</p> <p>Abdominal pain</p> <p>Headache</p> <p>Disorientation</p> <p>Retrograde and anterograde memory loss</p> <p>Ophthalmoplegia</p> <p>Coma</p> Seizures</td> <td> <p>Supportive care</p> <p>Activated charcoal</p> Treat seizures with benzodiazepines (eg, lorazepam)</td> </tr> <tr> <td>Pufferfish poisoning</td> <td>Pufferfish</td> <td> <p>Japan</p> USA</td> <td> <p>Tetrodotoxin (liver)</p> Saxitoxin (muscle)</td> <td>Tetrodotoxin: <ul> <li>Paresthesias </li> <li>Nausea </li> <li>Dizziness </li> <li>Paralysis </li> <li>Hypotension </li> </ul> <br /> Saxitoxin: <ul> <li>Same as paralytic shellfish poisoning above </li> </ul> </td> <td>Tetrodotoxin: <ul> <li>Supportive care </li> <li>Gastric lavage </li> <li>Activated charcoal </li> <li>Give fluid therapy and vasopressors as for distributive shock in patients with hypotension </li> <li>Mechanical ventilation for respiratory failure </li> </ul> <br /> Saxitoxin: <ul> <li>As for paralytic shellfish poisoning </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Gastropod mollusks (eg, whelks, moon snails, and abalone), crustaceans (eg, Dungeness crab, shrimp, and lobster), pufferfish, and zooplanktivorous fish (eg, salmon, herring, or mackerel) can also become contaminated with saxitoxin and potentially cause paralytic shellfish poisoning although human disease has most commonly been described with bivalve mollusks.</div><div id=\"graphicVersion\">Graphic 90120 Version 2.0</div></div></div>"},"90122":{"type":"graphic_picture","displayName":"Inverse lichen planus","title":"Inverse lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Inverse lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:313px;\" src=\"images/DERM/90122_Inverse_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous plaques in the axilla.</div><div id=\"graphicVersion\">Graphic 90122 Version 1.0</div></div></div>"},"90125":{"type":"graphic_picture","displayName":"Globulo-streak-like pattern","title":"Minor dermoscopic patterns seen in acquired melanocytic nevi of palms and soles: Globulo-streak-like pattern","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Minor dermoscopic patterns seen in acquired melanocytic nevi of palms and soles: Globulo-streak-like pattern</div><div class=\"cntnt\"><img style=\"width:499px; height:325px;\" src=\"images/DERM/90125_Globulo_streak_lk_patt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Globulo-streak-like pattern seen in two small acquired melanocytic nevi (arrows) affecting the arch areas.</div><div id=\"graphicVersion\">Graphic 90125 Version 2.0</div></div></div>"},"90126":{"type":"graphic_picture","displayName":"Transition pattern","title":"Dermoscopy of acral melanocytic lesions: Transition pattern","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of acral melanocytic lesions: Transition pattern</div><div class=\"cntnt\"><img style=\"width:502px; height:347px;\" src=\"images/DERM/90126_Transition_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopy, this nevus located on the inner aspect of the right heel shows the parallel furrow pattern in the lower portion and the reticular pattern in the upper portion. This pattern is characteristic of melanocytic nevi of the glabrous/nonglabrous skin transition zone. Inset: clinical photograph.</div><div id=\"graphicVersion\">Graphic 90126 Version 2.0</div></div></div>"},"90127":{"type":"graphic_picture","displayName":"Fibrillar pattern oblique view ","title":"Oblique-view dermoscopy of the fibrillar pattern in an acral melanocytic nevus","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Oblique-view dermoscopy of the fibrillar pattern in an acral melanocytic nevus</div><div class=\"cntnt\"><img style=\"width:511px; height:387px;\" src=\"images/DERM/90127_Fib_patt_oblique_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This melanocytic nevus of the sole shows the regular fibrillar pattern on the ordinary dermoscopy (A). The green lines correspond to the furrows of the skin marking visualized by the furrow ink test. Oblique view dermoscopy using a noncontact dermatoscope changes the fibrillar pattern to the parallel furrow pattern, dotted line variant (B).</div><div id=\"graphicVersion\">Graphic 90127 Version 2.0</div></div></div>"},"90128":{"type":"graphic_picture","displayName":"Nevus transition area","title":"Clinical and histopathologic features of a melanocytic nevus located on a transition area","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Clinical and histopathologic features of a melanocytic nevus located on a transition area</div><div class=\"cntnt\"><img style=\"width:482px; height:350px;\" src=\"images/DERM/90128_Nevustransitionarea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanocytic nevus located in the fourth interdigital space of the right foot of a 23-year-old woman. This brownish black macule, 5 mm in diameter, shows virtually no irregularity in shape or color.</div><div class=\"graphic_reference\">Reproduced with permission from: Saida T, Kawachi S, Koga H. Anatomic transitions and the histopathologic features of melanocytic nevi. Arch Dermatol 2008; 144:1232. Copyright &copy; 2008 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90128 Version 7.0</div></div></div>"},"90129":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosing PML","title":"Algorithm for diagnosing progressive multifocal leukoencephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosing progressive multifocal leukoencephalopathy</div><div class=\"cntnt\"><img style=\"width:431px; height:513px;\" src=\"images/NEURO/90129_AlgodiagnosingPML.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal&nbsp;fluid;&nbsp;FLAIR: fluid-attenuated inversion recovery; JCV: JC virus; PML: progressive multifocal leukoencephalopathy; PCR: polymerase chain reaction; PRES: posterior reversible encephalopathy syndrome; VZV: varicella-zoster virus.</div><div class=\"graphic_reference\">Reproduced with permission from: Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80:1430. DOI: <a href=\"http://www.neurology.org/content/80/15/1430\" target=\"_blank\">10.1212/WNL.0b013e31828c2fa1</a>. Copyright &copy; 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90129 Version 7.0</div></div></div>"},"90130":{"type":"graphic_algorithm","displayName":"Management of intestinal metaplasia","title":"Management of intestinal metaplasia","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Management of intestinal metaplasia</div><div class=\"cntnt\"><img style=\"width:650px; height:322px;\" src=\"images/GAST/90130_Manag_gast_precanc_lesions.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IM: intestinal metaplasia.<br />* Individuals at increased of gastric cancer include those with a family history of gastric cancer; non-Caucasian race/ethnicity, including African-Americans, Hispanics, and Asians; and first generation immigrants from high incidence regions (eg, Eastern Asia, mountainous Latin America).</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: Clinical implications. Am J Gastroenterol 2010; 105:493. Copyright &copy; 2010. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 90130 Version 3.0</div></div></div>"},"90131":{"type":"graphic_algorithm","displayName":"Diagnostic algorithm for granulomatous gastritis","title":"Diagnostic algorithm for granulomatous gastritis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for granulomatous gastritis</div><div class=\"cntnt\"><img style=\"width:598px; height:532px;\" src=\"images/GAST/90131_Diagalgogranulgastritis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">H. pylori: Helicobacter pylori; EUS: endoscopic ultrasound; CT: computerized tomography; PAS: period acid-Schiff; TB: tuberculosis; CBC: complete blood count; ACE: angiontensin-converting enzyme; AFB: acid fast bacilli; PCR: polymerase chain reaction; T. whipplei: Tropheryma whipplei.</div><div class=\"graphic_reference\">Rothstein RI, Dulai PS. Disseminated sarcoidosis presenting as granulomatous gastritis a clinical review of the gastrointestinal and hepatic manifestations of sarcoidosis. J Clin Gastroenterol 2012; 46:367. DOI: <a href=\"http://journals.lww.com/jcge/pages/articleviewer.aspx?year=2012&amp;issue=05000&amp;article=00007&amp;type=abstract\" target=\"_blank\">10.1097/MCG.0b013e318247106b</a>. Copyright &copy; 2012 Wolters Kluwer Health, Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90131 Version 7.0</div></div></div>"},"90132":{"type":"graphic_figure","displayName":"Gastric biopsy mapping protocol","title":"Gastric biopsy mapping protocol","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastric biopsy mapping protocol</div><div class=\"cntnt\"><img style=\"width:504px; height:459px;\" src=\"images/GAST/90132_Gast_biop_mapping_protocol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric biopsies should be obtained from the following sites:<BR>(1) Antrum, greater curvature, within 3 to 5&nbsp;cm of pylorus<BR>(2) Antrum, lesser curvature, within&nbsp;3 to 5&nbsp;cm of pylorus<BR>(3) Incisura angularis<BR>(4) Corpus, lesser curvature<BR>(5) Corpus, greater curvature</div><div id=\"graphicVersion\">Graphic 90132 Version 2.0</div></div></div>"},"90133":{"type":"graphic_table","displayName":"DDx CLL path","title":"Differential diagnosis of chronic lymphocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of chronic lymphocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Histologic morphology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)</td> <td> <p>\"Typical\" CLL cells are small, mature-appearing lymphocytes with a dense nucleus; partially aggregated chromatin; no discernible nucleoli; and a narrow border of cytoplasm.</p> A minority of cells may have a prolymphocytic morphology.</td> <td>Typically express B cell antigens (CD19, CD22, CD79a, FMC7); CD5; and CD23. Expression of CD20 and surface immunoglobulin is dim.</td> <td>Deletion 13q, trisomy 12, deletion 11q, and deletion 17p. TCR genes are <strong>not</strong> clonally rearranged.</td> </tr> <tr> <td>Monoclonal B cell lymphocytosis</td> <td>Absolute increase in the number of clonal B lymphocytes in the peripheral blood does not exceed 5000/microL [5 x 10<sup>9</sup>/L].</td> <td>Immunophenotype identical to CLL.</td> <td>Patients have no lymphadenopathy, organomegaly, cytopenias, or disease-related symptoms.</td> </tr> <tr> <td>B cell prolymphocytic leukemia</td> <td> <p>&#62;55 percent of circulating lymphocytes are \"prolymphocytes\".</p> The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells.</td> <td>Express bright surface IgM +/&ndash; IgD and bright CD20, as well as other B cell antigens (CD19, CD22, CD79a, FMC7).</td> <td> <p>t(11;14) must be excluded.</p> <p>No associated paraproteinemia.</p> TCR genes are not clonally rearranged.</td> </tr> <tr> <td>Mantle cell lymphoma</td> <td>Can have a leukemic phase that mimics CLL morphologically with circulating small lymphocytes with irregular or cleaved nuclei.</td> <td>Like CLL, coexpress CD20 and CD5, and do not express CD23, but stain strongly for cyclin D1 and surface membrane immunoglobulin.</td> <td>t(11;14)</td> </tr> <tr> <td>Hairy cell leukemia and hairy cell leukemia variant</td> <td>Typical hairy cells are mononuclear and one to two times the size of a mature lymphocyte. The nuclei are often eccentric, lack prominent nucleoli, and have a reticular chromatin pattern. The cytoplasmic outline is indistinct with&nbsp;projections. Hairy cell variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes.</td> <td>Unlike CLL, most cases of HCL are negative for CD5, express CD11c, CD103, CD123, cyclin D1, and/or annexin A1.</td> <td>&nbsp;BRAF V600E positive</td> </tr> <tr> <td>Lymphoplasmacytic lymphoma</td> <td>Peripheral blood involvement is usually less prominent; circulating malignant cells usually have a plasmacytoid appearance.</td> <td>Lacks CD23 expression and stains strongly for surface IgM, CD20, and cytoplasmic Ig.</td> <td>&nbsp;</td> </tr> <tr> <td>Splenic marginal zone lymphoma</td> <td>Circulating tumor cells may resemble CLL cells.</td> <td>Like CLL, express CD23, CD43, CD5, and IgD. Unlike CLL, can have bright SmIg and CD20.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TCR: T cell receptor.</div><div id=\"graphicVersion\">Graphic 90133 Version 5.0</div></div></div>"},"90136":{"type":"graphic_picture","displayName":"Atypical melanosis foot clinical","title":"Clinical image of atypical melanosis of the foot","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Clinical image of atypical melanosis of the foot</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/90136_Atypic_melanosis_foot_clin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 45 x 25 mm brownish macule with irregular shape and color on the volar aspect of the great toe.</div><div id=\"graphicVersion\">Graphic 90136 Version 2.0</div></div></div>"},"90137":{"type":"graphic_picture","displayName":"Atypical melanosis foot dermoscopy","title":"Dermoscopic image of atypical melanosis of the foot","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of atypical melanosis of the foot</div><div class=\"cntnt\"><img style=\"width:504px; height:409px;\" src=\"images/DERM/90137_Atyp_melano_ft_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On dermoscopic examination, atypical melanosis of the foot shows a typical parallel ridge pattern.</div><div id=\"graphicVersion\">Graphic 90137 Version 2.0</div></div></div>"},"90138":{"type":"graphic_picture","displayName":"Atypical melanosis foot histo","title":"Histopathologic characteristic of atypical melanosis of the foot","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathologic characteristic of atypical melanosis of the foot</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/90138_Atyp_melanosis_foot_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The melanocytes in the crista profunda intermedia are slightly increased in number. Eccrine ducts run through the epidermal rete ridges.</div><div id=\"graphicVersion\">Graphic 90138 Version 2.0</div></div></div>"},"90139":{"type":"graphic_picture","displayName":"Acral nevus equivocal dermoscopy ","title":"Acral melanocytic lesion with equivocal dermoscopic features","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acral melanocytic lesion with equivocal dermoscopic features</div><div class=\"cntnt\"><img style=\"width:504px; height:460px;\" src=\"images/DERM/90139_Acral_nev_equiv_dermosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A brown macule 6.5 mm in maximum diameter is present on the right fifth toe of a 63-year-old woman. On dermoscopic examination, the lesion does not show any typical/regular patterns.</div><div id=\"graphicVersion\">Graphic 90139 Version 2.0</div></div></div>"},"90140":{"type":"graphic_picture","displayName":"Furrow ink test 1","title":"The furrow ink test: Parallel furrow pattern","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">The furrow ink test: Parallel furrow pattern</div><div class=\"cntnt\"><img style=\"width:464px; height:504px;\" src=\"images/DERM/90140_Furrow_ink_test_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this acral lesion, the pigmented lines correspond to the furrows of the skin markings. The parallel furrow pattern is typical of acquired acral nevi.</div><div id=\"graphicVersion\">Graphic 90140 Version 2.0</div></div></div>"},"90141":{"type":"graphic_picture","displayName":"Furrow ink test 2","title":"The furrow ink test: Parallel ridge pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">The furrow ink test: Parallel ridge pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:382px;\" src=\"images/DERM/90141_Furrow_ink_test_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this acral melanocytic lesion, the band-like pigmentation is detected between the furrows, on the ridges of the skin markings. The parallel ridge pattern is typical of acral melanoma.</div><div id=\"graphicVersion\">Graphic 90141 Version 2.0</div></div></div>"},"90142":{"type":"graphic_figure","displayName":"Pathology of PML","title":"Pathology of progressive multifocal leukoencephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of progressive multifocal leukoencephalopathy</div><div class=\"cntnt\"><img style=\"width:423px; height:516px;\" src=\"images/NEURO/90142_PathologyPML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Luxol fast blue staining with hematoxylin counterstain of the frontal lobe in a patient with progressive multifocal leukoencephalopathy (PML) shows extensive multifocal and confluent areas of demyelination. Small islands of demyelination coalesce to produce large confluent areas resulting in a \"ground glass\" bright appearance on T2-weighted MRI scan.<br />(B) Enlarged oligodendrocyte with a large inclusion-bearing nucleus is characteristic of PML. No discrete intranuclear inclusion is seen.<br />(C) A large bizarre astrocyte is depicted.<br />(D) Immunostaining with polyclonal antibody to JC virus from Abcam Inc. shows dark brown staining of nuclei of several oligodendrocytes.<br />(E) Electron micrograph of crystalline array of assembled JC virions in nuclei of infected oligodendrocyte in PML brain lesion. Virions measure 40 nm in diameter.</div><div class=\"graphic_reference\">Reproduced with permission from: Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80:1430. DOI: <A href=\"http://www.neurology.org/content/80/15/1430\" target=_blank>10.1212/WNL.0b013e31828c2fa1</A>. Copyright © 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90142 Version 6.0</div></div></div>"},"90143":{"type":"graphic_picture","displayName":"Volar melanotic macule","title":"Volar melanotic macule","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Volar melanotic macule</div><div class=\"cntnt\"><img style=\"width:502px; height:406px;\" src=\"images/DERM/90143_Volar_melanotic_macule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows one of several light-brown macules noted on the soles of a middle-aged Japanese man. The macule has regular borders and even pigmentation. On dermoscopy, it shows a typical parallel ridge pattern.</div><div id=\"graphicVersion\">Graphic 90143 Version 2.0</div></div></div>"},"90149":{"type":"graphic_table","displayName":"Findings of chemical and biological terrorist agent exposure","title":"Clinical findings of chemical and biological terrorist agent exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings of chemical and biological terrorist agent exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Chemical agent</td> <td class=\"subtitle1\">Toxins</td> <td class=\"subtitle1\">Biologic agents</td> </tr> <tr> <td><strong>Timing of symptoms</strong></td> <td>Often rapid onset (minutes to days)*</td> <td>Delayed (hours to days)</td> <td>Delayed (days to weeks)</td> </tr> <tr> <td><strong>Unusual fog or smoke</strong></td> <td>Not necessarily*</td> <td>No</td> <td>No</td> </tr> <tr> <td><strong>Multiple simultaneous victims with similar symptoms</strong></td> <td>Common, geographically concentrated</td> <td>Common, geographically concentrated</td> <td>Less likely, may be geographically dispersed</td> </tr> <tr> <td><strong>Fever</strong></td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td><strong>Respiratory distress</strong></td> <td>Often</td> <td>Often</td> <td>Often</td> </tr> <tr> <td><strong>Rash</strong></td> <td>No</td> <td>Rare</td> <td>Frequent</td> </tr> <tr> <td><strong>Vesicles</strong></td> <td>Sulfur mustard, Lewisite, and, less commonly, riot-control agents</td> <td>T-2 exposure only</td> <td>Some agents</td> </tr> <tr> <td><strong>Bleeding</strong></td> <td>Uncommon</td> <td>Some cases</td> <td>Many agents</td> </tr> <tr> <td><strong>Neuromuscular effects (eg, seizures, weakness)</strong></td> <td>Cyanide or nerve agents</td> <td>Botulinum exposure</td> <td>No</td> </tr> <tr> <td><strong>Failure to respond to typical therapy</strong></td> <td>Depends upon severity of exposure<sup>&#182;</sup></td> <td>Sometimes<sup>&#916;</sup></td> <td>Yes (eg, multi-antibiotic resistant organisms)</td> </tr> <tr> <td><strong>Unexplained human deaths</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Unexplained deaths of animals, fish, or plants</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Exposure to some liquid forms of chemical weapons may take many hours to be absorbed and cause symptoms. Morever, chemical vapors may be invisible.<br />&para; For example, victims exposed to pulmonary agents may have unremitting respiratory failure despite the use of advanced therapies.<br />&Delta; For many toxins, therapy is mainly supportive and may be ineffective if the dose is high or recognition has been delayed.</div><div class=\"graphic_reference\">Data from: Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 2001; 21:593.</div><div id=\"graphicVersion\">Graphic 90149 Version 5.0</div></div></div>"},"90150":{"type":"graphic_table","displayName":"Framework for a goals of care discussion in palliative care","title":"Framework for a goals of care discussion in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framework for a goals of care discussion in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Introduction</td> </tr> <tr> <td class=\"indent1\">I would like to take some time with you to consider your medical care in the future. Okay?</td> </tr> <tr> <td class=\"indent1\">We have some important issues to discuss about your medical care in order to prepare for the future</td> </tr> <tr> <td class=\"subtitle1_single\">The patient's perspective</td> </tr> <tr> <td class=\"indent1\">What is your understanding about your medical situation now?</td> </tr> <tr> <td class=\"indent1\">What have the doctors told you is likely to happen next?</td> </tr> <tr> <td class=\"subtitle1_single\">Information and decision making preferences</td> </tr> <tr> <td class=\"indent1\">How can I best help you to be informed and make your medical decisions?</td> </tr> <tr> <td class=\"indent1\">Do you like to get all the facts about your illness, even if there is bad news, or just the \"broad strokes\"?</td> </tr> <tr> <td class=\"indent1\">Do you want your family to be informed? How (by you or your doctors)?</td> </tr> <tr> <td class=\"indent1\">If you don't want to participate in decision making yourself, do you prefer to have your family represent you, or leave decisions to your medical team?</td> </tr> <tr> <td class=\"subtitle1_single\">Concerns (prognosis, aggressiveness of care, debility, suffering)</td> </tr> <tr> <td class=\"indent1\">What are your main worries (hopes, fears) about your situation?</td> </tr> <tr> <td class=\"indent1\">Have you wondered about what might happen with your condition as time goes on?</td> </tr> <tr> <td class=\"indent1\">Are you worried about your (prognosis, debility, suffering, treatment toxicity)?</td> </tr> <tr> <td class=\"subtitle1_single\">Goals (including acceptability of functional states [eg, inability to communicate or care for self] and tolerance of uncomfortable procedures [eg, intensive care])</td> </tr> <tr> <td class=\"indent1\">What are you hoping for (or what are your goals) in the coming months? How would that change if your medical situation worsens?</td> </tr> <tr> <td class=\"indent1\">Has someone close to you had to face an end of life decision, such as deciding about withdrawing a ventilator or going on hospice? What would you have wanted in such a situation?</td> </tr> <tr> <td class=\"indent1\">If tradeoffs have to be made, given your current condition, how would you balance aggressive, potentially debilitating treatment of your disease that might prolong life versus a focus on avoiding or relieving suffering without striving to prolong life? How would that balance change if your condition worsened?</td> </tr> <tr> <td class=\"indent1\">How about if you became so sick that you could no longer speak or care for yourself? Would you want to be kept alive in every possible way or just be allowed to die comfortably?</td> </tr> <tr> <td class=\"subtitle1_single\">Educate (about the medical condition, its prognosis and options for management) while exploring treatment options and preferences. May include reassurances about unlikely future complications or reasons not to try potentially harmful or non-beneficial treatments.</td> </tr> <tr> <td class=\"indent1\">What is your understanding about your treatment options at this point?</td> </tr> <tr> <td class=\"indent1\">What have your doctors told you about the benefits, burdens, and chances of success with treatment?</td> </tr> <tr> <td class=\"indent1\">What is your understanding about cardiopulmonary resuscitation (CPR)? The chances of recovering in an acceptable state of health if you require CPR?</td> </tr> <tr> <td class=\"indent1\">If your condition became seriously worse, have you had thoughts about whether to pursue aggressive treatments like CPR or use of a mechanical ventilator (intubation)?</td> </tr> <tr> <td class=\"subtitle1_single\">Recommendations</td> </tr> <tr> <td class=\"indent1\">Given what you have told me about yourself and what we have discussed about your condition, I recommend...[for example]* <ul> <li>Not attempting CPR or intubation, but continuing to search for all other treatments that might help treat your disease </li> <li>Continuing all aggressive treatment including CPR and intubation, and revisiting these options only if there is a significant change in your condition </li> <li>Setting limits on the most aggressive treatments, but continuing to look for \"easy\" (relatively non-toxic) treatments that might help without also causing harm </li> <li>Shifting gears toward an approach that focuses purely on comfort </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Elicit reactions and confirm mutual understanding</td> </tr> <tr> <td class=\"indent1\">Elicit and answer questions fully</td> </tr> <tr> <td class=\"indent1\">Confirm and clarify understanding about what has been agreed upon</td> </tr> <tr> <td class=\"indent1\">Continue to elicit concerns and to respond to emotions</td> </tr> <tr> <td class=\"subtitle1_single\">Proxy and advance care directives</td> </tr> <tr> <td class=\"indent1\">Do you have a health care proxy - someone who would be able to make decisions about your medical treatment in the future if you became too ill to make decisions yourself?</td> </tr> <tr> <td class=\"indent1\">Do your proxy (or your family) and physician know how you would want to be treated under such circumstances?</td> </tr> <tr> <td class=\"indent1\">What kinds of instructions have you given them? Have you written down your wishes in an advance care directive?</td> </tr> <tr> <td class=\"subtitle1_single\">Follow-up</td> </tr> <tr> <td class=\"indent1\">Reassure about non-abandonment (eg, \"The clinical team will work this through with you and your family no matter what the clinical course\")</td> </tr> <tr> <td class=\"indent1\">Plan for follow-up, including with proxy and family</td> </tr> <tr> <td class=\"indent1\">Document in the medical record and share what has been decided with other involved clinicians</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All of these approaches should also include careful efforts to palliate and minimize suffering.</div><div class=\"graphic_reference\">Source: Bernacki RE, Block SD, American Colleges of Physicians High Value Care Task Force. Communication about serious illness care goals: a review and synthesis of best practices. JAMA intern medicine 2014; 174:1994.</div><div id=\"graphicVersion\">Graphic 90150 Version 3.0</div></div></div>"},"90152":{"type":"graphic_algorithm","displayName":"Testing and treatment for minimal hepatic encephalopathy","title":"Testing and treatment for minimal hepatic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing and treatment for minimal hepatic encephalopathy</div><div class=\"cntnt\"><img style=\"width:420px; height:567px;\" src=\"images/GAST/90152_Test_treat_min_hep_enceph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HE: hepatic encephalopathy; MHE: minimal hepatic encephalopathy; PHES: psychometric hepatic encephalopathy score; RBANS: repeatable battery for the assessment of neuropsychological status.</div><div class=\"graphic_reference\">Reproduced from: Iduru S, Mullen KD. The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology 2008; 135:1455. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90152 Version 1.0</div></div></div>"},"90157":{"type":"graphic_table","displayName":"Initial digoxin maintenance dose for patients with heart failure","title":"Initial digoxin maintenance dose for adult patients with heart failure targeting a serum concentration of 0.5 to 0.9 nmol/L","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial digoxin maintenance dose for adult patients with heart failure targeting a serum concentration of 0.5 to 0.9 nmol/L</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ideal body weight (kg)*</td> <td class=\"subtitle1\">Creatinine clearance (mL/minute)<sup>&#182;</sup></td> <td class=\"subtitle1\">Digoxin oral dose per day (mg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">45 to 50</td> <td>&#8804;60</td> <td>0.0625<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#62;60</td> <td>0.125</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">51 to 60</td> <td>&#8804;45</td> <td>0.0625<sup>&#916;</sup></td> </tr> <tr> <td>46 to 110</td> <td>0.125</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;110</td> <td>0.25</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">61 to 70</td> <td>&#8804;35</td> <td>0.0625<sup>&#916;</sup></td> </tr> <tr> <td>36 to 110</td> <td>0.125</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;110</td> <td>0.25</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">71 to 80</td> <td>&#8804;20</td> <td>0.0625<sup>&#916;</sup></td> </tr> <tr> <td>21 to 80</td> <td>0.125</td> </tr> <tr class=\"divider_bottom\"> <td>&#62;80</td> <td>0.25</td> </tr> <tr> <td rowspan=\"3\">81 to 90</td> <td>&#8804;10</td> <td>0.0625<sup>&#916;</sup></td> </tr> <tr> <td>11 to 70</td> <td>0.125</td> </tr> <tr> <td>&#62;70</td> <td>0.25</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients with unstable renal function or stage 5 renal disease requiring renal replacement therapy, pregnant patients, and patients who were receiving medications known to significantly interact with digoxin (ie, amiodarone, quinidine, verapamil, or macrolide antibiotics) were excluded from the population in which this nomogram was validated. For adjustment of initial dose based upon response and serum digoxin concentration at steady state (ie, after 7 to 10 days or more of daily use), refer to the topic review.</div><div class=\"graphic_footnotes\">* A calculator to determine ideal body weight (method of Devine) is available in UpToDate.<br />&para; A calculator to estimate creatinine clearance according to Cockcroft and Gault equation is available in UpToDate.<br />&Delta; 0.0625 mg daily dose can be given as 0.125 mg every other day.</div><div class=\"graphic_reference\">Sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006; 166:2539.</li>&#xD;&#xA;    <li>DiDomenico RJ, Bress AP, Na-Thalang K, et al. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy 2014.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90157 Version 10.0</div></div></div>"},"90159":{"type":"graphic_algorithm","displayName":"Diagnosis of chemical weapons exposure algorithm","title":"Algorithm for the clinical diagnosis of a chemical weapons exposure","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Algorithm for the clinical diagnosis of a chemical weapons exposure</div><div class=\"cntnt\"><img style=\"width:800px; height:567px;\" src=\"images/EM/90159_Diag_chem_weapon_expo_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Signs of upper airway (central compartment) irritation consistent with type I (eg, hydrogen chloride or hydrogen fluoride)&nbsp;or combination (eg, chlorine)&nbsp;pulmonary agent exposure.<br />¶ Signs of pulmonary edema (peripheral compartment) suggesting type II pulmonary agent exposure (eg, phosgene).<br />Δ For example, miosis, nausea, vomiting, diarrhea, bronchorrhea, sweating, twitching, fasciculations, weakness, and paralysis.<br /><FONT class=lozenge>◊</FONT> For example, dilated pupils, dry mouth, flushing, dry skin, tachycardia, delirium, hallucinations.<br />§ May also have flushed skin and normal or dilated pupils.</div><div id=\"graphicVersion\">Graphic 90159 Version 4.0</div></div></div>"},"90162":{"type":"graphic_figure","displayName":"Stages of cancer cachexia","title":"Stages of cancer cachexia","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Stages of cancer cachexia</div><div class=\"cntnt\"><img style=\"width:558px; height:290px;\" src=\"images/ONC/90162_Stage_cancer_cachexia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cachexia represents a spectrum through which not all patients will progress. At present there are no robust biomarkers to identify those precachectic patients who are likely to progress further or at the rate at which they will do so. Refractory cachexia is defined essentially on the basis of the patient's clinical characteristics and circumstances.</div><div class=\"graphic_footnotes\">BMI: body-mass index.</div><div class=\"graphic_reference\">Reproduced from: Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90162 Version 1.0</div></div></div>"},"90166":{"type":"graphic_picture","displayName":"Urticaria - Multiple images","title":"Urticaria - Multiple images","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria - Multiple images</div><div class=\"cntnt\"><img style=\"width:429px; height:620px;\" src=\"images/ALLRG/90166_Urticaria_multiple_images.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple images of urticaria are shown. Urticarial lesions may be rounded (F) or irregular (A) in shape and uniform or mixed (G) in morphology. Individual lesions may be small (H) or large (D). Urticaria are raised plaques, although they may appear flattened in patients taking antihistamines (C). Although lesions are consistently erythematous, this may be difficult to appreciate on darkly pigmented skin (I). Some urticaria show central clearing (E).</div><div class=\"graphic_reference\">Panel B courtesy of Andrew Samel, MD.<br />Panels C, F, G, and H reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.<br />Panel D courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.<br />Panel E reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.<br />Panel I reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90166 Version 5.0</div></div></div>"},"90172":{"type":"graphic_picture","displayName":"Diversion colitis","title":"Diversion colitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diversion colitis</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/GAST/90172_Diversion_colitis_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Edematous and friable rectal mucosa&nbsp;with areas with spontaneous hemorrhage.</div><div id=\"graphicVersion\">Graphic 90172 Version 1.0</div></div></div>"},"90173":{"type":"graphic_table","displayName":"Differentiated thyroid cancer monitoring during first year","title":"Differentiated thyroid cancer: Monitoring during the first year after thyroid surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiated thyroid cancer: Monitoring during the&nbsp;first year after thyroid surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Risk of recurrence</td> </tr> <tr> <td class=\"subtitle2\">Low</td> <td class=\"subtitle2\">Intermediate</td> <td class=\"subtitle2\">High</td> </tr> <tr> <td><strong>Non-stimulated&nbsp;Tg*</strong></td> <td> <p>Four to six weeks&nbsp;</p> <p>Three to six months</p> 9 to 12 months</td> <td> <p>Four to&nbsp;six weeks&nbsp;</p> <p>Three to six months</p> 9 to 12 months</td> <td> <p>Four to six weeks&nbsp;</p> <p>Three to six months</p> 9 to 12 months</td> </tr> <tr> <td><strong>Neck ultrasound</strong></td> <td>At 6 to 12 months</td> <td>At 6 to 12 months</td> <td>Every 6 to 12 months</td> </tr> <tr> <td><strong>Diagnostic WBS</strong></td> <td>Usually not indicated</td> <td>Case-specific</td> <td>Case-specific</td> </tr> <tr> <td><strong>MRI, CT</strong></td> <td>Not indicated</td> <td>Not indicated</td> <td>If Tg elevated or high clinical suspicion</td> </tr> <tr> <td><strong>FDG-PET</strong></td> <td>Not indicated</td> <td>Not indicated</td> <td>If Tg &#62;10 ng/mL</td> </tr> <tr> <td><strong>Serum TSH goal</strong></td> <td> <p> 0.1 to&nbsp;0.5 ng/mL if non-stimulated Tg detectable</p> 0.5 to 2.0 ng/mL if non-stimulated Tg undetectable</td> <td>0.1 to 0.5 ng/mL</td> <td>&#60;0.1 ng/mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; FDG-PET: fludeoxyglucose-positron emission tomography; MRI: magnetic resonance imaging; Tg: thyroglobulin; TSH: thyroid-stimulating hormone; WBS: whole-body scan.<br />*Stimulated Tg may be required to document excellent response to therapy unless the functional sensitivity of the Tg assay is &lt;0.2 ng/mL.</div><div class=\"graphic_reference\">Data from: Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</div><div id=\"graphicVersion\">Graphic 90173 Version 3.0</div></div></div>"},"90174":{"type":"graphic_table","displayName":"Adaptive skills defining intellectual disability","title":"Summary of adaptive skills used to define severity of intellectual disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of adaptive skills used to define severity of intellectual disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Skills</td> </tr> <tr> <td><strong>Conceptual domain</strong></td> <td>These skills include language, reading, and writing (literacy); money, time, and number concepts (mathematics); reasoning; memory; self-direction; and judgment in novel situations.</td> </tr> <tr> <td><strong>Social domain</strong></td> <td>These skills include interpersonal social communication, empathy, ability to relate to peers as friends and social problem-solving. Social responsibility, self-esteem, gullibility, the ability to follow rules and avoid being victimized may also be included.</td> </tr> <tr> <td><strong>Practical domain</strong></td> <td>These skills include activities of personal care or daily living, such as eating, dressing, mobility, and toileting. Further skills may include following a schedule or routine, using a telephone, managing money, preparing meals, occupational skills, and abilities in transportation/travel, health care, and safety.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A diagnosis of intellectual disabilty (ID) requires impaired functioning in intellectual functions (intelligence), AND impaired functioning in at least one of the domains of adaptive functioning listed above, which affects participation in multiple settings (eg, home, community, and/or school), and requires ongoing support. The severity of ID is defined according to the level of supports needed.</div><div class=\"graphic_reference\">Adapted from the following sources:<br /><ol>&#xD;&#xA;    <li>American Psychiatric Association. Intellectual Disability (Intellectual Developmental Disorder). In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association.</li>&#xD;&#xA;    <li>American Association of Intellectual and Developmental Disabilities (AAIDD), Definition of Intellectual Disability, available at: http://aaidd.org/intellectual-disability/definition (Accessed on July 11, 2013).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90174 Version 1.0</div></div></div>"},"90175":{"type":"graphic_table","displayName":"Diseases caused by loss-of-function mutations","title":"Diseases caused by \"loss-of-function\" mutations in receptor genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases caused by \"loss-of-function\" mutations in receptor genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Receptor</td> <td class=\"subtitle1\">Disease</td> </tr> <tr> <td>Arginine vasopressin receptor 2</td> <td>Nephrogenic diabetes insipidus</td> </tr> <tr> <td>Melanocortin 2 receptor</td> <td>Familial glucocorticoid deficiency type 1</td> </tr> <tr> <td>Luteinizing hormone receptor</td> <td>Familial hypogonadism</td> </tr> <tr> <td>Follicle-stimulating hormone receptor</td> <td>Infertility</td> </tr> <tr> <td>Gonadotropin-releasing hormone receptor</td> <td>Hypogonadism</td> </tr> <tr> <td>KISS1 and KISS1 receptor</td> <td>Hypogonadism</td> </tr> <tr> <td>NK3 receptor</td> <td>Hypogonadism</td> </tr> <tr> <td>Prokinectin receptor 2</td> <td>Hypogonadism</td> </tr> <tr> <td>Thyrotropin-releasing hormone receptor</td> <td>Hypothyroidism</td> </tr> <tr> <td>TSH receptor</td> <td>Euthyroid hyperthyroidism/central hypothyroidism</td> </tr> <tr> <td>Growth hormone-releasing hormone receptor</td> <td>Short stature (growth hormone deficiency)</td> </tr> <tr> <td>Ghrelin receptor</td> <td>Short stature</td> </tr> <tr> <td>Melanocortin 4 receptor</td> <td>Extreme obesity</td> </tr> <tr> <td>Parathyroid hormone and parathyroid-related protein receptors</td> <td>Chondrodysplasia</td> </tr> <tr> <td>Calcium-sensing receptor</td> <td>Benign familial hypocalciuric hypercalcemia/neonatal severe primary hyperparathyroidism</td> </tr> <tr> <td>Rhodopsins</td> <td>Retinal degeneration</td> </tr> <tr> <td>Thromboxane receptor</td> <td>Platelet dysfunction</td> </tr> <tr> <td>Frizzled/wnt</td> <td>Vitreoretinopathy</td> </tr> <tr> <td>Ocular albinism type 1</td> <td>Reduced visual acuity/hypopigmentation of retina</td> </tr> <tr> <td>Endothelin B receptor</td> <td>Hirschsprung disease</td> </tr> <tr> <td>N-formyl-peptide receptor</td> <td>Impaired chemotaxis</td> </tr> <tr> <td>&nbsp;Androgen receptor</td> <td>Complete androgen insensitivity syndrome<sup>[1]</sup></td> </tr> <tr> <td>&nbsp;ACTH</td> <td>Familial ACTH resistance<sup>[2]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; ACTH: corticotropin.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Hughes IA, Davies JD, Bunch TI, et al. Androgen insensitivity syndrome. Lancet 2012; 380:1419.</LI>&#xD;&#xA;<LI>Meimaridou E, Hughes CR, Kowalczyk J, et al. ACTH resistance: Genes and mechanism. Endocr Dev 2013; 24:57.</LI></OL>Modified from: Vassart G, Costagliola S. G protein-coupled receptors: Mutations and endocrine diseases. Nat Rev Endocrinol 2011; 7:362.</div><div id=\"graphicVersion\">Graphic 90175 Version 3.0</div></div></div>"},"90176":{"type":"graphic_table","displayName":"Diseases caused by gain-of-function mutations","title":"Diseases caused by \"gain-of-function\" mutations in receptor genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases caused by \"gain-of-function\" mutations in receptor genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Receptor</td> <td class=\"subtitle1\">Disease</td> </tr> <tr> <td>Arginine vasopressin receptor 2</td> <td>Inappropriate diuresis</td> </tr> <tr> <td>Luteinizing hormone receptor</td> <td>Male-limited precocious puberty</td> </tr> <tr> <td>Follicle-stimulating hormone receptor</td> <td>Spontaneous ovarian hyperstimulation syndrome</td> </tr> <tr> <td>TSH receptor</td> <td>Hyperthyroidism/thyroid adenomas</td> </tr> <tr> <td>KISS1 and KISS1&nbsp;receptor</td> <td>Precocious puberty</td> </tr> <tr> <td>Parathyroid hormone and parathyroid related protein receptors</td> <td>Metaphyseal chondrodysplasia</td> </tr> <tr> <td>Alpha-2A adrenergic receptor</td> <td>Type 2 diabetes mellitus</td> </tr> <tr> <td>Calcium-sensing receptor</td> <td>Hypoparathyroidism</td> </tr> <tr> <td>Rhodopsins</td> <td>Congenital night blindness</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div class=\"graphic_reference\">Modified from: Vassart G, Costagliola S. G protein-coupled receptors: Mutations and endocrine diseases. Nat Rev Endocrinol 2011; 7:362.</div><div id=\"graphicVersion\">Graphic 90176 Version 3.0</div></div></div>"},"90181":{"type":"graphic_picture","displayName":"Diversion pouchitis","title":"Diversion pouchitis","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Diversion pouchitis</div><div class=\"cntnt\"><img style=\"width:583px; height:442px;\" src=\"images/GAST/90181_Diversion_pouchitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diversion pouchitis with severe edema, friability, and hemorrhage of the pouch mucosa.</div><div id=\"graphicVersion\">Graphic 90181 Version 1.0</div></div></div>"},"90182":{"type":"graphic_table","displayName":"Differential diagnosis of opioid poorly responsive pain","title":"Differential diagnosis of opioid poorly responsive pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of opioid poorly responsive pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pain related to the underlying disease</td> </tr> <tr> <td class=\"indent1\">Cancer progression (eg, new fracture at site of known bone metastases)</td> </tr> <tr> <td class=\"indent1\">New onset of specific etiologies of pain (eg, neuropathic pain, skin ulceration, rectal tenesmus, myalgia) that are known to be less responsive to systemic opioids or opioid monotherapy</td> </tr> <tr> <td class=\"indent1\">Psychological/spiritual pain related to the experience of an end stage illness (existential pain of impending death)</td> </tr> <tr> <td class=\"subtitle1_single\">Opioid pharmacology/technical problems</td> </tr> <tr> <td class=\"indent1\">Opioid tolerance (eg, rapid dose escalation with no analgesic effect)</td> </tr> <tr> <td class=\"indent1\">Dose-limiting opioid toxicity (eg, sedation, delirium, hyperalgesia, nausea)</td> </tr> <tr> <td class=\"indent1\">Poor oral absorption (for oral medications) or skin absorption (eg, transdermal patch adhesive failure)</td> </tr> <tr> <td class=\"indent1\">Pump, needle, or catheter problems (intravenous, subcutaneous, or spinal opioids)</td> </tr> <tr> <td class=\"subtitle1_single\">Pain unrelated to the primary disease process</td> </tr> <tr> <td class=\"indent1\">Worsening of a preexisting noncancer pain syndrome (eg, diabetic neuropathy)</td> </tr> <tr> <td class=\"indent1\">New noncancer pain syndrome (eg, dental abscess)</td> </tr> <tr> <td class=\"subtitle1_single\">Other psychological problems</td> </tr> <tr> <td class=\"indent1\">Depression, anxiety, somatization, hypochondria, factitious disorders</td> </tr> <tr> <td class=\"indent1\">Dementia and delirium both can effect a patient's report of and experience of pain</td> </tr> <tr> <td class=\"indent1\">Opioid substance use disorders or opioid diversion</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Sacks T, Weissman DE, Arnold R. Opioid Poorly-Responsive Pain. Fast Facts and Concepts. May 2009; 215. Available at: <A spellcheck=true href=\"https://www.capc.org/fast-facts/215-opioid-poorly-responsive-cancer-pain/\" target=_blank>https://www.capc.org/fast-facts/215-opioid-poorly-responsive-cancer-pain/</A>. Copyright © 2009 EPERC.</div><div id=\"graphicVersion\">Graphic 90182 Version 3.0</div></div></div>"},"90183":{"type":"graphic_algorithm","displayName":"Approach to the child with suspected epiglottitis","title":"Approach to the child with suspected epiglottitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the child with suspected epiglottitis</div><div class=\"cntnt\"><img style=\"width:402px; height:256px;\" src=\"images/EM/90183_Appchildsusepiglottitis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Epiglottitis is more likely in un- or under-immunized children and those with drooling but no cough.</div><div class=\"graphic_reference\">Reproduced with permission from: Harper MB, Fleisher GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S (Eds), 6th edition, Lippincott Williams &amp; Wilkins, 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90183 Version 5.0</div></div></div>"},"90186":{"type":"graphic_table","displayName":"Characteristics and sources of common FODMAPs","title":"Characteristics and sources of common FODMAPs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics and sources of common FODMAPs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Word that corresponds to letter in acronym</td> <td class=\"subtitle1\">Compounds in this category</td> <td class=\"subtitle1\">Foods that contain these compounds</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>F</strong></td> <td colspan=\"3\"><strong>F</strong>ermentable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>O</strong></td> <td><strong>O</strong>ligosaccharides</td> <td>Fructans, galacto-oligosaccharides</td> <td>Wheat, barley, rye, onion, leek, white part of spring onion, garlic, shallots, artichokes, beetroot, fennel, peas, chicory, pistachio, cashews, legumes, lentils, and chickpeas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>D</strong></td> <td><strong>D</strong>isaccharides</td> <td>Lactose</td> <td>Milk, custard, ice cream, and yogurt</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>M</strong></td> <td><strong>M</strong>onosaccharides</td> <td>\"Free fructose\" (fructose in excess of glucose)</td> <td>Apples, pears, mangoes, cherries, watermelon, asparagus, sugar snap peas, honey, high-fructose corn syrup</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>A</strong></td> <td colspan=\"3\"><strong>A</strong>nd</td> </tr> <tr> <td class=\"centered\"><strong>P</strong></td> <td><strong>P</strong>olyols</td> <td>Sorbitol, mannitol, maltitol, and xylitol</td> <td>Apples, pears, apricots, cherries, nectarines, peaches, plums, watermelon, mushrooms, cauliflower, artificially sweetened chewing gum and confectionery</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FODMAPs: fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:707. Copyright © 2013. <A href=\"http://www.nature.com/ajg\" target=_blank>www.nature.com/ajg</A>.</div><div id=\"graphicVersion\">Graphic 90186 Version 2.0</div></div></div>"},"90188":{"type":"graphic_table","displayName":"Names for vasculitides from CHCC2012","title":"Names for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Names for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Large-vessel vasculitis</td> </tr> <tr> <td class=\"indent1\">Takayasu arteritis</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> </tr> <tr> <td class=\"subtitle1_single\">Medium-vessel vasculitis</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"subtitle1_single\">Small-vessel vasculitis</td> </tr> <tr> <td class=\"indent1\">ANCA-associated vasculitis</td> </tr> <tr> <td class=\"indent2\">Microscopic polyangiitis</td> </tr> <tr> <td class=\"indent2\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent2\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> <tr> <td class=\"indent1\">Immune complex small-vessel vasculitis</td> </tr> <tr> <td class=\"indent2\">Anti-glomerular basement membrane disease</td> </tr> <tr> <td class=\"indent2\">Cryoglobulinemic vasculitis</td> </tr> <tr> <td class=\"indent2\">IgA vasculitis (Henoch-Sch&#246;nlein)</td> </tr> <tr> <td class=\"indent2\">Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)</td> </tr> <tr> <td class=\"subtitle1_single\">Variable-vessel vasculitis</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et's&nbsp;syndrome</td> </tr> <tr> <td class=\"indent1\">Cogan's syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Single-organ vasculitis</td> </tr> <tr> <td class=\"indent1\">Cutaneous leukocytoclastic angiitis</td> </tr> <tr> <td class=\"indent1\">Cutaneous arteritis</td> </tr> <tr> <td class=\"indent1\">Primary central nervous system vasculitis</td> </tr> <tr> <td class=\"indent1\">Isolated aortitis</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis associated with systemic disease</td> </tr> <tr> <td class=\"indent1\">Lupus vasculitis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid vasculitis</td> </tr> <tr> <td class=\"indent1\">Sarcoid vasculitis</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitis associated with probable etiology</td> </tr> <tr> <td class=\"indent1\">Hepatitis C virus-associated cryoglobulinemic vasculitis</td> </tr> <tr> <td class=\"indent1\">Hepatitis B virus-associated vasculitis</td> </tr> <tr> <td class=\"indent1\">Syphilis-associated aortitis</td> </tr> <tr> <td class=\"indent1\">Drug-associated immune complex vasculitis</td> </tr> <tr> <td class=\"indent1\">Drug-associated ANCA-associated vasculitis</td> </tr> <tr> <td class=\"indent1\">Cancer-associated vasculitis</td> </tr> <tr> <td class=\"indent1\">Others</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANCA: antineutrophil cytoplasmic antibody; IgA: immunoglobulin A.</div><div class=\"graphic_reference\">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1. Reproduced with permission from John Wiley &amp; Sons, Inc. Copyright &copy; 2013 by the American College of Rheumatology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90188 Version 4.0</div></div></div>"},"90189":{"type":"graphic_table","displayName":"Definitions for vasculitides from CHCC2012","title":"Definitions for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (CHCC2012)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions for vasculitides adopted by the 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (CHCC2012)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CHCC2012 name</td> <td class=\"subtitle1\">CHCC2012 definition</td> </tr> <tr> <td><strong>Large-vessel vasculitis</strong></td> <td>Vasculitis affecting large arteries more often than other vasculitides. Large arteries are the aorta and its major branches. Any size artery may be affected.</td> </tr> <tr> <td class=\"indent1\">Takayasu arteritis (TAK)</td> <td>Arteritis, often granulomatous, predominantly affecting the aorta and/or its major branches. Onset usually in patients younger than 50 years.</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis (GCA)</td> <td>Arteritis, often granulomatous, usually affecting the aorta and/or its major branches, with a predilection for the branches of the carotid and vertebral arteries. Often involves the temporal artery. Onset usually in patients older than 50 years and often associated with polymyalgia rheumatica.</td> </tr> <tr> <td><strong>Medium-vessel vasculitis</strong></td> <td>Vasculitis predominantly affecting medium arteries defined as the main visceral arteries and their branches. Any size artery may be affected. Inflammatory aneurysms and stenoses are common.</td> </tr> <tr> <td class=\"indent1\">Polyarteritis nodosa (PAN)</td> <td>Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis in arterioles, capillaries, or venules, and not associated with antineutrophil cytoplasmic antibodies (ANCAs).</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease (KD)</td> <td>Arteritis associated with the mucocutaneous lymph node syndrome and predominantly affecting medium and small arteries. Coronary arteries are often involved. Aorta and large arteries may be involved. Usually occurs in infants and young children.</td> </tr> <tr> <td><strong>Small-vessel vasculitis</strong></td> <td>Vasculitis predominantly affecting small vessels, defined as small intraparenchymal arteries, arterioles, capillaries, and venules. Medium arteries and veins may be affected.</td> </tr> <tr> <td class=\"indent1\">ANCA-associated vasculitis (AAV)</td> <td>Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (ie, capillaries, venules, arterioles, and small arteries), associated with myeloperoxidase (MPO) ANCA or proteinase 3 (PR3) ANCA. Not all patients have ANCA. Add a prefix indicating ANCA reactivity, eg, MPO-ANCA, PR3-ANCA, ANCA-negative.</td> </tr> <tr> <td class=\"indent1\">Microscopic polyangiitis (MPA)</td> <td>Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (ie, capillaries, venules, or arterioles). Necrotizing arteritis involving small and medium arteries may be present. Necrotizing glomerulonephritis is very common. Pulmonary capillaritis often occurs. Granulomatous inflammation is absent.</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's) (GPA)</td> <td>Necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract, and necrotizing vasculitis affecting predominantly small to medium vessels (eg, capillaries, venules, arterioles, arteries and veins). Necrotizing glomerulonephritis is common.</td> </tr> <tr> <td class=\"indent1\">Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA)</td> <td>Eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis predominantly affecting small to medium vessels, and associated with asthma and eosinophilia. ANCA is more frequent when glomerulonephritis is present.</td> </tr> <tr> <td class=\"indent1\">Immune complex vasculitis</td> <td>Vasculitis with moderate to marked vessel-wall deposits of immunoglobulin and/or complement components predominantly affecting small vessels (ie, capillaries, venules, arterioles, and small arteries). Glomerulonephritis is frequent.</td> </tr> <tr> <td class=\"indent1\">Anti-glomerular basement membrane (anti-GBM) disease</td> <td>Vasculitis affecting glomerular capillaries, pulmonary capillaries, or both, with GBM deposition of anti-GBM autoantibodies. Lung involvement causes pulmonary hemorrhage, and renal involvement causes glomerulonephritis with necrosis and crescents.</td> </tr> <tr> <td class=\"indent1\">Cryoglobulinemic vasculitis (CV)</td> <td>Vasculitis with cryoglobulin immune deposits affecting small vessels (predominantly capillaries, venules, or arterioles) and associated with serum cryoglobulins. Skin, glomeruli, and peripheral nerves are often involved.</td> </tr> <tr> <td class=\"indent1\">IgA vasculitis (Henoch-Sch&#246;nlein) (IgAV)</td> <td>Vasculitis, with IgA1-dominant immune deposits, affecting small vessels (predominantly capillaries, venules, or arterioles). Often involves skin and gastrointestinal tract, and frequently causes arthritis. Glomerulonephritis indistinguishable from IgA nephropathy may occur.</td> </tr> <tr> <td class=\"indent1\">Hypocomplementemic urticarial vasculitis (HUV) (anti-C1q vasculitis)</td> <td>Vasculitis accompanied by urticaria and hypocomplementemia affecting small vessels (ie, capillaries, venules, or arterioles), and associated with anti-C1q antibodies. Glomerulonephritis, arthritis, obstructive pulmonary disease, and ocular inflammation are common.</td> </tr> <tr> <td><strong>Variable-vessel vasculitis</strong></td> <td>Vasculitis with no predominant type of vessel involved that can affect vessels of any size (small, medium, and large) and type (arteries, veins, and capillaries).</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et's&nbsp;syndrome</td> <td>Vasculitis occurring in patients with&nbsp;Beh&#231;et's&nbsp;syndrome that can affect arteries or veins.&nbsp;Beh&#231;et's&nbsp;syndrome is characterized by recurrent oral and/or genital aphthous ulcers accompanied by cutaneous, ocular, articular, gastrointestinal, and/or central nervous system inflammatory lesions. Small-vessel vasculitis, thromboangiitis, thrombosis, arteritis, and arterial aneurysms may occur.</td> </tr> <tr> <td class=\"indent1\">Cogan's syndrome</td> <td>Vasculitis occurring in patients with Cogan's syndrome.&nbsp;Cogan's syndrome&nbsp;is&nbsp;characterized by ocular inflammatory lesions, including interstitial keratitis, uveitis, and episcleritis, and inner ear disease, including sensorineural hearing loss and vestibular dysfunction. Vasculitic manifestations may include arteritis (affecting small, medium, or large arteries), aortitis, aortic aneurysms, and aortic and mitral valvulitis.</td> </tr> <tr> <td><strong>Single-organ vasculitis</strong></td> <td>Vasculitis in arteries or veins of any size in a single organ that has no features that indicate that it is a limited expression of a systemic vasculitis. The involved organ and vessel type should be included in the name (eg, cutaneous small-vessel vasculitis, testicular arteritis, central nervous system vasculitis). Vasculitis distribution may be unifocal or multifocal (diffuse) within an organ. Some patients originally diagnosed as having&nbsp;single-organ vasculitis&nbsp;will develop additional disease manifestations that warrant redefining the case as one of the systemic vasculitides (eg, cutaneous arteritis later becoming systemic polyarteritis nodosa, etc).</td> </tr> <tr> <td><strong>Vasculitis associated with systemic disease</strong></td> <td>Vasculitis that is associated with and may be secondary to (caused by) a systemic disease. The name (diagnosis) should have a prefix term specifying the systemic disease (eg, rheumatoid vasculitis, lupus vasculitis, etc).</td> </tr> <tr> <td><strong>Vasculitis associated with probable etiology</strong></td> <td>Vasculitis that is associated with a probable specific etiology. The name (diagnosis) should have a prefix term specifying the association (eg, hydralazine-associated microscopic polyangiitis, hepatitis B virus-associated vasculitis, hepatitis C virus-associated cryoglobulinemic vasculitis, etc).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1. Reproduced with permission from John Wiley &amp; Sons, Inc. Copyright &copy; 2013 by the American College of Rheumatology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90189 Version 5.0</div></div></div>"},"90194":{"type":"graphic_table","displayName":"Meds in pts with CLD or cirrhosis","title":"Medications (other than analgesics*) used in adult patients with advanced chronic liver disease or cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications (other than analgesics*) used in adult patients with advanced chronic liver disease or cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Altered response and pharmacokinetics</td> <td class=\"subtitle1\">Management suggestions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alcohol abstinence</td> </tr> <tr> <td class=\"indent1\">Baclofen</td> <td> <ul> <li>Limited hepatic metabolism. </li> <li>Preliminary safety data in cirrhosis are promising; however, efficacy is not well established. </li> </ul> </td> <td> <ul> <li>Total daily dose titrated to 30 to 60 mg, given in divided doses, has been tolerated by patients with cirrhosis. </li> <li>Refer to UpToDate topic review of ascites in adults with cirrhosis initial therapy, section on alcohol abstinence. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Disulfiram</td> <td> <ul> <li>Hepatically metabolized and subject to numerous drug interactions. </li> <li>Reports of fulminant hepatotoxicity. </li> </ul> </td> <td> <ul> <li>Avoid or use with extreme caution in cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anticonvulsants</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td> <ul> <li>Carbamazepine is a potent inducer of hepatic enzymes and has been associated with hepatotoxicity and serious allergic reactions in genetically predisposed individuals. </li> <li>May precipitate decompensation in patents with cirrhosis. </li> </ul> </td> <td> <ul> <li>In general, carbamazepine should be avoided as there are safer options for management of seizures in patients with advanced CLD or cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lamotrigine</td> <td> <ul> <li>Half-life is increased up to threefold in moderate to severe hepatic impairment. </li> </ul> </td> <td> <ul> <li>No adjustment required for mild impairment. </li> <li>Reduce dose by 25% for moderate to severe hepatic impairment without ascites. </li> <li>Reduce dose by 50% for moderate to severe impairment with ascites. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Levetiracetam</td> <td> <ul> <li>PK unaltered in liver disease in patients with adequate renal function (Crcl &#8805;60 mL/minute). </li> <li>Drug accumulation may occur in patients with renal insufficiency and advanced cirrhosis. </li> </ul> </td> <td> <ul> <li>No adjustment required for compensated cirrhosis. </li> <li>Reduce dose by approximately 50% in patients with advanced CLD and renal insufficiency (Crcl &#60;60 mL/minute). </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Oxcarbazepine</td> <td> <ul> <li>PK seems to be unaltered in mild to moderate hepatic impairment with adequate renal function (Crcl &#8805;30 mL/minute). </li> </ul> </td> <td> <ul> <li>No specific adjustment recommended for compensated cirrhosis with mild to moderate hepatic impairment. </li> <li>Use in severe hepatic impairment or decompensated disease is not recommended as data are lacking. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td> <ul> <li>Extensively metabolized in liver and a potent inducer of hepatic CYP enzymes. </li> <li>Highly bound to serum albumin; hypoalbuminemic patients with advanced CLD or cirrhosis generally require lower <strong>total</strong> plasma concentrations for seizure control relative to healthy individuals. </li> </ul> </td> <td> <ul> <li>In general, phenytoin should be avoided in patients with cirrhosis. </li> <li>In the absence of other effective options for control of seizures, use cautiously in compensated cirrhosis. </li> <li>Avoid in patients who are actively using alcohol. </li> <li>Free phenytoin levels may be useful for monitoring serum concentrations. </li> <li>Refer to UpToDate topic review on pharmacology of antiepileptic drugs. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Topiramate</td> <td> <ul> <li>Topiramate clearance can be reduced in patients with advanced CLD or cirrhosis who are also receiving enzyme-inducing antiepileptic drugs and/or with renal insufficiency (Crcl &#60;70 mL/minute). </li> <li>Metabolic acidosis is a frequent adverse effect of topiramate treatment. Refer to UpToDate topic review on pharmacology of antiepileptic drugs. </li> </ul> </td> <td> <ul> <li>Topiramate dose adjustment may be needed in patients with advanced CLD or cirrhosis receiving enzyme inducing antiepileptic drugs and/or renal impairment. </li> <li>Drug interactions between topiramate and enzyme-inducing antiepileptic drugs may be intensified in hepatic impairment. </li> <li>Serum concentration monitoring may be useful. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Valproate (valproic acid)</td> <td> <ul> <li>Extensively metabolized in liver and highly bound to serum albumin. </li> <li>Drug accumulation and toxicity has been observed in valproate treated patients with advanced CLD or cirrhosis. </li> <li>Valproate associated hyperammonemia may complicate management of HE. </li> </ul> </td> <td> <ul> <li>Valproate should generally be avoided in advanced CLD or cirrhosis. </li> <li>Use is contraindicated in severe hepatic impairment. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidepressants</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> <td> <ul> <li>Reduced clearance and prolonged half-life in alcoholics and in patients with severe hepatic impairment. </li> </ul> </td> <td> <ul> <li>Do not exceed 75 mg per day (immediate release), 100 mg per day (sustained release), or 150 mg every other day (extended release) in patients with early or moderate compensated cirrhosis. </li> <li>Avoid in severe or decompensated cirrhosis and in patients at risk for seizures. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td> <ul> <li>Extensively metabolized in liver by CYPs 2C19 and 3A4. </li> <li>Exposure (plasma concentration versus time curve) increased twofold in setting of cirrhosis. </li> <li>Patients with cirrhosis, particularly if there is a TIPS or surgical shunt present, may be at elevated risk of developing potentially fatal ventricular arrhythmias due to QT prolongation. </li> </ul> </td> <td> <ul> <li>Do not exceed 20 mg daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Desvenlafaxine</td> <td> <ul> <li>Metabolized in liver primarily by UGT glucuronidation. </li> <li>PK unaltered in mild hepatic impairment. </li> </ul> </td> <td> <ul> <li>Initiate at 50 mg daily. Do not exceed 100 mg daily. </li> <li>Avoid in decompensated cirrhosis, cirrhosis with renal failure, and in patients at risk for seizures. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td> <ul> <li>85% reduction in clearance and three- to fivefold increase in half-life and exposure (plasma concentration versus time curve) in moderate cirrhosis. </li> </ul> </td> <td> <ul> <li>Alcohol abuse or CLD may be risk factors in duloxetine associated hepatotoxicity. </li> <li>Use should be avoided in hepatic impairment. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td> <ul> <li>Extensively metabolized in liver by CYPs 2C19 and 3A4. </li> <li>Clearance reduced by 37%, half-life increased approximately twofold in setting of cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate at a low dose (5 mg daily) for first two weeks or more. </li> <li>Do not exceed 10 mg daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td> <ul> <li>Reduced clearance. </li> <li>Half-life of active metabolite may exceed 12 days in cirrhosis. </li> <li>New steady-state concentrations may not be reached until two or more months following a dose adjustment. </li> </ul> </td> <td> <ul> <li>Reduce dose or frequency in cirrhosis by 50%. </li> <li>Initiate at a low dose (eg, 5 or 10 mg daily) and titrate gradually to prevent accumulation. </li> <li>Do not exceed 20 to 40 mg daily in mild hepatic impairment. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td> <ul> <li>Extensively metabolized in liver by CYP2D6 and undergoes first-pass extraction. </li> <li>Oral bioavailability is increased and half-life prolonged to 22 to 26 hours in setting of cirrhosis. </li> </ul> </td> <td> <ul> <li>Reduce dose by 50%. </li> <li>Initiate at a low dose (eg, 25 mg daily) and titrate gradually to prevent accumulation. </li> <li>Do not exceed 100 mg daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mirtazapine</td> <td> <ul> <li>Half-life increased by 40% and exposure (plasma concentration versus time curve) increased approximately 55% in mild to moderate hepatic impairment. </li> </ul> </td> <td> <ul> <li>Do not exceed 30 mg per day. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td> <ul> <li>Extensively metabolized in liver by CYP2D6 and undergoes first-pass extraction. </li> <li>Half-life prolonged and exposure (plasma concentration versus time curve) increased approximately twofold in advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate at 10 mg daily and titrate gradually. </li> <li>Do not exceed 40 mg daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td> <ul> <li>Extensively metabolized in liver by CYP2D6 and undergoes first-pass extraction. </li> <li>Half-life prolonged by 2.5-fold and exposure (plasma concentration versus time curve) increased by up to fourfold in advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate at 25 mg daily and titrate gradually to prevent accumulation. </li> <li>Do not exceed 100 mg daily. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venlafaxine</td> <td> <ul> <li>Extensively metabolized in liver by CYP2D6 and undergoes first-pass hepatic extraction. </li> <li>Wide inter-individual PK variability seen in patients with cirrhosis. </li> <li>Oral bioavailability is increased by two- to threefold in patients with mild to moderate hepatic impairment. </li> <li>Half-life of venlafaxine and its active metabolites is prolonged by up to 1.4-fold in mild to moderate hepatic impairment. </li> </ul> </td> <td> <ul> <li>Initiate at a low dose (eg, 37.5 to 75 mg daily) and titrate gradually to prevent accumulation. Do not exceed 150 mg daily. </li> <li>Avoid in decompensated cirrhosis, cirrhosis with renal failure, and in patients at risk for seizures. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipsychotics</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td> <ul> <li>Complex hepatic metabolism includes CYP3A4 and 2D6 transformations and active metabolites. </li> <li>Consistent alteration of PK in hepatic impairment has not been identified. </li> <li>Patients with cirrhosis, particularly if there is a TIPS or surgical shunt present, may be at elevated risk of developing potentially fatal ventricular arrhythmias due to QT prolongation. </li> </ul> </td> <td> <ul> <li>No specific dose adjustment. </li> <li>Avoid with active alcohol consumption. </li> <li>Avoid or use caution with alcohol withdrawal syndrome due to risk of seizures. </li> <li>Preferable to benzodiazepines in patients with HE. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> <td> <ul> <li>Undergoes extensive metabolism in liver by CYPs 1A2 and 2D6. </li> <li>Half-life is expected to be increased in advanced hepatic impairment. </li> </ul> </td> <td> <ul> <li>In advanced hepatic impairment initiate orally at 5 mg daily and escalate dose, if needed, more gradually. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Quetiapine</td> <td> <ul> <li>Undergoes extensive metabolism in liver by CYP3A4. </li> <li>Half-life is expected to be increased in advanced hepatic impairment. </li> </ul> </td> <td> <ul> <li>Initiate orally at 25 mg daily (immediate release) and titrate in low increments (eg, 25 to 50 mg daily) according to response. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anti-infectives<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Antifungals</td> </tr> <tr> <td class=\"indent3\">Azoles</td> <td> <ul> <li>Azole antifungals are variably metabolized in liver, and all have been associated with hepatic function abnormalities. </li> <li>Ketoconazole, itraconazole, voriconazole, and posaconazole have potent inhibitory effects on hepatic CYP metabolism. </li> </ul> </td> <td> <ul> <li>Use azoles with caution in advanced CLD or cirrhosis. </li> <li>Maintenance dose reduction and serum level monitoring are recommended for voriconazole. </li> <li>Dose of fluconazole should be adjusted in advanced CLD or cirrhosis with renal insufficiency. </li> <li>Avoid ketoconazole in patients with CLD. </li> <li>Refer to UpToDate topic review of pharmacology of azole antifungals. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Echinocandins</td> <td> <ul> <li>Caspofungin and micafungin undergo hepatic metabolism. </li> <li>Anidulafungin is not hepatically metabolized; alteration of PK due to CLD or renal insufficiency is not expected. </li> <li>Modest asymptomatic increases in hepatic transaminases occur in approximately 10% of echinocandin-treated patients without CLD. </li> </ul> </td> <td> <ul> <li>Caspofungin requires dose adjustment in moderate CLD. </li> <li>A specific dose adjustment recommendation for caspofungin is not available for advanced CLD or cirrhosis. </li> <li>Regular monitoring of hepatic transaminases is suggested during echinocandin treatment. </li> <li>Refer to UpToDate topic on pharmacology of echinocandins. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Antimicrobials</td> <td colspan=\"2\"> <ul> <li>Hydrophilic antimicrobials (ie, aminoglycosides, beta-lactams, daptomycin, vancomycin) tend to exhibit increased Vd in patients with advanced CLD or cirrhosis with ascites or hypoalbuminemia. Loading dose(s) and monitoring of blood concentrations where available should be considered for treating seriously ill patients. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Beta-lactams, carbapenems</td> <td> <ul> <li>Beta-lactam-associated leukopenia may complicate impaired reticular endothelial cell function in advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Monitor for beta-lactam-associated leukopenia. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Fluoroquinolones</td> <td> <ul> <li>Norfloxacin, ciprofloxacin, and levofloxacin are eliminated renally and do not undergo extensive hepatic metabolism. Levofloxacin distributes in ascitic fluid, but less extensively than cefotaxime. </li> <li>Patients with cirrhosis, particularly if there is a TIPS or surgical shunt present, may be at elevated risk of developing potentially fatal ventricular arrhythmias due to QT prolongation. </li> </ul> </td> <td> <ul> <li>Norfloxacin, levofloxacin, and ciprofloxacin dose should be adjusted for advanced CLD or cirrhosis with renal impairment. Refer to Lexicomp monographs. </li> <li>Use caution in patients with prolonged QT intervals. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Macrolides</td> <td> <ul> <li>Extensively metabolized in liver. </li> <li>Erythromycin estolate (not available in United States) may cause cholestasis in CLD. </li> <li>Certain macrolides can increase QTc interval. </li> </ul> </td> <td> <ul> <li>Use clarithromycin with caution in advanced CLD or cirrhosis. </li> <li>Avoid erythromycin estolate. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Metronidazole</td> <td> <ul> <li>Metabolized in liver, reduced clearance and prolonged half-life (18 to 21 hours) in advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Increase interval to every 12 hours in patients with advanced CLD or cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Tetracyclines</td> <td> <ul> <li>Tetracyclines are metabolized in liver and half-life may be prolonged in advanced CLD and cirrhosis. </li> </ul> </td> <td> <ul> <li>Reduced dose should be considered in compensated disease. </li> <li>Use caution in advanced CLD or cirrhosis. </li> <li>In general, avoid tetracyclines in decompensated cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Tigecycline</td> <td> <ul> <li>Tigecycline is eliminated largely by biliary excretion and does not undergo extensive metabolism in the liver. </li> </ul> </td> <td> <ul> <li>Dose of tigecycline should be adjusted in severe hepatic impairment. Refer to Lexicomp monograph. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td> <ul> <li>Renally excreted. </li> <li>PK appears unaltered in mild to moderate hepatic impairment. </li> </ul> </td> <td> <ul> <li>No dose adjustment recommended for CLD or cirrhosis with mild to moderate hepatic impairment. </li> <li>Reduce dose in renal insufficiency. </li> <li>Use should be avoided in severe hepatic impairment and decompensated disease according to the licensed product information. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Antituberculosis drugs (isoniazid, pyrazinamide, rifampin)</td> <td> <ul> <li>Isoniazid may accumulate in advanced CLD and cirrhosis. </li> <li>Rifampin is eliminated in bile and can potentially worsen jaundice in patients with cirrhosis due to competitive excretory inhibition. </li> <li>Increased risk of DILI. </li> </ul> </td> <td> <ul> <li>Closely monitor and consider dose reduction. </li> <li>Refer to UpToDate topic on treatment of pulmonary tuberculosis in HIV-negative patients. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hepatitis B antivirals (adefovir, entecavir, lamivudine, tenofovir)</td> <td> <ul> <li>Minor or no hepatic metabolism. </li> <li>PK unaltered in CLD. </li> <li>Safely used in decompensated cirrhosis when treatment indicated. </li> </ul> </td> <td> <ul> <li>No dose adjustment necessary in CLD or cirrhosis. </li> <li>Dose reductions needed for renal impairment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">HIV antiretrovirals</td> <td colspan=\"2\"> <ul> <li>Management of HIV antiretroviral therapy in patients with hepatic impairment is reviewed separately. Refer to UpToDate topic on dose modification of antiretroviral agents in adults with renal or hepatic dysfunction and separate table in UpToDate on antiretroviral dosing recommendations in patients with renal or hepatic insufficiency. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antidiabetic</td> </tr> <tr> <td class=\"indent1\">Insulins</td> <td> <ul> <li>Insulins are frequently used for treatment of diabetes with CLD. </li> </ul> </td> <td> <ul> <li>Insulins are dosed based upon effect with close blood glucose monitoring. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Metformin</td> <td> <ul> <li>Used safely in advanced CLD and compensated cirrhosis. </li> <li>Beneficial in treatment of diabetes with various forms of CLD including NAFLD. </li> </ul> </td> <td> <ul> <li>In general, a good choice for most diabetic patients with mild to moderate CLD and compensated cirrhosis. </li> <li>Dose metformin based on response. </li> <li>Metformin should be avoided in patients who consume excessive alcohol or with renal insufficiency or advanced CLD or cirrhosis due to risk of lactic acidosis, a rare but potentially fatal complication of metformin treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfonylureas and meglitinides</td> <td> <ul> <li>Sulfonylureas (eg, glipizide) are frequently prescribed to patients with diabetes and CLD. </li> <li>Sulfonylureas and meglitinides (eg, repaglinide, nateglinide) are hepatically metabolized, and increased concentrations in cirrhosis are expected, but specific data are lacking. </li> </ul> </td> <td> <ul> <li>Sulfonylureas and meglitinides are generally safe in mild to moderate CLD and compensated cirrhosis using lowest initial dose, gradual titration based on close monitoring, and a reduced maintenance dose. </li> <li>Low-dose gliclazide (not available in United States), repaglinide, and nateglinide may be reasonable choices due to shorter duration of action and less risk of hypoglycemia observed in general diabetic population. </li> <li>Sulfonylureas should be avoided or used cautiously in older adults with cirrhosis and in patients with renal insufficiency and advanced cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Antiarrhythmics</td> <td> <ul> <li>Hepatic impairment decreases the elimination of many antiarrhythmics. </li> </ul> </td> <td> <ul> <li>Dose reductions are usually required. </li> <li>Refer to Lexicomp individual drug monographs. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Amiodarone</td> <td> <ul> <li>Amiodarone is highly tissue- and protein-bound, undergoes extensive hepatic metabolism by various CYPs including 3A4 and 2C8, and is excreted fecally via bile. </li> <li>Its extremely long half-life of 25 to 100 days is expected to be further prolonged in hepatic impairment. </li> </ul> </td> <td> <ul> <li>Dose reduction is expected to be necessary in hepatic impairment and cirrhosis. </li> <li>No specific recommendation is available. </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Antihypertensives</td> </tr> <tr> <td class=\"indent3\">ACE inhibitors</td> <td> <ul> <li>ACE inhibitors are generally well tolerated. </li> <li>Minor PK differences in cirrhosis include increased drug bioavailability (ie, lisinopril) or slowed conversion to active drug form (ie, enalapril), but do not translate to a markedly altered response. </li> <li>ACE inhibitors do not adequately decrease portal venous pressure to protect against variceal bleeding. </li> </ul> </td> <td> <ul> <li>No dose adjustment of ACE inhibitors required in advanced CLD or compensated cirrhosis. </li> <li>Non-prodrugs (eg, lisinopril) preferred to prodrugs (eg, quinapril, enalapril). </li> <li>If combined with diuretic, use cautiously and in reduced doses. </li> <li>Consider discontinuing ACE inhibitors in patients who develop diuretic resistant ascites. Refer to UpToDate topic reviews of managing ascites. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Beta-blockers</td> <td> <ul> <li>PK characteristics and metabolism of individual beta-blockers vary. </li> <li>Propranolol and metoprolol have increased oral bioavailability in advanced CLD and cirrhosis due to high first-pass extraction and protein binding. </li> <li>Carvedilol is extensively metabolized by CYP, whereas nadolol and sotalol are not. </li> <li>Decreased therapeutic effect of beta-adrenergic blockade therapy may be observed in setting of advanced CLD and decompensated cirrhosis. </li> <li>Labetalol use has been associated with hepatoxicity. </li> </ul> </td> <td> <ul> <li>Start at low dose and titrate based upon clinical response. </li> <li>Carvedilol dose should be reduced by up to 80%. </li> <li>Nadolol and sotalol are not hepatically metabolized. Dose adjustment needed for renal impairment. </li> <li>Nadolol and propranolol can be used for treatment of portal hypertension and the prevention of variceal hemorrhage. Refer to UpToDate topic reviews of prophylaxis against variceal hemorrhage. </li> <li>Discontinuation of beta-blockers may be necessary in patients who develop diuretic resistant ascites. Refer to UpToDate topic reviews of managing ascites. </li> <li>Labetalol is generally avoided in treatment of patients with cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Calcium channel blockers</td> <td> <ul> <li>Diltiazem oral bioavailability is increased, and half-life of oral and IV are prolonged by up to 50%. </li> <li>Oral bioavailability of verapamil is doubled, and half-life of oral and IV are prolonged by fourfold. </li> <li>Amlodipine is highly protein-bound and undergoes extensive hepatic metabolism via CYP3A4. Half-life is expected to be prolonged (&#8805;56 hours) in hepatic impairment. </li> </ul> </td> <td> <ul> <li>Start oral diltiazem at low dose and titrate gradually based on response. </li> <li>Reduce verapamil dose by approximately 50%. </li> <li>Initiate amlodipine at lowest dose (eg, 2.5 to 5 mg) and titrate at intervals of no less than 10 to 14 days based upon response. </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Diuretics</td> </tr> <tr> <td class=\"indent3\">Furosemide, torsemide, bumetanide</td> <td> <ul> <li>Reduced natriuretic potency depending on disease severity. </li> <li>Increased sensitivity to hypokalemia and volume depletion. </li> </ul> </td> <td> <ul> <li>Furosemide is usually given orally and gradually titrated to effect. </li> <li>Combination of furosemide with spironolactone can mitigate loop-diuretic-associated hypokalemia and improve diuresis in treatment of ascites. </li> <li>Refer to UpToDate topic on initial therapy of ascites in adults with cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Spironolactone</td> <td> <ul> <li>Extensively metabolized in liver. </li> <li>Several active metabolites with prolonged half-life in cirrhosis permit once-daily dosing and, in some patients, alternate-day dosing. </li> <li>In combination with furosemide, counteracts hypokalemia and improves diuresis in treatment of ascites. </li> </ul> </td> <td> <ul> <li>Spironolactone 100 mg per day in combination with <strong>oral</strong> furosemide 40 mg per day is suggested for initial treatment of ascites. </li> <li>Spironolactone and furosemide are titrated gradually based upon response using a ratio of 100 mg spironolactone to 40 mg furosemide. </li> <li>Refer to UpToDate topic on initial therapy of ascites in adults with cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent3\">Triamterene</td> <td> <ul> <li>Triamterene clearance decreased. </li> <li>Diuretic effect relatively unchanged in compensated disease. </li> </ul> </td> <td> <ul> <li>Lower starting doses and less frequent dosing depending on severity of CLD. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Nitrates</td> <td> <ul> <li>Most nitrates undergo non-CYP hepatic and extrahepatic metabolism. </li> <li>Orally administered isosorbide dinitrate undergoes first-pass hepatic extraction; bioavailability may be increased in advanced CLD or cirrhosis. </li> <li>Patients with advanced CLD or cirrhosis may have a more pronounced response to nitrates, including nitrate-associated adverse effects (eg, hypotension, bradycardia). </li> </ul> </td> <td> <ul> <li>No specific dose adjustment available. </li> <li>Dose should be titrated based upon clinical response. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ranolazine</td> <td> <ul> <li>Ranolazine undergoes complex hepatic CYP3A and extrahepatic metabolism; concentrations are significantly elevated in moderate to severe hepatic impairment. </li> <li>Patients with cirrhosis, particularly if there is a TIPS or surgical shunt present, may be at elevated risk of developing potentially fatal ventricular arrhythmias due to QT prolongation. </li> </ul> </td> <td> <ul> <li>Use of ranolazine in patients with cirrhosis and any degree of hepatic impairment is contraindicated according to the licensed product information. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Statins</td> <td> <ul> <li>Statins are generally well tolerated in patients with compensated cirrhosis and have established CVD benefits in treatment of patients with NAFLD, viral hepatitis, and primary biliary cirrhosis. </li> <li>Most statins are subject to high first-pass extraction and/or are highly bound to plasma proteins, which can increase blood concentrations in patients with hepatic impairment. </li> <li>Pravastatin does not undergo CYP metabolism; its clearance is largely dependent upon renal function. </li> <li>Safety data are reassuring among pravastatin-treated patients with compensated non-cholestatic CLD. </li> <li>A pronounced hypolipidemic response in relation to dose may be evidence of statin accumulation. </li> </ul> </td> <td> <ul> <li>Initiate statin treatment at lowest daily dose (eg, pravastatin 10 mg) and titrate gradually based upon hypolipidemic response. </li> <li>While no longer recommended in the general population, ALT monitoring is reasonable for statin treatment of patients with cirrhosis. </li> <li>Avoid statins with decompensated disease or significant cholestasis. </li> <li>Refer to UpToDate topic review of statin actions, side effects, and administration. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Proton pump inhibitors</td> <td> <ul> <li>Proton pump inhibitors appear to be a potential risk factor for SBP, <em>C. difficile</em>, and other serious infections in patients with cirrhosis. </li> <li>Proton pump inhibitors appear to be a potential risk factor for hepatic encephalopathy. </li> </ul> </td> <td> <ul> <li>Acid-suppressive medications should only be given to patients who have clear indications for their use. </li> <li>Refer to UpToDate topics on overview of the use of proton pump inhibitors for the treatment of acid-related disorders and on treatment and prophylaxis of spontaneous bacterial peritonitis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Herbal medicines and supplements</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td> <ul> <li>A variety of herbal medicines and supplements may be used by patients with cirrhosis (eg, silymarin [milk thistle]). </li> <li>Herbs and supplements may contain undisclosed ingredients and contaminants, including prescription medications that may be hepatotoxic or interact with other medications (eg, St. John's wort). </li> </ul> </td> <td> <ul> <li>It is important for the clinician to ask patients with CLD or cirrhosis about herbal medicines and supplements. </li> <li>For information on silymarin (milk thistle), refer to UpToDate topic review of investigational therapies for hepatitis C virus infection. </li> <li>Additional information is found in UpToDate topic review of hepatoxicity due to herbal medications and supplements. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hypnotics and sedatives</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td> <ul> <li>Extensive metabolism in liver by CYP to active metabolites. </li> <li>Clearance decreased by 50%. </li> <li>Half-life of drug and active metabolites prolonged two- to fivefold (ie, up to 500 hours). </li> </ul> </td> <td> <ul> <li>No adjustment needed for initial dose. </li> <li>Risk of accumulation and over-sedation with repeated doses. </li> <li>Reduce maintenance dose and frequency by up to 50% or consider another sedative option. </li> <li>Prolonged effect might be useful for patients being treated for alcohol withdrawal or seizures. </li> <li>Avoid in patients with HE. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td> <ul> <li>Undergoes metabolism by glucuronidation, which is relatively preserved in mild to moderate hepatic insufficiency. </li> </ul> </td> <td> <ul> <li>Generally a good choice when benzodiazepine treatment indicated. </li> <li>No specific dose adjustment; titrate gradually due to prolonged onset. </li> <li>With prolonged use or use as a continuous infusion risk of drug accumulation and oversedation. </li> <li>Avoid in patients with HE. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td> <ul> <li>Extensively metabolized in the liver by CYP3A4 and, when administered orally, undergoes first-pass hepatic extraction. </li> <li>Half-life of drug and active metabolite are increased in hepatic impairment. </li> </ul> </td> <td> <ul> <li>Oral preparation should be avoided in patients with advanced CLD or cirrhosis due to unpredictable bioavailability. </li> <li>For IV use, no specific dose adjustment; once adequately sedated using small incremental doses, a reduced maintenance dose and frequency may be needed to avoid accumulation and oversedation of patients with advanced CLD or cirrhosis. </li> <li>Avoid in patients with HE. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zolpidem</td> <td> <ul> <li>Half-life prolonged twofold in moderate hepatic impairment and fourfold or more in advanced CLD. </li> </ul> </td> <td> <ul> <li>Use lowest possible dose in patients with mild to moderate hepatic impairment. </li> <li>Immediate release preparation may be broken to provide 2.5 mg dose. </li> <li>Avoid use in advanced CLD; may precipitate or worsen HE. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioid use disorder (opioid addiction) treatment</td> </tr> <tr> <td class=\"indent1\">Buprenorphine-naloxone</td> <td> <ul> <li>Buccally and sublingually administered naloxone, which is included in this combination to deter abuse (ie, crushing, snorting, injecting), is systemically absorbed in patients with moderate to severe hepatic impairment. </li> <li>Absorption of naloxone can reverse effect of buprenorphine and precipitate an opioid withdrawal syndrome. </li> </ul> </td> <td> <ul> <li>Buprenorphine-naloxone combination is not recommended in patients with advanced CLD or cirrhosis due to increased bioavailability of naloxone. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This is not a complete list of cautionary information and dose adjustments for use of medications by patients with hepatic impairment. Refer to the Lexicomp individual drug monographs included with UpToDate for additional information. Patients with cirrhosis seem to be at increased risk of adverse outcomes due to drug-drug interactions and drugs that cause QTc prolongation, particularly in the setting of advanced or decompensated disease and in those who have undergone TIPS or surgical shunts. Refer to topic on acquired long QT syndrome for details.<br />Separate calculators are available in UpToDate for determination of Child Pugh classification for severity of cirrhosis based upon patient clinical and laboratory data (conventional or SI units). &#xD;&#xA;<UL>&#xD;&#xA;<LI>Most drugs used in the treatment of frequently encountered chronic diseases and infections can be used safely in patients with chronic liver disease or compensated cirrhosis.</LI>&#xD;&#xA;<LI>Often, a reduced dose, frequency of administration, or avoidance of certain medications is recommended in the setting of advanced CLD or cirrhosis based upon changes in drug disposition (eg, increased oral bioavailability, decreased metabolism or protein binding), altered toxicity, or due to risk of precipitating cirrhosis-associated complications (ie, avoidance of drugs or regimens that can cause GI bleeding, SBP, HE, or renal failure).</LI></UL></div><div class=\"graphic_footnotes\">CLD: chronic liver disease; Crcl: creatinine clearance; CVD: cardiovascular disease; CYP: cytochrome P-450; DILI: drug-induced liver injury; GI: gastrointestinal; HE: hepatic encephalopathy; NAFLD: nonalcoholic fatty liver disease; SBP: spontaneous bacterial peritonitis; TIPS: transjugular intrahepatic portosystemic shunts; Vd: volume of distribution; PK: pharmacokinetics; UGT: uridine 5'-diphospho-glucuronosyltransferase hepatic metabolism.<br />* Refer to UpToDate topic review of management of pain in patients with cirrhosis including a separate table on analgesics use in adult patients with advanced chronic liver disease or cirrhosis.<br />&para; NOTE: The following are antibiotics and antifungals not listed in the table above that should be used with caution in advanced CLD or cirrhosis: chloramphenicol, griseofulvin, nalidixic acid, nitrofurantoin (chronic use), and telithromycin.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lewis JH, Stine JG. Review article: Prescribing medications in patients with cirrhosis &ndash; a practical guide. Aliment Pharmacol Ther 2013; 37:1132.</li>&#xD;&#xA;    <li>Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147.</li>&#xD;&#xA;    <li>Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46:985.</li>&#xD;&#xA;    <li>Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010; 85:349.</li>&#xD;&#xA;    <li>Mauri CM, Fiorentini SP, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet 2014; 53:1069.</li>&#xD;&#xA;    <li>Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017; 152:134.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90194 Version 9.0</div></div></div>"},"90196":{"type":"graphic_table","displayName":"Analgesics in pts with CLD or cirrhosis","title":"Analgesic use in adult patients with advanced chronic liver disease or cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Analgesic use in adult patients with advanced chronic liver disease or cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Altered response and pharmacokinetics</td> <td class=\"subtitle1\">Management suggestions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Non-opioid analgesics</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (paracetamol)</td> <td> <ul> <li>Glutathione tissue stores needed to block formation of acetaminophen's toxic metabolite (NAPQI) are reduced in individuals with cirrhosis or malnutrition, thereby lowering the dose threshold of acetaminophen that can be safely administered each day. </li> <li>Active alcohol consumption further reduces available glutathione stores. </li> <li>Half-life of acetaminophen may be prolonged by up to twofold compared with healthy patients. </li> </ul> </td> <td> <ul> <li>Acetaminophen is generally well tolerated in patients with CLD or cirrhosis who do not consume alcohol, provided the total daily dose is limited to no more than 2 g/day. </li> <li>For short-term or one-time use, a maximum total acetaminophen dose of up to 3 g/day may be considered in lower risk patients (eg, do not consume alcohol) with CLD or early-stage compensated cirrhosis. </li> <li>Warn patients concerning acetaminophen content in combination prescription analgesics (eg, oxycodone-acetaminophen) and non-prescription (OTC) preparations. </li> <li>Avoid use in patients with advanced CLD or cirrhosis who are actively consuming alcohol, malnourished, not eating, receiving multiple medications that undergo hepatic biotransformations, or any co-administered medication that is a potent inducer of hepatic enzymes. </li> <li>A list of medications that induce hepatic enzymes is provided in a separate table. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin</td> <td> <ul> <li>NSAIDs can decrease GFR and impair renal function in patients with advanced CLD or cirrhosis. </li> <li>Most NSAIDs are metabolized by CYP and highly bound to serum albumin, increasing drug bioavailability and potential for toxicity in patients with advanced CLD or cirrhosis. </li> <li>An increased risk of GI mucosal bleeding, variceal hemorrhage, impaired renal function, and development of diuretic-resistant ascites is seen with use of NSAIDs in patients with cirrhosis with portal hypertension. </li> <li>Individual NSAIDs (eg, diclofenac) have been associated with hepatotoxicity in general population. </li> </ul> </td> <td> <ul> <li>NSAIDs and aspirin should be avoided in patients with advanced CLD or cirrhosis. </li> <li>Low-dose acetaminophen should be used instead of NSAIDs. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Selective COX-2 inhibitors</td> <td> <ul> <li>Available data are inadequate to establish the safety of selective COX-2 inhibitors in patients with advanced CLD or cirrhosis. See text for detail. </li> <li>Excess cardiovascular events have been observed with this class of medications when used by patients without cirrhosis. </li> </ul> </td> <td> <ul> <li>We advise against use of selective COX-2 inhibitors in patients with advanced CLD or cirrhosis, pending availability of additional safety data. </li> <li>If used, celecoxib product information suggests a 50% dose reduction for Child-Pugh class B cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioid analgesics (see important note)*</td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td> <ul> <li>Metabolized by CYP3A4 to inactive (nontoxic) metabolites. </li> <li>Parent drug can accumulate after repeated dosing or when administered as a continuous infusion due to tissue and protein binding. </li> <li>Less histamine release than other opiates. </li> <li>Less hemodynamic disturbance than other opiates. </li> </ul> </td> <td> <ul> <li>Generally a good choice for patients with CLD or cirrhosis when opiate treatment indicated. </li> <li>Useful option in patients with renal failure in setting of cirrhosis. </li> <li>No dose adjustment needed for single dose. </li> <li>With repeated dosing, reduce dose and frequency by approximately 25 to 50%. </li> <li>Initiate transdermal patch at half usual dose. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hydrocodone, oxycodone</td> <td> <ul> <li>Metabolized to active metabolite by CYP2D6 and 3A4 which may result in a prolonged time to onset, variable analgesic efficacy, and risk of accumulation in patients with advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Due to variability of onset and analgesic efficacy in hepatic insufficiency, fentanyl or hydromorphone may be better tolerated and more safely and predictably adjusted than hydrocodone and oxycodone in patients with advanced CLD or cirrhosis. </li> <li>If used, reduce dose and frequency. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hydromorphone</td> <td> <ul> <li>Hepatically metabolized by non-CYP transformations (glucuronidation) to apparently inactive metabolites. </li> <li>Oral bioavailability in advanced CLD or cirrhosis seems to be increased relative to healthy individuals due to diminished first-pass extraction, but specific data are lacking, and wide inter-individual variability is observed. </li> </ul> </td> <td> <ul> <li>Generally a good choice for patients with advanced CLD or cirrhosis. </li> <li>Reduce dose and frequency by approximately 50%. </li> <li>Titrate dose gradually to avoid accumulation of active drug. </li> <li>Useful option in patients with renal failure in setting of cirrhosis. </li> <li>Small volume for IV preparation and non-CYP3A4 metabolism may be advantageous given clinical setting. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Meperidine (pethidine), codeine</td> <td> <ul> <li>Altered oral bioavailability and elevated risk of accumulation of intermediates (codeine) or toxic metabolite (meperidine). </li> <li>Meperidine is highly bound to serum protein. </li> <li>Unpredictable analgesic efficacy and increased risk of toxicity in patients with advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Meperidine and codeine should be avoided in patients with advanced CLD or cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Morphine</td> <td> <ul> <li>Oral bioavailability in advanced CLD or cirrhosis increased up to 100% relative to healthy individuals due to diminished first-pass extraction. Wide inter-individual variability may be seen. </li> <li>Hepatically metabolized by non CYP transformations (glucuronidation). </li> <li>Half-life can be increased by up to twofold. </li> <li>Accumulation of metabolites with complex effects (eg, respiratory depression, analgesic tolerance, neurotoxicity) can occur in patients with cirrhosis and renal failure. </li> </ul> </td> <td> <ul> <li>Reduce dose and frequency by approximately 50% in advanced CLD or cirrhosis. </li> <li>Titrate dose gradually to avoid accumulation of active drug. </li> <li>Avoid in patients with cirrhosis and renal failure. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Naloxone-containing opioid combinations</p> <p>&nbsp;</p> </td> <td> <ul> <li>Orally administered naloxone, which is included&nbsp;in these combinations to deter abuse (ie, crushing, snorting)&nbsp;and counteract constipation by a&nbsp;local effect,&nbsp;is systemically absorbed&nbsp;in patients with&nbsp;moderate to severe hepatic impairment. </li> <li>Systemic absorption of naloxone will reverse analgesic efficacy and can precipitate opioid withdrawal. </li> </ul> </td> <td> <ul id=\"_telerik_insertedList_id\"> <li>Oxycodone-naloxone: <ul> <li>Reduce starting dose by one-half to two-thirds in mild hepatic impairment </li> <li>Use in advanced CLD or cirrhosis is contraindicated </li> </ul> </li> <li>Pentazocine-naloxone: Avoid use </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Remifentanil</p> </td> <td> <ul> <li>Cleared by non-specific plasma esterases to inactive metabolites. </li> <li>Does not accumulate in hepatic or renal insufficiency. </li> <li>Prompt reversal of analgesia and sedation upon discontinuation. </li> </ul> </td> <td> <ul> <li>No adjustment needed. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tramadol</td> <td> <ul> <li>Hepatically metabolized to active metabolite by CYP3A4, 2D6 and glucuronidation. </li> <li>Unpredictable onset, variable analgesic efficacy, and risk of accumulation in patients with cirrhosis. </li> <li>Can interact with serotoninergic medications including antidepressants. </li> </ul> </td> <td> <ul> <li>Avoid use in patients with decompensated cirrhosis. </li> <li>Avoid use in patients at risk for seizures. </li> <li>Based upon limited experience, a reduced dose of 25 mg every eight hours may be considered for treatment of pain in patients with advanced CLD or well-compensated cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Adjunctive agents for neuropathic pain</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td> <ul> <li>Carbamazepine is a potent inducer of hepatic enzymes and has been associated with hepatotoxicity and serious allergic reactions in genetically predisposed individuals. </li> <li>May precipitate rapid decompensation in patients with cirrhosis. </li> </ul> </td> <td> <ul> <li>Carbamazepine should be avoided as there are safer options for treatment of neuropathic pain in patients with advanced CLD or cirrhosis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gabapentin</td> <td> <ul> <li>Not hepatically metabolized or bound to plasma proteins. </li> <li>Highly dependent upon renal function for clearance of unchanged drug. </li> <li>Sedation, ataxia, dizziness, and nausea may limit usefulness in patients with advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate treatment at 300 mg orally per day and gradually titrate dose if needed over weeks due to delayed onset of action and to improve tolerability. </li> <li>Maintenance dose is dependent upon renal function. For specific adjustment, refer to Lexicomp monograph included with UpToDate. </li> <li>According to the product information, should not be abruptly stopped due to risk of discontinuation symptoms (eg, nausea, insomnia, anxiety) and/or rebound seizures in at-risk patients. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lidocaine topical patch</td> <td> <ul> <li>Low (3 to 5%) systemic absorption through intact skin. </li> </ul> </td> <td> <ul> <li>A good choice for local relief of pain in limited areas of intact skin in patients with advanced CLD or cirrhosis. </li> <li>No adjustment needed in hepatic impairment. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td> <ul> <li>Subject to extensive first pass metabolism and CYP2D6 transformations, which include active and inactive metabolites. </li> <li>Accumulation of metabolites in hepatic impairment is less likely with nortriptyline than amitriptyline. </li> <li>Dose-related anticholinergic and cardiovascular side effects may be poorly tolerated in medically-ill patients with advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate treatment at 10 mg orally each night and gradually titrate dose if needed over weeks due to delayed onset of action and to improve tolerability. </li> <li>Use \"low\" maintenance dose for neuropathic pain (eg, 25 mg to no more than 50 mg daily) to decrease risk of accumulation. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pregabalin</td> <td> <ul> <li>Not hepatically metabolized or bound to plasma proteins. </li> <li>Highly dependent upon renal function for clearance of unchanged drug. </li> <li>Sedation and dizziness may limit usefulness in patients with advanced CLD or cirrhosis. </li> </ul> </td> <td> <ul> <li>Initiate treatment at 50 mg orally twice per day and gradually titrate dose if needed over weeks due to delayed onset of action. </li> <li>Maintenance dose is dependent upon renal function. For specific adjustment, refer to Lexicomp monograph included with UpToDate. </li> <li>According to the product information, should not be abruptly stopped due to risk of discontinuation symptoms (eg, nausea, insomnia, anxiety) and/or rebound seizures in at-risk patients. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For information about use and adjustment of medications other than analgesics in chronic liver disease, refer to separate table in UpToDate on non-analgesic medications used in adult patients with advanced chronic liver disease or cirrhosis.</div><div class=\"graphic_footnotes\">OTC: over the counter analgesic; COX-2: cyclooxygenase 2; CLD: chronic liver disease; CYP: cytochrome P-450; NSAID: nonsteroidal anti-inflammatory drug; NAPQI: n-acetyl-p-benzoquinone imine; HE: hepatic encephalopathy.<br />* <strong>NOTE:</strong> All opioids can worsen or precipitate HE and should be used cautiously or avoided in patients with portal hypertension and preexisting HE.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lewis JH, Stine JG. Review article: Prescribing medications in patients with cirrhosis &ndash; a practical guide. Aliment Pharmacol Ther 2013; 37:1132.</li>&#xD;&#xA;    <li>Chandok N, Watt KD. Pain management in the cirrhotic patient: The clinical challenge. Mayo Clin Proc 2010; 85(5):451.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90196 Version 11.0</div></div></div>"},"90199":{"type":"graphic_table","displayName":"Exserohilum susceptibility","title":"Antifungal susceptibility testing results for clinical isolates of <em>Exserohilum rostratum</em> associated with the outbreak of central nervous system and joint infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antifungal susceptibility testing results for clinical isolates of <em>Exserohilum rostratum</em> associated with the outbreak of central nervous system and joint infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Antifungal agent<br /> (number of isolates tested)</td> <td class=\"subtitle1\" colspan=\"4\">Minimum inhibitory concentration<br /> (in mcg/mL) at 48 to 72 hours</td> </tr> <tr> <td class=\"subtitle2\">Range<br /> (lowest to highest value)</td> <td class=\"subtitle2\">MIC<sub>50</sub></td> <td class=\"subtitle2\">MIC<sub>90</sub></td> <td class=\"subtitle2\">Mode<br /> (most frequent value)</td> </tr> <tr> <td>Voriconazole (50)</td> <td class=\"centered\">1 to 4</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">1 to 2</td> </tr> <tr> <td>Fluconazole (50)</td> <td class=\"centered\">16 to 256</td> <td class=\"centered\">64</td> <td class=\"centered\">64</td> <td class=\"centered\">64</td> </tr> <tr> <td>Itraconazole (50)</td> <td class=\"centered\">0.25 to 4</td> <td class=\"centered\">0.5</td> <td class=\"centered\">1</td> <td class=\"centered\">0.5</td> </tr> <tr> <td>Posaconazole (49)</td> <td class=\"centered\">0.25 to 1</td> <td class=\"centered\">0.5</td> <td class=\"centered\">1</td> <td class=\"centered\">0.5</td> </tr> <tr> <td>Amphotericin B (48)</td> <td class=\"centered\">0.032 to 2</td> <td class=\"centered\">0.25</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.38</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak investigation. Laboratory testing and results from the outbreak. Available at:&nbsp;<A href=\"http://www.cdc.gov/hai/outbreaks/laboratory/index.html\">http://www.cdc.gov/hai/outbreaks/laboratory/index.html</A> (Accessed&nbsp;February 13, 2014).</div><div id=\"graphicVersion\">Graphic 90199 Version 6.0</div></div></div>"},"90202":{"type":"graphic_table","displayName":"Typical symptoms of hypoglycemia and hyperglycemia in children","title":"Typical symptoms of hypoglycemia and hyperglycemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical symptoms of hypoglycemia and hyperglycemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Hypoglycemia</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Autonomic signs and symptoms</td> </tr> <tr> <td class=\"indent1\">Trembling, tremors, or anxiety</td> <td rowspan=\"5\">Note that hypoglycemia does not consistently cause autonomic sign and symptoms, especially in children and/or in individuals with recurrent hypoglycemia (\"hypoglycemia unawareness\").</td> </tr> <tr> <td class=\"indent1\">Hunger</td> </tr> <tr> <td class=\"indent1\">Diaphoresis (\"cold sweats\")</td> </tr> <tr> <td class=\"indent1\">Pallor</td> </tr> <tr> <td class=\"indent1\">Palpitations</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Neuroglycopenic signs and symptoms</td> </tr> <tr> <td class=\"indent1\">Behavior changes (irritability, erratic behavior)</td> <td rowspan=\"8\">These neuroglycopenic signs and symptoms typically indicate moderate or severe hypoglycemia, and are usually seen in association with the autonomic signs and symptoms described above (except in patients with hypoglycemia unawareness, who typically do not have autonomic symptoms before development of neuroglycopenic symptoms).</td> </tr> <tr> <td class=\"indent1\">Poor concentration, judgment or memory; confusion</td> </tr> <tr> <td class=\"indent1\">Lethargy, weakness, difficulty walking</td> </tr> <tr> <td class=\"indent1\">Loss of coordination</td> </tr> <tr> <td class=\"indent1\">Slurred speech</td> </tr> <tr> <td class=\"indent1\">Visual disturbances (blurring, double vision, or disturbed color vision)</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Loss of consciousness, seizure</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Hyperglycemia</td> </tr> <tr> <td class=\"indent1\">Increased thirst and urination</td> <td rowspan=\"5\">Note that hyperglycemia cannot be reliably detected by symptoms. Many of these symptoms are nonspecific; others appear only after ketoacidosis develops (*).</td> </tr> <tr> <td class=\"indent1\">Fatigue, tiredness, sleepiness</td> </tr> <tr> <td class=\"indent1\">Loss of appetite*</td> </tr> <tr> <td class=\"indent1\">Rapid breathing*</td> </tr> <tr> <td class=\"indent1\">Fruity odor to breath*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note that hypoglycemia does not consistently cause symptoms, especially in young, preschool aged children. Therefore, blood glucose (BG) monitoring should be performed regularly in individuals with type 1 diabetes, regardless of symptoms, and BG should always be checked if any of the above symptoms arise.</div><div class=\"graphic_footnotes\">* These are symptoms and signs of ketosis/ketoacidosis, rather than hyperglcycemia itself.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Clarke W, Jones T, Rewers A, et al. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2009; 10 (Suppl 12):134.</li>&#xD;&#xA;    <li>Gonder-Frederick LA, Snyder AL, Clarke WL. Accuracy of blood glucose estimation by children with IDDM and their parents. Diabetes Care 1991; 14:565.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90202 Version 3.0</div></div></div>"},"90208":{"type":"graphic_picture","displayName":"Posterior intra-articular view of knee joint","title":"Posterior intra-articular view of knee joint","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Posterior intra-articular view of knee joint</div><div class=\"cntnt\"><img style=\"width:494px; height:499px;\" src=\"images/EM/90208_Pstintrartclrvwknjnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Lower limb. In: Clinically Oriented Anatomy, 7th ed, Moore KL, Dalley AF, Agur AMR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90208 Version 3.0</div></div></div>"},"90209":{"type":"graphic_picture","displayName":"Lateral knee in flexion and extension","title":"Lateral knee in flexion and extension","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Lateral knee in flexion and extension</div><div class=\"cntnt\"><img style=\"width:690px; height:432px;\" src=\"images/EM/90209_Ltrl_knee_flxn_extnsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Originally published in: Sobotta Atlas der Anatomie des Menschen, 22. Auflage, Band 1, Band 2; M&uuml;nchen: Elsevier/Urban &amp; Fischer &copy; 2006. The English translation was undertaken by Lippincott Williams &amp; Wilkins and published in: Anatomy: A Regional Atlas of the Human Body, 6th ed, Clemente CD (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90209 Version 1.0</div></div></div>"},"90215":{"type":"graphic_figure","displayName":"Butylcyanoacrlyate versus octylcyanoacrylate application","title":"Butylcyanoacrlyate versus octylcyanoacrylate application","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Butylcyanoacrlyate versus octylcyanoacrylate application</div><div class=\"cntnt\"><img style=\"width:598px; height:321px;\" src=\"images/EM/90215_Butylcyanvsoctylcyanappl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the butylcyanoacrylates, the adhesive is applied as discrete bead (left). With the octylcyanoacrylates, the adhesive is applied as one continuous film across the entire wound (right).</div><div class=\"graphic_reference\">Reproduced with permission from: Hollander JE. Use of tissue adhesives in laceration repair. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90215 Version 5.0</div></div></div>"},"90229":{"type":"graphic_algorithm","displayName":"HLH therapy algorithm","title":"Algorithm for therapy of hemophagocytic lymphohistiocytosis","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Algorithm for therapy of hemophagocytic lymphohistiocytosis</div><div class=\"cntnt\"><img style=\"width:459px; height:512px;\" src=\"images/HEME/90229_HLN_therapy_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The algorithm shows our approach to the management of patients with hemophagocytic lymphohistiocytosis (HLH). Triggering conditions include infections and rheumatologic conditions. High risk factors include HLH gene mutations, central nervous system (CNS) disease, and hematologic malignancies. This algorithm is meant as an overview only. Refer to the UpToDate topics on the diagnosis and treatment of HLH for further details of diagnosis and management.</div><div class=\"graphic_footnotes\">HLH: hemophagocytic lymphohistiocytosis; CNS: central nervous system.<br />* With increasing ferritin, D-dimer, liver enzymes, worsening cytopenias.</div><div id=\"graphicVersion\">Graphic 90229 Version 1.0</div></div></div>"},"90233":{"type":"graphic_table","displayName":"Effects of ADT on cardiac risk factors","title":"The effects of androgen deprivation therapy (ADT) on cardiac risk factors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effects of androgen deprivation therapy (ADT) on cardiac risk factors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Obesity</td> <td>Increased fat mass</td> <td>Fat accumulation is primarily subcutaneous fat</td> </tr> <tr> <td>Serum lipids</td> <td>Increased LDL cholesterol and triglycerides</td> <td>HDL cholesterol is also increased</td> </tr> <tr> <td>Insulin sensitivity</td> <td>Increased fasting plasma insulin and decreased insulin sensitivity</td> <td>Small increase in glycosylated hemoglobin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein.</div><div class=\"graphic_reference\">Modified from: Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121:833.</div><div id=\"graphicVersion\">Graphic 90233 Version 1.0</div></div></div>"},"90238":{"type":"graphic_diagnosticimage","displayName":"Schmorls nodes","title":"Schmorl's nodes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schmorl's nodes</div><div class=\"cntnt\"><img style=\"width:427px; height:369px;\" src=\"images/PC/90238_Schmorls_nodes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schmorl's nodes. Sagittal image from a spine MRI shows intraverebral disc herniation (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Jarvik, MD, MPH.</div><div id=\"graphicVersion\">Graphic 90238 Version 2.0</div></div></div>"},"90258":{"type":"graphic_table","displayName":"LMW heparin dose renal insufficiency (adults)","title":"Suggested dose adjustments of low molecular weight heparins in renal insufficiency for adults<SUP>[1-5]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested dose adjustments of low molecular weight heparins in renal insufficiency for adults<SUP>[1-5]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">VTE treatment</td> <td class=\"subtitle1\">VTE prophylaxis*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dalteparin</strong></td> <td> <p><strong>Cl<sub>cr</sub> &#8805;30 mL/min:</strong> No adjustment</p> <strong>Cl<sub>cr</sub> 20 to 29 mL/min:</strong> Due to variable response, adjust dose based upon anti-factor Xa levels<sup>&#182;</sup></td> <td><strong>Cl<sub>cr</sub> &#8805;20 mL/min:</strong> No adjustment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Enoxaparin</strong></td> <td> <p><strong>Cl<sub>cr</sub> &#8805;30 mL/min:</strong> No adjustment</p> <strong>Cl<sub>cr</sub> 20 to 29 mL/min:</strong> Reduce to 1 mg/kg once daily<sup>&#182;</sup></td> <td> <p><strong>Cl<sub>cr</sub> &#8805;30 mL/min:</strong> No adjustment</p> <strong>Cl<sub>cr</sub> 20 to 29 mL/min:</strong> Reduce to 30 mg once daily (medical or surgical patients)</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Nadroparin</strong></p> <p>(not available in US)</p> </td> <td> <p><strong>Cl<sub>cr</sub> &#8805;50 mL/min:</strong> No adjustment</p> <p><strong>Cl<sub>cr</sub> 30 to 50 mL/min:</strong> Reduce dose by 25 to 33 percent (optional)<sup>&#916;</sup></p> <strong>Cl<sub>cr</sub> &#60;30 mL/min:</strong> Contraindicated</td> <td> <p><strong>Cl<sub>cr</sub> &#8805;50 mL/min:</strong> No adjustment</p> <p><strong>Cl<sub>cr</sub> 30 to 50 mL/min:</strong> Reduce dose by 25 to 33 percent (optional)</p> <p><strong>Cl<sub>cr</sub> 20 to 29 mL/min:</strong> Reduce dose by 25 to 33 percent</p> </td> </tr> <tr> <td> <p><strong>Tinzaparin</strong></p> <p>(not available in US)</p> </td> <td> <p><strong>Cl<sub>cr</sub> &#8805;30 mL/min:</strong> No adjustment</p> <strong>Cl<sub>cr</sub> 20 to 29 mL/min:</strong> Not adequately studied. Patients age &#8805;70 years seem at elevated mortality risk. If used, adjustment of dose based upon anti-factor Xa levels is advised.<sup>&#182;</sup></td> <td><strong>Cl<sub>cr</sub> &#8805;30 mL/min:</strong> No adjustment</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Suggested dose adjustment of LMW heparins for reduced renal function. All dosing&nbsp;in this table refers to subcutaneous dosing. Caution should be used in all patients with renal insufficiency, and patients should be observed for signs of bleeding. Repeated doses of LMW heparin to patients with renal insufficiency may lead to accumulation and increased risk of bleeding to varying degrees. In contrast,&nbsp;unfractionated heparin&nbsp;is not dependent primarily upon renal function for clearance and may be a preferred option for patients with Cl<SUB>cr</SUB> &lt;20 mL/min, kidney failure, or receiving dialysis. Use of LMW heparin in patients with renal insufficiency has been associated with hyperkalemia. Refer to the UpToDate topics on the use of heparin and LMW heparin in specific clinical conditions for specific indications. Dose adjustment for renal insufficiency in acute coronary syndromes&nbsp;and myocardial infarction is discussed in UpToDate&nbsp;tables on those conditions.&nbsp;Refer to UpToDate content on infants and children for dosing in these groups.</div><div class=\"graphic_footnotes\">LMW heparin: low molecular weight heparin; VTE: venous thromboembolism; Cl<SUB>cr</SUB>: creatinine clearance as determined by Cockcroft-Gault equation, a calculator is available in UpToDate. <br />* For short-term VTE prophylaxis (ie, up to 10 days). For long-term use, periodic anti-factor Xa activity testing may be useful to rule out drug accumulation.<br />¶&nbsp;Anti-factor Xa activity levels should be measured four to six hours after dosing, after&nbsp;the third or fourth dose. The following target ranges have been suggested:<br /><UL>&#xD;&#xA;<LI>Dalteparin:&nbsp;0.5 to 1.5&nbsp;anti-factor Xa units/mL (target 1.05) in once-daily use</LI>&#xD;&#xA;<LI>Nadroparin: 0.6 to 1 anti-factor Xa units/mL in twice-daily use; 1.3 anti-Xa units/mL in once-daily use</LI>&#xD;&#xA;<LI>Tinzaparin: 0.85 anti-factor Xa units/mL in&nbsp;once-daily u<SUP></SUP>se<SUP>[5]</SUP></LI></UL>Δ Dosing suggested in prescribing information; other approaches including dose adjustment based on anti-factor Xa activity are discussed in UpToDate topics on use of LMW heparin.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Dalteparin sodium injection. US FDA approved prescribing information (revised January, 2015). Available at <A spellcheck=true href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020287s062lbl.pdf\" target=_blank>http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020287s062lbl.pdf</A> </LI>&#xD;&#xA;<LI>Enoxaparin sodium injection. US FDA approved prescribing information (revised October, 2013). Available at: at: <A spellcheck=true href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020164s102lbl.pdf\" target=_blank>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020164s102lbl.pdf</A></LI>&#xD;&#xA;<LI>Nadroparin calcium injection. Canada product monograph (December 14, 2017). Available at <FONT style=\"TEXT-DECORATION: underline\" color=#0066cc><A spellcheck=true href=\"https://pdf.hres.ca/dpd_pm/00042608.PDF\" target=_blank>https://pdf.hres.ca/dpd_pm/00042608.PDF</A></FONT><A href=\"http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp\"></A></LI>&#xD;&#xA;<LI>Tinzaparin sodium injection. Canada product monograph (May 26, 2017). Available at <A spellcheck=true href=\"https://pdf.hres.ca/dpd_pm/00040736.PDF\" target=_blank>https://pdf.hres.ca/dpd_pm/00040736.PDF</A></LI>&#xD;&#xA;<LI>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.</LI></OL></div><div id=\"graphicVersion\">Graphic 90258 Version 4.0</div></div></div>"},"90259":{"type":"graphic_table","displayName":"Patch test positivity preservatives","title":"Frequency of patch test positivity for preservatives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of patch test positivity for preservatives</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Preservative</td> <td class=\"subtitle1\">NACDG 2011-2012 reactions<br /> (percent)</td> </tr> <tr> <td>Formaldehyde</td> <td class=\"centered\">6.6</td> </tr> <tr> <td>Quaternium 15</td> <td class=\"centered\">6.4</td> </tr> <tr> <td>MCI/MI</td> <td class=\"centered\">5.0</td> </tr> <tr> <td>Iodopropynyl butylcarbamate</td> <td class=\"centered\">4.2</td> </tr> <tr> <td>Methyldibromoglutaronitrile</td> <td class=\"centered\">3.7</td> </tr> <tr> <td>Diazolidinyl urea</td> <td class=\"centered\">2.1</td> </tr> <tr> <td>2-bromo-2-nitropropane-1,3-diol</td> <td class=\"centered\">1.6</td> </tr> <tr> <td>Imidazolidinyl urea</td> <td class=\"centered\">1.6</td> </tr> <tr> <td>DMDM hydantoin</td> <td class=\"centered\">1.6</td> </tr> <tr> <td>Parabens</td> <td class=\"centered\">1.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCI/MI: methylchloroisothiazolone/methylisothiazolinone.</div><div class=\"graphic_reference\">Data from: Warshaw EM, Maibach HI, Taylor JS, et al. North American contact dermatitis group patch test results: 2011-2012. Dermatitis 2015; 26:49.</div><div id=\"graphicVersion\">Graphic 90259 Version 2.0</div></div></div>"},"90262":{"type":"graphic_figure","displayName":"Manhattan plot","title":"Manhattan plot for displaying information from a genome-wide association study","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Manhattan plot for displaying information from a genome-wide association study</div><div class=\"cntnt\"><img style=\"width:628px; height:242px;\" src=\"images/PC/90262_Manhattan_plot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a Manhattan plot. This type of plot is used to represent and summarize&nbsp;results from a genome-wide association study (GWAS). The x-axis plots the physical positions of single nucleotide polymorphisms (SNPs)&nbsp;along each chromosome, and the y-axis&nbsp;plots&nbsp;the inverse logarithm of the P-value for the association of each SNP&nbsp;with the trait of interest. A higher value on the y-axis reflects a more significant association. The dashed red line shows the significance threshold for genome-wide significance; data points (SNPs)&nbsp;above this line are considered significant. This type of plot was named for its similarity to the appearance of skyscrapers in the skyline of Manhattan in the United States.</div><div id=\"graphicVersion\">Graphic 90262 Version 1.0</div></div></div>"},"90264":{"type":"graphic_picture","displayName":"Endoscopic treatment for NSAID-induced injury","title":"Endoscopic treatment for NSAID-induced injury","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Endoscopic treatment for NSAID-induced injury</div><div class=\"cntnt\"><img style=\"width:513px; height:199px;\" src=\"images/GAST/90264_Endosc_treat_NSAID_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) NSAID-induced ileal stricture with proximally retained capsule endoscope (arrow) seen at retrograde double-balloon enteroscopy.<br />(B) Needle-knife electroincision of the stricture.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drug.</div><div id=\"graphicVersion\">Graphic 90264 Version 1.0</div></div></div>"},"90267":{"type":"graphic_figure","displayName":"Fenton growth chart premature infants - Boys","title":"Fenton growth chart for premature infants - Boys","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Fenton growth chart for premature infants - Boys</div><div class=\"cntnt\"><img style=\"width:594px; height:783px;\" src=\"images/PEDS/90267_Fenton_gr_ch_pre_infant_by.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fenton growth chart for preterm infant boys.</div><div class=\"graphic_footnotes\">%: Percent.</div><div class=\"graphic_reference\">Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatrics 2013; 13:59. Copyright © 2013 Fenton and Kim. Reproduced from BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 90267 Version 1.0</div></div></div>"},"90268":{"type":"graphic_picture","displayName":"Eschmann tracheal tube introducer","title":"Eschmann tracheal tube introducer","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Eschmann tracheal tube introducer</div><div class=\"cntnt\"><img style=\"width:590px; height:420px;\" src=\"images/EM/90268_Eschmannintroducer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Eschmann stylet is a reusable Dacron tracheal tube introducer.</div><div class=\"graphic_reference\">Reproduced with permission from: Bougies and airway stylets. In: Atlas of Airway Management, 2nd ed, Orebaugh SL, Bigeleisen P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90268 Version 5.0</div></div></div>"},"90270":{"type":"graphic_picture","displayName":"Nevus sebaceous histopathology","title":"Nevus sebaceous","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Nevus sebaceous</div><div class=\"cntnt\"><img style=\"width:590px; height:485px;\" src=\"images/DERM/90270_Nevussebaceoushisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There&nbsp;is epidermal hyperplasia and papillomatosis. Superficially, a basaloid epithelial neoplasm is seen, and dilated apocrine glands are present in the dermis. This scalp lesion lacks anagen follicles.</div><div class=\"graphic_reference\">Reproduced with permission from: Stewart CL, Novoa RA, Seykora JT. Tumors of the Epidermal Appendages. In: Lever's Histopathology of the Skin, 11th ed, Elder DE, Elenitsas R, Johnson BL Jr, et al, Lippincott Williams &amp; Wilkins, 2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90270 Version 6.0</div></div></div>"},"90272":{"type":"graphic_picture","displayName":"Inferior shoulder dislocation","title":"Inferior shoulder dislocation","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Inferior shoulder dislocation</div><div class=\"cntnt\"><img style=\"width:483px; height:576px;\" src=\"images/EM/90272_Infer_shoulder_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As in this photograph, patients with an inferior shoulder dislocation hold the involved arm above their head, sometimes bending the elbow and resting their forearm atop their head. They are unable to adduct the involved arm.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott Sherman, MD.</div><div id=\"graphicVersion\">Graphic 90272 Version 1.0</div></div></div>"},"90273":{"type":"graphic_movie","displayName":"Reduction of inferior shoulder dislocation","title":"Reduction of inferior shoulder dislocation","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Reduction of inferior shoulder dislocation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/90273_Reducinfshdislocatvideo.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:504px; height:378px;\" src=\"images/EM/90273_Reducinfshdislocatimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows the reduction of an inferior shoulder dislocation using axial traction on the abducted arm and counter traction provided by an assistant via sheets under the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: Scott Sherman, MD.</div><div id=\"graphicVersion\">Graphic 90273 Version 2.0</div></div></div>"},"90275":{"type":"graphic_table","displayName":"Parabens food","title":"Foods potentially containing parabens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods potentially containing parabens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Baked goods and candies</td> </tr> <tr> <td>Frozen dairy products</td> </tr> <tr> <td>Jams and jellies</td> </tr> <tr> <td>Marinated fish products</td> </tr> <tr> <td>Mayonnaise</td> </tr> <tr> <td>Mustard</td> </tr> <tr> <td>Processed vegetables</td> </tr> <tr> <td>Salad dressings</td> </tr> <tr> <td>Soft drinks and fruit juices</td> </tr> <tr> <td>Spiced sauces</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Allergy to parabens. DermNet NZ. Available at: <a href=\"http://dermnetnz.org/dermatitis/parabens-allergy.html\" target=\"_blank\">http://dermnetnz.org/dermatitis/parabens-allergy.html</a> (Accessed on August 8, 2013).</li>&#xD;&#xA;    <li>Fisher's Contact Dermatitis, Rietschel RL, Fowler JFF Jr (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2001.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90275 Version 1.0</div></div></div>"},"90276":{"type":"graphic_table","displayName":"Balsam of Peru cross reactions","title":"Substances cross-reacting with balsam of Peru","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Substances cross-reacting with balsam of Peru</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Benzoin</td> </tr> <tr> <td>Benzyl benzoate</td> </tr> <tr> <td>Benzyl salicylate/alcohol</td> </tr> <tr> <td>Cinnamates</td> </tr> <tr> <td>Cinnamic aldehyde/alcohol</td> </tr> <tr> <td>Eugenol</td> </tr> <tr> <td>Perfumes/fragrances</td> </tr> <tr> <td>Rosin (colophony)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Fisher's Contact Dermatitis. Rietschel RL, Fowler JFF Jr (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2001.</div><div id=\"graphicVersion\">Graphic 90276 Version 1.0</div></div></div>"},"90277":{"type":"graphic_table","displayName":"Balsam of Peru potential cross reactions","title":"Products potentially causing reactions in individuals allergic to balsam of Peru","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Products potentially causing reactions in individuals allergic to balsam of Peru</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Citrus derived products (orange, lemon, grapefruit, tangerine, mandarin oranges)</td> </tr> <tr> <td>Ice cream</td> </tr> <tr> <td>Chutney</td> </tr> <tr> <td>Cola</td> </tr> <tr> <td>Cinnamon</td> </tr> <tr> <td>Cloves</td> </tr> <tr> <td>Vanilla</td> </tr> <tr> <td>Curry</td> </tr> <tr> <td>Ketchup/chili sauce</td> </tr> <tr> <td>Pickled vegetables</td> </tr> <tr> <td>Vermouth</td> </tr> <tr> <td>Tomatoes</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Fisher's Contact Dermatitis. Rietschel RL, Fowler JFF Jr (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2001.</li>&#xD;&#xA;    <li>Hjorth N. Eczematous allergy to balsams, allied perfumes and flavouring agents, with special reference to balsam of Peru. Acta Derm Venereol Suppl (Stockh) 1961; 41(Suppl 46):1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90277 Version 1.0</div></div></div>"},"90279":{"type":"graphic_diagnosticimage","displayName":"Imaging studies of capitate fracture","title":"Imaging studies of capitate fracture","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Imaging studies of capitate fracture</div><div class=\"cntnt\"><img style=\"width:591px; height:526px;\" src=\"images/RADIOL/90279_Imag_fracture_capitate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An&nbsp;AP&nbsp;radiograph of the wrist (A) shows a subtle sclerotic region through the capitate (arrow). A CT scan of the wrist (B) is reformatted in the coronal plane and suggests a subtle non displaced fracture. A T1 weighted MRI performed two months later confirms a fracture through the mid-portion of the capitate.</div><div class=\"graphic_footnotes\">AP: anteroposterior; CT: computed tomography; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 90279 Version 2.0</div></div></div>"},"90280":{"type":"graphic_diagnosticimage","displayName":"X-ray and CT capitate fracture","title":"X-ray and CT of capitate fracture","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">X-ray and CT of capitate fracture</div><div class=\"cntnt\"><img style=\"width:599px; height:226px;\" src=\"images/RADIOL/90280_Xray_CT_fract_capitate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P x-ray of the wrist (A) shows a subtle fracture through the capitate (arrow). A CT scan of the wrist (B) shows a subacute non displaced fracture.</div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Waite, MD.</div><div id=\"graphicVersion\">Graphic 90280 Version 1.0</div></div></div>"},"90281":{"type":"graphic_diagnosticimage","displayName":"CT pisiform fracture","title":"CT of pisiform fracture ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT of pisiform fracture </div><div class=\"cntnt\"><img style=\"width:598px; height:181px;\" src=\"images/RADIOL/90281_CT_pisiform_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An coronal CT scan of the right wrist (A) shows a nondisplaced fracture of the pisiform (arrow). Image B is an axial view of the fracture (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Charles Allison, MD.</div><div id=\"graphicVersion\">Graphic 90281 Version 1.0</div></div></div>"},"90283":{"type":"graphic_algorithm","displayName":"SALT mass casualty triage algorithm ","title":"SALT mass casualty triage algorithm ","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">SALT mass casualty triage algorithm </div><div class=\"cntnt\"><img style=\"width:469px; height:498px;\" src=\"images/EM/90283_SALT_mass_casu_triage_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">SALT mass casualty triage: concept endorsed by the American College of Emergency Physicians, American College of Surgeons Committee on Trauma, American Trauma Society, National Association of EMS Physicians, National Disaster Life Support Education Consortium, and State and Territorial Injury Prevention Directors Association. Disaster Med Public Health Prep 2008; 2:245. Copyright &copy; 2008 Society for Disaster Medicine and Public Health, Inc. Reprinted with the permission of Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 90283 Version 3.0</div></div></div>"},"90285":{"type":"graphic_table","displayName":"Six-minute walk test technique","title":"Six-minute walk test technique","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six-minute walk test technique</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Flat, straight corridor 30 m (100 feet) in length </li> </ul> </td> </tr> <tr> <td> <ul> <li>Turnaround points marked with a cone </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient should wear comfortable clothes and shoes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient rests in chair for at least 10 minutes prior to test (ie, no warm-up period) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Heart rate and pulse&nbsp;oxygen saturation (SpO<sub>2</sub>)&nbsp;should be monitored throughout the test&nbsp;</li> </ul> </td> </tr> <tr> <td> <ul> <li>If the patient is using supplemental oxygen, record the flow rate and type of device </li> </ul> </td> </tr> <tr> <td> <ul> <li>Have patient stand and rate baseline dyspnea and overall fatigue using Borg scale*<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Set lap counter to zero and timer to six minutes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Instruct the patient: Remember that the object is to walk AS FAR AS POSSIBLE for 6 minutes, but don't run or jog. Pivot briskly around the cone. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Standardized encouragement statements should be provided at one minute intervals, such as \"You are doing well. You have _ minutes to go\" and \"Keep up the good work. You have _ minutes to go.\"</li> </ul> </td> </tr> <tr> <td> <ul> <li>At the end of the test, mark the spot where the patient stopped on the floor </li> </ul> </td> </tr> <tr> <td> <ul> <li>If using a pulse oximeter, measure the pulse rate and SpO<sub>2</sub> and record </li> </ul> </td> </tr> <tr> <td> <ul> <li>After the test record the Borg*<sup>[1]</sup> dyspnea and fatigue levels </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ask, \"What, if anything, kept you from walking farther?\" </li> </ul> </td> </tr> <tr> <td> <ul> <li>Calculate the distance walked and record </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate table on the modified Borg Scale.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377.</LI></OL>Adapted from:<br /><OL>&#xD;&#xA;<LI>American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.</LI>&#xD;&#xA;<LI>Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014; 44:1428.</LI></OL></div><div id=\"graphicVersion\">Graphic 90285 Version 3.0</div></div></div>"},"90286":{"type":"graphic_algorithm","displayName":"Suspected DVT in pregnancy","title":"Diagnostic algorithm for suspected deep venous thrombosis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for suspected deep venous thrombosis in pregnancy</div><div class=\"cntnt\"><img style=\"width:437px; height:336px;\" src=\"images/PULM/90286_Suspect_DVT_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CUS: compression ultrasound.<BR>* Refers to patients with an initial negative CUS in whom clinical suspicion remains that is not high. Refer to UpToDate topics on deep vein thrombosis in pregnancy.<BR><FONT class=bullet>•</FONT> Alternative imaging techniques include doppler ultrasound of the iliac vein and contrast or magnetic resonance venography.<BR>Δ Consideration can be given to measuring a D-dimer level using enzyme linked immunosorbent assay (ELISA) or red blood cell agglutination (SimpliRED). A D-dimer level &lt;500 ng/mL is considered negative and no further testing is needed. A D-dimer level &gt;500 ng/mL is not diagnostic and has no value in directing further testing in pregnant women.</div><div id=\"graphicVersion\">Graphic 90286 Version 1.0</div></div></div>"},"90288":{"type":"graphic_table","displayName":"Implanted metal hypersensitivity","title":"Criteria for the diagnosis of hypersensitivity to implanted metals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of hypersensitivity to implanted metals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\">Eruption overlying the metal implant</td> </tr> <tr> <td class=\"indent1\">Positive patch test reaction to a metal used in the implant</td> </tr> <tr> <td class=\"indent1\">Complete recovery following removal of the offending implant</td> </tr> <tr> <td class=\"indent1\">Chronic dermatitis beginning weeks to months after metallic implantation</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Dermatitis reaction is therapy resistant</td> </tr> <tr> <td class=\"indent1\">Morphology consistent with dermatitis (erythema, induration, papules, vesicles)</td> </tr> <tr> <td class=\"indent1\">Systemic allergic dermatitis reaction</td> </tr> <tr> <td class=\"indent1\">Histology consistent with allergic contact dermatitis</td> </tr> <tr> <td class=\"indent1\">Positive in vitro test to metals, eg, the lymphocyte transformation test</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Thyssen JP, Menn&eacute; T, Schalock PC, et al. Pragmatic approach to the clinical work-up of patients with putative allergic disease to metallic orthopaedic implants before and after surgery. Br J Dermatol 2011; 164:473.</li>&#xD;&#xA;    <li>Schalock PC, Menn&eacute; T, Johansen JD, et al. Hypersensitivity reactions to metallic implants - diagnostic algorithm and suggested patch test series for clinical use. Contact Dermatitis 2012; 66:4.</li>&#xD;&#xA;    <li>Schalock PC, Thyssen JP. Patch testers' opinions regarding diagnostic criteria for metal hypersensitivity reactions to metallic implants. Dermatitis 2013; 24:183.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90288 Version 1.0</div></div></div>"},"90289":{"type":"graphic_table","displayName":"Heavy menstrual bleeding coagulopathy screening","title":"Screening for bleeding disorders in women with heavy menstrual bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening for bleeding disorders in women with heavy menstrual bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial screening for an underlying disorder of hemostasis in patients with excessive menstrual bleeding should be structured by medical history (positive screen comprises any of the following):*</td> </tr> <tr> <td class=\"indent1\">Heavy menstrual bleeding since menarche</td> </tr> <tr> <td class=\"sublist2_start\">One of the following:</td> </tr> <tr> <td class=\"sublist2\">Postpartum hemorrhage</td> </tr> <tr> <td class=\"sublist2\">Surgery-related bleeding</td> </tr> <tr> <td class=\"sublist2\">Bleeding associated with dental work</td> </tr> <tr> <td class=\"sublist2_start\">Two or more of the following symptoms:</td> </tr> <tr> <td class=\"sublist2\">Bruising one to two times per month</td> </tr> <tr> <td class=\"sublist2\">Epistaxis one to two times per month</td> </tr> <tr> <td class=\"sublist2\">Frequent gum bleeding</td> </tr> <tr> <td class=\"sublist2\">Family history of bleeding symptoms</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with a positive screen should be considered for further evaluation, including consultation with a hematologist and testing of von Willebrand factor and ristocetin cofactor.</div><div class=\"graphic_reference\">Original figure modified for this publication. Kouides PA, Conard J, Peyvandi F, et al. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril 2005; 84:1345. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90289 Version 1.0</div></div></div>"},"90290":{"type":"graphic_picture","displayName":"Angioinvasive LyP","title":"Angioinvasive lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Angioinvasive lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:483px; height:598px;\" src=\"images/DERM/90290_AngioinvasiveLyP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eschar-like ulcer on the face (A), healing with a scar (B). This patient experienced several recurrences on the face (C-E) and trunk (F).</div><div class=\"graphic_reference\">Reproduced with permission from: Kempf W, Kazakov DV, Scharer L, et al. Angioinvasive lymphomatoid papulosis: A new variant simulating aggressive lymphomas. Am J Surg Pathol 2013; 37:1. DOI: <a href=\"http://journals.lww.com/ajsp/pages/articleviewer.aspx?year=2013&amp;issue=01000&amp;article=00001&amp;type=abstract\" target=\"_blank\">10.1097/PAS.0b013e3182648596</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90290 Version 6.0</div></div></div>"},"90292":{"type":"graphic_picture","displayName":"Angioinvasive LiP histo","title":"Histopathologic features of angioinvasive lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of angioinvasive lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:508px; height:598px;\" src=\"images/DERM/90292_AngioinvasiveLiPhisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical medium-sized lymphocytes surrounding and infiltrating blood vessels (A). Rimming of atypical lymphoid cells around adipocytes (B). Staining for CD30 (C), CD4 (D), CD8 (E), and TIA-1 (F). Note the small number of CD8+ cells (E), whereas TIA-1 is expressed by most lymphocytes (F).</div><div class=\"graphic_reference\">Reproduced with permission from: Kempf W, Kazakov DV, Scharer L, et al. Angioinvasive lymphomatoid papulosis: A new variant simulating aggressive lymphomas. Am J Surg Pathol 2013; 37:1. DOI: <a href=\"http://journals.lww.com/ajsp/pages/articleviewer.aspx?year=2013&amp;issue=01000&amp;article=00001&amp;type=abstract\" target=\"_blank\">10.1097/PAS.0b013e3182648596</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90292 Version 6.0</div></div></div>"},"90295":{"type":"graphic_diagnosticimage","displayName":"Imaging hiatus hernia incidental finding","title":"Incidental finding of a hiatus hernia on chest x-ray and CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incidental finding of a hiatus hernia on chest x-ray and CT scan</div><div class=\"cntnt\"><img style=\"width:343px; height:397px;\" src=\"images/RADIOL/90295_Img_hiatus_he_ini_find.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The A-P chest x-ray (A) shows a hiatus hernia (asterisk) with an air fluid level (arrows). A lateral chest x-ray (B) confirms a hiatus hernia (asterisk) and an air fluid level in the hernia (arrows). A CT scan in the axial plane (C) shows contrast in the hiatus hernia (asterisk). <br /></div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90295 Version 2.0</div></div></div>"},"90296":{"type":"graphic_diagnosticimage","displayName":"Barium swallow normal and hiatus hernia","title":"Barium swallow in a patient with a hiatus hernia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium swallow in a patient with a hiatus hernia </div><div class=\"cntnt\"><img style=\"width:309px; height:599px;\" src=\"images/RADIOL/90296_Bar_img_hiatus_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal barium swallow showing the gastroesophageal junction (arrow) is at the level of the diaphragm (arrowhead) and the gastric folds (dashed arrow) are at the same level as the diaphragm. <br />(B) Barium swallow showing a sliding hiatus hernia (asterisk). The gastroesophageal junction (arrow) is above the diaphragm (arrowhead) and the gastric folds (dashed arrow) are above the diaphragm. <br />(C) Barium swallow&nbsp;showing a paraesophageal hernia (asterisk). The gastroesophageal junction (arrow) is below the diaphragm (arrowhead).</div><div id=\"graphicVersion\">Graphic 90296 Version 2.0</div></div></div>"},"90297":{"type":"graphic_diagnosticimage","displayName":"Barium swallow sliding hiatus hernia ","title":"Barium swallow in a patient with a sliding hiatus hernia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium swallow in a patient with a sliding hiatus hernia </div><div class=\"cntnt\"><img style=\"width:224px; height:397px;\" src=\"images/RADIOL/90297_Bari_swa_hiat_hern_gas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium swallow shows a moderate sized sliding hiatus hernia (asterisk) above the diaphragm (arrowhead), with well-defined gastric folds (arrow).</div><div id=\"graphicVersion\">Graphic 90297 Version 2.0</div></div></div>"},"90298":{"type":"graphic_diagnosticimage","displayName":"Barium swallow and CT scan paraesophageal hernia","title":"Barium swallow and computed tomography (CT) scan in a patient with a paraesophageal hernia","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Barium swallow and computed tomography (CT) scan in a patient with a paraesophageal hernia</div><div class=\"cntnt\"><img style=\"width:596px; height:298px;\" src=\"images/RADIOL/90298_Img_paraesophag_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A barium swallow showing a paraesophageal hernia (asterisk). The gastroesophageal junction (arrow) is at the level of the diaphragm (arrowhead). <br />(B) An axial CT scan through the lower chest showing the region of the gastroesophageal junction (arrow) at the level of the diaphragm (arrowhead) with a paraesophageal hernia (asterisk).</div><div id=\"graphicVersion\">Graphic 90298 Version 2.0</div></div></div>"},"90299":{"type":"graphic_diagnosticimage","displayName":"Barium swallow type III hiatus hernia ","title":"Barium swallow in a patient with a type III paraesophageal hernia ","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Barium swallow in a patient with a type III paraesophageal hernia </div><div class=\"cntnt\"><img style=\"width:599px; height:301px;\" src=\"images/RADIOL/90299_Upper_GI_III_esoph_hern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A chest x-ray prior to contrast administration shows the nasogastric tube coiled in the chest (arrows). <br />(B) Following barium administration through the nasogastric tube, the gastroesophageal junction and the entire stomach are noted within the chest.</div><div id=\"graphicVersion\">Graphic 90299 Version 2.0</div></div></div>"},"90300":{"type":"graphic_diagnosticimage","displayName":"Barium swallow and CT type IV paraesophageal hiatus hernia","title":"Barium swallow and computed tomography (CT) scan in a patient with a type IV paraesophageal hiatus hernia ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Barium swallow and computed tomography (CT) scan in a patient with a type IV paraesophageal hiatus hernia </div><div class=\"cntnt\"><img style=\"width:598px; height:243px;\" src=\"images/RADIOL/90300_Img_IV_hiat_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A barium swallow showing the entire stomach within the chest (asterisk). The gastroesophageal junction (arrow) is above the diaphragm (arrowhead) and the first part of the duodenum (dashed arrow) is at the level of the diaphragm. <br />(B) A CT scan through the lower chest&nbsp;showing the herniated stomach (asterisk) and portions of the colon within the hernial sac in the chest (arrow).</div><div id=\"graphicVersion\">Graphic 90300 Version 2.0</div></div></div>"},"90304":{"type":"graphic_table","displayName":"NSAID pseudoallergic and allergic reactions","title":"Pseudoallergic and allergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pseudoallergic and allergic reactions to nonsteroidal anti-inflammatory drugs (NSAIDs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Eliciting NSAID</td> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Timing of onset of signs/symptoms</td> <td class=\"subtitle1\">Patient comorbidities</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Pseudoallergic NSAID reactions:</strong><br /> <ul> <li>Elicited by multiple NSAIDs (including aspirin) in a susceptible patient </li> <li>Related to the pharmacologic ability of NSAIDs to inhibit COX-1 enzyme </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Type 1</td> <td>Multiple (including aspirin)</td> <td>Common:<br /> <ul class=\"decimal_heading\"> <li>Severe rhinitis, nasal obstruction </li> <li>Bronchospasm </li> <li>Conjunctival injection </li> <li>Facial flushing </li> </ul> Uncommon:<br /> <ul class=\"decimal_heading\"> <li>Throat tightness/laryngospasm </li> <li>Nausea/vomiting </li> <li>Diarrhea </li> <li>Hypotension </li> </ul> </td> <td>Delayed: 30 minutes to three hours after ingestion or administration</td> <td> <ul> <li>Asthma (present in most but not all patients) </li> <li>Chronic rhinosinusitis with nasal polyposis <span style=\"color: black;\">(patients usually have extensive sinusitis on CT&nbsp;and often report anosmia) </span></li> <li>AERD* </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Type 2</td> <td>Multiple (including aspirin)</td> <td>Urticaria and/or angioedema</td> <td>30 to 90 minutes</td> <td>Chronic urticaria (patients may report being able to tolerate NSAIDs when urticaria is in remission)</td> </tr> <tr> <td class=\"indent1\">Type 3</td> <td>Multiple (including aspirin)</td> <td>Urticaria and/or angioedema</td> <td>30 to 90 minutes</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Type 4</td> <td>Multiple (including aspirin)</td> <td>Symptoms affecting both the respiratory tract and skin. Includes patients with AERD who develop cutaneous symptoms in the context of respiratory reactions.</td> <td>Variable depending upon the type of reaction: 30 to 90 minutes</td> <td> <ul> <li>Some patients have AERD and experience systemic reactions with cutaneous symptoms </li> <li>Other patients have no underlying conditions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Allergic NSAID reactions:</strong><br /> <ul> <li>Elicited by a single NSAID (or rarely by more than one agent with very similar structure) in a susceptible patient </li> <li><strong>Not</strong> reported with aspirin </li> <li>Presumed to be IgE-mediated </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Type 5</td> <td>A single NSAID (not aspirin)</td> <td>Cutaneous: Urticaria, pruritus, angioedema</td> <td>Variable: Minutes to a few hours after ingestion/administration</td> <td>None</td> </tr> <tr> <td class=\"indent1\">Type 6</td> <td>A single NSAID (not aspirin)</td> <td>Anaphylaxis (probably a more severe form of type 5)</td> <td>Variable: Minutes to a few hours after ingestion/administration</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COX-1: cyclooxygenase, isoform 1; CT: computed tomography; AERD: aspirin-exacerbated respiratory disease; IgE: immunoglobulin E.<br />* AERD refers to the triad of asthma, chronic rhinosinusitis with nasal polyposis, and aspirin (or NSAID)-induced type 1 pseudoallergic reactions.</div><div id=\"graphicVersion\">Graphic 90304 Version 18.0</div></div></div>"},"90308":{"type":"graphic_table","displayName":"Trials of hydration and nutrition at end of life","title":"Selected trials of hydration and/or nutrition in end of life patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected trials of hydration and/or nutrition in end of life patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Authors</td> <td class=\"subtitle1\">Journal</td> <td class=\"subtitle1\">Year of publication</td> <td class=\"subtitle1\">Study design</td> <td class=\"subtitle1\">Participant characteristics</td> <td class=\"subtitle1\">Fluid regimen</td> <td class=\"subtitle1\">Outcome variables</td> <td class=\"subtitle1\">Description of results</td> <td class=\"subtitle1\">Impact of hydration</td> <td class=\"subtitle1\">Sample size</td> </tr> <tr class=\"divider_bottom\"> <td>Waller, Hershkowitz, Adunsky</td> <td>Am J Hosp Palliat Care</td> <td>1994</td> <td>Observational study</td> <td>68 consecutive advanced cancer patients within 48 hours of death</td> <td>13 received fluids</td> <td>State of consciousness</td> <td>State of consciousness correlated inversely with sodium and urine osmolality; no correlation between administration of fluids and hydration status, or improvement in consciousness</td> <td>Negative</td> <td>68</td> </tr> <tr class=\"divider_bottom\"> <td>McCann, Hall, Groth-Juncker</td> <td>JAMA</td> <td>1994</td> <td>Uncontrolled trial</td> <td>32 mentally aware, with terminal illness in comfort care unit</td> <td>Provision of comfort care without forced feeding, forced hydration, or parenteral nutrition</td> <td>Symptoms of hunger, thirst, dry mouth</td> <td>63 percent no hunger, 34 percent only initial hunger, 62 percent no thirst or only initial thirst</td> <td>Negative</td> <td>32</td> </tr> <tr class=\"divider_bottom\"> <td>Musgrave, Bartal, Opstad</td> <td>J Palliat Care</td> <td>1995</td> <td>Uncontrolled trial</td> <td>30 cancer patients in last day of life</td> <td>All received IV fluids (500 to 3000 mL)</td> <td>Level of thirst</td> <td>Among alert patients, all experienced some level of thirst</td> <td>Negative</td> <td>30</td> </tr> <tr class=\"divider_bottom\"> <td>Ellershaw, Sutcliffe, Saunders</td> <td>J Pain Symptom Manage</td> <td>1995</td> <td>Observational study</td> <td>82 cancer patients two days before death</td> <td>No artificial fluids</td> <td>Symptoms of respiratory secretions, thirst, dry mouth</td> <td>No relationship between dehydration (osmolality) and thirst</td> <td>Negative</td> <td>82</td> </tr> <tr class=\"divider_bottom\"> <td>Cerchietti, Navigante, Sauri, Palazzo</td> <td>Int J Palliat Nurs</td> <td>2000</td> <td>Randomized controlled trial</td> <td>42 advanced cancer patients thought to be dehydrated</td> <td>Two day intervention; 1000 mL/day</td> <td>Thirst, nausea, delirium, score on the mini-mental status examination (MMSE), anguish, mood; adverse effects</td> <td>Generally not significantly different in groups, equivocal findings regarding nausea</td> <td>Negative</td> <td>42</td> </tr> <tr class=\"divider_bottom\"> <td>Morita, Tei, Tsunoda, et al</td> <td>Support Care Cancer</td> <td>2001</td> <td>Observational study</td> <td>88 consecutive terminally ill cancer patients in hospice care</td> <td>None</td> <td>Intensity of thirst on visual analogue scale (VAS)</td> <td>No correlation of thirst scores and total protein, blood urea nitrogen, creatinine, sodium, hematocrit or atrial natriuretic peptide, osmolality</td> <td>Negative</td> <td>88</td> </tr> <tr class=\"divider_bottom\"> <td>Bruera, Sala, Rico, et al</td> <td>J Clin Oncol</td> <td>2005</td> <td>Randomized controlled trial</td> <td>Patients with advanced cancer thought to be dehydrated; 27 treatment patients and 33 control patients</td> <td>Two day intervention; 1000 mL/day</td> <td>Global assessment of overall benefit of hydration by patient and clinician; sedation, fatigue, hallucinations, myoclonus, MMSE, adverse effects</td> <td>Sedation and myoclonus, and composite score of four symptoms (sedation, fatigue, hallucinations, myoclonus) improved in intervention group; proportion of participants perceived to benefit &#62;50 percent was significant for clinicians but not for patients</td> <td>Mixed result</td> <td>60</td> </tr> <tr class=\"divider_bottom\"> <td>Morita, Hyodo, Yoshimi, et al</td> <td>Ann Oncol</td> <td>2005</td> <td>Prospective controlled trial</td> <td>Advanced cancer patients; 59 hydrated patients and 167 non-hydrated patients</td> <td>Three week intervention; 1000 mL/day</td> <td>Dehydration, fluid retention (ascites, bronch secretions, edema), delirium, myoclonus, bedsores, agitation, communication capacity</td> <td>No significant difference</td> <td>Negative</td> <td>226</td> </tr> <tr class=\"divider_bottom\"> <td>Bruera, Hui, Dalal, et al</td> <td>J Clin Oncol</td> <td>2013</td> <td>Randomized controlled trial</td> <td>129 cancer patients in hospice care</td> <td>Hydration with 1000 milliliters (mL) versus 100 mL for seven days</td> <td>Symptoms and scales for dehydration, delirium, myoclonus, survival</td> <td>No difference between treatment and control groups in delirium scores or dehydration symptoms (a composite score of fatigue, myoclonus, sedation and hallucinations), at day four or day seven</td> <td>Negative</td> <td>129</td> </tr> <tr> <td>Nakajima, Hata, Kusumuto</td> <td>J Palliat Med</td> <td>2013</td> <td>Observational study</td> <td>75 terminally ill patients with GI malignancy</td> <td>Hydration 1000 mL one and three weeks before death (n = 32) versus no hydration (n = 43)</td> <td>Deterioration in hydration score</td> <td>Dehydration score higher in non-hydration group (35 versus 13 percent, p.03); edema/ascites/bronch secretions higher in hydration group (57 versus 33 percent, p.04)</td> <td>No net benefit (benefit counter balanced by adverse affects)</td> <td>75</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90308 Version 1.0</div></div></div>"},"90313":{"type":"graphic_table","displayName":"ADP mutations","title":"Mutations identified in ALA dehydratase porphyria (ADP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mutations identified in ALA dehydratase porphyria (ADP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Case</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\" colspan=\"2\">Mutations</td> <td class=\"subtitle1\">Reference(s)</td> </tr> <tr> <td>1</td> <td>15</td> <td>Germany</td> <td>V153M</td> <td>818delITC</td> <td>Akagi R, Shimizu R, Furuyama K, et al. Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria. Hepatology 2000; 31:704.</td> </tr> <tr> <td>2</td> <td>15</td> <td>Germany</td> <td>R240W</td> <td>A274T</td> <td> <p>Ishida N, Fujita H, Noguchi T, et al. Message amplification phenotyping of an inherited delta-aminolevulinate dehydratase deficiency in a family with acute hepatic porphyria. Biochem Biophys Res Commun 1990; 172:237.</p> Ishida N, Fujita H, Fukuda Y, et al. Cloning and expression of the defective genes from a patient with d-aminolevulinate dehydratase porphyria. J Clin Invest 1992; 89:1431.</td> </tr> <tr> <td>3</td> <td>Birth</td> <td>Sweden</td> <td>G133R</td> <td>V275M</td> <td> <p>Plewinska M, Thunell S, Holmberg L, et al. D-aminolevulinate dehydratase deficient porphyria: Identification of the molecular lesions in a severely affected homozygote. Am J Hum Genet 1991; 49:167.</p> Maruno M, Furuyama K, Akagi R, et al. Highly heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 2001; 97:2972.</td> </tr> <tr> <td>4</td> <td>63</td> <td>Belgium</td> <td>K59N; G133R</td> <td>&nbsp;</td> <td>Akagi R, Nishitani C, Harigae H, et al. Molecular analysis of delta-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria. Blood 2000; 96:3618.</td> </tr> <tr> <td>5</td> <td>15</td> <td>Germany</td> <td>&ndash;11C&#62;T</td> <td>&ndash;11C&#62;A</td> <td>Doss MO, Stauch T, Gross U, et al. The third case of doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 2004; 27:529.</td> </tr> <tr> <td>6</td> <td>14</td> <td>United States</td> <td>E89K</td> <td>C132R</td> <td>Akagi R, Kato N, Inoue R, et al. D-aminolevulinate dehydratase (ALAD) porphyria: The first case in north america with two novel ALAD mutations. Mol Genet Metab 2006; 87:329.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table shows mutations identified in ALA dehydratase porphyria (ADP) in order of the initial case reports. Please refer to the UpToDate topic on ADP for further details.</div><div class=\"graphic_footnotes\">ALA: delta-aminolevulinic acid; ADP: ALA dehydratase porphyria.</div><div id=\"graphicVersion\">Graphic 90313 Version 1.0</div></div></div>"},"90314":{"type":"graphic_figure","displayName":"Benefit of human milk on necrotizing enterocolitis","title":"The beneficial effect of human milk on reducing pathogenetic risk factors for necrotizing enterocolitis (NEC)","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">The beneficial effect of human milk on reducing pathogenetic risk factors for necrotizing enterocolitis (NEC)</div><div class=\"cntnt\"><img style=\"width:534px; height:602px;\" src=\"images/PEDS/90314_Ben_hum_milk_entercolitis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Immaturity of the intestinal epithelial barrier and neonatal mucosal immune system predispose the premature infant to bacterial invasion, which triggers the sequence of NEC. Stimulation of pro-inflammatory cytokines compromises intestinal defenses. Imbalance between epithelial cell injury and repair leads to a cycle of bacterial invasion, immune activation, uncontrolled inflammation, and gut barrier failure.<br />(B) Human milk provides oligosaccharides, acetylhydrolase, and mucosal immune components; alters bacterial flora; affects mucus coat; decreases epithelial permeability; increases peristalsis (motility); and lowers gastric pH, which enhances barrier function.</div><div class=\"graphic_footnotes\">NICU: neonatal intensive care unit; NO: nitric oxide; TNF-&alpha;: tumor necrosis factor-alpha.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Pediatric Research. Hunter CJ, Upperman JS, Ford HR, Camerini V. Understanding the Susceptibility of the Premature Infant to Necrotizing Enterocolitis (NEC). Pediatr Res 2008; 63:117. Copyright &copy; 2008. <a href=\"http://www.nature.com/pr\" target=\"_blank\">www.nature.com/pr</a>.</div><div id=\"graphicVersion\">Graphic 90314 Version 2.0</div></div></div>"},"90315":{"type":"graphic_picture","displayName":"HIVAN light microscopy","title":"HIVAN light microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">HIVAN light microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/NEPH/90315_HIVAN_light_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The glomerular capillary lumina are obliterated by collapse of glomerular basement membranes, with hypertrophy and hyperplasia of overlying glomerular epithelial cells containing numerous protein resorption droplets (Jones' methenamine silver, 400x).</div><div class=\"graphic_reference\">Reproduced from: Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: Clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol 2008; 28:513. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90315 Version 1.0</div></div></div>"},"90316":{"type":"graphic_picture","displayName":"HIVAN electron microscopy ","title":"HIVAN electron microscopy ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">HIVAN electron microscopy </div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/NEPH/90316_HIVAN_electron_microscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large tubuloreticular inclusion is seen within a glomerular endothelial cell (electron micrograph, x40,000).</div><div class=\"graphic_reference\">Reproduced from: Wyatt CM, Klotman PE, D'Agati VD. HIV-associated nephropathy: Clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy. Semin Nephrol 2008; 28:513. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90316 Version 2.0</div></div></div>"},"90319":{"type":"graphic_picture","displayName":"Vitiligo PI","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/90319_Vitiligo_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vitiligo often affects the fingers and hands.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90319 Version 1.0</div></div></div>"},"90320":{"type":"graphic_picture","displayName":"Segmental vitiligo PI","title":"Segmental vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segmental vitiligo</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PI/90320_Segmental_vitiligo_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental vitiligo often does not affect the left and right side of the body in the same way.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 90320 Version 1.0</div></div></div>"},"90323":{"type":"graphic_table","displayName":"Donor exclusion criteria for fecal microbiota transplant","title":"Donor exclusion criteria for fecal microbiota transplant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Donor exclusion criteria for fecal microbiota transplant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute</td> </tr> <tr> <td class=\"subtitle2_single\">Risk of infectious agent</td> </tr> <tr> <td class=\"indent1\">Known HIV, hepatitis B or C infections</td> </tr> <tr> <td class=\"indent1\">Known exposure to HIV or viral hepatitis (within the previous 12 months)</td> </tr> <tr> <td class=\"indent1\">High-risk sexual behaviors</td> </tr> <tr> <td class=\"indent1\">Use of illicit drugs</td> </tr> <tr> <td class=\"indent1\">Tattoo or body piercing within six months</td> </tr> <tr> <td class=\"indent1\">Incarceration or history of incarceration</td> </tr> <tr> <td class=\"indent1\">Known current communicable disease (eg, upper respiratory tract infection)</td> </tr> <tr> <td class=\"indent1\">Risk factors for variant Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"indent1\">Travel (within the last six months) to areas of the world where diarrheal illnesses are endemic or risk of traveler's diarrhea is high</td> </tr> <tr> <td class=\"subtitle2_single\">Gastrointestinal comorbidities</td> </tr> <tr> <td class=\"indent1\">History of inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">History of IBS, idiopathic chronic constipation, or chronic diarrhea</td> </tr> <tr> <td class=\"indent1\">History of gastrointestinal malignancy or known polyposis</td> </tr> <tr> <td class=\"subtitle2_single\">Factors that can or do affect the composition of the intestinal microbiota</td> </tr> <tr> <td class=\"indent1\">Antibiotics within the preceding three months</td> </tr> <tr> <td class=\"indent1\">Major immunosuppressive medications (eg, calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc)</td> </tr> <tr> <td class=\"indent1\">Systemic antineoplastic agents</td> </tr> <tr> <td class=\"subtitle2_single\">Additional recipient-specific considerations</td> </tr> <tr> <td class=\"indent1\">Recent ingestion of a potential allergen (eg, nuts) where recipient has a known allergy to this (these) agent(s)</td> </tr> <tr> <td class=\"subtitle1_single\">Relative exclusion criteria that might be appropriate to consider</td> </tr> <tr> <td class=\"indent1\">History of major gastrointestinal surgery (eg, gastric bypass)</td> </tr> <tr> <td class=\"indent1\">Metabolic syndrome</td> </tr> <tr> <td class=\"indent1\">Systemic autoimmunity (eg, multiple sclerosis, connective tissue disease)</td> </tr> <tr> <td class=\"indent1\">Atopic diseases including asthma and eczema, eosinophilic disorders of the gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Chronic pain syndromes (eg, chronic fatigue syndrome, fibromyalgia)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; IBS: irritable bowel syndrome.</div><div class=\"graphic_reference\">Data from: Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044.</div><div id=\"graphicVersion\">Graphic 90323 Version 2.0</div></div></div>"},"90325":{"type":"graphic_table","displayName":"GRADE","title":"GRADE for practice guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GRADE for practice guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade of recommendation*</td> <td class=\"subtitle1\">Clarity of risk/benefit</td> <td class=\"subtitle1\">Quality of supporting evidence</td> <td class=\"subtitle1\">Implications</td> </tr> <tr class=\"divider_bottom\"> <td> <p>1A</p> <p>Strong recommendation</p> High quality evidence</td> <td>Benefits clearly outweigh risk and burdens, or vice versa</td> <td>Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.</td> <td>Strong recommendation, can apply to most patients in most circumstances without reservation</td> </tr> <tr class=\"divider_bottom\"> <td> <p>1B</p> <p>Strong recommendation</p> Moderate quality evidence</td> <td>Benefits clearly outweigh risk and burdens, or vice versa</td> <td>Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.</td> <td>Strong recommendation, likely to apply to most patients</td> </tr> <tr class=\"divider_bottom\"> <td> <p>1C</p> <p>Strong recommendation</p> Low quality evidence</td> <td>Benefits appear to outweigh risk and burdens, or vice versa</td> <td>Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.</td> <td>Relatively strong recommendation; might change when higher quality evidence becomes available</td> </tr> <tr class=\"divider_bottom\"> <td> <p>2A</p> <p>Weak recommendation</p> High quality evidence</td> <td>Benefits closely balanced with risks and burdens</td> <td>Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.</td> <td>Weak recommendation, best action may differ depending on circumstances or patients or societal values</td> </tr> <tr class=\"divider_bottom\"> <td> <p>2B</p> <p>Weak recommendation</p> Moderate quality evidence</td> <td>Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens</td> <td>Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.</td> <td>Weak recommendation, alternative approaches likely to be better for some patients under some circumstances</td> </tr> <tr> <td> <p>2C</p> <p>Weak recommendation</p> Low quality evidence</td> <td>Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens</td> <td>Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.</td> <td>Very weak recommendation; other alternatives may be equally reasonable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* GRADE can be implemented with either three or four levels of quality of evidence. UpToDate implements three levels and uses numbers and letters to represent strength of recommendation and quality of evidence respectively.</div><div id=\"graphicVersion\">Graphic 90325 Version 2.0</div></div></div>"},"90330":{"type":"graphic_figure","displayName":"Modified Karaydakis flap","title":"Modified Karydakis flap - Lateral advancing flap","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Modified Karydakis flap - Lateral advancing flap</div><div class=\"cntnt\"><img style=\"width:515px; height:292px;\" src=\"images/SURG/90330_ModifiedKaraydakisflap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flap should be created first, usually 2 cm wide and 0.5 cm deep. The skin flap should be gently pulled across the midline with skin hooks to determine if the outer rim of the \"ellipse\" has been made correctly on the skin. The ellipse should include all sinuses. </div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Karydakis GE. New approach to the problem of pilonidal sinus. Lancet 1973; 2:1414. </LI>&#xD;&#xA;<LI>Karydakis GE. Easy and successful treatment of pilonidal sinus after explanation of its causative processes. Aust NZ J Surg 1992; 62:385. </LI>&#xD;&#xA;<LI>Bascom J, Bascom T. Failed pilonidal surgery: New paradigm and new operation leading to cures. Arch Surg 2002; 137:1146. </LI>&#xD;&#xA;<LI>Kitchen PR. Pilonidal sinus: Excision and primary closure with a lateralised wound - The Karydakis operation. Aust N Z J Surg 1982; 52:302.</LI></OL></div><div id=\"graphicVersion\">Graphic 90330 Version 4.0</div></div></div>"},"90331":{"type":"graphic_diagnosticimage","displayName":"MERS-CoV chest imaging","title":"Imaging findings at presentation in Saudi patients with Middle East respiratory syndrome cororavirus infection","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Imaging findings at presentation in Saudi patients with Middle East respiratory syndrome cororavirus infection</div><div class=\"cntnt\"><img style=\"width:512px; height:279px;\" src=\"images/ID/90331_MERS_CoV_chest_imaging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Chest radiograph of a 61-year-old man, showing bilateral fine reticulonodular air-space opacities, increased vascular markings, and cardiomegaly.<br />(Panel B) Chest radiograph of an 83-year-old man, showing right lung consolidation, right basal pleural thickening, and reticulonodular air-space opacities; rib fractures on the right are old.<br />(Panel C) Chest radiograph of a 56-year-old man, showing extensive bilateral extensive diffuse and focal alveolar space opacities, with opacification of the left lower lobe.<br />(Panel D) Chest radiograph of a 67-year-old man, showing extensive bilateral disease, with diffuse alveolar space densities, opacification, reticulonodular opacities, and bronchial wall thickening.<br />(Panel E) Chest radiograph of a 49-year-old man, showing extensive bilateral mid and lower zone disease, with diffuse reticulonodular alveolar space opacities. A thoracic&nbsp;computed tomography&nbsp;scan in the same patient (Panel F) shows extensive bilateral opacities and ground-glass reticulonodular shadowing and bronchiolar wall thickening.</div><div class=\"graphic_reference\">Reproduced from: Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90331 Version 4.0</div></div></div>"},"90332":{"type":"graphic_table","displayName":"How children understand death","title":"Childhood developmental understanding of death","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Childhood developmental understanding of death</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infants and toddlers (0 to 2 years)</td> </tr> <tr> <td>Developmental context: establishing attachment and trust<br /> <ul class=\"decimal_heading\"> <li>Have no understanding of finality of separation, but feel absence of a familiar caregiver </li> <li>May be distressed by disruptions in routines </li> <li>Will be affected by the emotional distress/grief of surviving adult caregivers </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Pre-schoolers (3 to 6 years)</td> </tr> <tr> <td>Developmental context: driven by egocentrism, magical thinking, associative logic<br /> <ul class=\"decimal_heading\"> <li>Are not able to understand that death is irreversible and permanent </li> <li>May attribute death or survivors' emotional distress to own actions or attributes </li> <li>Distress and behavioral changes may be fueled by disruption in routine </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">School-age children (7 to 12 years)</td> </tr> <tr> <td>Developmental context: mastering skills, fairness, cause and effect logic, peer relationships<br /> <ul class=\"decimal_heading\"> <li>Understand that death is final and irreversible </li> <li>May have difficulty with abstract/spiritual issues </li> <li>May ask factual questions that can be painful or offensive to adults </li> <li>May struggle with unfairness of loss </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Adolescents (13 and above)</td> </tr> <tr> <td>Developmental context: working on separation-individuation, identity formation<br /> <ul class=\"decimal_heading\"> <li>Understand that death is final, irreversible, and universal </li> <li>May struggle with existential issues </li> <li>May focus on personal effects of loss </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Muriel AC, Rauch PK. Talking with families and children about the death of a parent. In: Oxford Textbook of Palliative Medicine, 4th ed, Hanks G, Cherny NI, Christakis NA, et al (Eds), Oxford University Press 2010. Reproduced by permission of Oxford University Press. Copyright &copy; 2010. <a href=\"http://www.oup.com/\" target=\"_blank\">www.oup.com</a>.</div><div id=\"graphicVersion\">Graphic 90332 Version 3.0</div></div></div>"},"90333":{"type":"graphic_table","displayName":"Preparing children for visits to an ill or dying parent","title":"Facilitating visits by children to an ill or dying parent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Facilitating visits by children to an ill or dying parent</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Provide supported visits to all children</td> </tr> <tr> <td>Explore and alleviate worries or reluctance about visiting</td> </tr> <tr> <td>Prepare children for what they will see:<br /> <ul class=\"decimal_heading\"> <li>Hospital or hospice setting </li> <li>Medical equipment </li> <li>Physical condition of parent </li> <li>Functional status of parent </li> <li>Other patients </li> </ul> </td> </tr> <tr> <td>Bring an extra supportive adult who can leave when the child is ready</td> </tr> <tr> <td>Provide structure or activity for younger children</td> </tr> <tr> <td>Avoid an agitated or delirious parent</td> </tr> <tr> <td>Debrief after the visit</td> </tr> <tr> <td>Provide alternatives to an in-person visit</td> </tr> <tr> <td>Remember that there are many opportunities to say goodbye</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Muriel AC, Rauch PK. Talking with families and children about the death of a parent. In: Oxford Textbook of Palliative Medicine, 4th ed, Hanks G, Cherny NI, Christakis NA, et al (Eds), Oxford University Press 2010. Reproduced by permission of Oxford University Press. Copyright &copy; 2010. <a href=\"http://www.oup.com/\"  target=\"_blank\">www.oup.com</a>.</div><div id=\"graphicVersion\">Graphic 90333 Version 3.0</div></div></div>"},"90334":{"type":"graphic_picture","displayName":"Plaque psoriasis on knee PI","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/90334_Plaque_psoriasis_knee_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque-type psoriasis causes the skin to form red, raised, scaly areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90334 Version 1.0</div></div></div>"},"90335":{"type":"graphic_picture","displayName":"Guttate psoriasis on trunk PI","title":"Guttate psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Guttate psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PI/90335_Guttate_psoriasis_trunk_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Guttate psoriasis causes many small, red, scaly plaques to appear on the body.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90335 Version 1.0</div></div></div>"},"90338":{"type":"graphic_table","displayName":"Initiating parenteral nutrition","title":"Initiating parenteral nutrition (PN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initiating parenteral nutrition (PN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup wdith=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Step</td> <td class=\"subtitle1\">Calculations and considerations</td> </tr> <tr class=\"divider_bottom\"> <td>1. Assess medical status and determine nutrition goals</td> <td> <p>Does the patient meet indications for parenteral nutrition (PN)?</p> <p>Is anticipated duration of PN &#62;2 weeks?</p> Will PN be used to provide full or partial nutritional requirements?</td> </tr> <tr class=\"divider_bottom\"> <td>2. Assess venous access</td> <td> <p>Does the patient require central venous access to meet nutritional needs (as for most patients requiring PN)?</p> If central venous access is necessary, consider type of catheter and number of lumens needed to accommodate PN and any other therapies. Verify that catheter is centrally placed prior to starting PN, using radiography.</td> </tr> <tr class=\"divider_bottom\"> <td>3. Determine weight</td> <td>Consider which weight measure will be used to determine the patient's nutritional targets (eg, actual body weight, dry weight, ideal body weight, usual body weight, or an adjusted body weight).</td> </tr> <tr class=\"divider_bottom\"> <td>4. Calculate fluid requirements/volume of PN to be provided</td> <td> <p>Review patient's fluid status, intake/output balance, gastrointestinal losses, etc.</p> <p>Use Holliday-Segar formula to estimate initial fluid requirements, and then adjust as needed based on the patient's individual needs.</p> The estimated fluid requirement determines the approximate total volume available for PN. Most patients can tolerate fluid administration at 30 to 50 percent above maintenance needs.</td> </tr> <tr class=\"divider_bottom\"> <td>5. Assess total energy requirements and approximate targets for carbohydrate, fat and protein intake</td> <td> <p>Estimate energy (caloric) needs for PN at ~80 percent of enteral requirements.</p> Provide 40 to 60 percent of calories from dextrose, 20 to 50 percent of calories from fat, and 10 to 20 percent of calories from protein/amino acid.</td> </tr> <tr class=\"divider_bottom\"> <td>6. Assess protein requirements</td> <td> <p>Assess whether the patient has increased protein needs (eg, due to gastrointestinal protein losses, wound healing, etc).</p> Calculate total grams of protein in g/kg, g/day, and g/L.</td> </tr> <tr class=\"divider_bottom\"> <td>7. Calculate grams of fat or mL of lipid</td> <td> <p>20 percent lipid emulsion provides 20 g fat per 100 mL solution, or 2 kcal/mL.</p> Energy from fat (kcal/day) &#247; 2 kcal/mL = mL/day of lipid.</td> </tr> <tr class=\"divider_bottom\"> <td>8. Calculate grams of dextrose</td> <td>Energy to be provided from dextrose &#247; 3.4 kcal/g of dextrose = g dextrose.</td> </tr> <tr class=\"divider_bottom\"> <td>9. Calculate glucose infusion rate (GIR)</td> <td> <p>GIR (mg/kg/min) = grams dextrose/kg x 1000 mg/g &#247; minutes of infusion</p> (minutes of infusion = 1440 min. if given for 24 hours).</td> </tr> <tr class=\"divider_bottom\"> <td>10. Assess electrolyte requirements</td> <td> <p>Determine mEq per kilogram and total mEq/L.</p> Refer to table describing electrolyte requirements.</td> </tr> <tr class=\"divider_bottom\"> <td>11. Assess vitamin/mineral and trace element requirements</td> <td>Check with pharmacist to see which products are available and what concentrations are compatible.</td> </tr> <tr class=\"divider_bottom\"> <td>12. Calculate osmolality of solution (if intravenous access is peripheral)</td> <td> <p>mOsm/L = (g amino acid/L x 10) + (g dextrose x 5) + [(mEq Na + K + Ca/L) x 2].</p> Solution must be &#60;900 mOsm/L for peripheral administration.</td> </tr> <tr> <td>13. Determine rate of infusion</td> <td> <p>Total volume to be infused in mL &#247; hours of infusion time = rate mL/hour.</p> Refer to section on \"cycling\" if infusion &#60;24 hours.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">mEq: milliequivalents; mOsm: milliosmoles.</div><div class=\"graphic_reference\">Modified with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90338 Version 7.0</div></div></div>"},"90341":{"type":"graphic_figure","displayName":"Pediatric parenteral nutrition calculation","title":"Pediatric parenteral nutrition calculation","html":"<div class=\"graphic\"><div style=\"width: 718px\" class=\"figure\"><div class=\"ttl\">Pediatric parenteral nutrition calculation</div><div class=\"cntnt\"><img style=\"width:698px; height:886px;\" src=\"images/PEDS/90341_Ped_parenteral_nutrit_calc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PN: parenteral nutrition; NPO: nil per os (nothing by mouth); PICC: peripherally inserted central catheter; CHO: carbohydrate; AAS: amino acid solution; IVFE: intravenous fat emulsion; D50: 50 percent dextrose in water (500 mg dextrose/mL).</div><div class=\"graphic_reference\">Courtesy of Drs. Susan and Robert Baker.</div><div id=\"graphicVersion\">Graphic 90341 Version 3.0</div></div></div>"},"90342":{"type":"graphic_figure","displayName":"HLH mechanics of cytotoxic function","title":"Mechanics of cytotoxic function revealed by HLH-associated gene mutations","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Mechanics of cytotoxic function revealed by HLH-associated gene mutations</div><div class=\"cntnt\"><img style=\"width:606px; height:370px;\" src=\"images/HEME/90342_HLH_mech_cytotoxic_funct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HLH-associated genetic abnormalities (in the indicated genes) may affect granule-dependent lymphocyte cytotoxicity by impairing trafficking, docking, priming for exocytosis, or membrane fusion of cytolytic granules. The function of this pathway may also be severely impaired by loss of functional perforin, the key delivery molecule for proapoptotic granzymes. Diverse mutations in this pathway all give rise to similar clinical phenotypes (albeit of variable severity). Lyst (the gene affected in Chediak-Higashi syndrome) is not portrayed because its function is not entirely clear, although it appears to play an important role in the maintenance of normally sized (and functional) cytolytic granules. Refer to the UpToDate topics on HLH for further details.</div><div class=\"graphic_footnotes\">HLH: hemophagocytic lymphohistiocytosis; CTL: cytotoxic T lymphocyte; NK cell: natural killer cell; SNARE: Soluble N-ethylmaleimide-Sensitive-Fusion-attachment protein REceptor; v-SNARE: vesicle-SNARE ; t-SNARE: target compartment SNARE.</div><div class=\"graphic_reference\">This research was originally published in Blood. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011; 118:4041-52. Copyright © 2011 the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 90342 Version 1.0</div></div></div>"},"90346":{"type":"graphic_figure","displayName":"Immune activation","title":"Immune activation and checkpoint inhibition","html":"<div class=\"graphic\"><div style=\"width: 956px\" class=\"figure\"><div class=\"ttl\">Immune activation and checkpoint inhibition</div><div class=\"cntnt\"><img style=\"width:936px; height:732px;\" src=\"images/ONC/90346_Immune_activation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Scott Gettinger, MD.</div><div id=\"graphicVersion\">Graphic 90346 Version 1.0</div></div></div>"},"90347":{"type":"graphic_table","displayName":"Fracture healing rates according to primary cancer type","title":"Fracture healing rates according to primary cancer type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fracture healing rates according to primary cancer type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Underlying disease</td> <td class=\"subtitle1\">Fracture healing rate (percent)</td> </tr> <tr> <td>Myeloma</td> <td class=\"centered\">67</td> </tr> <tr> <td>Renal cell cancer</td> <td class=\"centered\">44</td> </tr> <tr> <td>Breast cancer</td> <td class=\"centered\">37</td> </tr> <tr> <td>Lung cancer</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Gainor BJ, et al. Clin Orthop Relat Res 1983; 178:297.</div><div id=\"graphicVersion\">Graphic 90347 Version 2.0</div></div></div>"},"90356":{"type":"graphic_picture","displayName":"Spider nevus","title":"Cutaneous spider angioma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cutaneous spider angioma</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/PULM/90356_Spider_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spider nevus in a patient with liver cirrhosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90356 Version 1.0</div></div></div>"},"90357":{"type":"graphic_figure","displayName":"PD1 versus PDL1","title":"PD1 versus PDL1 blockade","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">PD1 versus PDL1 blockade</div><div class=\"cntnt\"><img style=\"width:538px; height:458px;\" src=\"images/ONC/90357_PD1_versus_PDL1.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90357 Version 2.0</div></div></div>"},"90358":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis II","title":"Right middle lobe atelectasis after right upper lobe lobectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis after right upper lobe lobectomy</div><div class=\"cntnt\"><img style=\"width:429px; height:442px;\" src=\"images/PULM/90358_RML_atelectasis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Status post right upper lobe lobectomy with right middle lobe atelectasis mimicking a loculated right pleural effusion.</div><div id=\"graphicVersion\">Graphic 90358 Version 1.0</div></div></div>"},"90359":{"type":"graphic_diagnosticimage","displayName":"RML atelectasis III","title":"Right middle lobe atelectasis after right upper lobe lobectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right middle lobe atelectasis after right upper lobe lobectomy</div><div class=\"cntnt\"><img style=\"width:430px; height:405px;\" src=\"images/PULM/90359_RML_atelectasis_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Status post right upper lobe lobectomy with right middle lobe atelectasis mimicking a right hilar mass.</div><div id=\"graphicVersion\">Graphic 90359 Version 1.0</div></div></div>"},"90362":{"type":"graphic_picture","displayName":"Pustular psoriasis pustules PI","title":"Pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/PI/90362_Pustular_psoriasis_pust_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin redness and numerous pustules occur in pustular psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90362 Version 1.0</div></div></div>"},"90363":{"type":"graphic_picture","displayName":"Nail psoriasis pits PI","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/90363_Nail_psoriasis_pits_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with psoriasis sometimes develop pits on their nails, like the ones shown here.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90363 Version 1.0</div></div></div>"},"90364":{"type":"graphic_picture","displayName":"Nail psoriasis oil spots PI","title":"Nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/90364_Nail_psoriasis_oil_spot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nails of people with psoriasis sometimes develop tan-brown color changes, like those shown here. &nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90364 Version 1.0</div></div></div>"},"90365":{"type":"graphic_picture","displayName":"Onychoschizia","title":"Onychoschizia","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Onychoschizia</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/90365_Onychoschizia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychoschizia is characterized by horizontal splits of the distal nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90365 Version 1.0</div></div></div>"},"90366":{"type":"graphic_diagnosticimage","displayName":"Skin fold mimicking a pneumothorax I","title":"Skin fold mimicking a left simple pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin fold mimicking a left simple pneumothorax</div><div class=\"cntnt\"><img style=\"width:440px; height:363px;\" src=\"images/PULM/90366_Skin_fold_mim_pneumo_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with left ventricular failure and pulmonary edema. The left-sided skin fold that was initially mistaken for a pneumothorax displays a gradual lateral increase in opacity with an abrupt drop-off and a dark Mach band as its lateral contour (arrows) instead of a white visceral pleural line. Note the pulmonary vascular structures and the lung texture extending beyond the skin fold. These skin folds can develop when technologists insert the cassette under a supine patient from the opposite side of the skin fold and bunch up the skin of the back.</div><div id=\"graphicVersion\">Graphic 90366 Version 1.0</div></div></div>"},"90367":{"type":"graphic_diagnosticimage","displayName":"Simple pneumothorax I","title":"Left simple pneumothorax","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left simple pneumothorax</div><div class=\"cntnt\"><img style=\"width:441px; height:340px;\" src=\"images/PULM/90367_Simple_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows left simple pneumothorax with arrows pointing to the site of measurements in order to estimate the percentage pneumothorax as the average of the three measurements in millimeters.</div><div id=\"graphicVersion\">Graphic 90367 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"90369":{"type":"graphic_diagnosticimage","displayName":"Skin fold mimicking a pneumothorax II","title":"Skin fold mimicking a right simple pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin fold mimicking a right simple pneumothorax</div><div class=\"cntnt\"><img style=\"width:440px; height:469px;\" src=\"images/PULM/90369_Skin_fold_mim_pneumo_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates a right skin fold superimposed on the right lung (arrows). This skin fold shows gradual increase in opacity towards the periphery with an abrupt drop-off and a black Mach band. Pulmonary vessels extend beyond the edge of the skin fold towards the periphery. The skin fold was formed during the insertion of the cassette from left to right.</div><div id=\"graphicVersion\">Graphic 90369 Version 1.0</div></div></div>"},"90370":{"type":"graphic_diagnosticimage","displayName":"Bilateral bullae","title":"Bullae mimicking pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullae mimicking pneumothorax</div><div class=\"cntnt\"><img style=\"width:442px; height:379px;\" src=\"images/PULM/90370_Bilateral_bullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with bilateral large upper lobe bullae. The inferomedial contour of the bullae is concave superolaterally and allows for differentiation from the straight or convex visceral pleural lines formed by a pneumothorax.</div><div id=\"graphicVersion\">Graphic 90370 Version 1.0</div></div></div>"},"90371":{"type":"graphic_diagnosticimage","displayName":"Giant bullae","title":"Giant bullae mimicking pneumothorax with compressive atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Giant bullae mimicking pneumothorax with compressive atelectasis</div><div class=\"cntnt\"><img style=\"width:439px; height:448px;\" src=\"images/PULM/90371_Giant_bullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with bilateral giant upper lobe bullae. The straight or convex visceral pleural line characteristic of a pneumothorax is absent. The lower lobes on both sides are retracted caudad.</div><div id=\"graphicVersion\">Graphic 90371 Version 1.0</div></div></div>"},"90372":{"type":"graphic_diagnosticimage","displayName":"Iatrogenic pneumothorax","title":"Iatrogenic pneumothorax due to chest tube in bulla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iatrogenic pneumothorax due to chest tube in bulla</div><div class=\"cntnt\"><img style=\"width:432px; height:489px;\" src=\"images/PULM/90372_Iatrogenic_pneumothor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in the same patient with bilateral giant upper lobe bullae. A right-sided chest tube was inserted by mistake. Now a small inferolateral pneumothorax can be seen with a vertical visceral pleural line visible (arrow).</div><div id=\"graphicVersion\">Graphic 90372 Version 1.0</div></div></div>"},"90373":{"type":"graphic_diagnosticimage","displayName":"Tension pneumothorax II","title":"Right tension pneumothorax due to bronchial rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right tension pneumothorax due to bronchial rupture</div><div class=\"cntnt\"><img style=\"width:441px; height:502px;\" src=\"images/PULM/90373_Tension_pneumothorax_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph with right-sided tension pneumothorax in a patient with bronchial rupture after car accident. Marked shift of the cardiomediastinal structures into the left hemithorax is evident.</div><div id=\"graphicVersion\">Graphic 90373 Version 2.0</div></div></div>"},"90374":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothorax I","title":"CT scan of traumatic bilateral pneumothoraces","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of traumatic bilateral pneumothoraces</div><div class=\"cntnt\"><img style=\"width:442px; height:274px;\" src=\"images/PULM/90374_Bilateral_pneumothorax_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT thorax with bilateral anterior pneumothoraces and pneumomediastinum in a patient with tracheobronchial injury after car accident.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90374 Version 2.0</div></div></div>"},"90375":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothorax III","title":"Bilateral pneumothorax post cardiac surgery: The \"buffalo chest\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral pneumothorax post cardiac surgery: The \"buffalo chest\"</div><div class=\"cntnt\"><img style=\"width:429px; height:370px;\" src=\"images/PULM/90375_Bilat_pneumothorax_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative upright chest radiograph post cardiac transplant with bilateral apical pneumothoraces (arrows) due to disruption of the anterior junction line complex and subsequent free communication of both pleural spaces, so called buffalo chest physiology.</div><div id=\"graphicVersion\">Graphic 90375 Version 1.0</div></div></div>"},"90376":{"type":"graphic_diagnosticimage","displayName":"Anterior pneumothorax","title":"Right anterior pneumothorax with trapped lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right anterior pneumothorax with trapped lung</div><div class=\"cntnt\"><img style=\"width:442px; height:346px;\" src=\"images/PULM/90376_Anterior_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT thorax shows a right anterior pneumothorax in a patient with a so called trapped lung due to malignant pleural disease with thickening of the visceral pleura encasing the lung and hampering the re-expansion.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90376 Version 2.0</div></div></div>"},"90377":{"type":"graphic_diagnosticimage","displayName":"Basal pneumothorax I","title":"Basal pneumothorax in a supine patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basal pneumothorax in a supine patient</div><div class=\"cntnt\"><img style=\"width:442px; height:412px;\" src=\"images/PULM/90377_Basal_pneumothorax_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedside, supine chest radiograph demonstrates an atypical right basal pneumothorax in a patient on mechanical ventilation. Note right basal pleural adhesion that extends towards the right hemidiaphragm and is outlined by pneumothorax gas.</div><div id=\"graphicVersion\">Graphic 90377 Version 1.0</div></div></div>"},"90378":{"type":"graphic_diagnosticimage","displayName":"Spontaneous pneumothorax with bulla","title":"Left simple pneumothorax with apical bulla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left simple pneumothorax with apical bulla</div><div class=\"cntnt\"><img style=\"width:439px; height:475px;\" src=\"images/PULM/90378_Spontan_pneumoth_bulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows simple, spontaneous pneumothorax on the left side. The left lung is completely collapsed (arrow) with an apical bulla (arrowhead) which may have been the source of the air leak.</div><div id=\"graphicVersion\">Graphic 90378 Version 1.0</div></div></div>"},"90379":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothorax II","title":"Bilateral pneumothorax post cardiac surgery: The \"buffalo chest\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral pneumothorax post cardiac surgery: The \"buffalo chest\"</div><div class=\"cntnt\"><img style=\"width:441px; height:459px;\" src=\"images/PULM/90379_Bilateral_pneumothorax_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative, semiupright chest radiograph in a patient after cardiac transplantation. Bilateral pneumothoraces with lateral collections of pleural gas outlining the visceral pleura. This is an example of a \"buffalo chest\" with disruption of the anterior pleural junction line and free communication of the right and left pleural space.</div><div id=\"graphicVersion\">Graphic 90379 Version 1.0</div></div></div>"},"90380":{"type":"graphic_diagnosticimage","displayName":"Basal pneumothorax II","title":"Basal pneumothorax in an upright patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basal pneumothorax in an upright patient</div><div class=\"cntnt\"><img style=\"width:440px; height:443px;\" src=\"images/PULM/90380_Basal_pneumothorax_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph with atypical right basal pneumothorax in a patient with pleural adhesions. Due to the adhesions,&nbsp;gas is trapped in a basal position.</div><div id=\"graphicVersion\">Graphic 90380 Version 2.0</div></div></div>"},"90381":{"type":"graphic_diagnosticimage","displayName":"Hydropneumothorax","title":"Left hydropneumothorax in a patient with metastatic osteogenic sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left hydropneumothorax in a patient with metastatic osteogenic sarcoma</div><div class=\"cntnt\"><img style=\"width:441px; height:365px;\" src=\"images/PULM/90381_Hydropneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a young patient with metastatic osteogenic sarcoma, status post right forequarter amputation and left spontaneous hydropneumothorax. Multiple bilateral pulmonary nodules are visible and a left basal gas-liquid level is present (arrow).</div><div id=\"graphicVersion\">Graphic 90381 Version 1.0</div></div></div>"},"90382":{"type":"graphic_diagnosticimage","displayName":"Deep sulcus sign","title":"Deep sulcus sign displaying a pneumothorax in a supine patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep sulcus sign displaying a pneumothorax in a supine patient</div><div class=\"cntnt\"><img style=\"width:441px; height:445px;\" src=\"images/PULM/90382_Deep_sulcus_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedside supine chest radiograph in a&nbsp;trauma patient with left pneumothorax and deep sulcus sign. Contusion of the left lung precludes its complete collapse. Pulmonary edema is visible in the contralateral right lung.</div><div id=\"graphicVersion\">Graphic 90382 Version 1.0</div></div></div>"},"90383":{"type":"graphic_diagnosticimage","displayName":"Simple pneumothorax II","title":"Simple pneumothorax in patient with lung fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Simple pneumothorax in patient with lung fibrosis</div><div class=\"cntnt\"><img style=\"width:440px; height:448px;\" src=\"images/PULM/90383_Simple_pneumothorax_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a&nbsp;patient with advanced idiopathic pulmonary fibrosis and spontaneous right apical pneumothorax (arrow).</div><div id=\"graphicVersion\">Graphic 90383 Version 1.0</div></div></div>"},"90384":{"type":"graphic_diagnosticimage","displayName":"Simple pneumothorax III","title":"Large left simple pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large left simple pneumothorax</div><div class=\"cntnt\"><img style=\"width:437px; height:478px;\" src=\"images/PULM/90384_Simp_pneumothorax_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows simple, spontaneous left pneumothorax with non strangulating, uncomplicated,&nbsp;asymptomatic,&nbsp;torsion of the left upper lobe (arrow).</div><div id=\"graphicVersion\">Graphic 90384 Version 2.0</div></div></div>"},"90385":{"type":"graphic_diagnosticimage","displayName":"Right simple pneumothorax","title":"Right simple pneumothorax with complete lung collapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right simple pneumothorax with complete lung collapse</div><div class=\"cntnt\"><img style=\"width:441px; height:406px;\" src=\"images/PULM/90385_Right_simp_pneumthorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows spontaneous, simple right-sided pneumothorax with complete collapse of the right lung and&nbsp;asymptomatic, non strangulating, uncomplicated,&nbsp;torsion of the right upper lobe (arrow) and with only minimal contralateral shift of the mediastinal structures.</div><div id=\"graphicVersion\">Graphic 90385 Version 2.0</div></div></div>"},"90386":{"type":"graphic_diagnosticimage","displayName":"Basal pneumothorax ex vacuo","title":"Persistent basal pneumothorax due to obstructive atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistent basal pneumothorax due to obstructive atelectasis</div><div class=\"cntnt\"><img style=\"width:441px; height:446px;\" src=\"images/PULM/90386_Basal_pneumoth_ex_vacu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in a patient with atelectasis of the right middle and right lower lobes due to bronchogenic carcinoma with an accompanying malignant pleural effusion. After thoracentesis, a residual right basal pneumothorax ex vacuo persists related to the retractile effect of the overlying atelectatic lung.</div><div id=\"graphicVersion\">Graphic 90386 Version 1.0</div></div></div>"},"90387":{"type":"graphic_picture","displayName":"A lumbricoides larvae","title":"Larvae of <em>Ascaris lumbricoides</em> hatching from eggs","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Larvae of <em>Ascaris lumbricoides</em> hatching from eggs</div><div class=\"cntnt\"><img style=\"width:511px; height:259px;\" src=\"images/ID/90387_A_lumbricoides_larvae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Larva of <EM>A. lumbricoides</EM> hatching from an egg.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Ascariasis. Available at: <A href=\"http://www.cdc.gov/dpdx/ascariasis/index.html\">http://www.cdc.gov/dpdx/ascariasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 90387 Version 3.0</div></div></div>"},"90390":{"type":"graphic_diagnosticimage","displayName":"Erlotinib-induced pulmonary toxicity","title":"Erlotinib-induced pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Erlotinib-induced pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:508px; height:363px;\" src=\"images/ONC/90390_Erlotinib_induced_pulm_tox.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of erlotinib-related pulmonary toxicity. Axial image of a chest CT scan in a patient receiving erlotinib demonstrating diffuse bilateral reticular infiltrates, which resolved after discontinuation of the drug.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90390 Version 2.0</div></div></div>"},"90391":{"type":"graphic_table","displayName":"Differential diagnosis of mediastinal mass","title":"Differential diagnosis of mediastinal mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of mediastinal mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anterior compartment</td> <td class=\"subtitle1\">Middle compartment</td> <td class=\"subtitle1\">Posterior compartment</td> </tr> <tr class=\"divider_bottom\"> <td>Thymus<br /> <ul> <li>Thymoma </li> <li>Thymic cyst </li> <li>Thymic hyperplasia </li> <li>Thymic carcinoma </li> </ul> </td> <td>Bronchogenic cyst</td> <td>Neurogenic tumors<br /> <ul> <li>Neurofibroma </li> <li>Neurilemmoma</li> <li>Neurosarcoma </li> <li>Ganglioneuroma </li> <li>Ganglioneuroblastoma </li> <li>Neuroblastoma </li> <li>Chemodectoma </li> <li>Pheochromocytoma </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lymphoma</td> <td>Pericardial cyst</td> <td>Meningoceles</td> </tr> <tr class=\"divider_bottom\"> <td>Germ cell tumor<br /> <ul> <li>Teratoma/dermoid cyst </li> <li>Seminoma </li> <li> <p>Non-seminoma</p> <p>- Yolk sac tumor</p> <p>- Embryonal carcinoma</p> - Choriocarcinoma </li> </ul> </td> <td>Lymphadenopathy<br /> <ul> <li>Lymphoma </li> <li>Sarcoid </li> <li>Metastatic lung cancer </li> </ul> </td> <td>Thoracic spine lesions (eg, Pott's disease)</td> </tr> <tr class=\"divider_bottom\"> <td>Intrathoracic thyroid<br /> <ul> <li>Substernal goiter </li> <li>Ectopic thyroid tissue </li> </ul> </td> <td>Enteric cyst</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Parathyroid adenoma</td> <td>Esophageal tumors</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hemangioma</td> <td>Vascular masses and enlargement</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Lipoma</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Liposarcoma</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Fibroma</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Fibrosarcoma</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Foramen of Morgagni hernia</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90391 Version 5.0</div></div></div>"},"90393":{"type":"graphic_table","displayName":"Presenting clinical features of neoplastic pathologic fractures","title":"Presenting clinical features of neoplastic pathologic fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting clinical features of neoplastic pathologic fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Pain at the fracture site</td> </tr> <tr> <td>Inability to bear weight</td> </tr> <tr> <td>Point tenderness</td> </tr> <tr> <td>Ecchymosis or skin discoloration</td> </tr> <tr> <td>Pain that radiates (with nerve involvement)</td> </tr> <tr> <td>Edema or joint effusion</td> </tr> <tr> <td>Loss of bony or limb contour</td> </tr> <tr> <td>Extremity shortening</td> </tr> <tr> <td>Decreased range of motion</td> </tr> <tr> <td>Open wound and bone exposure</td> </tr> <tr> <td>Significantly diminished mobility</td> </tr> <tr> <td>Soft tissue mass or swelling at the site of pain</td> </tr> <tr> <td>Sensory disturbance of the distal extremity</td> </tr> <tr> <td>Radiculopathy (vertebral compression facture)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Johnson SK, Knobf MT. Surgical interventions for cancer patients with impending or actual pathologic fractures. Orthop Nurs 2008; 27:160. DOI: <a href=\"http://journals.lww.com/orthopaedicnursing/pages/articleviewer.aspx?year=2008&amp;issue=05000&amp;article=00003&amp;type=abstract\" target=\"_blank\">10.1097/01.NOR.0000320543.90115.d5</a>. Copyright &copy; 2008 National Association of Orthopaedic Nurses. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90393 Version 6.0</div></div></div>"},"90399":{"type":"graphic_table","displayName":"Discriminating features between stress and pathologic fractures","title":"Discriminating features between stress and pathologic fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Discriminating features between stress and pathologic fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Stress fracture</td> <td class=\"subtitle1\">Pathologic fracture</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Radiograph</td> <td>Endosteal thickening</td> <td>Aggressive bone marrow pattern of destruction</td> </tr> <tr> <td>Benign-appearing periosteal reaction</td> <td>Mineralized matrix</td> </tr> <tr class=\"divider_bottom\"> <td>Absence of any aggressive features</td> <td> <p>Endosteal scalloping</p> <p>Aggressive periosteal reaction</p> Associated soft tissue mass</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">CT</td> <td>Endosteal thickening</td> <td>Aggressive bone marrow and cortical destruction</td> </tr> <tr> <td>Benign-appearing periosteal reaction</td> <td>Mineralized matrix</td> </tr> <tr class=\"divider_bottom\"> <td>Absence of any aggressive features</td> <td> <p>Endosteal scalloping</p> <p>Aggressive periosteal reaction</p> Associated soft tissue mass</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">MRI</td> <td>Linear or band-like signal abnormality</td> <td>Well-defined T1-weighted bone marrow abnormality</td> </tr> <tr> <td>Surrounding bone marrow T2-weighted signal abnormality (edema)</td> <td>Endosteal scalloping</td> </tr> <tr class=\"divider_bottom\"> <td>Absence of or ill-defined T1-weighted signal bone marrow abnormality</td> <td> <p>Massive muscle edema</p> Associated soft tissue mass</td> </tr> <tr class=\"divider_bottom\"> <td>Scintigraphy</td> <td>Focal or linear uptake</td> <td>Diffuse uptake</td> </tr> <tr> <td>PET scan</td> <td>Focal or linear uptake</td> <td>Diffuse uptake</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography.</div><div class=\"graphic_reference\">Skeletal Radiology, Distinguishing stress fractures from pathologic fractures: a multimodality approach, Vol. 34, 2005, p. 245, Fayad LM, Kamel IR, Kawamoto S, et al, © ISS 2005. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 90399 Version 4.0</div></div></div>"},"90401":{"type":"graphic_picture","displayName":"Onychogryphosis","title":"Onychogryphosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Onychogryphosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90401_Onychogryphosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychogryphosis, also called \"ram's horn nail,\" usually affects the great toenail of&nbsp;older adult&nbsp;and neglected individuals. The nail appears thickened, yellow-brown in color, increased in length, and distorted.</div><div class=\"graphic_reference\">Image created by Ken Gross, MD. Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90401 Version 4.0</div></div></div>"},"90402":{"type":"graphic_picture","displayName":"Hyaline vascular histopathologic subtype unicentric CD","title":"Pathologic features of hyaline vascular histopathologic subtype of unicentric Castleman disease","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Pathologic features of hyaline vascular histopathologic subtype of unicentric Castleman disease</div><div class=\"cntnt\"><img style=\"width:513px; height:387px;\" src=\"images/HEME/90402_HyalinevasCastledis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two follicles are present in this field. The follicles contain small, regressed germinal centers. The follicle&nbsp;to the left of the field contains more than one germinal center (\"twinning\"). Hematoxylin and eosin stain.<br />(B) Hyaline deposits are present within the germinal center. Hematoxylin and eosin stain.<br />(C) Hyaline vascular (\"lollipop\") lesion in which a follicle is radially penetrated by a sclerotic blood vessel. Hematoxylin and eosin stain.<br />(D) The follicle is surrounded by a broad mantle zone composed of concentric rings of small lymphocytes (so-called \"onion skin\"). Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Castleman lymphadenopathy. In: Ioachim's Lymph Node Pathology, 4th ed, Ioachim HL, Medeiros LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=_blank>www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90402 Version 7.0</div></div></div>"},"90403":{"type":"graphic_picture","displayName":"HHV-8-associated MCD, plasmablastic histopathology","title":"Pathologic features of HHV-8-associated multicentric Castleman disease, plasmablastic histopathology","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Pathologic features of HHV-8-associated multicentric Castleman disease, plasmablastic histopathology</div><div class=\"cntnt\"><img style=\"width:515px; height:390px;\" src=\"images/HEME/90403_HHV8posplasmaCastle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In this field, the interfollicular regions are expanded by numerous plasma cells, and sinuses are patent. Small lymphoid follicles are also present. Hematoxylin and eosin stain.<br />(B) In this field, the boundary between the follicle mantle zone and the interfollicular region is indistinct. Hematoxylin and eosin stain.<br />(C) In the follicle mantle zones, large, atypical plasmablasts are present. Hematoxylin and eosin stain.<br />(D) HHV-8+ cells are preferentially identified in the mantle zones. Some of these cells are large, consistent with plasmablasts. Immunohistochemistry with antibody specific for HHV-8 latent nuclear antigen-1 with hematoxylin counterstain.</div><div class=\"graphic_footnotes\">HHV-8: human herpesvirus-8. </div><div class=\"graphic_reference\">Reproduced with permission from: Castleman lymphadenopathy. In: Ioachim's Lymph Node Pathology, 4th ed, Ioachim HL, Medeiros LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=_blank>www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90403 Version 7.0</div></div></div>"},"90404":{"type":"graphic_picture","displayName":"Plasma cell histopathologic subtype unicentric Castleman disease","title":"Pathologic features of plasma cell histopathologic subtype of unicentric Castleman disease","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Pathologic features of plasma cell histopathologic subtype of&nbsp;unicentric Castleman disease</div><div class=\"cntnt\"><img style=\"width:473px; height:361px;\" src=\"images/HEME/90404_HHV8negplasmaCastle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Reactive lymphoid follicles and interfollicular plasmacytosis are present.<br />(B) In this field, the reactive germinal center is radially penetrated by a prominent blood vessel.<br />(C) Sheets of cytologically mature plasma cells are present within the interfollicular region. Hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Castleman lymphadenopathy. In: Ioachim's Lymph Node Pathology, 4th ed, Ioachim HL, Medeiros LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=_blank>www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90404 Version 6.0</div></div></div>"},"90405":{"type":"graphic_table","displayName":"Dx procedures and complications NLST","title":"Low-dose CT scanning for lung cancer screening: Follow-up diagnostic procedures in the NLST","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low-dose CT scanning for lung cancer screening: Follow-up diagnostic procedures in the NLST</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\"> <p>Lung cancer confirmed</p> <p>(649)</p> </td> <td class=\"subtitle1\" colspan=\"4\"> <p>Lung cancer not confirmed</p> <p>(17,053)</p> </td> </tr> <tr> <td class=\"subtitle2\">Procedure</td> <td class=\"subtitle2\">Major complication*</td> <td class=\"subtitle2\">Intermediate complication<sup>&#182;</sup></td> <td class=\"subtitle2\">Death<sup>&#916;</sup></td> <td class=\"subtitle2\">Procedure</td> <td class=\"subtitle2\">Major complication*</td> <td class=\"subtitle2\">Intermediate complication<sup>&#182;</sup></td> <td class=\"subtitle2\">Death<sup>&#916;</sup></td> </tr> <tr> <td><strong>Thoracotomy, thoracoscopy, or mediastinoscopy</strong></td> <td class=\"centered\">509</td> <td class=\"centered\">71</td> <td class=\"centered\">81</td> <td class=\"centered\">5</td> <td class=\"centered\">164</td> <td class=\"centered\">9</td> <td class=\"centered\">13</td> <td class=\"centered\">2</td> </tr> <tr> <td><strong>Bronchoscopy</strong></td> <td class=\"centered\">76</td> <td class=\"centered\">2</td> <td class=\"centered\">5</td> <td class=\"centered\">4</td> <td class=\"centered\">227</td> <td class=\"centered\">2</td> <td class=\"centered\">9</td> <td class=\"centered\">4</td> </tr> <tr> <td><strong>Needle biopsy</strong></td> <td class=\"centered\">33</td> <td class=\"centered\">0</td> <td class=\"centered\">7</td> <td class=\"centered\">1</td> <td class=\"centered\">66</td> <td class=\"centered\">0</td> <td class=\"centered\">6</td> <td class=\"centered\">0</td> </tr> <tr> <td><strong>No procedure</strong></td> <td class=\"centered\">31</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> <td class=\"centered\">0</td> <td class=\"centered\">16,596</td> <td class=\"centered\">1</td> <td class=\"centered\">16</td> <td class=\"centered\">5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; NLST: National Lung Screening Trial.<br />* Major complications include treatment-related acute respiratory failure, major cardiovascular event, death, thromboembolic complication, and anaphylaxis.<br />¶ Intermediate complications include blood loss requiring transfusion, infection requiring antibiotics, respiratory distress, and pain requiring pain specialty consultation.<br />Δ Death included if it occurred within 60 days of a positive screening result. It is not known if the procedure itself was the cause of death.</div><div class=\"graphic_reference\">Data from: National Lung Cancer Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.</div><div id=\"graphicVersion\">Graphic 90405 Version 2.0</div></div></div>"},"90415":{"type":"graphic_table","displayName":"Collodion baby disorders","title":"Disorders associated with a collodion baby presentation ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with a collodion baby presentation </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Genetic basis</td> </tr> <tr> <td>ARCI</td> <td><em>TGM1</em>, <em>ALOXE3</em>, <em>ALOX12B</em>, <em>NIPAL4</em>, <em>ABCA12</em>, <em>CYP4F22</em></td> </tr> <tr> <td>Anhidrotic ectodermal dysplasia</td> <td><em>EDA</em>, <em>EDAR</em></td> </tr> <tr> <td>Gaucher disease</td> <td><em>GBA</em></td> </tr> <tr> <td>Keratitis-ichthyosis-deafness</td> <td><em>GJB2</em>, <em>GJB6</em></td> </tr> <tr> <td>Trichothiodystrophy</td> <td><em>ERCC2/XPD</em>, <em>ERCC3/XPB</em>, <em>GTF2H5</em></td> </tr> <tr> <td>Sj&#246;gren-Larsson syndrome</td> <td><em>ALDH3A2</em></td> </tr> <tr> <td>Neutral lipid storage disease</td> <td><em>ABHD5</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARCI: autosomal recessive congenital ichthyosis.</div><div id=\"graphicVersion\">Graphic 90415 Version 3.0</div></div></div>"},"90418":{"type":"graphic_table","displayName":"CML response to TKIs first-line treatment","title":"Definition of the response to tyrosine kinase inhibitors as first-line treatment of chronic myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of the response to tyrosine kinase inhibitors as first-line treatment of chronic myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Optimal</td> <td class=\"subtitle1\">Warning</td> <td class=\"subtitle1\">Failure</td> </tr> <tr> <td><strong>Baseline</strong></td> <td>NA</td> <td>High risk or CCA/Ph+, major route</td> <td>NA</td> </tr> <tr> <td><strong>Three months</strong></td> <td>BCR-ABL1 &#8804;10 percent and/or Ph+ &#8804;35 percent</td> <td>BCR-ABL1 &#62;10 percent and/or Ph+ 36 to 95 percent</td> <td>Non-CHR and/or Ph+ &#62;95 percent</td> </tr> <tr> <td><strong>Six months</strong></td> <td>BCR-ABL1 &#60;1 percent and/or Ph+ 0</td> <td>BCR-ABL1 1 to 10 percent and/or Ph+ 1 to 35 percent</td> <td>BCR-ABL1 &#62;10 percent and/or Ph+ &#62;35 percent</td> </tr> <tr> <td><strong>12 months</strong></td> <td>BCR-ABL1 &#8804;0.1 percent</td> <td>BCR-ABL1 &#62;0.1 to 1 percent</td> <td>BCR-ABL1 &#62;1 percent and/or Ph+ &#62;0</td> </tr> <tr> <td><strong>Then, and at any time</strong></td> <td>BCR-ABL1 &#8804;0.1 percent</td> <td>CCA/Ph&ndash; (&ndash;7, or 7q&ndash;)</td> <td> <p>Loss of CHR</p> <p>Loss of CCyR</p> <p>Confirmed loss of MMR*</p> <p>Mutations</p> CCA/Ph+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The definitions are the same for patients in chronic phase, accelerated phase, and blast crisis and apply also to second-line treatment, when first-line treatment was changed for intolerance. The response can be assessed with either a molecular or a cytogenetic test, but both are recommended whenever possible. Cutoff values have been used to define the boundaries between optimal and warning, and between warning and failures. Because cutoff values are subjected to fluctuations, in case of cytogenetic or molecular data close to the indicated values, a repetition of the tests is recommended. After 12 months, if an MMR is achieved, the response can be assessed by real quantitative polymerase chain reaction (RQ-PCR) every three to six months, and cytogenetics is required only in case of failure or if standardized molecular testing is not available. Note that MMR (MR<SUP>3.0</SUP> or better) is optimal for survival, but that a deeper response is likely to be required for a successful discontinuation of treatment.</div><div class=\"graphic_footnotes\">NA: not applicable; MMR: BCR-ABL1 ≤0.1 percent = MR<SUP>3.0</SUP> or better; CCA/Ph+: clonal chromosome abnormalities in Ph+ cells; CCA/Ph–: clonal chromosome abnormalities in Ph– cells; CHR: complete hematologic response; CCyR: complete cytogenetic response; MMR: major molecular response.<BR>* In two consecutive tests, of which one with a BCR-ABL1 transcripts level ≥1 percent.</div><div class=\"graphic_reference\">This research was originally published in Blood. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:872-84. Copyright &copy; the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 90418 Version 1.0</div></div></div>"},"90419":{"type":"graphic_picture","displayName":"Cannulation of the papilla of Vater PI","title":"Cannulation of the papilla of Vater","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Cannulation of the papilla of Vater</div><div class=\"cntnt\"><img style=\"width:452px; height:460px;\" src=\"images/PI/90419_Cannulat_papilla_Vater_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thin plastic tube (cannula) is passed through the endoscope into the orifice of the papilla.</div><div id=\"graphicVersion\">Graphic 90419 Version 1.0</div></div></div>"},"90420":{"type":"graphic_table","displayName":"Macronutrient guidelines for PN in children","title":"Macronutrient guidelines for initiation and advancement of parenteral nutrition in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Macronutrient guidelines for initiation and advancement of parenteral nutrition in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Carbohydrate/dextrose*</td> <td class=\"subtitle1\">Protein/amino acid<sup>&#182;</sup></td> <td class=\"subtitle1\">Fat/lipid</td> </tr> <tr class=\"divider_bottom\"> <td><strong>&#60;1 year</strong></td> <td> <p>Initial: 6 to 8 mg/kg/min</p> Goal: 10 to 14 mg/kg/min</td> <td> <p>Initial: 2 to 3 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 3 g/kg/day</td> <td> <p>Initial: 1 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 3 g/kg/day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1 to 10 years</strong></td> <td> <p>Initial: 10 to 12.5 percent</p> Daily increase: 5 percent increments (maximum 15 mg/kg/min)</td> <td> <p>Initial: 1 to 2 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 2.5 to 3 g/kg/day</td> <td> <p>Initial: 1 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 3 g/kg/day</td> </tr> <tr> <td><strong>&#62;10 years</strong></td> <td> <p>Initial: 10 to 15 percent</p> Daily increase: 5 percent increments (maximum 8.5 mg/kg/min)</td> <td> <p>Initial: 1 to 1.5 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 1.5 to 2 g/kg/day</td> <td> <p>Initial: 1 g/kg/day</p> <p>Daily increase: 1 g/kg/day</p> Maximum: 2 g/kg/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Carbohydrate intake is given as the glucose infusion rate (GIR), in mg/kg/minute. See topic text for explanation of how to calculate the GIR.<br />&para; Starting protein intake at the low end of the range then advancing is generally recommended. This is out of caution, because there is no good evidence suggesting the need to limit initial protein to less than calculated needs.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90420 Version 5.0</div></div></div>"},"90421":{"type":"graphic_table","displayName":"CML response to second-line therapy in imatinib failure","title":"Definitions of the response to second-line therapy in chronic myeloid leukemia after failure of imatinib","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of the response to second-line therapy in chronic myeloid leukemia after failure of imatinib</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Optimal</td> <td class=\"subtitle1\">Warning</td> <td class=\"subtitle1\">Failure</td> </tr> <tr> <td><strong>Baseline</strong></td> <td>NA</td> <td>No CHR or loss of CHR on imatinib or lack of CyR to first-line TKI or high risk</td> <td>NA</td> </tr> <tr> <td><strong>Three months</strong></td> <td>BCR-ABL1 &#8804;10 percent and/or Ph+ &#60;65 percent</td> <td>BCR-ABL1 &#62;10 percent and/or Ph+ 65 to 95 percent</td> <td>No CHR or Ph+ &#62;95 percent or new mutations</td> </tr> <tr> <td><strong>Six months</strong></td> <td>BCR-ABL1 &#8804;10 percent and/or Ph+ &#60;35 percent</td> <td>Ph+ 35 to 65 percent</td> <td>BCR-ABL1 &#62;10 percent and/or Ph+ &#62;65 percent and/or new mutations</td> </tr> <tr> <td><strong>12 months</strong></td> <td>BCR-ABL1 &#60;1 percent and/or Ph+ 0</td> <td>BCR-ABL1 1 to 10 percent and/or Ph+ 1 to 35 percent</td> <td>BCR-ABL1 &#62;10 percent and/or Ph+ &#62;35 percent and/or new mutations</td> </tr> <tr> <td><strong>Then, and at any time</strong></td> <td>BCR-ABL1 &#8804;0.1 percent</td> <td>CCA/Ph&ndash; (&ndash;7 or 7q&ndash;) or BCR-ABL1 &#62;0.1 percent</td> <td> <p>Loss of CHR or loss of CCyR or PCyR</p> <p>New mutations</p> <p>Confirmed loss of MMR*</p> CCA/Ph+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These definitions are mainly based on data reported for nilotinib and dasatinib, but can be used provisionally also for bosutinib and ponatinib, until more data are available. These definitions cannot apply to the evaluation of the response to third-line treatment.</div><div class=\"graphic_footnotes\">NA: not applicable; CHR: complete hematologic response; CCyR: complete cytogenetic response; TKI: tyrosine kinase inhibitors; CCA/Ph–: clonal chromosome abnormalities in Ph– cells; PCyR: partial cytogenetic response; MMR: major molecular response, BCR-ABL1 ≥0.1 percent = MR<SUP>3.0</SUP> or better; CCA/Ph+: clonal chromosome abnormalities in Ph+ cells.<BR>* In two consecutive tests, of which one with a BCR-ABL transcripts level ≥1 percent.</div><div class=\"graphic_reference\">This research was originally published in Blood. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:872-84. Copyright &copy; the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 90421 Version 1.0</div></div></div>"},"90422":{"type":"graphic_picture","displayName":"Actinic prurigo child","title":"Actinic prurigo","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Actinic prurigo</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90422_Actinic_prurigo_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Escoriated papular lesions on the face of a child with actinic prurigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90422 Version 1.0</div></div></div>"},"90423":{"type":"graphic_table","displayName":"Suggested monitoring parameters for PN in children","title":"Suggested monitoring parameters and schedule for parenteral nutrition in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested monitoring parameters and schedule for parenteral nutrition in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Parameter</td> <td class=\"subtitle1\" colspan=\"2\">Suggested frequency</td> </tr> <tr> <td class=\"subtitle2\">Initial/hospitalized</td> <td class=\"subtitle2\">Follow up/home</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Growth</td> </tr> <tr> <td class=\"indent1\">Weight</td> <td>Daily</td> <td>Daily to monthly</td> </tr> <tr> <td class=\"indent1\">Height</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Head circumference</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Triceps skin fold</td> <td>Monthly</td> <td>Monthly to annually</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mid arm muscle circumference</td> <td>Monthly</td> <td>Monthly to annually</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Serum*</td> </tr> <tr> <td class=\"indent1\">Electrolytes</td> <td>Daily to weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">BUN, creatinine</td> <td>Weekly</td> <td>Monthly</td> </tr> <tr> <td class=\"indent1\">Calcium, phosphorus, magnesium</td> <td>Twice weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Acid-base status (venous bicarbonate)</td> <td>Until stable</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Albumin</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Prealbumin<sup>&#182;</sup></td> <td>Weekly</td> <td>Monthly</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td>Daily to weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Triglycerides</td> <td>Daily while increasing lipid</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Liver function tests (AST, ALT, GGTP and alkaline phosphatase)</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">CBC and differential</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Platelets</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">PT, PTT, INR</td> <td>Weekly</td> <td>Weekly to monthly</td> </tr> <tr> <td class=\"indent1\">Iron indices<sup>&#916;</sup></td> <td>As indicated</td> <td>Biannually to annually</td> </tr> <tr> <td class=\"indent1\">Trace elements<sup>&#9674;</sup></td> <td>As indicated</td> <td>Biannually to annually</td> </tr> <tr> <td class=\"indent1\">Fat soluble vitamins<sup>&#167;</sup></td> <td>As indicated</td> <td>Biannually to annually</td> </tr> <tr> <td class=\"indent1\">Carnitine</td> <td>As indicated</td> <td>As indicated</td> </tr> <tr> <td class=\"indent1\">Ammonia</td> <td>As indicated</td> <td>Biannually to annually</td> </tr> <tr> <td class=\"indent1\">Blood culture from central venous catheter</td> <td>As indicated</td> <td>Biannually to annually</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CRP or ESR</td> <td>As indicated</td> <td>As indicated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Urine</td> </tr> <tr> <td class=\"indent1\">Glucose</td> <td>2 to 6 times/day</td> <td>Daily to weekly</td> </tr> <tr> <td class=\"indent1\">Ketones</td> <td>2 to 6 times/day</td> <td>Daily to weekly</td> </tr> <tr> <td class=\"indent1\">Urine specific gravity</td> <td>As indicated</td> <td>As indicated</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Urea nitrogen</td> <td>As indicated</td> <td>As indicated</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical observations</td> </tr> <tr> <td class=\"indent1\">Vital signs<sup>&#165;</sup></td> <td>Daily, or as indicated</td> <td>Daily, or as indicated</td> </tr> <tr> <td class=\"indent1\">Intake and output</td> <td>Daily</td> <td>Daily</td> </tr> <tr> <td class=\"indent1\">Check administration system</td> <td>6 to 12 times/day</td> <td>2 to 6 times/day</td> </tr> <tr> <td class=\"indent1\">Catheter site/dressing</td> <td>6 to 12 times/day</td> <td>2 to 6 times/day</td> </tr> <tr> <td class=\"indent1\">Developmental milestones</td> <td>As indicated</td> <td>As indicated</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Frequency depends on clinical condition.</div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGTP: gamma glutamyl transpeptidase; CBC: complete blood count; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.<br />* Metabolically unstable patients may need more frequent checks.<br />¶ Prealbumin is also known as thyroxine-binding prealbumin (TBA) or transthyretin. It is an index of the short-term adequacy of protein intake. However, prealbumin is also suppressed by the acute phase response, so it is not useful as a measure of adequate protein intake in the setting of inflammatory disease.<br />Δ Iron indices are serum iron (Fe), total iron binding capacity (TIBC), ferritin, and/or soluble transferrin receptor levels.<br /><FONT class=lozenge>◊</FONT> Adequacy of trace elements is monitored by measuring whole-blood or erythrocyte manganese (Mn), copper (Cu); serum zinc (Zn) and alkaline phosphatase; and plasma selenium (Se). Chromium (Cr) concentrations should be monitored periodically in patients on long-term PN with renal impairment.<br />§ Fat soluble vitamins are measured as serum retinol (for vitamin A); 25-hydroxyvitamin D (for vitamin D); and alpha-tocopherol (for vitamin E). Serum concentrations of alpha-tocopherol are strongly influenced by concentrations of serum lipids, so the effective vitamin E levels are calculated as the ratio of alpha-tocopherol/(cholesterol + triglycerides), where a normal ratio is &gt;0.8. For vitamin K, measurements of PT and PTT are used to screen for deficiency.<br />¥ Vital signs include respiratory rate, heart rate, temperature, and blood pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90423 Version 4.0</div></div></div>"},"90424":{"type":"graphic_picture","displayName":"Actinic prurigo 2","title":"Actinic prurigo","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Actinic prurigo</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90424_Actinic_prurigo_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Escoriated papular and nodular lesions on the arms of a child with actinic prurigo. Healed lesions leave hypo- or hyperpigmented scars.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90424 Version 1.0</div></div></div>"},"90425":{"type":"graphic_table","displayName":"Indications for parenteral nutrition in children","title":"Indications for parenteral nutrition (PN) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for parenteral nutrition (PN) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Partially functioning gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Cannot meet nutritional requirements after maximizing enteral support</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Multi-organ failure</td> </tr> <tr> <td class=\"sublist2_start\">Malabsorption</td> </tr> <tr> <td class=\"sublist2\">Short bowel syndrome</td> </tr> <tr> <td class=\"sublist2\">Chronic intractable diarrhea</td> </tr> <tr> <td class=\"sublist2\">Congenital small bowel malabsorptive syndromes such as congenital chloride diarrhea, tufting enteropathy, or microvillus inclusion disease</td> </tr> <tr> <td class=\"sublist2\">Pseudo-obstruction</td> </tr> <tr> <td class=\"indent1\">Severe malnutrition with hypoproteinemia and bowel edema</td> </tr> <tr> <td class=\"subtitle1_single\">Non-functional gastrointestinal tract</td> </tr> <tr> <td class=\"indent1\">Paralytic ileus</td> </tr> <tr> <td class=\"indent1\">Small bowel ischemia</td> </tr> <tr> <td class=\"indent1\">Necrotizing enterocolitis</td> </tr> <tr> <td class=\"sublist2_start\">Gastrointestinal surgery</td> </tr> <tr> <td class=\"sublist2\">Gastroschisis, omphalocele, gastrointestinal atresias (parenteral nutrition is indicated until the enteral route is functional and accessible)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90425 Version 2.0</div></div></div>"},"90426":{"type":"graphic_picture","displayName":"Phototoxic eruption 3","title":"Phototoxic eruption","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Phototoxic eruption</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90426_Phototoxiceruption3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent erythema on the dorsum of the hands following sun exposure in a child taking doxycycline. Note initial blistering on the right hand and the sparing of the area covered by a watch.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90426 Version 4.0</div></div></div>"},"90427":{"type":"graphic_figure","displayName":"Low Risk Ankle Rule","title":"Low Risk Ankle Rule for otherwise healthy children 3 to 16 years of age with an acute (≤72 hours) ankle injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low Risk Ankle Rule for otherwise healthy children 3 to 16 years of age with an acute (≤72 hours) ankle injury</div><div class=\"cntnt\"><img style=\"width:441px; height:640px;\" src=\"images/EM/90427_Low_risk_ankle_rule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Low Risk Ankle Rule defines low risk injury of the ankle in a child&nbsp;when tenderness, swelling or both are isolated to the distal fibula and/or adjacent lateral ligaments distal to the tibial joint line (Regions A and B of the figure). Radiography may be omitted in such children. Low risk fractures by this rule include distal fibular avulsion and nondisplaced Salter-Harris I and Salter-Harris II fractures.</div><div id=\"graphicVersion\">Graphic 90427 Version 2.0</div></div></div>"},"90428":{"type":"graphic_picture","displayName":"Phytophotodermatitis leg","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/90428_Phytophotodermatitis_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Meadow grass-induced phytophotodermatitis. The bizarre, linear hyperpigmented lesions on the lower leg correspond to the areas of contact with the grass.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90428 Version 2.0</div></div></div>"},"90429":{"type":"graphic_table","displayName":"European Leukemia treatment of chronic phase CML","title":"European LeukemiaNet recommentations for the treatment of chronic myeloid leukemia in chronic phase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European LeukemiaNet recommentations for the treatment of chronic myeloid leukemia in chronic phase</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First-line</td> </tr> <tr> <td class=\"indent1\">Imatinib or nilotinib or dasatinib</td> </tr> <tr> <td class=\"indent1\">HLA type patients and siblings only in case of baseline warnings (high risk, major route CCA/Ph+)</td> </tr> <tr> <td class=\"subtitle1_single\">Second-line, intolerance to the first TKI</td> </tr> <tr> <td class=\"indent1\">Anyone of the other TKIs approved first-line (imatinib, nilotinib, dasatinib)</td> </tr> <tr> <td class=\"subtitle1_single\">Second-line, failure of imatinib first-line</td> </tr> <tr> <td class=\"indent1\">Dasatinib or nilotinib or bosutinib or ponatinib</td> </tr> <tr> <td class=\"indent1\">HLA type patients and siblings</td> </tr> <tr> <td class=\"subtitle1_single\">Second-line, failure of nilotinib first-line</td> </tr> <tr> <td class=\"indent1\">Dasatinib or bosutinib or ponatinib</td> </tr> <tr> <td class=\"indent1\">HLA type patients and siblings; search for an unrelated stem cell donor; consider alloSCT</td> </tr> <tr> <td class=\"subtitle1_single\">Second-line, failure of dasatinib first-line</td> </tr> <tr> <td class=\"indent1\">Nilotinib or bosutinib or ponatinib</td> </tr> <tr> <td class=\"indent1\">HLA type patients and siblings; search for an unrelated stem cell donor; consider alloSCT</td> </tr> <tr> <td class=\"subtitle1_single\">Third-line, failure of and/or intolerance to two TKIs</td> </tr> <tr> <td class=\"indent1\">Any one of the remaining TKIs; alloSCT recommended in all eligible patients</td> </tr> <tr> <td class=\"subtitle1_single\">Any line, T315I mutation</td> </tr> <tr> <td class=\"indent1\">Ponatinib</td> </tr> <tr> <td class=\"indent1\">HLA type patients and siblings; search for an unrelated stem cell donor; consider alloSCT</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In first-line, the choice is among three TKIs that are currently approved and available, but are not always reimbursable, worldwide. The approved doses are 400 mg once daily for imatinib, 300 mg twice daily for nilotinib, and 100 mg once daily for dasatinib. Higher doses of all three drugs were tested, and a superiority of a higher dose was reported only in one study of imatinib. There are no recognized and solid criteria that can be recommended for making the choice. Provisional clinical criteria can be the characteristics of the disease (high risk, CCA/Ph+) on one hand, and the relationship between the patient (comorbidities) and the safety profile of the drugs on the other hand. In second-line, a change of drug is preferred to an increase of imatinib dose. To make the switch from one TKI to another, there are things that must always be taken into account: the presence and type of a mutation, the side effects and the toxicity of the previous TKI, and different comorbidities that can be of concern with different TKIs. The definition of intolerance may sometimes be objective and based on evidence, but sometimes is subjective and open to criticism. Experience and common sense suggest that a patient who is intolerant to one TKI can easily respond to other TKIs, whereas a patient in whom one TKI has failed, and who is intolerant to another TKI, is at considerable risk of subsequent treatment failure. Recommendations for alloSCT are based on the results from HLA-identical siblings or HLA-matched unrelated donors, myeloablative and RIC, T cell replete or T cell depleted. They do not include cord blood or haplotype-matched donors, or experimental conditioning regimens. The EBMT risk score is still of value, although insufficient numbers of patients have been transplanted in recent years and after TKI therapy to allow a robust reanalysis.</div><div class=\"graphic_footnotes\">CCA/Ph+: clonal chromosome abnormalities in Ph+ cells; TKI: tyrosine kinase inhibitors; alloSCT: allogeneic stem cell transplantation.</div><div class=\"graphic_reference\">This research was originally published in Blood. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:872-84. Copyright &copy; the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 90429 Version 1.0</div></div></div>"},"90430":{"type":"graphic_table","displayName":"Cytogenetic and molecular monitoring recommendations for CML","title":"Recommendations for cytogenetic and molecular monitoring for patients with chronic myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for cytogenetic and molecular monitoring for patients with chronic myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>At diagnosis</strong></td> <td> <p>Chromosome banding analysis (CBA) of marrow cell metaphases</p> <p>FISH in case of Ph negativity to identify variant, cryptic translocations</p> Qualitative PCR (identification of transcript type)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>During treatment</strong></td> <td> <p>Quantitative real-time PCR (RQ-PCR) for the determination of <em>BCR-ABL1</em> transcripts level, to be performed every three months until an MMR (BCR-ABL1 &#8804;0.1 percent, or MR<sup>3.0</sup>) has been achieved, then every three to six months</p> <p><strong>and/or</strong></p> CBA of marrow cell metaphases (at least 20 banded metaphases), to be performed at 3, 6, and 12 months until a CCyR has been achieved, then every 12 months. Once a CCyR is achieved, FISH on blood cells can be done. If adequate molecular monitoring can be ensured, cytogenetics can be spared.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Failure, progression</strong></td> <td>RQ-PCR, mutational analysis, and CBA of marrow cell metaphases. Immunophenotyping in BP.</td> </tr> <tr> <td><strong>Warning</strong></td> <td>Molecular and cytogenetic tests to be performed more frequently. CBA of marrow cell metaphases recommended in case of myelodysplasia or CCA/Ph&ndash; with chromosome 7 involvement.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The responses can be assessed either with molecular tests alone or with cytogenetic tests alone, depending on the local laboratory facilities; but, whenever possible, both cytogenetic and molecular tests are recommended until a CCyR and an MMR are achieved. Then RQ-PCR alone may be sufficient. Mutational analysis by conventional Sanger sequencing is recommended in case of progression, failure, and warning. In case of failure, warning, and development of myelodysplastic features (unexpected leucopenia, thrombocytopenia, or anemia), CBA of marrow cell metaphases is recommended.</div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; PCR: polymerase chain reaction; CBA: chromosome banding analysis; CCyR: complete cytogenetic response; CCA/Ph&ndash;: clonal chromosome abnormalities in Ph&ndash; cells.</div><div class=\"graphic_reference\">This research was originally published in Blood. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122:872-84. Copyright &copy; the American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 90430 Version 4.0</div></div></div>"},"90433":{"type":"graphic_picture","displayName":"Thyroid acropachy","title":"Thyroid acropachy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Thyroid acropachy</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90433_Thyroid_acropachy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital clubbing and soft-tissue swelling in a patient with Graves disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90433 Version 1.0</div></div></div>"},"90440":{"type":"graphic_table","displayName":"Risk factors for recurrent thrombosis and bleeding in malignancy","title":"Risk factors for recurrent venous thromboembolism and bleeding in patients with malignancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for recurrent venous thromboembolism and bleeding in patients with malignancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recurrent VTE</td> <td class=\"subtitle1\">Bleeding</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General factors</td> </tr> <tr> <td class=\"indent1\">Poor adherence to medication</td> <td>Older age (&#62;65 years)</td> </tr> <tr> <td class=\"indent1\">Inadequate dosing</td> <td>Higher intensity anticoagulation</td> </tr> <tr> <td class=\"indent1\">Presence of HIT</td> <td>Prior gastrointestinal bleeding</td> </tr> <tr> <td class=\"indent1\">Inherited thrombophilia disorders</td> <td>Thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Acquired factors (eg, presence of venous catheter, recent surgery)</td> <td>Overdosing</td> </tr> <tr> <td class=\"indent1\">Interruption of therapy for procedures</td> <td rowspan=\"6\">Bleeding diathesis (eg, elevated INR in cirrhosis)</td> </tr> <tr> <td class=\"indent1\">Drugs (eg, tamoxifen bevacizumab)</td> </tr> <tr> <td class=\"indent1\">Prolonged immobilization</td> </tr> <tr> <td class=\"indent1\">Heart failure</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Patient-related factors<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Younger patients (&#60;65 years)</td> <td>Immobilization</td> </tr> <tr> <td class=\"indent1\">PE at study entry</td> <td>Presence of metastases</td> </tr> <tr> <td class=\"indent1\">Newly diagnosed cancer (&#60;3 months)</td> <td>Creatinine clearance &#60;30 mL/min</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; HIT: heparin-induced thrombocytopenia; INR: international normalized ratio; PE: pulmonary embolism.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:435.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90440 Version 2.0</div></div></div>"},"90443":{"type":"graphic_figure","displayName":"Olsen growth chart preterm and term infants - Girls","title":"Olsen growth chart for preterm and term infants - Girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Olsen growth chart for preterm and term&nbsp;infants - Girls</div><div class=\"cntnt\"><img style=\"width:337px; height:780px;\" src=\"images/PEDS/90443_Olsengrwthpreminfgirl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intrauterine growth curves for girls.<br />(A) Weight-for-age in grams (gm).<br />(B) Length- and head circumference (HC)-for-age. <br />Of note, 3<SUP>rd</SUP> and 97<SUP>th</SUP> percentiles on all curves for 23 weeks should be interpreted cautiously, given the small sample size.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 125, Pages e214-e224. Copyright © 2010 by the AAP.</div><div id=\"graphicVersion\">Graphic 90443 Version 8.0</div></div></div>"},"90444":{"type":"graphic_figure","displayName":"Olsen growth chart preterm and term infants - Boys","title":"Olsen growth chart for preterm and term infants - Boys","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Olsen growth chart for preterm and term&nbsp;infants - Boys</div><div class=\"cntnt\"><img style=\"width:339px; height:776px;\" src=\"images/PEDS/90444_Olsengrwthpreminfboy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intrauterine growth curves for boys.<br />(A) Weight-for-age in grams (gm).<br />(B) Length- and head circumference (HC)-for-age. <br />Of note, 3<SUP>rd</SUP> and 97<SUP>th</SUP> percentiles on all curves for 23 weeks should be interpreted cautiously, given the small sample size; for boys' HC curve at 24 weeks, all percentiles should be interpreted cautiously because the distribution of data is skewed left.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 125, Pages e214-e224. Copyright © 2010 by the AAP.</div><div id=\"graphicVersion\">Graphic 90444 Version 8.0</div></div></div>"},"90447":{"type":"graphic_table","displayName":"Classification of malnutrition","title":"Classification of malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Measurement</td> <td class=\"subtitle1\">Normal</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Acute</td> </tr> <tr> <td class=\"indent1\">Weight for height</td> <td>110 to 90 percent</td> <td>90 to 85 percent</td> <td>85 to 75 percent</td> <td>&#60;75 percent</td> </tr> <tr> <td class=\"indent1\">Weight for age</td> <td>110 to 90 percent</td> <td>90 to 81 percent</td> <td>80 to 61 percent</td> <td>&#60;60 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Chronic</td> </tr> <tr> <td class=\"indent1\">Weight for height</td> <td>&#62;90 percent</td> <td>90 to 81 percent</td> <td>80 to 70 percent</td> <td>&#60;70 percent</td> </tr> <tr> <td class=\"indent1\">Weight for age</td> <td>&#62;90 percent</td> <td>90 to 76 percent</td> <td>75 to 61 percent</td> <td>&#60;60 percent</td> </tr> <tr> <td class=\"indent1\">Height for age</td> <td>&#62;95 percent</td> <td>95 to 90 percent</td> <td>89 to 85 percent</td> <td>&#60;85 percent</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table outlines one of several approaches to categorizing malnutrition in children, using the \"percent of the median\" method. Each parameter is given as a percentage of \"expected\", ie, the patient's measure &divide; the 50th percentile for age. For more information, refer to the UpToDate topics on assessment of malnutrition in children.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90447 Version 3.0</div></div></div>"},"90448":{"type":"graphic_table","displayName":"Surgical options for fixing pathologic fracture lower extremity","title":"Overview of surgical options for fixation and reconstruction of pathologic fractures of the lower extremity according to anatomic site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of surgical options for fixation and reconstruction of pathologic fractures of the lower extremity according to anatomic site</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site of fracture</td> <td class=\"subtitle1\">Common practice</td> <td class=\"subtitle1\">Controversies and considerations</td> </tr> <tr> <td>Femoral neck</td> <td>Hemiarthroplasty</td> <td> <p>Standard versus long-stem</p> Cemented versus non-cemented</td> </tr> <tr> <td>Intertrochanteric/subtrochanteric</td> <td>Reconstruction nail versus hemiarthroplasty</td> <td> <p>ORIF versus endoprosthetic replacement hemiarthroplasty</p> Standard versus cementless calcar-replacement hemiarthroplasty versus proximal femoral replacement</td> </tr> <tr> <td>Femoral diaphysis</td> <td>Reconstruction nail</td> <td> <p>Closed versus open with curettage</p> Cemented versus non-cemented</td> </tr> <tr> <td>Distal femur</td> <td>Reconstruction nail versus retrograde nail versus locked plate/screws versus combination</td> <td> <p>Unusual location</p> <p>Cemented versus non-cemented</p> Distal femoral replacement for advanced destruction</td> </tr> <tr> <td>Proximal tibia</td> <td>Plate versus antegrade tibial nail versus combination</td> <td> <p>Unusual location</p> <p>Cemented versus non-cemented</p> Proximal tibial replacement for advanced destruction</td> </tr> <tr> <td>Tibial diaphysis</td> <td>Antegrade tibial nail</td> <td> <p>Closed versus open with curettage</p> Cemented versus non-cemented</td> </tr> <tr> <td>Acetabulum</td> <td>Total hip with protrusio cage versus curettage/cement</td> <td>Arthroplasty versus curettage/cementing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ORIF: open reduction internal fixation.</div><div id=\"graphicVersion\">Graphic 90448 Version 1.0</div></div></div>"},"90450":{"type":"graphic_table","displayName":"Surgical options for fixing pathologic fracture upper extremity","title":"Overview of surgical options for fixation and reconstruction of pathologic fractures of the upper extremity according to anatomic site","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of surgical options for fixation and reconstruction of pathologic fractures of the upper extremity according to anatomic site</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anatomic site</td> <td class=\"subtitle1\">Common practice</td> <td class=\"subtitle1\">Controversies and considerations</td> </tr> <tr> <td>Proximal humerus</td> <td>Hemiarthroplasty versus antegrade humeral nail</td> <td> <p>ORIF versus endoprosthetic replacement</p> Cemented versus non-cemented</td> </tr> <tr> <td>Humeral diaphysis</td> <td>Antegrade humeral nail versus locked plate/screws</td> <td> <p>Nail versus plate versus intercalary humeral device</p> Cemented versus non-cemented</td> </tr> <tr> <td>Distal humerus</td> <td>Dual 90:90 plating versus retrograde IM stabilization</td> <td> <p>Nail versus plate</p> <p>Cement versus non-cemented</p> Distal humeral replacement arthroplasty for advanced destruction</td> </tr> <tr> <td>Scapula</td> <td>Nonoperative versus partial/total scapulectomy</td> <td>Unusual location</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramedullary; ORIF: open reduction internal fixation.</div><div id=\"graphicVersion\">Graphic 90450 Version 2.0</div></div></div>"},"90451":{"type":"graphic_table","displayName":"GEMOX biliary","title":"Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and oxaliplatin (GEMOX) for locally advanced or metastatic biliary cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days*</td> </tr> <tr> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline<sup>&#182;</sup> (concentration no more than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1, 8<sup>&#916;</sup>, and 15</td> </tr> <tr class=\"divider_bottom\"> <td>Oxaliplatin</td> <td>100 mg/m<sup>2</sup> IV<sup>&#9674;</sup></td> <td>Dilute in 500 mL 5% dextrose in water (D5W)<sup>&#182;</sup> and administer over two hours.</td> <td>Days 1 and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on days 1 and 15.<br /> LOW on day 8.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated for gemcitabine or oxaliplatin.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (incidence of neutropenic fever was 7%<sup>[1]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity.</li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of gemcitabine may be needed for patients with liver impairment.<sup>[2]</sup> A lower starting dose of oxaliplatin may be needed for severe renal impairment.<sup>[3]</sup></li> <li>Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess pulmonary function prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>A new cycle of treatment should not start until the WBC count is &#8805;3000/microL and platelet count is &#8805;100,000/microL. Intracycle dose reduction: If WBC are &#60;3000/microL and/or platelets are &#60;100,000/microL, interrupt treatment for seven days (these criteria are to be applied to any day of treatment administration). If recovery occurs within the seven days, continue treatment without dose reduction, otherwise reduce doses of gemcitabine and oxaliplatin by 25%.<sup>[1]</sup> Omitted doses may be administered within the subsequent two weeks.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For &#62;grade 1 peripheral sensory neuropathy persisting over seven days, reduce dose of oxaliplatin by 25%. Discontinue oxaliplatin for grade 3 or 4 peripheral sensory neuropathy.<sup>[1]</sup></li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[2]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Discontinue gemcitabine immediately and permanently. Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded.</li> <li>Refer to UpToDate topics on \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\" and \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; ECG: electrocardiogram; CBC: complete blood count; WBC: white blood cell.<br />* The original protocol administered gemcitabine as a fixed dose rate infusion (1000 mg/m<SUP>2</SUP> delivered 10 mg/m<SUP>2</SUP>/min) on days 1 and 15, and oxaliplatin 100 mg/m<SUP>2</SUP> on days 2 and 16.<SUP>[4]</SUP> This regimen has not been adopted widely because of inconvenience.<br />¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies). Oxaliplatin is incompatible with normal saline and a D5W flush is recommended prior to starting the drug infusion.<br />Δ Many clinicians eliminate the day 8 gemcitabine to improve hematologic tolerability.<br /><FONT class=lozenge>◊</FONT> Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Harder J, et al. Br J Cancer 2006; 95:848.</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. Available online at dailymed.nlm.nih.gov, accessed June 5, 2012.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. Available online at dailymed.nlm.nih.gov, accessed on June 5, 2012.</LI>&#xD;&#xA;<LI>Andre T, et al. Ann Oncol 2004; 15:1339.</LI></OL></div><div id=\"graphicVersion\">Graphic 90451 Version 10.0</div></div></div>"},"90452":{"type":"graphic_figure","displayName":"Functional difficulties CYSHCN","title":"Types of functional difficulties among children and youth with special health care needs, United States 2009-2010","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of functional difficulties among children and youth with special health care needs, United States 2009-2010</div><div class=\"cntnt\"><img style=\"width:404px; height:482px;\" src=\"images/PEDS/90452_FunctdifficultiesCSHCN.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Breathing or respiration, swallowing or digestion; blood circulation; chronic physical pain including headaches; seeing even when wearing glasses or contacts; hearing even when using a hearing aid.<br />¶ Self-care, coordination or moving around, using hands, learning, understanding or paying attention, speaking, communicating or being understood.</div><div class=\"graphic_reference\">Reproduced from: US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau. The National Survey of Children with Special Health Care Needs Chartbook 2009-2010. Rockville, Maryland: US Department of Health and Human Services, 2013. <A href=\"http://mchb.hrsa.gov/cshcn0910\" target=_blank>mchb.hrsa.gov/cshcn0910</A> (Accessed on July 23, 2013).</div><div id=\"graphicVersion\">Graphic 90452 Version 3.0</div></div></div>"},"90453":{"type":"graphic_table","displayName":"Fluid requirements in parenteral nutrition","title":"Fluid requirements in parenteral nutrition (PN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluid requirements in parenteral nutrition (PN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Body weight</td> <td class=\"subtitle1\">Amount of fluid per day</td> </tr> <tr> <td>1 to 10 kg</td> <td>100 mL/kg</td> </tr> <tr> <td>11 to 20 kg</td> <td>1000 mL + 50 mL/kg for each kg &#62;10 kg</td> </tr> <tr> <td>&#62;20 kg</td> <td>1500 mL + 20 mL/kg for each kg &#62;20 kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Based on the Holliday-Segar method for calculating maintenance fluid requirements in children.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Meyers RS. Pediatric fluid and electrolyte therapy. Pediatr Pharmacol Ther 2009; 14:204.</LI>&#xD;&#xA;<LI>Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics 1957; 19:823.</LI></OL></div><div id=\"graphicVersion\">Graphic 90453 Version 1.0</div></div></div>"},"90454":{"type":"graphic_table","displayName":"Factors that may require increased or decreased fluid admin","title":"Factors that may require increased or decreased fluid administration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that may require increased or decreased fluid administration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Increased fluids</td> <td class=\"subtitle1\">Decreased fluids</td> </tr> <tr> <td>Fever</td> <td>Congestive heart failure</td> </tr> <tr> <td>Polyuria</td> <td>Head trauma</td> </tr> <tr> <td>Losses through gastrointestinal tract (eg, short bowel syndrome, or a stoma)</td> <td>Renal insufficiency</td> </tr> <tr> <td>Vomiting</td> <td>Bronchopulmonary dysplasia</td> </tr> <tr> <td>Diarrhea</td> <td>&nbsp;</td> </tr> <tr> <td>Nasogastric suctioning</td> <td>&nbsp;</td> </tr> <tr> <td>Ostomy output</td> <td>&nbsp;</td> </tr> <tr> <td>Prematurity</td> <td>&nbsp;</td> </tr> <tr> <td>Increased insensible losses through the skin (eg, extensive burns)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90454 Version 4.0</div></div></div>"},"90455":{"type":"graphic_table","displayName":"Reasons for alteration in energy requirements","title":"Reasons for alteration in energy requirements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reasons for alteration in energy requirements</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Increased energy requirements</td> <td class=\"subtitle1\">Decreased energy requirements</td> </tr> <tr> <td>Trauma</td> <td>Immobility</td> </tr> <tr> <td>Surgery</td> <td>Mechanical ventilation</td> </tr> <tr> <td>Sepsis</td> <td>Extracorporeal membrane oxygenation (ECMO)</td> </tr> <tr> <td>Burns</td> <td>Medical sedation/paralysis</td> </tr> <tr> <td>Tumors</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Seizures</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Hypertonia</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Spinal cord injury</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric Parenteral Nutrition, Baker RD, Baker SS, Davis AM (Eds), Aspen Publishers, Inc, Gaithersburg 2001. Copyright &copy; 2001 Robert D Baker, MD, PhD; Susan S Baker, MD, PhD; and Anne M Davis, RD, CNSD.</div><div id=\"graphicVersion\">Graphic 90455 Version 2.0</div></div></div>"},"90456":{"type":"graphic_table","displayName":"Mirels scoring system to predict impending pathologic fracture","title":"Mirels scoring system to predict impending pathologic fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mirels scoring system to predict impending pathologic fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">Site</td> <td class=\"subtitle1\">Radiographic nature</td> <td class=\"subtitle1\">Degree of pain</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">1</td> <td>1/3 of cortex</td> <td>Upper extremity</td> <td>Osteoblastic lesions</td> <td>Mild</td> <td>Non-impending</td> </tr> <tr> <td class=\"centered\">2</td> <td>1/3 to 2/3 of cortex</td> <td>Lower extremity</td> <td>Mixed osteolytic and osteoblastic lesions</td> <td>Moderate</td> <td>Borderline</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td>More than 2/3 of cortex</td> <td>Peritrochanteric region</td> <td>Purely osteolytic lesions</td> <td>Limits function</td> <td>Impending fracture</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Points</td> <td class=\"subtitle1\" colspan=\"2\">Fracture risk</td> <td class=\"subtitle1\" colspan=\"2\">Recommendation</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">&#8804;7</td> <td colspan=\"2\">&#60;10 percent</td> <td colspan=\"2\">Observe</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">8</td> <td colspan=\"2\">15 percent</td> <td colspan=\"2\">Consider fixation</td> </tr> <tr> <td class=\"centered\" colspan=\"2\">&#8805;9</td> <td colspan=\"2\">33 percent for 9 points, &#62;50 percent for 10 points or more</td> <td colspan=\"2\">Prophylactic fixation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Mirels scoring system reproduced with permission from: Johnson SK, Knobf MT. Surgical interventions for cancer patients with impending or actual pathologic fractures. Orthop Nurs 2008; 27:160. DOI: <a href=\"http://journals.lww.com/orthopaedicnursing/pages/articleviewer.aspx?year=2008&amp;issue=05000&amp;article=00003&amp;type=abstract\" target=\"_blank\">10.1097/01.NOR.0000320543.90115.d5</a>. Copyright &copy; 2008 National Association of Orthopaedic Nurses. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90456 Version 7.0</div></div></div>"},"90457":{"type":"graphic_diagnosticimage","displayName":"CT psoas abscess","title":"Psoas abscess on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Psoas abscess on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:246px;\" src=\"images/RADIOL/90457_CT_psoas_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper pelvis (A) shows a gas containing abscess (arrow) in the left psoas muscle. A coronal reconstruction (B) shows the ovoid shaped abscess extending into the iliacus muscle (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90457 Version 1.0</div></div></div>"},"90459":{"type":"graphic_figure","displayName":"Classification of abdominal aortic aneurysm","title":"Classification of abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Classification of abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:535px; height:348px;\" src=\"images/SURG/90459_Classification_of_AAA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal aortic aneurysms (AAAs)&nbsp;are commonly described based on the relation to the renal arteries.&nbsp; &#xD;&#xA;<UL>&#xD;&#xA;<LI>Suprarenal AAA: The aneurysm involves the origins of one or more visceral arteries but does not extend into the chest.</LI>&#xD;&#xA;<LI>Pararenal AAA: The renal arteries arise from the aneurysmal aorta but the aorta at the level of the superior mesenteric artery is not aneurysmal.</LI>&#xD;&#xA;<LI>Juxtarenal AAA: The aneurysm originates just beyond the origins of the renal arteries. There is no segment of nonaneurysmal aorta distal to the renal arteries, but the aorta at the level of the renal arteries is not aneurysmal. </LI>&#xD;&#xA;<LI>Infrarenal AAA: The aneurysm originates distal to the renal arteries. There is a segment of nonaneurysmal aorta that extends distal to the origins of the renal arteries. </LI></UL></div><div id=\"graphicVersion\">Graphic 90459 Version 2.0</div></div></div>"},"90460":{"type":"graphic_picture","displayName":"Skeletal anatomy of the hip","title":"Skeletal anatomy of the hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skeletal anatomy of the hip</div><div class=\"cntnt\"><img style=\"width:410px; height:509px;\" src=\"images/ONC/90460_Skeletal_anatomy_hip.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90460 Version 1.0</div></div></div>"},"90463":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa Hurley stage I","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:500px; height:367px;\" src=\"images/DERM/90463_Hidraden_suppur_Hurl_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hurley stage I disease. An inflamed nodule (arrow) and an open comedo (arrowhead) are visible. Sinus tracts and fibrosis are absent.</div><div id=\"graphicVersion\">Graphic 90463 Version 3.0</div></div></div>"},"90464":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa Hurley stage II","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:504px; height:338px;\" src=\"images/DERM/90464_Hidraden_suppur_Hurley_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hurley stage II disease involving the breast. Inflamed papules and nodules as well as bridged scars overlying sinus tracts. Comedones are visible in the center of the image.</div><div id=\"graphicVersion\">Graphic 90464 Version 1.0</div></div></div>"},"90465":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa Hurley stage III","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:504px; height:366px;\" src=\"images/DERM/90465_Hidradenitis_supp_Hurl_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hurley stage III disease involving the axilla. Diffuse involvement of the axilla with deep-seated inflamed nodules, interconnecting sinus tracts, purulent drainage, and rope-like scars.</div><div id=\"graphicVersion\">Graphic 90465 Version 2.0</div></div></div>"},"90466":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa pathology","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/DERM/90466_Hidradenitissuppuratpath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><FONT size=2>The histology of hidradenitis suppurativa in microcosm in a 4 mm punch mini-unroofing specimen. Note the dilated follicular portion of the folliculopilosebaceous unit, the ruptured follicular wall, the minor intraductal inflammation, the intense perifollicular inflammation, the psoriasiform change in the follicular wall, and the complete loss of the pilar and sebaceous structures in the inflammatory material deep to the follicular stub.</FONT></div><div id=\"graphicVersion\">Graphic 90466 Version 3.0</div></div></div>"},"90467":{"type":"graphic_algorithm","displayName":"Management of thyroid nodules in children","title":"Management of thyroid nodules in children","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Management of thyroid nodules in children</div><div class=\"cntnt\"><img style=\"width:632px; height:579px;\" src=\"images/PEDS/90467_Mgmt_thyroid_nod_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FNA: fine-needle aspiration; N: normal; &uarr;: increased; &darr;: decreased; TSH: thyroid-stimulating hormone (thyrotropin); US-FNA: ultrasound-guided fine-needle aspiration.<br />* For a discussion of gene expression modifiers, refer to the topic review on the diagnostic approach to and treatment of thyroid nodules.</div><div class=\"graphic_reference\">Modified from: Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract 2003; 9:128.</div><div id=\"graphicVersion\">Graphic 90467 Version 3.0</div></div></div>"},"90471":{"type":"graphic_diagnosticimage","displayName":"Chest CT C gattii ","title":"<EM>Cryptococcus gattii </EM>pulmonary nodules","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Cryptococcus gattii </EM>pulmonary nodules</div><div class=\"cntnt\"><img style=\"width:504px; height:466px;\" src=\"images/ID/90471_CT_chest_C_gattii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan showing a spiculated 1.6 x 2 cm left lower lobe lung nodule with multiple, bilateral subcentimeter pulmonary nodules in a patient with <EM>C. gattii </EM>infection.</div><div class=\"graphic_reference\">Reproduced from: Byrnes EJ III, Li W, Lewit Y, et al. First reported case of Cryptococcus gattii in the southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS ONE 2009; 4: e5851. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 90471 Version 2.0</div></div></div>"},"90472":{"type":"graphic_table","displayName":"Choice of closure method for minor wounds","title":"Choice of closure method for minor wounds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of closure method for minor wounds</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Wound selection*</td> <td class=\"subtitle1\">Wound with actively oozing blood</td> <td class=\"subtitle1\">Use for wounds in hair or near moist regions of the body (eg, axilla, perineum)</td> <td class=\"subtitle1\">Use if wound under tension (eg, hands, feet, or over joints)</td> <td class=\"subtitle1\">Use in patients with conditions associated with poor healing<sup>&#182;</sup></td> <td class=\"subtitle1\">Pain of repair</td> <td class=\"subtitle1\">Speed of closure</td> <td class=\"subtitle1\">Difficulty of technique</td> </tr> <tr> <td>Sutures</td> <td>Any laceration through the dermis, especially wounds that require careful wound approximation (eg, vermillion border)</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>+++</td> <td>Slower</td> <td>+++</td> </tr> <tr> <td>Staples</td> <td>Scalp wounds, wounds in noncosmetic areas, especially long linear wounds</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>+++</td> <td>Fast</td> <td>++</td> </tr> <tr> <td>Tissue adhesives</td> <td>Linear wounds under low tension, skin tears and flaps in patients with fragile skin (eg, elderly)</td> <td>No</td> <td>No<sup>&#916;</sup></td> <td>No<sup>&#9674;</sup></td> <td>Yes</td> <td>None/+</td> <td>Fast</td> <td>+</td> </tr> <tr> <td>Wound closure tapes</td> <td>Linear, low tension lacerations, skin tears and flaps in patients with fragile skin (eg, elderly)</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> <td>None/+</td> <td>Fast</td> <td>+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Wounds eligible for closure must be appropriately irrigated, debrided of all devitalized tissue and foreign bodies, and have no signs of infection. Refer to UpToDate topics on minor wound preparation.<br />¶ For example, diabetes mellitus, peripheral vascular disease, chronic steroid use, or history of keloids. The clinician should use judgment regarding whether wound closure is preferred to healing by secondary intention in such patients. Factors to take into account include the size of the wound, age of the wound, degree of wound contamination, and the severity of the underlying disorder.<br />Δ Tissue adhesives may be used on hairy areas such as the scalp, if the hair is first trimmed.<br /><FONT class=lozenge>◊</FONT> Tissue adhesives can be used on hands, feet, or over joints, if the involved area is immobilized with a splint or cast.</div><div id=\"graphicVersion\">Graphic 90472 Version 6.0</div></div></div>"},"90473":{"type":"graphic_table","displayName":"Characteristics and sources of common FODMAPs PI","title":"Characteristics and sources of common FODMAPs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics and sources of common FODMAPs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Word that corresponds to letter in acronym</td> <td class=\"subtitle1\">Compounds in this category</td> <td class=\"subtitle1\">Foods that contain these compounds</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>F</strong></td> <td colspan=\"3\"><strong>F</strong>ermentable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>O</strong></td> <td><strong>O</strong>ligosaccharides</td> <td>Fructans, galacto-oligosaccharides</td> <td>Wheat, barley, rye, onion, leek, white part of spring onion, garlic, shallots, artichokes, beetroot, fennel, peas, chicory, pistachio, cashews, legumes, lentils, and chickpeas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>D</strong></td> <td><strong>D</strong>isaccharides</td> <td>Lactose</td> <td>Milk, custard, ice cream, and yogurt</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>M</strong></td> <td><strong>M</strong>onosaccharides</td> <td>\"Free fructose\" (fructose in excess of glucose)</td> <td>Apples, pears, mangoes, cherries, watermelon, asparagus, sugar snap peas, honey, high fructose corn syrup</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>A</strong></td> <td colspan=\"3\"><strong>A</strong>nd</td> </tr> <tr> <td class=\"centered\"><strong>P</strong></td> <td><strong>P</strong>olyols</td> <td>Sorbitol, mannitol, maltitol, and xylitol</td> <td>Apples, pears, apricots, cherries, nectarines, peaches, plums, watermelon, mushrooms, cauliflower, artificially sweetened chewing gum and confectionery</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">FODMAPs stands for \"fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.\" When you eat foods containing FODMAPs, they get fermented by bacteria in your gut. This fermentation produces gas and makes you feel gassy or bloated.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108:707. Copyright &copy; 2013. <a href=\"http://www.nature.com/ajg\" target=\"_blank\">www.nature.com/ajg</a>.</div><div id=\"graphicVersion\">Graphic 90473 Version 2.0</div></div></div>"},"90474":{"type":"graphic_picture","displayName":"Leukonychia striata","title":"Leukonychia striata (Mees' line)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Leukonychia striata (Mees' line)</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/DERM/90474_Leukonychia_striata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White bands running parallel to the nail base in a 40-year-old man with leukonychia striata.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <A href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</A>. Copyright © 2013. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90474 Version 1.0</div></div></div>"},"90475":{"type":"graphic_picture","displayName":"Total leukonychia","title":"Total leukonychia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Total leukonychia</div><div class=\"cntnt\"><img style=\"width:504px; height:329px;\" src=\"images/DERM/90475_Total_leukonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Milky porcelain-white nails in a 30-year-old woman with total leukonychia.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <A href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</A>. Copyright © 2013. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90475 Version 2.0</div></div></div>"},"90477":{"type":"graphic_table","displayName":"Intravenous multivitamin preparation for pediatric use","title":"Intravenous multivitamin preparation for pediatric use","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous multivitamin preparation for pediatric use</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"75%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Each 5 mL solution contains:</td> </tr> <tr> <td>Vitamin C (ascorbic acid)</td> <td class=\"centered\">80 mg</td> </tr> <tr> <td>Vitamin A (palmitate)</td> <td class=\"centered\">2300 IU</td> </tr> <tr> <td>Vitamin D (cholecalciferol)</td> <td class=\"centered\">400 IU</td> </tr> <tr> <td>Vitamin B1 (thiamine)</td> <td class=\"centered\">1.2 mg</td> </tr> <tr> <td>Vitamin B2 (riboflavin)</td> <td class=\"centered\">1.4 mg</td> </tr> <tr> <td>Vitamin B6 (pyridoxine)</td> <td class=\"centered\">1 mg</td> </tr> <tr> <td>Niacinamide</td> <td class=\"centered\">17 mg</td> </tr> <tr> <td>Dexpanthenol</td> <td class=\"centered\">5 mg</td> </tr> <tr> <td>Vitamin E</td> <td class=\"centered\">7 IU</td> </tr> <tr> <td>Vitamin K1 (phytonadione)</td> <td class=\"centered\">0.2 mg</td> </tr> <tr> <td>Folic acid</td> <td class=\"centered\">140 mcg</td> </tr> <tr> <td>Biotin</td> <td class=\"centered\">20 mcg</td> </tr> <tr> <td>Vitamin B12 (cyanocobalamin)</td> <td class=\"centered\">1 mcg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IU: international units.</div><div class=\"graphic_reference\">Data from: Product information - Infuvite Pediatric (Baxter Healthcare Corporation).</div><div id=\"graphicVersion\">Graphic 90477 Version 1.0</div></div></div>"},"90479":{"type":"graphic_table","displayName":"Daily electrolyte and mineral requirements for PN","title":"Daily electrolyte and mineral requirements for parenteral nutrition in pediatric patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Daily electrolyte and mineral requirements for parenteral nutrition in pediatric patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Electrolyte</td> <td class=\"subtitle1\">Preterm neonates</td> <td class=\"subtitle1\">Infants/children</td> <td class=\"subtitle1\">Adolescent</td> </tr> <tr> <td>Sodium</td> <td>2 to 5 mEq/kg</td> <td>2 to 5 mEq/kg</td> <td>1 to 2 mEq/kg</td> </tr> <tr> <td>Potassium</td> <td>2 to 4 mEq/kg</td> <td>2 to 4 mEq/kg</td> <td>1 to 2 mEq/kg</td> </tr> <tr> <td>Calcium</td> <td> <p>2 to 4 mEq/kg</p> (= 1 to 2 mmol/kg)*<sup>&#182;</sup></td> <td> <p>0.5 to 4 mEq/kg</p> (= 0.25 to 2 mmol/kg)*<sup>&#182;</sup></td> <td> <p>10 to 20 mEq total daily dose</p> (= 5 to 10 mmol)*<sup>&#182;</sup></td> </tr> <tr> <td>Phosphorus</td> <td>1 to 2 mmol/kg</td> <td>0.5 to 2 mmol/kg</td> <td>10 to 40 mmol</td> </tr> <tr> <td>Magnesium</td> <td>0.3 to 0.5 mEq/kg</td> <td>0.3 to 0.5 mEq/kg</td> <td>10 to 30 mEq</td> </tr> <tr> <td>Acetate<sup>&#916;</sup></td> <td>As needed</td> <td>As needed</td> <td>As needed</td> </tr> <tr> <td>Chloride<sup>&#916;</sup></td> <td>As needed</td> <td>As needed</td> <td>As needed</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These estimated requirements assume normal age-related organ function and normal loss.</div><div class=\"graphic_footnotes\">* For young infants (especially premature infants), calcium and phosphorus should be added in a <strong>molar</strong> ratio that is close to 1:1, to optimize phosphorus utilization. Refer to the UpToDate topic review on Parenteral nutrition in premature infants.<br />&para; Conversions: 1 mEq elemental calcium (20 mg) = 0.5 mmol = 215 mg calcium gluconate salt. The molecular weight of calcium gluconate is 430.373 g/mol.<br />&Delta; The ratio of acetate and chloride is adjusted as needed to maintain acid-base balance.</div><div class=\"graphic_reference\">From: Mirtallo J, Canada T, Johnson D, et al. Journal of parenteral and enteral nutrition (Volume 28, Issue 6). pp.S39-70, Copyright &copy; 2004 by the American Society for Parenteral and Enteral Nutrition. Reprinted by permission of SAGE Publications.</div><div id=\"graphicVersion\">Graphic 90479 Version 6.0</div></div></div>"},"90480":{"type":"graphic_form","displayName":"Pediatric total parenteral nutrition orders","title":"Example of pediatric total parenteral nutrition (PN) orders","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Example of pediatric total parenteral nutrition (PN) orders</div><div class=\"cntnt\"><img style=\"width:655px; height:1075px;\" src=\"images/PEDS/90480_Ped_tot_parenteral_nutr_ord.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DBILI: direct bilirubin; PED MVI: pediatric multivitamin solution; WCHOB: Women and Children's Hospital of Buffalo.<br />* WCHOB TES is a solution of trace elements made specifically for young&nbsp;infants&nbsp;by the WCHOB pharmacy.<br />• DBILI TES is a solution of trace elements designed for infants with cholestasis, which does not contain copper or manganese.</div><div class=\"graphic_reference\">Courtesy of Drs. Robert and Susan Baker and Women and Children's Hospital of Buffalo (WCHOB). Reproduced with permission from: Kaleida Health.</div><div id=\"graphicVersion\">Graphic 90480 Version 1.0</div></div></div>"},"90481":{"type":"graphic_picture","displayName":"Ichthyosis vulgaris palmar hyperlinearity","title":"Palmar hyperlinearity in ichthyosis vulgaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Palmar hyperlinearity in ichthyosis vulgaris</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90481_Ichthyosis_vulgaris_palmar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic palmar hyperlinearity in a patient with ichthyosis vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90481 Version 1.0</div></div></div>"},"90483":{"type":"graphic_figure","displayName":"PALM-COEIN AUB terminology","title":"PALM-COEIN classification system for abnormal uterine bleeding in nongravid reproductive-age women","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">PALM-COEIN classification system for abnormal uterine bleeding in nongravid reproductive-age women</div><div class=\"cntnt\"><img style=\"width:498px; height:356px;\" src=\"images/OBGYN/90483_PALM_COEIN_AUB_term.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Basic classification system. The basic system comprises four categories that are defined by visually objective structural criteria (PALM: polyp, adenomyosis, leiomyoma, and malignancy and hyperplasia), four that are unrelated to structural anomalies (COEI: coagulopathy, ovulatory dysfunction, endometrial, iatrogenic), and one reserved for entities that are not yet classified (N). The leiomyoma category (L) is subdivided into patients with at least one submucosal myoma (LSM) and those with myomas that do not impact the endometrial cavity (LO).</div><div class=\"graphic_reference\">Reproduced from: Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113:3. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90483 Version 2.0</div></div></div>"},"90484":{"type":"graphic_diagnosticimage","displayName":"Abnormal chest x-ray","title":"Abnormal chest radiograph in patient with a large anterior mediastinal mass","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Abnormal chest radiograph in patient with a large anterior mediastinal mass</div><div class=\"cntnt\"><img style=\"width:488px; height:439px;\" src=\"images/ONC/90484_Abnormal_chest_x_ray.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90484 Version 2.0</div></div></div>"},"90485":{"type":"graphic_figure","displayName":"Chamberlain procedure","title":"Illustration of Chamberlain procedure ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Illustration of Chamberlain procedure </div><div class=\"cntnt\"><img style=\"width:410px; height:365px;\" src=\"images/SURG/90485_Chamberlain_procedure.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90485 Version 3.0</div></div></div>"},"90486":{"type":"graphic_picture","displayName":"Conjunctival foreign body","title":"Conjunctival foreign body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conjunctival foreign body</div><div class=\"cntnt\"><img style=\"width:287px; height:287px;\" src=\"images/EM/90486_Conjunctival_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conjunctival foreign bodies are typically located in the pretarsal sulcus of the upper lid. Blinking results in a corneal abrasion.</div><div class=\"graphic_reference\">Reproduced with permission from: the University of Michigan Kellogg Eye Center, <A href=\"http://www.kellogg.umich.edu/\" target=_blank>http://www.kellogg.umich.edu</A>.</div><div id=\"graphicVersion\">Graphic 90486 Version 1.0</div></div></div>"},"90487":{"type":"graphic_figure","displayName":"Mediastinal biopsy via cervical mediastinoscopy","title":"Illustration of mediastinal biopsy via cervical mediastinoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Illustration of mediastinal biopsy via cervical mediastinoscopy</div><div class=\"cntnt\"><img style=\"width:411px; height:409px;\" src=\"images/SURG/90487_Mediastinal_biopsy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90487 Version 3.0</div></div></div>"},"90488":{"type":"graphic_figure","displayName":"Transcervical thymectomy","title":"Approach for a transcervical thymectomy","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Approach for a transcervical thymectomy</div><div class=\"cntnt\"><img style=\"width:498px; height:672px;\" src=\"images/SURG/90488_Transcervical_thymectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90488 Version 2.0</div></div></div>"},"90498":{"type":"graphic_figure","displayName":"Hemi-clamshell ","title":"Hemi-clamshell incision ","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Hemi-clamshell incision </div><div class=\"cntnt\"><img style=\"width:482px; height:379px;\" src=\"images/SURG/90498_Hemi-clamshell_incision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90498 Version 3.0</div></div></div>"},"90504":{"type":"graphic_table","displayName":"Inherited ichthyoses nonsyndromic","title":"Classification of inherited ichthyoses: Nonsyndromic forms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of inherited ichthyoses: Nonsyndromic forms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Mode of inheritance</td> <td class=\"subtitle1\">Gene(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Common ichthyoses*</td> </tr> <tr> <td class=\"indent1\">Ichthyosis vulgaris</td> <td>Autosomal semidominant</td> <td><em>FLG</em></td> </tr> <tr> <td class=\"indent1\">Recessive X-linked (nonsyndromic presentation)</td> <td>X-linked recessive</td> <td><em>STS</em>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Autosomal recessive congenital ichthyosis (ARCI)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Major types</td> </tr> <tr> <td class=\"indent2\">Harlequin ichthyosis</td> <td rowspan=\"3\">Autosomal recessive</td> <td><em>ABCA12</em></td> </tr> <tr> <td class=\"indent2\">Lamellar ichthyosis<sup>&#182;</sup></td> <td><em>TGM1</em>/<em>NIPAL4</em><sup>&#916;</sup>/<em>ALOX12B</em>/<em>ABCA12</em>/loci on 12p11.2-q13</td> </tr> <tr> <td class=\"indent2\">Congenital ichthyosiform erythroderma</td> <td><em>ALOXE3</em>/<em>ALOX12B</em>/<em>ABCA12</em>/<em>CYP4F22</em>/<em>NIPAL4</em><sup>&#916;</sup>/<em>TGM1</em>/loci on 12p11.2-q13</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Minor variants</td> </tr> <tr> <td class=\"indent2\">Self-healing collodion baby</td> <td rowspan=\"3\">Autosomal recessive</td> <td><em>TGM1</em>, <em>ALOX12B</em>, <em>ALOXE3</em></td> </tr> <tr> <td class=\"indent2\">Acral self-healing collodion baby</td> <td><em>TGM1</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Bathing suit ichthyosis</td> <td><em>TGM1</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Keratinopathic ichthyosis (KPI)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Major types</td> </tr> <tr> <td class=\"indent2\">Epidermolytic ichthyosis<sup>&#9674;</sup></td> <td rowspan=\"2\">Autosomal dominant</td> <td><em>KRT1</em>/<em>KRT10</em></td> </tr> <tr> <td class=\"indent2\">Superficial epidermolytic ichthyosis</td> <td><em>KRT2</em></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Minor variants</td> </tr> <tr> <td class=\"indent2\">Annular epidermolytic ichthyosis<sup>&#9674;</sup></td> <td rowspan=\"2\">Autosomal dominant</td> <td><em>KRT1</em>/<em>KRT10</em></td> </tr> <tr> <td class=\"indent2\">Ichthyosis Curth-Macklin</td> <td><em>KRT1</em></td> </tr> <tr> <td class=\"indent2\">Autosomal recessive epidermolytic ichthyosis</td> <td>Autosomal recessive</td> <td><em>KRT10</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Epidermolytic nevi<sup>&#167;</sup></td> <td>Somatic mutations</td> <td><em>KRT1</em>/<em>KRT10</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other forms</td> </tr> <tr> <td class=\"indent1\">Loricrin keratoderma</td> <td rowspan=\"2\">Autosomal dominant</td> <td><em>LOR</em></td> </tr> <tr> <td class=\"indent1\">Erythrokeratodermia variabilis<sup>&#165;</sup></td> <td><em>GJB3</em>/<em>GJB4</em></td> </tr> <tr> <td class=\"indent1\">Peeling skin disease</td> <td>Autosomal recessive</td> <td>Locus unknown</td> </tr> <tr> <td class=\"indent1\">Congenital reticular ichthyosiform erythroderma</td> <td>Autosomal dominant (?) (isolated cases)</td> <td>Locus unknown</td> </tr> <tr> <td class=\"indent1\">Keratosis linearis-ichthyosis congenita-keratoderma</td> <td>Autosomal recessive</td> <td><em>POMP</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Often delayed onset (in recessive X-linked ichthyosis, mild scaling and erythroderma may be present already at birth).<br />¶ Few cases of autosomal dominant lamellar ichthyosis described in literature (locus unknown).<br />Δ Also known as <EM>ICHTHYIN</EM> gene.<br /><FONT class=lozenge>◊</FONT> <EM>KRT1</EM> mutations are often associated with palmoplantar involvement.<br />§ May indicate gonadal mosaicism, which can cause generalized epidermolytic ichthyosis in offspring generation.<br />¥ Whether progressive symmetric erythrokeratodermia represents distinct Mendelian disorders of cornification form is debated.</div><div class=\"graphic_reference\">Reproduced from: Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 2010; 63:607. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90504 Version 5.0</div></div></div>"},"90509":{"type":"graphic_table","displayName":"Inherited ichthyoses syndromic","title":"Classification of inherited ichthyoses: Syndromic forms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of inherited ichthyoses: Syndromic forms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Mode of inheritance</td> <td class=\"subtitle1\">Gene(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">X-linked ichthyosis syndromes</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Recessive X-linked ichthyosis*</td> </tr> <tr> <td class=\"sublist2\">Syndromic presentation</td> <td class=\"sublist_other\">X-linked recessive</td> <td class=\"sublist_other\"><em>STS</em> (and others<sup>&#182;</sup>)</td> </tr> <tr> <td class=\"indent1\">Ichthyosis follicularis, atrichia, photophobia (IFAP) syndrome</td> <td>\"</td> <td><em>MBTPS2</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Conradi-H&#252;nermann-Happle syndrome (c<span class=\"title\" itemprop=\"name\">hondrodysplasia punctata 2, X-linked; </span>CDPX2)</td> <td>X-linked dominant</td> <td><em>EBP</em></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Autosomal ichthyosis syndromes (with)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Prominent hair abnormalities</td> </tr> <tr> <td class=\"sublist2\">Netherton syndrome</td> <td class=\"sublist_other\">Autosomal recessive</td> <td class=\"sublist_other\"><em>SPINK5</em></td> </tr> <tr> <td class=\"sublist2\">Ichthyosis hypotrichosis syndrome<sup>&#916;</sup></td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>ST14</em></td> </tr> <tr> <td class=\"sublist2\">Ichthyosis, hypotrichosis, sclerosing cholangitis syndrome<sup>&#9674;</sup></td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>CLDN1</em></td> </tr> <tr> <td class=\"sublist2\">Trichothiodystrophy</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>ERCC2/XPD ERCC3/XPB GTF2H5/TTDA</em></td> </tr> <tr> <td class=\"sublist2\">Trichothiodystrophy (not associated with congenital ichthyosis)*</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>C7Orf11/TTDN1</em></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Prominent neurologic signs</td> </tr> <tr> <td class=\"sublist2\">Sj&#246;gren-Larsson syndrome</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>ALDH3A2</em></td> </tr> <tr> <td class=\"sublist2\">Refsum syndrome (hereditary motor and sensory neuropathy IV; HMSN4)*</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>PHYH/PEX7</em></td> </tr> <tr> <td class=\"sublist2\">Mental retardation, enteropathy, deafness, neuropathy, ichthyosis, keratoderma (MEDNIK) syndrome</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>AP1S1</em></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Fatal diseases course</td> </tr> <tr> <td class=\"sublist2\">Gaucher syndrome type 2</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>GBA</em></td> </tr> <tr> <td class=\"sublist2\">Multiple sulfatase deficiency</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>SUMF1</em></td> </tr> <tr> <td class=\"sublist2\">Cerebral dysgenesis, neuropathy, ichthyosis, palmoplantar keratoderma (CEDNIK) syndrome</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>SNAP29</em></td> </tr> <tr> <td class=\"sublist2\">Arthrogryposis, renal dysfunction, cholestasis (ARC) syndrome</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>VPS33B</em></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Other associated signs</td> </tr> <tr> <td class=\"sublist2\">Keratitis, ichthyosis, deafness (KID) syndrome</td> <td class=\"sublist_other\">Autosomal dominant</td> <td class=\"sublist_other\"><em>GJB2 (GJB6)</em></td> </tr> <tr> <td class=\"sublist2\">Neutral lipid storage disease with ichthyosis</td> <td class=\"sublist_other\">Autosomal recessive</td> <td class=\"sublist_other\"><em>ABHD5</em></td> </tr> <tr> <td class=\"sublist2\">Ichthyosis prematurity syndrome</td> <td class=\"sublist_other\">\"</td> <td class=\"sublist_other\"><em>SLC27A4</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Often delayed onset (in RXLI mild scaling and erythroderma may be present already at birth).<br />&para; In context of contiguous gene syndrome.<br />&Delta; Clinical variant: congenital ichthyosis, follicular atrophoderma, hypotrichosis, and hypohidrosis syndrome.<br /><span class=\"lozenge\">&loz;</span> Also known as neonatal ichthyosis sclerosing cholangitis syndrome.</div><div class=\"graphic_reference\">Original figure modified for this publication. Oji V, Tadini G, Akiyama M, et al. Revised nomenclature and classification of inherited ichthyoses: Results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 2010; 63:607. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90509 Version 3.0</div></div></div>"},"90511":{"type":"graphic_figure","displayName":"Clamshell incision","title":"Clamshell incision for surgical approach to the mediastinum ","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Clamshell incision for surgical approach to the mediastinum </div><div class=\"cntnt\"><img style=\"width:521px; height:380px;\" src=\"images/SURG/90511_Clamshell_incision.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90511 Version 3.0</div></div></div>"},"90530":{"type":"graphic_table","displayName":"Failure rates after internal fixation for pathologic fractures","title":"Failure rates after internal fixation for pathologic fractures in patients with metastatic bone disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Failure rates after internal fixation for pathologic fractures in patients with metastatic bone disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of cases</td> <td class=\"subtitle1\">Failures</td> <td class=\"subtitle1\">Failure rate (percent)</td> </tr> <tr> <td><strong>Yazawa 1990<sup>[1]</sup></strong></td> <td>166</td> <td>15</td> <td>9</td> </tr> <tr> <td><strong>Dijkstra 1994<sup>[2]</sup></strong></td> <td>233</td> <td>26</td> <td>11</td> </tr> <tr> <td><strong>Dijkstra 1996<sup>[3]</sup></strong></td> <td>38</td> <td>4</td> <td>10.5</td> </tr> <tr> <td><strong>Wedin 1999<sup>[4]</sup></strong></td> <td>228</td> <td>25</td> <td>11</td> </tr> <tr> <td><strong>Ward 2000<sup>[5]</sup></strong></td> <td>89</td> <td>0</td> <td>0</td> </tr> <tr> <td><strong>Wedin 2005<sup>[6]</sup></strong></td> <td>37</td> <td>6</td> <td>16</td> </tr> <tr> <td><strong>Sharma 2007<sup>[7]</sup></strong></td> <td>25</td> <td>0</td> <td>0</td> </tr> <tr> <td><strong>Sarahrudi 2009<sup>[8]</sup></strong></td> <td>94</td> <td>3</td> <td>3.2</td> </tr> <tr> <td><strong>Steensma 2010<sup>[9]</sup></strong></td> <td>146</td> <td>16</td> <td>11</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Steensma 2012<sup>[10]</sup></strong></td> <td>82</td> <td>5</td> <td>6.1</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Overall</strong></td> <td>1138</td> <td>100</td> <td>8.8</td> </tr> <tr> <td><strong>Early studies</strong></td> <td>754&nbsp;</td> <td>70</td> <td>9.3</td> </tr> <tr> <td><strong>Modern era</strong></td> <td>384</td> <td>30</td> <td>7.8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Yazawa Y, Frassica FJ, Chao EY, et al. Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 1990; 251:213.</LI>&#xD;&#xA;<LI>Dijkstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg 1994; 160:535.</LI>&#xD;&#xA;<LI>Dijkstra S, Stapert J, Boxma H, Wiggers T. Treatment of pathological fractures of the humeral shaft due to bone metastases: a comparison of intramedullary locking nail and plate osteosynthesis with adjunctive bone cement. Eur J Surg Oncol 1996; 22:621.</LI>&#xD;&#xA;<LI>Wedin R, Bauer HCF, Wersall P. Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res 1999; 358:128.</LI>&#xD;&#xA;<LI>Ward WG, Spang J, Howe D. Metastatic disease of the femur. Surgical management. Orthop Clin North Am 2000; 31:633.</LI>&#xD;&#xA;<LI>Wedin R, Bauer HCF. Surgical treatment of skeletal metastatic lesions of the proximal femur. Endoprosthesis or reconstruction nail? J Bone Joint Surg 2005; 87:1653.</LI>&#xD;&#xA;<LI>Sharma H, Bhagat S, McCaul J, et al. Intramedullary nailing for pathological femoral fractures. J Orthop Surg 2007; 15:291.</LI>&#xD;&#xA;<LI>Sarahrudi K, Greitbauer M, Platzer P, et al. Surgical treatment of metastatic fractures of the femur: a retrospective analysis of 142 patients. J Trauma 2009; 66:1158.</LI>&#xD;&#xA;<LI>Steensma M, Healey JH, Boland PJ, et al. One Bone, One Operation? An analysis of reoperation for failed surgical treatment of femur metastases (paper 247). Proceedings of the American Academy of Orthopedic Surgeons Annual Meeting, p 780, New Orleans, 2010.</LI>&#xD;&#xA;<LI>Steensma M, Boland PJ, Morris CD, et al. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res 2012; 470:920.</LI></OL></div><div id=\"graphicVersion\">Graphic 90530 Version 1.0</div></div></div>"},"90537":{"type":"graphic_figure","displayName":"The relationship of the thymus to other mediastinal structures","title":"The relationship of the thymus to other mediastinal structures, from an anterior viewpoint.","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">The relationship of the thymus to other mediastinal structures, from an anterior viewpoint.</div><div class=\"cntnt\"><img style=\"width:523px; height:581px;\" src=\"images/SURG/90537_Anatomy_of_thymus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90537 Version 2.0</div></div></div>"},"90539":{"type":"graphic_table","displayName":"Failure rates of internal fix versus reconstruct proximal femur","title":"Failure rates in series comparing internal fixation versus endoprosthetic reconstruction for proximal femur pathologic fractures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Failure rates in series comparing internal fixation versus endoprosthetic reconstruction for proximal femur pathologic fractures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Internal fixation implant failure rate, percent</td> <td class=\"subtitle1\">Endoprosthetic implant failure rate, percent</td> </tr> <tr> <td><strong>Dijkstra 1994<sup>[1]</sup></strong></td> <td>70*</td> <td>10*</td> </tr> <tr> <td><strong>Wedin 1999<sup>[2]</sup></strong></td> <td>14 (22/162)</td> <td>2 (1/54)</td> </tr> <tr> <td><strong>Wedin 2005<sup>[3]</sup></strong></td> <td>16 (6/37)</td> <td>8 (9/109)</td> </tr> <tr> <td><strong>Sarahrudi 2009</strong><sup>[4]</sup></td> <td>3.2 (3/94)</td> <td>8.65 (2/23)&nbsp;</td> </tr> <tr> <td><strong>Harvey 2012<sup>[5]</sup></strong></td> <td>11 (5/46)</td> <td>0 (0/113)</td> </tr> <tr> <td><strong>Steensma 2012<sup>[6]</sup></strong></td> <td>6 (5/82)</td> <td>3 (6/197)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* By Kaplan Meier at four years.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Dijkstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg 1994; 160:535.</LI>&#xD;&#xA;<LI>Wedin R, Bauer HCF, Wersall P. Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res 1999; 358:128.</LI>&#xD;&#xA;<LI>Wedin R, Bauer HCF. Surgical treatment of skeletal metastatic lesions of the proximal femur. Endoprosthesis or reconstruction nail? J Bone Joint Surg 2005; 87:1653.</LI>&#xD;&#xA;<LI>Sarahrudi K, Greitbauer M, Platzer P, et al. Surgical treatment of metastatic fractures of the femur: a retrospective analysis of 142 patients.&nbsp;J Trauma 2009; 66:1158.</LI>&#xD;&#xA;<LI>Harvey N. Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin Orthop Relat Res 2012; 470:684.</LI>&#xD;&#xA;<LI>Steensma M, Boland PJ, Morris CD, et al. Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res 2012; 470:920.</LI></OL></div><div id=\"graphicVersion\">Graphic 90539 Version 2.0</div></div></div>"},"90540":{"type":"graphic_diagnosticimage","displayName":"Examples of CT scan appearance","title":"Examples of CT scan appearance of thymomas","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Examples of CT scan appearance of thymomas</div><div class=\"cntnt\"><img style=\"width:598px; height:244px;\" src=\"images/ONC/90540_Examples_CT_scan_appearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of CT scan appearance of thymomas (arrows indicate the thymoma).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90540 Version 2.0</div></div></div>"},"90549":{"type":"graphic_table","displayName":"Pulmonary embolism severity index","title":"Pulmonary embolism severity index scores: Full and simplified","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary embolism severity index scores: Full and simplified</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Pulmonary embolism severity index (PESI) - Full</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Clinical feature</td> <td class=\"subtitle2\">Points</td> </tr> <tr> <td colspan=\"2\">Age</td> <td class=\"centered\">x (eg, 65)</td> </tr> <tr> <td colspan=\"2\">Male gender</td> <td class=\"centered\">10</td> </tr> <tr> <td colspan=\"2\">History of cancer</td> <td class=\"centered\">30</td> </tr> <tr> <td colspan=\"2\">Heart failure</td> <td class=\"centered\">10</td> </tr> <tr> <td colspan=\"2\">Chronic lung disease</td> <td class=\"centered\">10</td> </tr> <tr> <td colspan=\"2\">Pulse &#8805;110/min</td> <td class=\"centered\">20</td> </tr> <tr> <td colspan=\"2\">Systolic blood pressure &#60;100 mmHg</td> <td class=\"centered\">30</td> </tr> <tr> <td colspan=\"2\">Respiratory rate &#8805;30/min</td> <td class=\"centered\">20</td> </tr> <tr> <td colspan=\"2\">Temperature &#60;36&#176; Celcius</td> <td class=\"centered\">20</td> </tr> <tr> <td colspan=\"2\">Altered mental status</td> <td class=\"centered\">60</td> </tr> <tr> <td colspan=\"2\">Arterial oxygen saturation &#60;90 percent</td> <td class=\"centered\">20</td> </tr> <tr class=\"divider_top\"> <td>Class I</td> <td class=\"centered\" rowspan=\"2\">Low risk</td> <td class=\"centered\">&#60;66</td> </tr> <tr> <td>Class II</td> <td class=\"centered\">66 to 85</td> </tr> <tr class=\"divider_top\"> <td>Class III</td> <td class=\"centered divider_bottom\" rowspan=\"3\">High risk</td> <td class=\"centered\">86 to 105</td> </tr> <tr> <td>Class IV</td> <td class=\"centered\">106 to 125</td> </tr> <tr class=\"divider_bottom\"> <td>Class V</td> <td class=\"centered\">&#62;125</td> </tr> <tr> <td class=\"subtitle1 divider_top\" colspan=\"3\">Simplified pulmonary embolism severity index (sPESI)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Clinical feature</td> <td class=\"subtitle2\">Points</td> </tr> <tr> <td colspan=\"2\">Age &#62;80 years</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"2\">History of cancer</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"2\">Chronic cardiopulmonary disease</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"2\">Pulse &#8805;110/min</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"2\">Systolic blood pressure &#60;100 mmHg</td> <td class=\"centered\">1</td> </tr> <tr> <td colspan=\"2\">Arterial oxygen saturation &#60;90 percent</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Low risk</td> <td class=\"centered\">0</td> </tr> <tr> <td colspan=\"2\">High risk</td> <td class=\"centered\">&#8805;1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The full PESI score is rarely calculated in clinical practice since it is generally considered cumbersome. In contrast, sPESI is brief, contains a limited number of easily accessible parameters, and is therefore, much more practical.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172:1041.</li>&#xD;&#xA;    <li>Jim&eacute;nez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170:1383.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90549 Version 4.0</div></div></div>"},"90550":{"type":"graphic_diagnosticimage","displayName":"Thymic mass that does not appear well circumscribed","title":"Thymic mass that does not appear well circumscribed and shows possible infiltration of surrounding structures","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Thymic mass that does not appear well circumscribed and shows possible infiltration of surrounding structures</div><div class=\"cntnt\"><img style=\"width:590px; height:401px;\" src=\"images/ONC/90550_Thymic_mass_not_well_circum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90550 Version 1.0</div></div></div>"},"90551":{"type":"graphic_diagnosticimage","displayName":"Examples of teratomas","title":"CT scan examples of teratomas","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT scan examples of teratomas</div><div class=\"cntnt\"><img style=\"width:598px; height:234px;\" src=\"images/ONC/90551_Examples_of_teratomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90551 Version 2.0</div></div></div>"},"90568":{"type":"graphic_diagnosticimage","displayName":"Malignant degeneration","title":"Teratoma with malignant degeneration","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Teratoma with malignant degeneration</div><div class=\"cntnt\"><img style=\"width:462px; height:454px;\" src=\"images/ONC/90568_Malignant_degeneration.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90568 Version 1.0</div></div></div>"},"90570":{"type":"graphic_picture","displayName":"Epidermolytic ichthyosis","title":"Epidermolytic ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epidermolytic ichthyosis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/90570_Epidermolyticichthyosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratosis and large erosions on the soles of an infant with epidermolytic ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90570 Version 2.0</div></div></div>"},"90578":{"type":"graphic_picture","displayName":"Epidermolytic ichthyosis neck","title":"Epidermolytic ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolytic ichthyosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90578_Epidermolyt_ichthyosis_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratosis is more prominent in flexural areas in patients with epidermolytic ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90578 Version 1.0</div></div></div>"},"90580":{"type":"graphic_picture","displayName":"Epidermolytic ichthyosis knees","title":"Epidermolytic ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Epidermolytic ichthyosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90580_Epidermoly_ichthyosis_knees.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratosis with typical accentuation over flexural areas in a child with epidermolytic ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90580 Version 1.0</div></div></div>"},"90583":{"type":"graphic_table","displayName":"Short-term weight loss following bariatric surgery","title":"Expected short-term weight loss following bariatric surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected short-term weight loss following bariatric surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Operative procedure</td> <td class=\"subtitle1\">Excess weight loss (percent)</td> <td class=\"subtitle1\">Time until weight stabilization (years)</td> </tr> <tr> <td>Gastric bypass</td> <td class=\"centered\">60 to 85</td> <td class=\"centered\">1 to 1.5</td> </tr> <tr> <td>Adjustable gastric band</td> <td class=\"centered\">45 to 55</td> <td class=\"centered\">2</td> </tr> <tr> <td>Sleeve gastrectomy</td> <td class=\"centered\">55 to 80</td> <td class=\"centered\">1 to 1.5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.</li>&#xD;&#xA;    <li>Ballantyne GH. Measuring outcomes following bariatric surgery: weight loss parameters, improvement in co-morbid conditions, change in quality of life and patient satisfaction. Obes Surg 2003; 13:954.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90583 Version 2.0</div></div></div>"},"90586":{"type":"graphic_table","displayName":"Pediatric meditation resources","title":"Selected resources related to meditation for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected resources related to meditation for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p><strong>The Mindful Child: How to Help Your Kid Manage Stress and Become Happier, Kinder, and More Compassionate</strong></p> by Susan Kaiser Greenland</td> </tr> <tr> <td> <p><strong>Planting Seeds: Practicing Mindfulness with Children</strong></p> by Thich Nhat Hanh</td> </tr> <tr> <td> <p><strong>Child's Mind: Mindfulness Practices to Help Our Children Be More Focused, Calm, and Relaxed</strong></p> by Christopher Willard, PsyD</td> </tr> <tr> <td> <p><strong>Mindfulness for Teen Anxiety: A Workbook for Overcoming Anxiety at Home, at School, and Everywhere Else</strong></p> by Christopher Willard, PsyD</td> </tr> <tr> <td> <p><strong>Peaceful Piggy Meditation (Albert Whitman Prairie Books)</strong></p> by Kerry Lee Maclean (author) and Kerry Maclean (illustrator)</td> </tr> <tr> <td> <p><strong>Sitting Still Like a Frog: Mindfulness Exercises for Kids (and Their Parents)</strong></p> by Eline Snel</td> </tr> <tr> <td> <p><strong>The Mindful Teen: Powerful Skills to Help You Handle Stress One Moment at a Time</strong></p> by Dzung X. Vo, MD, FAAP</td> </tr> <tr> <td> <p><strong>A Still Quiet Place: A Mindfulness Program for Teaching Children and Adolescents to Ease Stress and Difficult Emotions</strong></p> by Amy Saltzman, MD</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90586 Version 2.0</div></div></div>"},"90587":{"type":"graphic_picture","displayName":"Dermoscopy of tinea capitis","title":"Dermoscopic findings in tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Dermoscopic findings in tinea capitis</div><div class=\"cntnt\"><img style=\"width:485px; height:364px;\" src=\"images/DERM/90587_Dermosctineacapitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy of tinea capitis. Comma hairs (arrow), corkscrew hairs (arrowhead), and broken hairs (thick arrow) in a child with tinea capitis.</div><div class=\"graphic_reference\">Reproduced from: Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012; 67:1040. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90587 Version 3.0</div></div></div>"},"90590":{"type":"graphic_table","displayName":"Differential diagnosis of dyspepsia","title":"Differential diagnosis of dyspepsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of dyspepsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis</td> </tr> <tr> <td>Functional dyspepsia </td> </tr> <tr> <td class=\"subtitle2_single\">Dyspepsia caused by structural or biochemical disease</td> </tr> <tr> <td class=\"indent1\">Peptic ulcer disease</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux disease (GERD)</td> </tr> <tr> <td class=\"indent1\">Biliary pain</td> </tr> <tr> <td class=\"indent1\">Chronic abdominal wall pain</td> </tr> <tr> <td class=\"indent1\">Gastric or esophageal cancer</td> </tr> <tr> <td class=\"indent1\">Gastroparesis</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Carbohydrate malabsorption</td> </tr> <tr> <td class=\"indent1\">Medications (including potassium supplements, digitalis, iron, theophylline, oral antibiotics [especially ampicillin and erythromycin], nonsteroidal antiinflammatory drugs [NSAIDs], glucocorticoids, niacin, gemfibrozil, narcotics, colchicine, quinidine, estrogens, levodopa)</td> </tr> <tr> <td class=\"indent1\">Infiltrative diseases of the stomach (eg, Crohn disease, sarcoidosis)</td> </tr> <tr> <td class=\"indent1\">Metabolic disturbances (hypercalcemia, hyperkalemia)</td> </tr> <tr> <td class=\"indent1\">Hepatocellular carcinoma</td> </tr> <tr> <td class=\"indent1\">Ischemic bowel disease, celiac artery compression syndrome, superior mesenteric artery syndrome</td> </tr> <tr> <td class=\"indent1\">Systemic disorders (diabetes mellitus, thyroid and parathyroid disorders, connective tissue disease)</td> </tr> <tr> <td class=\"indent1\">Intestinal parasites (<em>Giardia</em>, <em>Strongyloides</em>)</td> </tr> <tr> <td class=\"indent1\">Abdominal cancer, especially pancreatic cancer</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Talley NJ, Silverstein MD, Agreus L, et al. American Gastroenterological Association (AGA) technical review: evaluation of dyspepsia. Gastroenterology 1998; 114:582.</LI>&#xD;&#xA;<LI>Fisher RS, Parkman HP. Management of nonulcer dyspepsia. N Engl J Med 1998; 339:1376.</LI></OL></div><div id=\"graphicVersion\">Graphic 90590 Version 10.0</div></div></div>"},"90592":{"type":"graphic_diagnosticimage","displayName":"CT scan appearance of seminoma","title":"CT scan appearance of seminoma (A) before and (B) after treatment with systemic chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT scan appearance of seminoma (A) before and (B) after treatment with systemic chemotherapy</div><div class=\"cntnt\"><img style=\"width:598px; height:217px;\" src=\"images/ONC/90592_CT_scan_appearance_seminoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90592 Version 2.0</div></div></div>"},"90593":{"type":"graphic_diagnosticimage","displayName":"CT scan appearances","title":"CT scan appearances of non-seminomatous germ cell tumors","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">CT scan appearances of non-seminomatous germ cell tumors</div><div class=\"cntnt\"><img style=\"width:596px; height:214px;\" src=\"images/ONC/90593_CT_scan_appearances.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90593 Version 2.0</div></div></div>"},"90594":{"type":"graphic_algorithm","displayName":"AUB nonpregnant reproductive-age evaluation","title":"Evaluation of abnormal uterine bleeding in nonpregnant reproductive-age women","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Evaluation of abnormal uterine bleeding in nonpregnant reproductive-age women</div><div class=\"cntnt\"><img style=\"width:580px; height:805px;\" src=\"images/OBGYN/90594_AUB_nonpreg_reprod_eval.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90594 Version 2.0</div></div></div>"},"90595":{"type":"graphic_table","displayName":"AUB nonpregnant reproductive-age evaluation diff diagnosis","title":"Evaluation and differential diagnosis of abnormal uterine bleeding (AUB) in nonpregnant reproductive-age women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation and differential diagnosis of abnormal uterine bleeding (AUB) in nonpregnant reproductive-age women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Bleeding pattern</td> <td class=\"subtitle1\" rowspan=\"2\">Other associated clinical features</td> <td class=\"subtitle1\" colspan=\"2\">Differential diagnosis</td> <td class=\"subtitle1\" rowspan=\"2\">Evaluation</td> </tr> <tr> <td class=\"subtitle2\">Common etiologies</td> <td class=\"subtitle2\">Less common etiologies</td> </tr> <tr> <td rowspan=\"4\">Regular menses that are heavy or prolonged</td> <td>Enlarged uterus on examination, discrete masses may be noted</td> <td>Uterine leiomyoma</td> <td>&nbsp;</td> <td> <p>- Pelvic ultrasound</p> - Saline infusion sonography or hysteroscopy (if intracavitary pathology is suspected)</td> </tr> <tr> <td> <p>- Dysmenorrhea</p> - Enlarged, boggy uterus on examination</td> <td>Adenomyosis</td> <td>&nbsp;</td> <td>Pelvic ultrasound</td> </tr> <tr> <td> <p>- Family history of bleeding disorder</p> <p>- Symptoms of bleeding diathesis</p> - Anticoagulant therapy</td> <td>Bleeding disorder</td> <td>&nbsp;</td> <td>Testing for bleeding disorder</td> </tr> <tr> <td>Risk factors for uterine malignancy</td> <td>&nbsp;</td> <td>Endometrial carcinoma or uterine sarcoma</td> <td>Endometrial sampling</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Regular menses with intermenstrual bleeding</td> <td>&nbsp;</td> <td>Endometrial polyp</td> <td>&nbsp;</td> <td> <p>- Pelvic ultrasound</p> - Saline infusion sonography or hysteroscopy (if available)</td> </tr> <tr> <td>Risk factors for uterine malignancy</td> <td>&nbsp;</td> <td>Endometrial carcinoma or uterine sarcoma</td> <td>Endometrial sampling</td> </tr> <tr> <td>Recent history of uterine or cervical procedure or childbirth, particularly if infection was present</td> <td>&nbsp;</td> <td>Chronic endometritis</td> <td>Endometrial sampling</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Irregular bleeding, may be more or less frequent than normal menses and volume and duration may vary</td> <td>&nbsp;</td> <td>Ovulatory dysfunction:</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Hirsutism, acne, and/or obesity</td> <td>PCOS</td> <td>&nbsp;</td> <td>Total testosterone and/or other androgens (may not be increased in all women with PCOS)</td> </tr> <tr> <td>Galactorrhea</td> <td>Hyperprolactinemia</td> <td>&nbsp;</td> <td>Prolactin</td> </tr> <tr> <td> <p>- Recent weight gain or loss</p> <p>- Heat or cold intolerance</p> - Family history of thyroid dysfunction</td> <td>Thyroid disease</td> <td>&nbsp;</td> <td>Thyroid function tests</td> </tr> <tr> <td>Risk factors for uterine malignancy</td> <td>&nbsp;</td> <td>Endometrial carcinoma or uterine sarcoma</td> <td>&nbsp;Endometrial sampling</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Secondary amenorrhea</td> <td>History of irregular bleeding</td> <td>Ovulatory dysfunction</td> <td>&nbsp;</td> <td>Refer to ovulatory dysfunction above</td> </tr> <tr> <td>Poor nutrition or intense exercise</td> <td>Hypothalamic amenorrhea</td> <td>&nbsp;</td> <td>- Follicle-stimulating hormone <p>- Luteinizing hormone</p> - Estradiol</td> </tr> <tr> <td>Hot flushes</td> <td>Premature ovarian insufficiency</td> <td>&nbsp;</td> <td>Follicle-stimulating hormone</td> </tr> <tr> <td rowspan=\"2\">Recent history of uterine or cervical procedure or childbirth, particularly if infection was present (menses may present, but abnormally light or brief)</td> <td>&nbsp;</td> <td>Cervical stenosis</td> <td>On pelvic examination, instrument cannot be passed through internal cervical os</td> </tr> <tr> <td>&nbsp;</td> <td>Intrauterine adhesions (Asherman syndrome)</td> <td>Hysteroscopy</td> </tr> <tr class=\"divider_top\"> <td>Irregular or heavy bleeding in a patient&nbsp;using hormonal contraceptives or with an intrauterine device</td> <td>&nbsp;</td> <td>Iatrogenic AUB</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Other uncommon etiologies of AUB include a uterine arteriovenous malformation or endometriosis.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovarian syndrome.</div><div id=\"graphicVersion\">Graphic 90595 Version 5.0</div></div></div>"},"90597":{"type":"graphic_diagnosticimage","displayName":"CT scans of diffuse large b-cell lymphoma A and B","title":"CT scans of 22-year-old female found to have diffuse large B-cell lymphoma (A) before and (B) after 6 cycles of R-EPOCH (rituximab, etoposide, vincristine, doxorubicin, and cyclophosphamide)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">CT scans of 22-year-old female found to have diffuse large B-cell lymphoma (A) before and (B) after 6 cycles of R-EPOCH (rituximab, etoposide, vincristine, doxorubicin, and cyclophosphamide)</div><div class=\"cntnt\"><img style=\"width:513px; height:169px;\" src=\"images/ONC/90597_CT_diff_b_cell_lym_A_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial CT-guided biopsy was diagnostic, and definitive diagnosis was obtained with biopsy via left VATS.</div><div class=\"graphic_footnotes\">CT: computed tomography; VATS: video-assisted thoracoscopic surgery.</div><div id=\"graphicVersion\">Graphic 90597 Version 3.0</div></div></div>"},"90598":{"type":"graphic_diagnosticimage","displayName":"CT scan examples of intra-thoracic extension","title":"CT scan examples of intra-thoracic extension of large goiters","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">CT scan examples of intra-thoracic extension of large goiters</div><div class=\"cntnt\"><img style=\"width:513px; height:219px;\" src=\"images/ONC/90598_CT_ex_intra_thor_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note deviation of trachea to the left in panel A, with significant narrowing of the airway lumen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90598 Version 2.0</div></div></div>"},"90600":{"type":"graphic_diagnosticimage","displayName":"PET-CT scan of a patient with adenopathy","title":"PET-CT scan of a patient with adenopathy in the middle mediastinum secondary to lymphoma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">PET-CT scan of a patient with adenopathy in the middle mediastinum secondary to lymphoma</div><div class=\"cntnt\"><img style=\"width:513px; height:199px;\" src=\"images/ONC/90600_PET_CT_pat_adenopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PET-CT: positron emission tomography-computed tomography.</div><div id=\"graphicVersion\">Graphic 90600 Version 2.0</div></div></div>"},"90601":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic and pericardial cyst CT scans","title":"CT scan demonstrating (A) a bronchogenic cyst and (B) a pericardial cyst","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">CT scan demonstrating (A) a bronchogenic cyst and (B) a pericardial cyst</div><div class=\"cntnt\"><img style=\"width:513px; height:202px;\" src=\"images/ONC/90601_Bronchoge_peri_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90601 Version 2.0</div></div></div>"},"90602":{"type":"graphic_diagnosticimage","displayName":"Schwannoma in the posterior mediastinum","title":"CT scan demonstrating a schwannoma in the posterior mediastinum.","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">CT scan demonstrating a schwannoma in the posterior mediastinum.</div><div class=\"cntnt\"><img style=\"width:504px; height:390px;\" src=\"images/ONC/90602_Schwanno_post_mediast.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90602 Version 2.0</div></div></div>"},"90619":{"type":"graphic_table","displayName":"Risk factors for neonatal rickets","title":"Risk factors for rickets in preterm infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for rickets in preterm infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Born at &#60;27 weeks gestation</td> </tr> <tr> <td>Birth weight &#60;1000 g</td> </tr> <tr> <td>Long-term parenteral nutrition (eg, &#62;4 to 5 weeks)</td> </tr> <tr> <td>Severe bronchopulmonary dysplasia, defined as treatment with loop diuretics (eg, furosemide) and fluid restriction</td> </tr> <tr> <td>Postnatal steroid use</td> </tr> <tr> <td>History of necrotizing enterocolitis</td> </tr> <tr> <td>Failure to tolerate formulas or human milk fortifiers with high mineral content</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 131, Pages e1676-e1683, Copyright © 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 90619 Version 8.0</div></div></div>"},"90620":{"type":"graphic_table","displayName":"Net retention of Ca of preterm enteral feeds","title":"Approximate calcium balance in a typical infant receiving 120 kcal/kg per day intake","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate calcium balance in a typical infant receiving 120 kcal/kg per day intake</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Calcium concentration<br /> (mg/dL)</td> <td class=\"subtitle1\">Intake<br /> (mg/kg per day)</td> <td class=\"subtitle1\">Absorption<br /> (percent)</td> <td class=\"subtitle1\">Total absorption<br /> (mg/kg per day)</td> <td class=\"subtitle1\">Approximate retention<br /> (mg/kg per day)</td> </tr> <tr> <td><strong>Human milk</strong>*</td> <td class=\"centered\">25</td> <td class=\"centered\">38</td> <td class=\"centered\">60</td> <td class=\"centered\">25</td> <td class=\"centered\">15 to 20</td> </tr> <tr> <td><strong>Preterm formula/fortified human milk</strong></td> <td class=\"centered\">145</td> <td class=\"centered\">220</td> <td class=\"centered\">50 to 60</td> <td class=\"centered\">120 to 130</td> <td class=\"centered\">100 to 120</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Human milk assumed to be 20 kcal/oz, and preterm formula and fortified human milk assumed to be 24 kcal/oz.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 131, Pages e1676-e1683, Copyright © 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 90620 Version 8.0</div></div></div>"},"90621":{"type":"graphic_table","displayName":"Ca P vit D content of preterm enteral feeds","title":"Intakes of calcium, phosphorus, and vitamin D from various enteral nutrition feedings for preterm infants in the United States, assuming formula intake of 160 mL/kg per day","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intakes of calcium, phosphorus, and vitamin D from various enteral nutrition feedings for preterm infants in the United States, assuming formula intake of&nbsp;160 mL/kg per day</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Recommended intake<sup>*</sup>&nbsp;</td> <td class=\"subtitle1\">Unfortified human milk<sup>&#182;</sup><br /> (20 kcal/oz)</td> <td class=\"subtitle1\">Fortified human milk<sup><span style=\"font-size: 13px;\">&#182;</span></sup><br /> (24 kcal/oz)</td> <td class=\"subtitle1\">Preterm formula<br /> (24 kcal/oz)</td> <td class=\"subtitle1\">Transitional formula<br /> (22 kcal/oz)</td> </tr> <tr> <td><strong>Calcium (mg/kg)</strong></td> <td>&nbsp;150 to 220</td> <td class=\"centered\">37</td> <td class=\"centered\">184 to 218</td> <td class=\"centered\">210 to 234</td> <td class=\"centered\">125 to 144</td> </tr> <tr> <td><strong>Phosphorus (mg/kg)</strong></td> <td>&nbsp;75 to 140</td> <td class=\"centered\">21</td> <td class=\"centered\">102 to 125</td> <td class=\"centered\">107 to 130</td> <td class=\"centered\">74 to 80</td> </tr> <tr> <td><strong>Vitamin D (int. units/day)</strong></td> <td>&nbsp;200 to 400</td> <td class=\"centered\">2.4<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td class=\"centered\">283 to 379<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td class=\"centered\">290 to 468<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> <td class=\"centered\">125 to 127<sup><span style=\"font-size: 13px;\">&#916;</span></sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Int. units: international units.<br />* Recommendations for preterm infants weighing 1000 to 1500 g.&nbsp;<br />¶ Human milk data based on mature human milk.<br />Δ&nbsp;Vitamin D intake is based on an infant weighing 1500 g. Concentrations of vitamin D vary considerably among different commercially available human milk fortifiers. </div><div class=\"graphic_reference\">Modified with permission from Pediatrics, Vol. 131, Pages e1676-e1683, Copyright © 2013 by the AAP.</div><div id=\"graphicVersion\">Graphic 90621 Version 8.0</div></div></div>"},"90629":{"type":"graphic_table","displayName":"Calculation of the glucose infusion rate","title":"Calculation of the glucose infusion rate (GIR) for parenteral nutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of the glucose infusion rate (GIR) for parenteral nutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>1. Calculate grams of glucose in the parenteral nutrition (PN) prescription</td> <td>Energy (kcals) from carbohydrates &#247; 3.4 kcal/g = grams glucose</td> </tr> <tr> <td>2. Convert to milligrams of glucose</td> <td>Grams glucose x 1000 = mg glucose</td> </tr> <tr> <td>3. Calculate milligrams of glucose per kilogram</td> <td>Mg glucose &#247; body weight (kg) = mg glucose/kg</td> </tr> <tr> <td> <p>4. Calculate milligrams of glucose per kilogram per minute</p> = <strong>glucose infusion rate (GIR)</strong></td> <td> <p>Mg glucose/kg &#247; minutes of infusion = mg glucose/kg/minute</p> (where minutes of infusion = 1440 if infusion is continuous over 24 hours)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Susan Baker, MD, and Robert Baker, MD.</div><div id=\"graphicVersion\">Graphic 90629 Version 2.0</div></div></div>"},"90630":{"type":"graphic_table","displayName":"High risk flu PI","title":"People at high risk from the flu","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">People at high risk from the flu</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The flu vaccine is especially important for:</td> </tr> <tr> <td class=\"indent1\">Children age 6 months through 4 years</td> </tr> <tr> <td class=\"indent1\">Adults age 50 or older</td> </tr> <tr> <td class=\"sublist2_start\">People with long-term health problems, such as:</td> </tr> <tr> <td class=\"sublist2\">Lung disease, including asthma or COPD</td> </tr> <tr> <td class=\"sublist2\">Heart disease</td> </tr> <tr> <td class=\"sublist2\">Diabetes</td> </tr> <tr> <td class=\"sublist2\">Severe obesity</td> </tr> <tr> <td class=\"sublist2_start\">People who have trouble fighting infections, for example because they:</td> </tr> <tr> <td class=\"sublist2\">Are being treated for cancer</td> </tr> <tr> <td class=\"sublist2\">Have HIV/AIDS</td> </tr> <tr> <td class=\"sublist2\">Had an organ transplant</td> </tr> <tr> <td class=\"indent1\">Women who are or will be pregnant during the flu season</td> </tr> <tr> <td class=\"indent1\">Children age 6 months through 18 years who take aspirin every day</td> </tr> <tr> <td class=\"indent1\">People who live in nursing homes or long-term care facilities</td> </tr> <tr> <td class=\"indent1\">Native Americans, including Alaska Natives</td> </tr> <tr> <td class=\"indent1\">People who live with or care for people at high risk (listed above)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 90630 Version 3.0</div></div></div>"},"90632":{"type":"graphic_picture","displayName":"CHILD syndrome","title":"CHILD syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">CHILD syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/90632_CHILD_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A female infant with congenital hemidysplasia, ichthyosiform erythroderma, and limb defects (CHILD) syndrome. Note the unilateral skin involvement with waxy, scaly plaques showing a sharp midline demarcation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90632 Version 1.0</div></div></div>"},"90634":{"type":"graphic_diagnosticimage","displayName":"IMRT treatment plan","title":"IMRT plan for treatment of prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">IMRT plan for treatment of prostate cancer</div><div class=\"cntnt\"><img style=\"width:504px; height:259px;\" src=\"images/ONC/90634_IMRT_treatment_plan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of IMRT plan for treatment of prostate cancer. Axial CT slice through the middle of prostate gland. Colors represent corresponding doses (in cGy) calculated to be received by the patient over the course of the entire treatment.</div><div class=\"graphic_footnotes\">IMRT: intensity-modulated radiation therapy; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90634 Version 2.0</div></div></div>"},"90643":{"type":"graphic_figure","displayName":"Treatment algorithm for patients","title":"Treatment algorithm for patients with metastatic melanoma","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for patients with metastatic melanoma</div><div class=\"cntnt\"><img style=\"width:726px; height:504px;\" src=\"images/ONC/90643_Treatment_algo_patients.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inclusion in clinical trial should be considered at all stages of patient management whenever possible.</div><div class=\"graphic_footnotes\">CNS: central nervous system; PS: performance status.<br />* High-dose interleukin-2 (IL-2) or checkpoint inhibition with an anti-PD1 monoclonal antibody (pembrolizumab, nivolumab) or the anti-CTLA4 monoclonal antibody impilimumab. For patients without CNS mets, good organ function, physiologic age &lt;70, normal LDH consider IL-2 or checkpoint inhibition with an anti-PD1 monoclonal antibody (pembrolizumab, nivolumab) or the anti-CTLA4 monoclonal antibody impilimumab. For all other patients (excepting those with autoimmune conditions) consider checkpoint inhibition with an anti-PD1 monoclonal antibody (pembrolizumab, nivolumab) or the anti-CTLA4 monoclonal antibody impilimumab alone.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Clinical Oncology. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013; 10:588. Copyright &copy; 2013. <a href=\"http://www.nature.com/nrclinonc\" target=\"_blank\">www.nature.com/nrclinonc</a>.</div><div id=\"graphicVersion\">Graphic 90643 Version 5.0</div></div></div>"},"90644":{"type":"graphic_diagnosticimage","displayName":"SCFE osteonecrosis","title":"Slipped capital femoral epiphysis with development of osteonecrosis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Slipped capital femoral epiphysis with development of osteonecrosis</div><div class=\"cntnt\"><img style=\"width:513px; height:426px;\" src=\"images/EM/90644_SCFE_osteonecrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Preoperatively this patient had a slipped capital femoral epiphysis on the right.<br />(B) One month postoperatively, there is evidence of resorption of the femoral head and widening of the joint line.<br />(C) Five months postoperatively, avascular necrosis of the femoral head is more evident.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 90644 Version 1.0</div></div></div>"},"90645":{"type":"graphic_table","displayName":"Rand trials lapatinib and or trastuzumab NACT HER2-pos pts","title":"Randomized trials of lapatinib and/or trastuzumab with neoadjuvant chemotherapy in HER2-positive patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Randomized trials of lapatinib and/or trastuzumab with neoadjuvant chemotherapy in HER2-positive patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Designation</td> <td class=\"subtitle1\" rowspan=\"2\">Neoadjuvant chemotherapy*</td> <td class=\"subtitle1\" rowspan=\"2\">HER2-targeted therapy<sup>&#182;</sup></td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\" colspan=\"2\">pCR rate (percent)</td> <td class=\"subtitle1\" rowspan=\"2\">BCS</td> </tr> <tr> <td class=\"subtitle2\">Breast</td> <td class=\"subtitle2\">Breast/axilla</td> </tr> <tr> <td rowspan=\"3\">NeoALTTO<sup>[1]</sup></td> <td rowspan=\"3\">wP x 12</td> <td>Trastuzumab (T)</td> <td rowspan=\"3\">455</td> <td>30</td> <td>28</td> <td>39</td> </tr> <tr> <td>Lapatinib 1500 mg</td> <td>25</td> <td>20</td> <td>43</td> </tr> <tr> <td>T/Lapatinib 1000 mg<sup>&#916;</sup></td> <td>51<sup>&#9674;</sup></td> <td>47<sup>&#9674;</sup></td> <td>41</td> </tr> <tr> <td rowspan=\"3\">CHER-LOB<sup>[2]</sup></td> <td rowspan=\"3\"> <p>wP x 12</p> &#8594; FEC x 4</td> <td>T</td> <td rowspan=\"3\">121</td> <td>NR</td> <td>25</td> <td>67</td> </tr> <tr> <td>Lapatinib 1500 mg<sup>&#916;</sup></td> <td>NR</td> <td>26</td> <td>58</td> </tr> <tr> <td>T/Lapatinib 1000 mg<sup>&#916;</sup></td> <td>NR</td> <td>47<sup>&#9674;</sup></td> <td>69</td> </tr> <tr> <td rowspan=\"3\">NSABP B-41<sup>[3]</sup></td> <td rowspan=\"3\"> <p>AC x 4</p> &#8594; wP x 12</td> <td>T</td> <td rowspan=\"3\">529</td> <td>52</td> <td>47</td> <td>NR</td> </tr> <tr> <td>Lapatinib 1250 mg</td> <td>53</td> <td>49</td> <td>NR</td> </tr> <tr> <td>T/Lapatinib 750 mg</td> <td>62</td> <td>60</td> <td>NR</td> </tr> <tr> <td rowspan=\"3\">CALGB 40601<sup>[4]</sup></td> <td rowspan=\"3\">wP x 16</td> <td>T</td> <td rowspan=\"3\">299</td> <td>47</td> <td>43</td> <td>NR</td> </tr> <tr> <td>Lapatinib 1500 mg<sup>&#916;</sup></td> <td>36</td> <td>29</td> <td>NR</td> </tr> <tr> <td>T/Lapatinib 1000 mg<sup>&#916;</sup></td> <td>56</td> <td>52</td> <td>NR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported; pCR: pathologic complete response; BCS: breast conserving therapy.<br />* wP: weekly paclitaxel 80 mg/m<SUP>2</SUP>; AC: doxorubicin 60 mg/m<SUP>2</SUP> and cyclophosphamide 600 mg/m<SUP>2</SUP> every three weeks; FEC: fluorouracil 600 mg/m<SUP>2</SUP>, epirubicin 75 mg/m<SUP>2</SUP>, and cyclophosphamide 600 mg/m<SUP>2</SUP> every three weeks.<br />¶ T: trastuzumab 4 mg/kg week 1 then 2 mg/kg weekly. On NeoALTTO, patients received a six-week \"biologic window\" of HER2-targeted therapy only before starting wP; on CHER-LOB, HER2-targeted therapy continued through wP and FEC, whereas on NSABP B-41, HER2-targeted therapy did not start until after AC.<br />Δ Lapatinib dose reduced during course of study due to toxicity (diarrhea).<br /><FONT class=lozenge>◊</FONT> Statistically significant difference versus trastuzumab only arm.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379:633.</li>&#xD;&#xA;    <li>Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30:1989.</li>&#xD;&#xA;    <li>Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012; 30s:LBA506 (abstract).</li>&#xD;&#xA;    <li>Carey LA, Berry DA, Ollila D, et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2013; 31s:500 (abstract).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90645 Version 5.0</div></div></div>"},"90646":{"type":"graphic_diagnosticimage","displayName":"Radiograph of neonatal rickets","title":"Neonatal rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neonatal rickets</div><div class=\"cntnt\"><img style=\"width:427px; height:474px;\" src=\"images/PEDS/90646_Radio_neonatal_rickets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic findings of rickets in a preterm infant. Radiologic findings are similar to those that are seen in older infants with rickets. The arrow demonstrates frayed metaphysis and also a dense white line at the end of the long bones. This white line can be associated with early healing of the rickets. When rickets is identified on radiographs, it generally requires about six weeks for healing to occur after therapeutic intervention.</div><div id=\"graphicVersion\">Graphic 90646 Version 1.0</div></div></div>"},"90647":{"type":"graphic_diagnosticimage","displayName":"Fracture in neonatal rickets","title":"Fractures in a premature infant with neonatal rickets","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fractures in a premature infant with neonatal rickets</div><div class=\"cntnt\"><img style=\"width:292px; height:352px;\" src=\"images/PEDS/90647_Frctr_neonatal_rickets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic findings showing long-bone fracture associated with rickets in a premature infant. Findings typical of rickets including frayed metaphyses can be seen along with the fractures. Long-bone fractures in preterm infants with rickets are radiologically similar to traumatic fractures and may be precipitated accidentally during care given by the medical team or the family.</div><div class=\"graphic_reference\">Copyright &copy; 2012 From Bone Health in Children by Abrams SA, Hawthorne KM. Reproduced by permission of Taylor and Francis Group, LLC, a division of Informa plc.</div><div id=\"graphicVersion\">Graphic 90647 Version 3.0</div></div></div>"},"90649":{"type":"graphic_movie","displayName":"Emergency intubation with endotracheal tube introducer","title":"Technique for emergency intubation with endotracheal tube introducer","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Technique for emergency intubation with endotracheal tube introducer</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/90649_Emintubendotratubevideo.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:504px; height:383px;\" src=\"images/EM/90649_Emintubendotratubeimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: J Adam Law, MD, FRCP(C).</div><div id=\"graphicVersion\">Graphic 90649 Version 1.0</div></div></div>"},"90651":{"type":"graphic_figure","displayName":"Tear duct PI","title":"Tear duct system","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Tear duct system</div><div class=\"cntnt\"><img style=\"width:509px; height:491px;\" src=\"images/PI/90651_Tear_duct_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medical term for the tear duct is \"nasolacrimal duct.\" This duct can get blocked anywhere, but a common spot for blockages is where tears drain into the nose.</div><div id=\"graphicVersion\">Graphic 90651 Version 2.0</div></div></div>"},"90653":{"type":"graphic_picture","displayName":"Sun-Med endotracheal tube introducer-bougie","title":"Sun-Med endotracheal tube introducer-bougie","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sun-Med endotracheal tube introducer-bougie</div><div class=\"cntnt\"><img style=\"width:71px; height:587px;\" src=\"images/EM/90653_SunMed_end_tube_intr_bg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The SunMed endotracheal tube introducer is an important tool for&nbsp;emergency airway management&nbsp;designed for single use.</div><div class=\"graphic_reference\">Reproduced with permission from: SunMed. Available at http://www.sun-med.com/products/intubation-aids/introducers/original/introducer-bougie.</div><div id=\"graphicVersion\">Graphic 90653 Version 3.0</div></div></div>"},"90655":{"type":"graphic_picture","displayName":"Intradiploic epidermoid cyst","title":"Intradiploic epidermoid cyst of the frontal bone with spontaneous fistulization to the eyelid","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Intradiploic epidermoid cyst of the frontal bone with spontaneous fistulization to the eyelid</div><div class=\"cntnt\"><img style=\"width:515px; height:155px;\" src=\"images/PEDS/90655_Intradipepidermocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The appearance of the patient on admission with a nonhealing ulcer on the left upper eyelid.<br />(B) Coronal computed tomography on admission showing a cystic intradiploic lesion located in the horizontal portion of the frontal bone. Inset: Three-dimensional image depicting the missing portion of the left lateral orbital wall because of the compression of the cyst (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Akbaba M, Karslioglu S, Damlacik A, Karcioglu ZA. Intradiploic epidermoid cyst of frontal bone with spontaneous fistulization to eyelid. Ophthal Plast Reconstr Surg 2011; 28:e15. DOI: <A href=\"http://journals.lww.com/op-rs/pages/articleviewer.aspx?year=2012&amp;issue=01000&amp;article=00037&amp;type=abstract\" target=_blank>10.1097/IOP.0b013e31821387ad</A>. Copyright © 2011 The American Society of Ophthalmic Plastic and Reconstructive Surgery. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90655 Version 7.0</div></div></div>"},"90656":{"type":"graphic_picture","displayName":"Williams syndrome","title":"Williams syndrome facial features","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Williams syndrome facial features</div><div class=\"cntnt\"><img style=\"width:343px; height:504px;\" src=\"images/PEDS/90656_Williamssyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The facial appearance in patients with Williams syndrome is remarkably uniform. This boy's eyebrows flare medially, his nasal bridge is depressed, the epicanthal folds are prominent, and the nares are anteverted. Note prominent lips and full cheeks.</div><div class=\"graphic_reference\">Reproduced with permission from: Child Neurology, 7th ed, Menkes JH, Sarnat HB, Maria BL (Eds), Lippincott Williams &amp; Wilkins, New York 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90656 Version 5.0</div></div></div>"},"90658":{"type":"graphic_picture","displayName":"X-linked ichthyosis 2","title":"X-linked ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">X-linked ichthyosis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90658_X_linked_ichthyosis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, fine brown scales on the trunk of a young child with X-linked recessive ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90658 Version 1.0</div></div></div>"},"90659":{"type":"graphic_picture","displayName":"X-linked ichthyosis 3","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:504px; height:325px;\" src=\"images/DERM/90659_X_linked_ichthyosis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, plate-like brown scales on the legs of a child with X-linked congenital ichthyosis. Note the characteristic sparing of the popliteal fossae.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <A href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</A>. Copyright © 2013. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90659 Version 1.0</div></div></div>"},"90662":{"type":"graphic_picture","displayName":"KID syndrome","title":"Keratitis, ichthyosis, and deafness (KID) syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Keratitis, ichthyosis, and deafness (KID) syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90662_KID_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized erythroderma and hyperkeratosis with a leathery aspect&nbsp;of the skin in a newborn with KID syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90662 Version 1.0</div></div></div>"},"90668":{"type":"graphic_diagnosticimage","displayName":"Radiologic features of TSC","title":"Radiologic features of TSC","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiologic features of TSC</div><div class=\"cntnt\"><img style=\"width:394px; height:516px;\" src=\"images/NEPH/90668_RadiofeaturesTSC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-D) Contrast-enhanced abdominal CTs obtained in 1991 (A), 1998 (B), 2008 (C), and 2013 (D) in a male patient with TSC. Typical radial, striated, or wedge-shaped appearance of numerous small AMLs in 1991, with progressive enlargement over the following 22 years. Coil in the lower pole of the left kidney from embolization of a large pseudoaneurysm in 2010 (D).<br />(E) CT showing a fat-poor AML, containing an area of hemorrhage; histologic examination of the resected mass revealed it to be an epithelioid AML.<br />(F) CT showing a fat-containing AML within a polycystic kidney, a finding pathognomonic for TSC.<br />(G) CT of the abdomen in a female patient with TSC, illustrating perirenal lymphangiomatous cysts.<br />(H) Ultrasound showing a small (11.2 cm) hyperechoic kidney in a 52-year-old patient presenting with CKD stage 4; the kidneys contain some cysts but do not have the appearance of polycystic kidneys and do not contain AMLs.</div><div class=\"graphic_footnotes\">CT: computed tomography; TSC: tuberous sclerosis complex; AML: angiomyolipoma; CKD: chronic kidney disease.</div><div id=\"graphicVersion\">Graphic 90668 Version 3.0</div></div></div>"},"90669":{"type":"graphic_picture","displayName":"Histologic features of AML","title":"Histologic features of AML","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Histologic features of AML</div><div class=\"cntnt\"><img style=\"width:514px; height:357px;\" src=\"images/NEPH/90669_Histologic_feaures_AML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Classic AML containing adipose tissue, abnormal blood vessels with thickened walls, and spindle smooth muscle-like cells.<br />(B) Epithelioid AML containing round-to-polygonal epithelioid cells with round nucleoli and abundant granular cytoplasm.</div><div class=\"graphic_footnotes\">AML: angiomyolipoma.</div><div id=\"graphicVersion\">Graphic 90669 Version 1.0</div></div></div>"},"90675":{"type":"graphic_movie","displayName":"Motile trichomonas vaginalis","title":"Motile trichomonas vaginalis","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Motile trichomonas vaginalis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/90675_Motiletrichomvaginavideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:504px; height:391px;\" src=\"images/OBGYN/90675_Motiletrichomvaginaimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: MicroVeda. Copyright &copy; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90675 Version 1.0</div></div></div>"},"90676":{"type":"graphic_movie","displayName":"Mobiluncus species","title":"Mobiluncus species","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Mobiluncus species</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/90676_Mobiluncusspeciesvideo.mp4\" style=\"width:512px;height:304px\"></div><img style=\"width:504px; height:504px;\" src=\"images/OBGYN/90676_Mobiluncusspeciesimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: MicroVeda. Copyright &copy; 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90676 Version 2.0</div></div></div>"},"90681":{"type":"graphic_table","displayName":"Prednisone alternate-day dosing schedule","title":"Potential option for tapering dose of prednisone after initiation of induction therapy for severe lupus nephritis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential option for tapering dose of prednisone after initiation of induction therapy for severe lupus nephritis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;<br /> Weeks</td> <td class=\"subtitle1\" colspan=\"2\">&nbsp;Oral prednisone dose (mg)</td> </tr> <tr> <td class=\"subtitle1\">Patients &#60;80 kg</td> <td class=\"subtitle1\">Patients &#8805;80 kg</td> </tr> <tr> <td>&nbsp;</td> <td colspan=\"2\"><strong>Weeks 1 to 14:&nbsp;Daily dose&nbsp;given in the morning</strong></td> </tr> <tr> <td>1 to 4</td> <td>60 mg in two divided doses</td> <td>80 mg in two divided doses</td> </tr> <tr> <td>5 to 6</td> <td>50 mg </td> <td>70 mg in two divided doses</td> </tr> <tr> <td>7 to 8</td> <td>50 mg </td> <td>60 mg</td> </tr> <tr> <td>9 to 10</td> <td>40 mg</td> <td>50 mg</td> </tr> <tr> <td>11 to 12</td> <td>40 mg</td> <td>40 mg </td> </tr> <tr> <td>13 to 14</td> <td>30 mg </td> <td>40 mg</td> </tr> <tr> <td>&nbsp;</td> <td colspan=\"2\"><strong>Weeks&nbsp;15 through 52:&nbsp;Alternating daily doses, given in the morning</strong></td> </tr> <tr> <td>15</td> <td>30 mg alternating with 25&nbsp;mg&nbsp;</td> <td>40 mg alternating with 35 mg</td> </tr> <tr> <td>16</td> <td>30 mg alternating with 20 mg</td> <td>40 mg alternating with 30 mg</td> </tr> <tr> <td>17</td> <td>30 mg alternating with 15 mg</td> <td>40 mg alternating with 15 mg</td> </tr> <tr> <td>18</td> <td>30 mg alternating with 10 mg</td> <td>40 mg alternating with 20 mg</td> </tr> <tr> <td>19</td> <td>30 mg alternating with 5 mg</td> <td>40 mg alternating with 15 mg</td> </tr> <tr> <td>20</td> <td>30 mg on alternate days only (ie, <strong>no </strong>prednisone on opposite alternate days)</td> <td>40 mg alternating with 10 mg</td> </tr> <tr> <td>21</td> <td>25 mg alternate days only</td> <td>40 mg alternating with 5 mg</td> </tr> <tr> <td>22</td> <td>20 mg alternate days only</td> <td>40 mg on alternate days only (ie, <strong>no </strong>prednisone on opposite alternate days)</td> </tr> <tr> <td>23</td> <td>20 mg alternate days only</td> <td>30 mg alternate days only</td> </tr> <tr> <td>23 to 52</td> <td>20 mg alternate days only</td> <td>25 mg alternate days only</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Lupus Nephritis, 2nd ed, Lewis EJ, Schwartz MM, Korbet SM (Eds), Oxford University Press 2011. Reproduced by permission of Oxford University Press. Copyright &copy; 2010. <a href=\"http://www.oup.com/\" target=\"_blank\">www.oup.com</a>.</div><div id=\"graphicVersion\">Graphic 90681 Version 4.0</div></div></div>"},"90682":{"type":"graphic_figure","displayName":"Risk of developing carbo infusion reaction BRCA versus non-BRCA","title":"Risk of developing a carboplatin infusion reaction over cumulative cycles of therapy for BRCA mutation carriers versus non-carriers","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Risk of developing a carboplatin infusion reaction over cumulative cycles of therapy for BRCA mutation carriers versus non-carriers</div><div class=\"cntnt\"><img style=\"width:559px; height:452px;\" src=\"images/ONC/90682_Risk_dev_carb_infusion_BRCA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HSR: hypersensitivity reactions.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: British Journal of Cancer. Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013; 109:1072. Copyright &copy; 2013. <a href=\"http://www.nature.com/bjc\" target=\"_blank\">www.nature.com/bjc</a>.</div><div id=\"graphicVersion\">Graphic 90682 Version 1.0</div></div></div>"},"90683":{"type":"graphic_figure","displayName":"Pathology of psoriasis PI","title":"Skin changes in psoriasis","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Skin changes in psoriasis</div><div class=\"cntnt\"><img style=\"width:488px; height:462px;\" src=\"images/DERM/90683_Pathology_of_psoriasis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin is made up of different layers. In psoriasis, the top layer of skin (called the epidermis) thickens, and blood vessels in the second layer (called the dermis) widen. The skin also becomes inflamed.</div><div id=\"graphicVersion\">Graphic 90683 Version 2.0</div></div></div>"},"90705":{"type":"graphic_table","displayName":"Anesthetic drug dosing in obesity","title":"Anesthetic drug dosing in obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anesthetic drug dosing in obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Weight for dosing</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sedative/hypnotics</td> </tr> <tr> <td class=\"indent1\">Propofol bolus doses</td> <td class=\"centered\">LBW</td> <td>The dose required for loss of consciousness in obese patients (BMI &#62;40 kg/m<sup>2</sup>)<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\">Propofol maintenance infusions</td> <td class=\"centered\">LBW</td> <td>Due to substantial interindividual variability, continuous infusions should be titrated to a clinical endpoint. A reasonable initial dose is based on LBW and titrated to achieve the desired clinical result. Several different dose calculation models have been used for target controlled infusion systems (not available in the United States)<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\">Etomidate</td> <td class=\"centered\">LBW</td> <td>Pharmacokinetic studies have not been done in obesity<sup>[3]</sup>.</td> </tr> <tr> <td class=\"indent1\">Thiopental</td> <td class=\"centered\">LBW</td> <td>Recommendation is based on computer models of plasma concentrations. Doses should be adjusted for high or low cardiac output, and rapid redistribution may result in more rapid awakening after a single bolus dose than in lean patients<sup>[4]</sup>.</td> </tr> <tr> <td class=\"indent1\">Midazolam (and other benzodiazepines) bolus doses</td> <td class=\"centered\">TBW</td> <td>As a sedative, usually dosed in small increments (eg, midazolam 1 mg IV) that are repeated until the clinical endpoint is reached. Caution should be exercised as patients with OSA may have increased central sensitivity to the sedative and respiratory effects of benzodiazepines. TBW is used for bolus dosing (eg, to induce general anesthesia) due to the significant increase in V<sub>d</sub> in these highly lipophilic drugs<sup>[5]</sup>.</td> </tr> <tr> <td class=\"indent1\">Midazolam (and other benzodiazepines) continuous infusions</td> <td class=\"centered\">LBW</td> <td>Although clearance is not substantially different from that in non-obese individuals<sup>[6]</sup>, there is substantial interindividual variability, so continuous infusions should be titrated to a clinical endpoint. A reasonable initial dose is based on LBW and titrated to achieve the desired clinical result.</td> </tr> <tr> <td class=\"indent1\">Dexmedetomidine</td> <td class=\"centered\">&nbsp;</td> <td>There are no specific dosing recommendations available in the obese, but as with other infusions, doses should be titrated to a clinical endpoint. The drug is highly lipophilic. Bolus (0.5 to 1 mcg/kg) and infusion dosing (0.2 to 0.8 mcg/kg) based on TBW (without a scalar) have been used in several studies<sup>[7-10]</sup>. This is within the manufacturer-suggested dose range. Dose adjustments may be required for other comorbidities or other sedative or anesthetic drugs used concomitantly.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Opioids</td> </tr> <tr> <td class=\"indent1\">Synthetic opioids (fentanyl, sufentanil, alfentanil, and remifentanil)</td> <td class=\"centered\">LBW</td> <td>On the basis of clinical pharmacokinetic studies in lean patients, physiologic changes in obesity, and supratherapeutic plasma levels with TBW dosing<sup>[6]</sup>.</td> </tr> <tr> <td class=\"indent1\">Morphine</td> <td class=\"centered\">IBW</td> <td>Initial dosing should be based on IBW and titrated to effect. This is a reasonable initial dose, as postoperative opioid consumption was 30 percent less in obese versus normal weight patients (on a morphine equivalent to kg basis)<sup>[11]</sup>.</td> </tr> <tr> <td class=\"indent1\">Hydromorphone</td> <td class=\"centered\">IBW</td> <td>As with morphine, initial dosing is based on IBW and titrated to effect.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neuromuscular blocking agents</td> </tr> <tr> <td class=\"indent1\">Non-depolarizing agents (eg, vecuronium, rocuronium)</td> <td class=\"centered\">IBW</td> <td>Generally polar compounds<sup>[12]</sup>. The dosing scalar will depend on the clinical circumstance. In general, a higher (ie, closer to TBW) intubating dose will result in faster onset and shorter time to complete NMB, but a longer duration of action. An IBW-based dosing will prolong the time to ideal intubating conditions, but assure a faster recovery from NMB<sup>[13]</sup>.</td> </tr> <tr> <td class=\"indent1\">Succinylcholine</td> <td class=\"centered\">TBW</td> <td>This is based on superior intubating conditions when succinylcholine 1 mg/kg TBW was compared with dosing on the basis of IBW or LBW<sup>[14]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LBW: lean body weight; TBW: total body weight; IBW: ideal body weight; BMI: body mass index; OSA: obstructive sleep apnea&nbsp;V<SUB>d</SUB>: volume of distribution; NMB: neuromuscular blockade.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011; 113:57.</li>&#xD;&#xA;    <li>Echevarria GC, Elgueta MF, Donosoto MT, et al. The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. Anesth Analg 2012; 115:823.</li>&#xD;&#xA;    <li>Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010; 105 Suppl 1:i16.</li>&#xD;&#xA;    <li>Wada DR, Bj&ouml;rkman S, Ebling WF, et al. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anesthesiology 1997; 87:884.</li>&#xD;&#xA;    <li>Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61:27.</li>&#xD;&#xA;    <li>Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol 2011; 25:27.</li>&#xD;&#xA;    <li>Feld J, Hoffman WE. Response entropy is more reactive than bispectral index during laparoscopic gastric banding. J Clin Monit Comput 2006; 20:229.</li>&#xD;&#xA;    <li>Bakhamees HS, El-Halafawy YM, El-Kerdawy HM, et al. Effects of dexmedetomidine in morbidly obese patients undergoing laparoscopic gastric bypass. Middle East J Anesthesiol 2007; 19:537.</li>&#xD;&#xA;    <li>Tufanogullari B, White PF, Peixoto MP, et al. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg 2008; 106:1741.</li>&#xD;&#xA;    <li>Ramsay MA. Bariatric surgery: The role of dexmedetomidine. Seminars in Anesthesia, Perioperative Medicine and Pain 2006; 25:51.</li>&#xD;&#xA;    <li>Rand CS, Kuldau JM, Yost RL. Obesity and post-operative pain. J Psychosom Res 1985; 29:43.</li>&#xD;&#xA;    <li>Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88:1.</li>&#xD;&#xA;    <li>Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090.</li>&#xD;&#xA;    <li>Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006; 102:438.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90705 Version 1.0</div></div></div>"},"90709":{"type":"graphic_figure","displayName":"Hysterectomy approach indication","title":"Surgical approach and indication for hysterectomy, 2010, United States","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Surgical approach and indication for hysterectomy, 2010, United States</div><div class=\"cntnt\"><img style=\"width:564px; height:586px;\" src=\"images/OBGYN/90709_Hysterectomyapproachind.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hysterectomies (percent) performed via each surgical route by year of procedure.<br />(B) Procedures (n) performed each year stratified by indication for surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JD, Herzog TJ, Tsui J, Ananth CV, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 2013; 122:233-41. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2013&amp;issue=08000&amp;article=00008&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0b013e318299a6cf</a>. Copyright &copy; 2013 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90709 Version 6.0</div></div></div>"},"90711":{"type":"graphic_picture","displayName":"Keratosis pilaris arm","title":"Keratosis pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris</div><div class=\"cntnt\"><img style=\"width:376px; height:504px;\" src=\"images/DERM/90711_Keratosispilarisarm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, keratotic, follicular papules are characteristic of keratosis pilaris.</div><div id=\"graphicVersion\">Graphic 90711 Version 2.0</div></div></div>"},"90712":{"type":"graphic_picture","displayName":"Keratosis pilaris pregnancy","title":"Keratosis pilaris ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris </div><div class=\"cntnt\"><img style=\"width:375px; height:501px;\" src=\"images/DERM/90712_Keratosis_pilaris_pregnan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient had a history of keratosis pilaris on her proximal arms and medial thighs, but developed lesions on the abdomen after delivering her first child. The linea nigra is still present.</div><div id=\"graphicVersion\">Graphic 90712 Version 1.0</div></div></div>"},"90714":{"type":"graphic_table","displayName":"Causes of hepatomegaly","title":"Causes of hepatomegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hepatomegaly</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Hepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Infections</td> </tr> <tr> <td>Acute and chronic viral hepatitis</td> </tr> <tr> <td>Bacterial liver abscess</td> </tr> <tr> <td>Parasitic infections</td> </tr> <tr> <td>Granulomatous hepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ischemia</td> </tr> <tr> <td>Ischemic hepatitis (\"shock liver\")</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Toxins</td> </tr> <tr> <td>Alcoholic hepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Steatosis</td> </tr> <tr> <td>Alcoholic fatty liver disease</td> </tr> <tr> <td>Nonalcoholic steatohepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Medications</td> </tr> <tr> <td>Drug induced liver injury (DILI)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Immune mediated hepatitis</td> </tr> <tr> <td>Autoimmune hepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Copper deposition</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Storage disorders</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Glycogen</td> </tr> <tr> <td>Glycogen storage disorders</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Lipid</td> </tr> <tr> <td>Gaucher disease</td> </tr> <tr> <td>Nonalcoholic steatohepatitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Protein</td> </tr> <tr> <td>Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Iron</td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Impaired venous outflow</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Cardiac</td> </tr> <tr> <td>Right heart failure</td> </tr> <tr> <td>Constrictive pericarditis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Hepatic vein or inferior vena cava obstruction</td> </tr> <tr> <td>Hepatic vein thrombosis</td> </tr> <tr> <td>Inferior vena cava web</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Intrahepatic</td> </tr> <tr> <td>Sinusoidal obstruction syndrome</td> </tr> <tr> <td>Peliosis hepatis</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Infiltrative disease affecting the liver</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Benign primary liver tumors</td> </tr> <tr> <td>Hemangiomas</td> </tr> <tr> <td>Adenomas</td> </tr> <tr> <td>Focal nodular hyperplasia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Malignant primary liver tumors</td> </tr> <tr> <td>Hepatocellular carcinoma</td> </tr> <tr> <td>Cholangiocarcinoma</td> </tr> <tr> <td>Fibrolamellar carcinoma</td> </tr> <tr> <td>Hemangioendothelioma</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Metastatic/disseminated tumors</td> </tr> <tr> <td>Myeloma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Metastatic solid tumors</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Biliary obstruction/cholestatic diseases</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Primary biliary cirrhosis</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Primary sclerosing cholangitis</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Biliary atresia</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Anatomic variations</td> </tr> <tr> <td>Riedel's lobe</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Cystic liver disease</td> </tr> <tr> <td>Polycystic liver disease</td> </tr> <tr> <td>Caroli's disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90714 Version 1.0</div></div></div>"},"90716":{"type":"graphic_table","displayName":"Recognition and initial treatment of chemical weapons exposure","title":"Recognition and initial treatment of chemical weapons exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recognition and initial treatment of chemical weapons exposure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chemical</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Decontamination*</td> <td class=\"subtitle1\">Management<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Nerve agent:<br /> <ul> <li>Tabun (GA) </li> <li>Sarin (GB) </li> <li>Soman (GD) </li> <li>Cyclosarin (GF) </li> <li>VX (O-ethyl S-[2-(diisopropylamino)ethyl] methylphosphonothioate) </li> </ul> </td> <td>Anticholinesterase: Muscarinic, nicotinic and CNS effects</td> <td> <p>Cholinergic crisis<sup>&#9674;</sup> with either:</p> <p>a) Sudden collapse, coma, apnea, and convulsions</p> <p class=\"indent1\">OR</p> b) Progression from local effects (see below) to generalized systemic effects (fasciculations, coma, seizures, paralysis):<br /> <ul> <li>Local effects from vapor inhalation: Miosis, rhinorrhea, salivation, difficulty breathing </li> <li>Local effects from liquid on skin: Local sweating, twitching, and fasciculations </li> </ul> </td> <td>Vapor:<br /> <ul> <li>Move to fresh air </li> <li>Remove clothes </li> <li>Wash hair </li> </ul> <br /> Liquid:<br /> <ul> <li>Remove clothes </li> <li>Use Reactive Skin Decontamination Liquid for spot decontamination </li> <li>Irrigate skin with water or soapy water </li> <li>Irrigate eyes and wounds with sterile saline or water </li> </ul> </td> <td><strong>Do not delay antidotal therapy if nerve agent exposure is suspected</strong><sup>&#167;</sup><strong>:</strong><br /> <ul> <li>Mild effects: Atropine </li> <li>Moderate effects: Atropine<sup>&#165;</sup> and pralidoxime </li> <li>Severe effects: Atropine<sup>&#165;&#135;</sup>, pralidoxime, and a benzodiazepine (eg, valium, lorazepam, or midazolam) </li> </ul> For specific dosing and indications refer to UpToDate topics on chemical terrorism</td> </tr> <tr class=\"divider_bottom\"> <td>Cyanide [AC]</td> <td>Cytochrome oxidase inhibition: Cellular anoxia, lactic acidosis</td> <td> <ul> <li>Tachypnea </li> <li>Coma </li> <li>Seizures </li> <li>Apnea </li> </ul> </td> <td> <p>Fresh air</p> Skin: Soap and wat&#135;er</td> <td><strong>Do not delay antidotal therapy if cyanide poisoning is suspected</strong><sup>&#167;</sup><strong>:</strong><br /> <ul> <li>Hydroxocobalamin (Cyanokit) OR </li> <li>Cyanide antidote kit: Amyl nitrite perles for inhalation and intravenous preparations of sodium nitrite and sodium thiosulfate </li> </ul> For specific dosing and indications refer to UpToDate topics on cyanide poisoning and chemical terrorism</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary, type I (central, eg, hydrogen chloride, hydrogen fluoride) or combination agents (eg, chlorine)</td> <td> <p>Type I: Various mechanisms causing irritation (including irritative laryngospasm) and partial to total airway obstruction</p> Combination: In addition to type I, various reactions causing fluid leakage and pulmonary edema</td> <td>Type I:<br /> <ul> <li>Airway noise (coughing, sneezing, hoarseness, inspiratory stridor, wheezing) </li> <li>Irritation of eyes, nose, and throat </li> <li>Irritative laryngospasm </li> </ul> <br /> Combination:<br /> <ul> <li>Type I findings </li> <li>Delayed onset chest tightness or shortness of breath </li> </ul> </td> <td> <p>Fresh air</p> Skin: Irrigate with water</td> <td> <ul> <li>Provide humidified oxygen </li> <li>Inhaled racemic epinephrine for stridor or upper airway obstruction </li> <li>Pulmonary toilet </li> <li>Bronchoscopy for severe upper airway obstruction </li> <li>Give antibiotics <strong>only</strong> after identification and testing of causative organism </li> <li>For combination agents, as above, and: <ul> <li>Strict bed rest </li> <li>Positive pressure ventilation, as needed to support breathing </li> <li>Admit to a pulmonary ICU </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Type II pulmonary agents (eg, phosgene[GG]) or combination agents (eg, chlorine)</td> <td> <p>Type II: Various reactions causing fluid leakage and pulmonary edema</p> Combination: In addition to type II effects, various mechanisms causing irritation (including irritative laryngospasm) and partial to total airway obstruction</td> <td> <p>Delayed onset chest tightness and shortness of breath</p> Combination, rapid onset of :<br /> <ul> <li>Airway noise(coughing, sneezing, hoarseness, inspiratory stridor, wheezing) </li> <li>Irritation of eyes, nose, and throat </li> <li>Irritative laryngospasm </li> </ul> </td> <td> <p>Fresh air</p> Skin: Irrigate with water</td> <td> <ul> <li>Strict bed rest </li> <li>High flow nasal cannula<sup>&#134;</sup>, nasal CPAP<sup>&#134;, </sup>or positive pressure ventilation, as needed to support breathing </li> <li>Admit to a pulmonary ICU </li> <li>For upper airway symptoms: <ul> <li>Provide humidified oxygen </li> <li>Pulmonary toilet </li> <li>Inhaled racemic epinephrine for stridor upper airway obstruction </li> <li>Bronchoscopy for severe upper airway obstruction </li> <li>Give antibiotics <strong>only</strong> after identification and testing of causative organism </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Riot control agents:<br /> <ul> <li>CS </li> <li>CN (mace) </li> <li>OC (pepper spray) </li> </ul> </td> <td> <p>Alkylation</p> Release of substance P (OC)</td> <td> <p>Eye: Tearing, pain, blepharospasm</p> <p>Nose and throat irritation</p> Type I pulmonary effects if very concentrated exposure</td> <td> <p>Skin: Flush with water or soapy water</p> <p>Eye: Water irrigation or air blown onto eyes</p> Avoid bleach</td> <td> <ul> <li>Ophthalmic analgesic topically (eg, proparacaine 0.5 percent one drop to each eye) </li> <li>Symptomatic care </li> <li>As for type I pulmonary agents if severe exposure with signs of upper airway compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mustard compounds (eg, sulfur mustard [H])</td> <td>Alkylation</td> <td> <p>Skin: Erythema, vesicles</p> <p>Eye: Inflammation</p> Respiratory tract: Inflammation</td> <td> <p>Skin: Soap and water</p> Eyes: Water (only effective if done within minutes of exposure)</td> <td>Symptomatic and supportive care for partial thickness burns, corneal toxicity, and bone marrow suppression</td> </tr> <tr class=\"divider_bottom\"> <td>Lewisite [L]</td> <td>&nbsp;</td> <td> <p>Skin: Erythema, vesicles</p> <p>Eye: Inflammation</p> Respiratory tract: Inflammation</td> <td> <p>Skin: Soap and water</p> Eyes: Water (only effective if done within minutes of exposure)</td> <td> <ul> <li>Symptomatic and supportive care as for partial thickness burns </li> <li>Dimercaprol [BAL] 3 to 4 mg/kg IM every four to six hours for systemic effects in severe cases </li> </ul> </td> </tr> <tr> <td>BZ (3-quinuclidinyl benzilate)</td> <td>Competitive antagonism of acetylcholine at muscarinic receptors</td> <td>Anticholinergic effects:<br /> <ul> <li>Peripheral: <ul> <li>Dilated pupils </li> <li>Dry mouth </li> <li>Flushed skin </li> <li>Tachycardia </li> <li>Hypertension </li> <li>Absent bowel sounds </li> <li>Urinary retention </li> </ul> </li> </ul> <ul> <li>Central: <ul> <li>Delirium </li> <li>Seizures </li> </ul> </li> </ul> </td> <td>Irrigate skin with water or soapy water</td> <td> <ul> <li>Benzodiazepines as needed for agitation </li> <li>Physostigmine for patients with peripheral and moderate to severe central effects (eg, delirium with danger to self or others or seizures) by providers familiar with its use </li> </ul> For specific indications and dosing, refer to UpToDate topics on chemical terrorism and anticholinergic poisoning</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.<br />* Decontamination, especially for patients with significant nerve agent or vesicant exposure, should be performed by health care providers wearing adequate personal protective equipment. For first receiving facilities (eg, hospital emergency departments), this consists of nonencapsulated, chemically-resistant body suit, boots, and gloves with a full-face air purifier mask/hood. Refer to UpToDate topics on chemical weapons for more information regarding the proper performance of decontamination of chemically exposed patients.<br />Δ Emergent supportive of chemical exposures should always include the ABCDDs: Airway, Breathing, Circulation, immediate Decontamination (meaning immediate local, or spot decontamination of any suspicious liquid on the skin or in wounds), and Drugs (including specific antidotes).<br /><FONT class=lozenge>◊</FONT> Signs of cholinergic crisis include miosis, bronchorrhea with wheezing, copious salivation, lacrimation, diaphoresis, vomiting, and diarrhea.<br />§ Intraosseous route is likely equivalent to intravenous for administration of antidotes. Refer to UpToDate topics on intraosseous infusion.<br />¥ Inhaled ipratropium bromide (500 mcg inhaled, may repeat once) may complement parenteral atropine administration for the treatment of bronchospasm. ‡Administration of scopolamine may help preserve atropine in the setting of large numbers of patients with severe nerve gas exposure. For scopolamine dosing refer to UpToDate topics on chemical terrorism.<br />†&nbsp;High flow nasal cannula and noninvasive positive pressure ventilation should be avoided in patients with upper airway obstruction after combination agent&nbsp;(eg, chlorine) exposure.</div><div id=\"graphicVersion\">Graphic 90716 Version 6.0</div></div></div>"},"90719":{"type":"graphic_figure","displayName":"Patient positioning for minimally invasive thoracic surgery","title":"Patient positioning for minimally invasive thoracic surgery","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Patient positioning for minimally invasive thoracic surgery</div><div class=\"cntnt\"><img style=\"width:523px; height:473px;\" src=\"images/ONC/90719_PatientpositioningforVATS.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90719 Version 7.0</div></div></div>"},"90720":{"type":"graphic_picture","displayName":"Leptospire electron micrograph","title":"Leptospire electron micrograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leptospire electron micrograph</div><div class=\"cntnt\"><img style=\"width:418px; height:582px;\" src=\"images/ID/90720_Leptospire_electron_microgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Leptospira </EM>are spiral-shaped, highly motile aerobic spirochetes with 18 or more coils per cell. They can be distinguished morphologically from other spirochetes by their unique \"question mark\" hook at the end of the bacterium.</div><div class=\"graphic_reference\">Courtesy of Dr. Vanaporn Wuthiekanun.</div><div id=\"graphicVersion\">Graphic 90720 Version 2.0</div></div></div>"},"90721":{"type":"graphic_table","displayName":"Alarm findings chronic abdominal pain children","title":"Alarm findings in the evaluation of children with chronic abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alarm findings in the evaluation of children with chronic abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Historical findings</td> </tr> <tr> <td class=\"indent1\">Involuntary weight loss</td> <td>Malabsorption (IBD, celiac disease, pancreatitis), malignancy</td> </tr> <tr> <td class=\"indent1\">Difficulty swallowing (dysphagia) or painful swallowing (odynophagia)</td> <td>Eosinophilic esophagitis, pill esophagitis, infectious esophagitis, achalasia</td> </tr> <tr> <td class=\"indent1\">Significant vomiting (bilious, protracted, projectile, or otherwise worrisome)</td> <td>Acid-peptic disease, cyclic vomiting syndrome, eosinophilic gastroenteritis, bowel obstruction, hepatobiliary disease, metabolic (eg, DKA, adrenal crisis), cholecystitis, intracranial lesion</td> </tr> <tr> <td class=\"indent1\">Chronic severe diarrhea (&#8805;3 loose or watery stools per day for more than two weeks) or nocturnal diarrhea</td> <td>Enteric infection (parasitic, bacterial, viral), IBD, immune deficiency, celiac disease, food protein-induced enteropathy</td> </tr> <tr> <td class=\"indent1\">Unexplained fever</td> <td>Infectious or inflammatory process; familial Mediterranean fever</td> </tr> <tr> <td class=\"indent1\">Urinary symptoms (change in bladder function, dysuria, hematuria, flank pain)</td> <td>Recurrent urinary tract infection; nephrolithiasis</td> </tr> <tr> <td class=\"indent1\">Back pain</td> <td>Referred pain (eg, chronic pancreatitis)</td> </tr> <tr> <td class=\"indent1\">Family history of IBD, celiac disease, peptic ulcer disease</td> <td>IBD, celiac disease, peptic ulcer disease</td> </tr> <tr> <td class=\"indent1\">Bloody diarrhea</td> <td>IBD</td> </tr> <tr> <td class=\"indent1\">Melena (black, tarry stools)</td> <td>Acid peptic disease, Meckel diverticulum</td> </tr> <tr> <td class=\"indent1\">Skin changes (rash, eczema, hives)</td> <td>IBD, celiac disease, food allergy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Examination findings</td> </tr> <tr> <td class=\"indent1\">Deceleration in linear growth (eg, height gain &#60;5 cm/year in a prepubertal child) and/or delayed puberty</td> <td>IBD, celiac disease</td> </tr> <tr> <td class=\"indent1\">Oral aphthous ulcerations</td> <td>IBD</td> </tr> <tr> <td class=\"indent1\">Localized right upper quadrant tenderness</td> <td>Hepatobiliary disease (eg, gallstones, cholecystitis, extrahepatic bile duct [choledochal cyst])</td> </tr> <tr> <td class=\"indent1\">Localized right lower quadrant pain</td> <td>Ovarian cyst or mass, chronic appendicitis</td> </tr> <tr> <td class=\"indent1\">Left lower quadrant pain</td> <td>Constipation, ovarian cyst or mass, ulcerative colitis</td> </tr> <tr> <td class=\"indent1\">Suprapubic tenderness</td> <td>Urinary tract infection</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> <td>Chronic hepatitis, hepatobiliary disease, storage disease (eg, Gaucher disease)</td> </tr> <tr> <td class=\"indent1\">Splenomegaly</td> <td>Hemolytic disease, splenic infarct, splenic abscess, storage disease</td> </tr> <tr> <td class=\"indent1\">Costovertebral angle tenderness</td> <td>Pyelonephritis</td> </tr> <tr> <td class=\"indent1\">Perianal abnormalities (eg, skin tags, fissures, fistulae)</td> <td>IBD</td> </tr> <tr> <td class=\"indent1\">Guaiac-positive stool</td> <td>Enteric infection, IBD, juvenile polyps, acid-peptic disease, foreign body, vasculitis (eg, polyarteritis nodosa); proximal small bowel disease (Crohn disease, <em>Helicobacter pylori</em>, peptic disease, celiac disease)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; DKA: diabetic ketoacidosis.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain. Chronic abdominal pain in children. Pediatrics 2005; 115:812.</LI>&#xD;&#xA;<LI>Chiou E, Nurko S. Functional abdominal pain and irritable bowel syndrome in children and adolescents. Therapy 2011; 8:315.</LI>&#xD;&#xA;<LI>Noe JD, Li BU. Navigating recurrent abdominal pain through clinical clues, red flags, and initial testing. Pediatr Ann 2009; 38:259.</LI>&#xD;&#xA;<LI>Hyams JS, Di Lorenzo C, Saps M, et al. Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology 2016; 150:1456.</LI></OL></div><div id=\"graphicVersion\">Graphic 90721 Version 7.0</div></div></div>"},"90722":{"type":"graphic_figure","displayName":"Biopsychosocial model of abdominal pain","title":"Biopsychosocial model of abdominal pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biopsychosocial model of abdominal pain</div><div class=\"cntnt\"><img style=\"width:450px; height:358px;\" src=\"images/PEDS/90722_Biophys_mod_abdomin_pain.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90722 Version 2.0</div></div></div>"},"90723":{"type":"graphic_table","displayName":"Organic causes chronic abdominal pain children","title":"Selected organic causes of chronic abdominal pain in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected organic causes of chronic abdominal pain in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Typical location</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Common causes</td> </tr> <tr> <td class=\"indent1\">Acid peptic disorders (eg, reflux esophagitis, gastritis, gastric and duodenal ulcers, <em>Helicobacter pylori</em> infection)</td> <td>Early morning pain, pain awakens at night; early satiety, nausea, sour breath, burping; occult blood in stool</td> <td>Epigastric, upper abdomen</td> </tr> <tr> <td class=\"indent1\">Carbohydrate malabsorption (eg, lactose)</td> <td>Crampy pain, diarrhea (bulky, watery, frothy), bloating, and/or intestinal gas related to ingestion of dairy products; meals, dairy products and foods containing dairy products</td> <td>Periumbilical, lower abdomen</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> <td>Crampy, nonspecific abdominal pain, chronic diarrhea, anorexia, abdominal distension, poor weight gain or weight loss, malnutrition, steatorrhea, flatulence; iron deficiency anemia; secondary amenorrhea</td> <td>Less likely to be epigastric</td> </tr> <tr> <td class=\"indent1\">Constipation (may have organic or functional etiology)</td> <td>Infrequent stooling, incomplete evacuation, fecal incontinence, history of large stools or stools that clog the toilet, abdominal distention, mass in the left lower abdominal quadrant, hard stool in rectal vault on digital examination</td> <td>Left-sided</td> </tr> <tr> <td class=\"indent1\">Dysmenorrhea*</td> <td>Cyclical pain related to menstruation</td> <td>Lower abdomen</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> <td>Respiratory symptoms, such a chronic cough, wheezing, laryngitis</td> <td>Epigastric, upper abdomen</td> </tr> <tr> <td class=\"indent1\">Musculoskeletal&nbsp;pain (eg, hernia, hematoma, anterior cutaneous nerve entrapment syndrome)</td> <td>Pain with specific physical activity; muscle tenderness on examination; positive Carnett sign<sup>&#182;</sup></td> <td>Abdominal wall</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parasitic infection (eg, <em>Giardia</em>, cryptosporidium)</td> <td>Diarrhea, crampy pain, bloating; exposure history</td> <td>Diffuse</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Less common causes</td> </tr> <tr> <td class=\"indent1\">Endometriosis*</td> <td>Severe progressive dysmenorrhea; may also have bowel symptoms (eg, rectal pain, constipation, painful defecation) and bladder symptoms (eg, dysuria, urgency, hematuria)</td> <td>Lower abdomen, pelvis</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> <td>Short stature; delayed sexual maturation; oral ulcers; perianal fistulae, skin tags, and fissures; diarrhea; gross or occult blood in stool; uveitis, arthritis; elevated ESR or CRP</td> <td>Lower abdomen</td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease*</td> <td>Cervical motion tenderness, adnexal tenderness, or adnexal mass on pelvic examination; pain may have onset or worsen during or shortly after menses; abnormal uterine bleeding; may have RUQ pain with perihepatitis</td> <td>Lower abdomen pelvis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Urinary tract infection</td> <td>Fever, urinary symptoms (dysuria, urgency, frequency, incontinence, macroscopic hematuria), flank pain</td> <td>Lower abdomen, flank</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rare causes</td> </tr> <tr> <td class=\"indent1\">Bezoar</td> <td>Nausea, vomiting, early satiety, anorexia, weight loss; patchy alopecia in patients with trichobezoars; history of gastric surgery</td> <td>Epigastric</td> </tr> <tr> <td class=\"indent1\">Burkitt lymphoma</td> <td>Ascites, bowel obstruction, gastrointestinal bleeding</td> <td>Diffuse, RLQ</td> </tr> <tr> <td class=\"indent1\">Chronic hepatitis</td> <td>Tender hepatomegaly</td> <td>RUQ</td> </tr> <tr> <td class=\"indent1\">Chronic pancreatitis</td> <td>Malabsorption, obstructive jaundice, growth failure, epigastric or upper abdominal tenderness that radiates to the back, pain worse after eating (especially fatty food), nausea, vomiting</td> <td>Epigastric, upper abdomen</td> </tr> <tr> <td class=\"indent1\">Pregnancy*</td> <td>Amenorrhea, nausea, breast enlargement, urinary frequency fatigue</td> <td>Lower abdomen</td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean fever</td> <td>Recurrent unexplained fever</td> <td>Diffuse</td> </tr> <tr> <td class=\"indent1\">Foreign body</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gallstones/chronic cholecystitis/choledochal cyst</td> <td>Jaundice, abnormal liver tests (elevation of AST and ALT early in the course; elevation of bilirubin, alkaline phosphatase, and GGT later in the course)</td> <td>RUQ or epigastric</td> </tr> <tr> <td class=\"indent1\">Heavy metal poisoning (eg, lead)</td> <td>Exposure history; crampy pain; sporadic vomiting; constipation</td> <td>Diffuse</td> </tr> <tr> <td class=\"indent1\">Hereditary angioedema</td> <td>Gastrointestinal colic, nausea, vomiting, diarrhea; skin symptoms; prodromal symptoms; attacks may be triggered by mild trauma, medications, hormonal changes; recurrent angioedema without urticaria; low C4 levels; family history of allergy</td> <td>Nonspecific</td> </tr> <tr> <td class=\"indent1\">Imperforate hymen with hematocolpos*</td> <td>Absence of menarche despite sexual maturity; cyclic abdominal or pelvic pain; imperforate hymen with bluish discoloration; may have back pain, pain with defecation, or difficulties with urination</td> <td>Lower abdomen/pelvis</td> </tr> <tr> <td class=\"indent1\">Malrotation (late presentation)</td> <td>Episodic episodes of vomiting (not necessarily bilious) and abdominal pain</td> <td>Diffuse</td> </tr> <tr> <td class=\"indent1\">Mesenteric ischemia</td> <td>Post-prandial abdominal pain, weight loss, nausea, vomiting, diarrhea</td> <td>Diffuse</td> </tr> <tr> <td class=\"indent1\">Nephrolithiasis</td> <td>Lower abdominal pain may radiate to the genitalia, may have gross hematuria, dysuria, urgency, nausea/vomiting</td> <td>Lower abdomen</td> </tr> <tr> <td class=\"indent1\">Psoas abscess</td> <td>Back or flank pain; radiation to hip or posterior thigh; positive psoas sign<sup>&#916;</sup></td> <td>Lower abdomen</td> </tr> <tr> <td class=\"indent1\">Ureteropelvic junction obstruction</td> <td>Intermittent flank or abdominal pain; pain may worsen during brisk diuresis (eg, after consumption of caffeine or alcohol), nausea, vomiting</td> <td>Periumbilical</td> </tr> <tr> <td class=\"indent1\">Vasculitis (eg, Henoch-Sch&#246;nlein purpura, polyarteritis nodosa)</td> <td>Extra-gastrointestinal manifestations (eg, arthritis, purpura, hematuria)</td> <td>Diffuse</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RLQ: right lower quadrant; RUQ: right upper quadrant; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase.<br />* Conditions exclusive to female adolescents.<br />¶ Positive Carnett sign: Focal pain increases or remains the same during abdominal wall contraction (elicited by asking the child to sit halfway forward from the supine position).<br />Δ Psoas sign: Pain exacerbated by extension of the hip.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Boyle JT. Abdominal pain. In: Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al. (Eds), BC Decker Inc, Hamilton, ON 2004. p.232.</LI>&#xD;&#xA;<LI>Dern MS, Stein MT. He keeps getting stomach aches, Doctor: What's wrong? Contemp Pediatr 1999; 16:43.</LI>&#xD;&#xA;<LI>Lake AM. Chronic abdominal pain in childhood: Diagnosis and management. Am Fam Physician 1999; 59:1823.</LI>&#xD;&#xA;<LI>Noe JD, Li BU. Navigating recurrent abdominal pain through clinical clues, red flags, and initial testing. Pediatr Ann 2009; 38:259.</LI>&#xD;&#xA;<LI>Siawash M, de Jager-Kievit JW, Ten WT, et al. Prevalence of anterior cutaneous nerve entrapment syndrome in a pediatric population with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2016; 62:399.</LI></OL></div><div id=\"graphicVersion\">Graphic 90723 Version 5.0</div></div></div>"},"90725":{"type":"graphic_figure","displayName":"Risk-stratified survival PV","title":"Risk-stratified survival in polycythemia vera","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Risk-stratified survival in polycythemia vera</div><div class=\"cntnt\"><img style=\"width:588px; height:422px;\" src=\"images/HEME/90725_Risk_stratified_survival_PV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk-stratified survival in 1545 patients with polycythemia vera. Adverse points are assigned to age &ge;67 years (5 points), age 57 to 66 years (2 points), leukocyte count &ge;15 x 10<sup>9</sup>/L (1 point) and venous thrombosis (1 point): low-risk (0 points), intermediate-risk (1 or 2 points), and high-risk (&ge;3 points).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publisher Ltd: Leukemia. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27:1874. Copyright © 2013. <A href=\"http://www.nature.com/leu\" target=_blank>www.nature.com/leu</A>.</div><div id=\"graphicVersion\">Graphic 90725 Version 1.0</div></div></div>"},"90726":{"type":"graphic_table","displayName":"Lab evaluation chronic abdominal pain","title":"Initial laboratory evaluation for children with chronic abdominal pain and alarm findings*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial laboratory evaluation for children with chronic abdominal pain and alarm findings*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Laboratory test</td> <td class=\"subtitle1\">Laboratory finding</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td>Stool for occult blood</td> <td>Positive</td> <td>Enteric infection, IBD, juvenile polyps, acid-peptic disease, foreign body, vasculitis (eg, polyarteritis nodosa); proximal small bowel disease (Crohn disease, <em>Helicobacter pylori</em>, peptic disease, celiac disease)</td> </tr> <tr> <td rowspan=\"4\">Complete blood count with differential</td> <td>Anemia</td> <td>Celiac disease, IBD</td> </tr> <tr> <td>Leukocytosis</td> <td>Infection or inflammation</td> </tr> <tr> <td>Eosinophilia</td> <td>Atopic disease, eosinophilic esophagitis; parasitic infection</td> </tr> <tr> <td>Thrombocytosis</td> <td>Iron deficiency, ongoing inflammation</td> </tr> <tr> <td>ESR/CRP</td> <td>Elevated ESR or CRP</td> <td>Active inflammatory process (nonspecific)</td> </tr> <tr> <td rowspan=\"4\">Metabolic panel</td> <td>Elevated ALT</td> <td>Hepatic inflammation (eg, chronic hepatitis)</td> </tr> <tr> <td>Elevated direct bilirubin</td> <td>Cholestasis</td> </tr> <tr> <td>Elevated GGT</td> <td>Common bile duct stone</td> </tr> <tr> <td>Decreased albumin</td> <td>Defective liver protein synthesis, intestinal protein loss (Crohn disease)</td> </tr> <tr> <td>Lipase</td> <td>Elevated</td> <td>Acute pancreatitis</td> </tr> <tr> <td>Antitissue transglutaminase</td> <td>Positive</td> <td>Celiac disease</td> </tr> <tr> <td>Urinalysis</td> <td>Hematuria</td> <td>Nephrolithiasis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase.<br />* Additional laboratory evaluation may be warranted if specific organic conditions are suspected.</div><div class=\"graphic_reference\">Adapted from: Noe JD, Li BU. Navigating recurrent abdominal pain through clinical clues, red flags, and initial testing. Pediatr Ann 2009; 38:259.</div><div id=\"graphicVersion\">Graphic 90726 Version 2.0</div></div></div>"},"90727":{"type":"graphic_figure","displayName":"Incidence and time for leukemic transformation of PV","title":"Cumulative incidence and time to event for leukemic transformation of polycythemia vera","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Cumulative incidence and time to event for leukemic transformation of polycythemia vera</div><div class=\"cntnt\"><img style=\"width:498px; height:500px;\" src=\"images/HEME/90727_Incid_time_leukem_trans_PV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative incidence and time to event for leukemic transformation of polycythemia vera among 1545 patients stratified by the first cytoreductive drugs they were exposed to. \"Leukemogenic\" drugs include chlorambucil, P32, and other alkylating agents; \"non-leukemogenic,\" for the purposes of this figure, signifies the use of interferon alfa or anagrelide only; \"nothing\" refers to patients who were not exposed to any cytoreductive agent.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publisher Ltd: Leukemia. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27:1874. Copyright © 2013. <A href=\"http://www.nature.com/leu\" target=_blank>www.nature.com/leu</A>.</div><div id=\"graphicVersion\">Graphic 90727 Version 2.0</div></div></div>"},"90730":{"type":"graphic_picture","displayName":"Electrocautery lip burns","title":"Lip burns caused by electrocautery devices during tonsillectomy and/or adenoidectomy","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Lip burns caused by electrocautery devices during tonsillectomy and/or adenoidectomy</div><div class=\"cntnt\"><img style=\"width:513px; height:189px;\" src=\"images/ALLRG/90730_Electrocaute_lip_burns.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90730 Version 1.0</div></div></div>"},"90731":{"type":"graphic_table","displayName":"Coping strategies functional abdominal pain","title":"Therapies to improve coping for children and adolescents with functional abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies to improve coping for children and adolescents with functional abdominal pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mind-body therapy</td> <td class=\"subtitle1\">Instructions/example</td> </tr> <tr class=\"divider_bottom\"> <td>Deep breathing</td> <td> <p>Place your hand over your belly</p> <p>Breathe deeply; feel your belly expand</p> <p>Breathe out through your mouth; allow your belly to deflate</p> Repeat as necessary for up to 30 minutes</td> </tr> <tr class=\"divider_bottom\"> <td>Progressive muscle relaxation</td> <td> <p>Lie down in a comfortable position</p> <p>Notice how the muscles feel in each part of your body</p> <p>Clench the muscles in your face for&nbsp;five seconds, take a deep breath, and release</p> <p>Repeat the sequence of clenching and releasing for other body areas (eg, shoulders, arms, hands, fingers, abdomen, thighs, lower legs, feet, toes)</p> <p>Clench all your muscles for 5five seconds;, take a deep breath, and release</p> Focus on how your muscles feel after release</td> </tr> <tr> <td rowspan=\"2\">Guided imagery/self-hypnosis</td> <td> <p><strong>Example 1:</strong></p> <p>Relax and imagine a happy, comfortable place&nbsp;&ndash; a place you have been or a place you would like to go</p> <p>Pretend that you are there</p> <p>What do you see? Hear? Smell? Feel?</p> Spend a few minutes enjoying everything about your special place</td> </tr> <tr> <td> <p><strong>Example 2:</strong></p> <p>Imagine floating on a big puffy cloud</p> <p>Imagine butter melting onto your hand and making your hand shiny and warm</p> <p>Place this hand on your belly</p> Imagine the butter melting through your belly and forming a coating that will protect it from irritation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Gerik SM. Pain management in children: Developmental considerations and mind-body therapies. South Med J 2005; 98:295.</LI>&#xD;&#xA;<LI>van Tilburg MA, Chitkara DK, Palsson OS, et al. Audio-recorded guided imagery treatment reduces functional abdominal pain in children:&nbsp;A pilot study. Pediatrics 2009; 124:e890.</LI></OL></div><div id=\"graphicVersion\">Graphic 90731 Version 2.0</div></div></div>"},"90732":{"type":"graphic_picture","displayName":"Ulerythema ophryogenes","title":"Ulerythema ophryogenes (keratosis pilaris atrophicans)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Ulerythema ophryogenes (keratosis pilaris atrophicans)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90732_Ulerythema_ophryogenes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema, keratotic follicular papules, and loss of the eyebrows in a child with keratosis follicularis atrophicans (ulerythema ophryogenes).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90732 Version 1.0</div></div></div>"},"90733":{"type":"graphic_picture","displayName":"Atrophoderma vermiculatum","title":"Atrophoderma vermiculatum","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Atrophoderma vermiculatum</div><div class=\"cntnt\"><img style=\"width:576px; height:374px;\" src=\"images/DERM/90733_Atrophoderma_vermiculatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pit-like depressions merging into each other produce a \"worm-eaten\" appearance on the cheeks of this 17-year-old boy with atrophoderma vermiculatum.</div><div class=\"graphic_reference\">Reproduced with permission from DermIS: Dermatology Information System. <a href=\"http://www.dermis.net/\" target=_blank>www.dermis.net</a>. Copyright © 2014. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90733 Version 1.0</div></div></div>"},"90734":{"type":"graphic_figure","displayName":"Diagram LV RV comparison apical 4 chamber","title":"Diagram showing comparison of the changes in size and appearance of the left ventricle (LV) and right ventricle (RV) in the apical 4 chamber view depending on angulation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram showing comparison of the changes in size and appearance of the left ventricle (LV) and right ventricle (RV) in the apical 4 chamber view depending on angulation</div><div class=\"cntnt\"><img style=\"width:274px; height:223px;\" src=\"images/CARD/90734_Diag_LV_RV_co_4_chamber.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the recommended apical 4-chamber (A4C) view with focus on the right ventricle (RV) (1*) and the sensitivity of right ventricular size with angular change (2,3) despite similar size and appearance of the left ventricle (LV). The lines of intersection of the A4C planes (1*,2,3) with a mid left ventricular short-axis are shown above and corresponding A4C views below.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90734 Version 1.0</div></div></div>"},"90735":{"type":"graphic_diagnosticimage","displayName":"Echo parasternal views RVOT measurements","title":"2D TTE from various parasternal views showing right ventricular outflow tract (RVOT) measurements","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">2D TTE from various parasternal views showing right ventricular outflow tract (RVOT) measurements</div><div class=\"cntnt\"><img style=\"width:514px; height:497px;\" src=\"images/CARD/90735_Ech_parastern_RVOT_meas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurement of right ventricular outflow tract (RVOT) dimensions at the proximal or subvalvular level (RVOT-Prox) and at the distal or pulmonic valve (RVOT-Distal) in the (A) parasternal long-axis RVOT anterior portion view, (B) basal parasternal short-axis view, and (C) parasternal short-axis of pulmonary bifurcation view.</div><div class=\"graphic_footnotes\"> PA: pulmonary artery dimension between valve and the bifurcation point.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90735 Version 1.0</div></div></div>"},"90736":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical 4 chamber calculation RV fractional area change","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4-chamber view showing calculation of right ventricular (RV) fractional area change","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4-chamber view showing calculation of right ventricular (RV) fractional area change</div><div class=\"cntnt\"><img style=\"width:548px; height:407px;\" src=\"images/CARD/90736_Ech_calc_RV_fract_chng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of right ventricular fractional area change (FAC). Percentage FAC = 100 end-diastolic area (area ED) endsystolic area (area ES)/end-diastolic area. The endocardial border is traced in apical 4-chamber (A4C) views from the tricuspid annulus along the free wall to the apex, then back to the annulus, along the interventricular septum at end-diastole (ED) and end-systole (ES). Trabeculation, tricuspid leaflets, and chords are included in the chamber.<br />(A) Normal subject, FAC 60 percent.<br />(B) Moderately dilated right ventricle (RV), FAC 40 percent, and a markedly dilated left ventricle (LV).<br />(C) Dilated RV, FAC 20 percent, and the left ventricle (LV) is foreshortened as a result of optimizing the view for the right ventricular chamber.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90736 Version 2.0</div></div></div>"},"90737":{"type":"graphic_diagnosticimage","displayName":"Echo tissue Doppler MPI calculation","title":"Echo tissue Doppler myocardial performance index (MPI) calculation","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Echo tissue Doppler myocardial performance index (MPI) calculation</div><div class=\"cntnt\"><img style=\"width:501px; height:385px;\" src=\"images/CARD/90737_Echo_tiss_Dopp_MPI_calc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calculation of right ventricular myocardial performance index (MPI) pulsed tissue Doppler. The tricuspid (valve) closure opening time (TCO) encompasses isovolumic contraction time, ejection time (ET), and isovolumic relaxation time.</div><div class=\"graphic_footnotes\">MPI =&nbsp;(TCO ET)/ET.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90737 Version 1.0</div></div></div>"},"90738":{"type":"graphic_algorithm","displayName":"Recommended treatment algorithm for patients with achalasia","title":"Recommended treatment algorithm for patients with achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recommended treatment algorithm for patients with achalasia</div><div class=\"cntnt\"><img style=\"width:431px; height:244px;\" src=\"images/GAST/90738_Recomm_treat_pat_achalasia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PD: pneumatic dilation.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: American Journal of Gastroenterology. Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: Diagnosis and management of achalasia. Am J Gastroenterol 2013; 108:1238. Copyright © 2013. <A href=\"http://www.nature.com/ajg\" target=_blank>www.nature.com/ajg</A>.</div><div id=\"graphicVersion\">Graphic 90738 Version 1.0</div></div></div>"},"90741":{"type":"graphic_diagnosticimage","displayName":"Chest x-rays of TOF_PA_MAPCAs","title":"Chest radiographs of patients with tetralogy of Fallot, pulmonary atresia, and MAPCAs with varying degrees of pulmonary blood flow","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Chest radiographs of patients with tetralogy of Fallot, pulmonary atresia, and MAPCAs with varying degrees of pulmonary blood flow</div><div class=\"cntnt\"><img style=\"width:541px; height:264px;\" src=\"images/PEDS/90741_Chest_x_TOF_PA_MAPCAs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph of an&nbsp;unrepaired patient with excessive pulmonary blood flow demonstrates perihilar and bilateral pulmonary edema.<BR>(B) Chest radiograph of an&nbsp;unrepaired patient with significant cyanosis showing a paucity of pulmonary blood flow.</div><div class=\"graphic_footnotes\">MAPCAs: major aortopulmonary collateral arteries.</div><div id=\"graphicVersion\">Graphic 90741 Version 1.0</div></div></div>"},"90742":{"type":"graphic_diagnosticimage","displayName":"Chest x-rays reperfusion edema in TOF_PA_MAPCAs","title":"Chest radiographs showing reperfusion pulmonary edema of the left upper lobe in a patient with TOF and PA after unifocalization","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Chest radiographs showing reperfusion pulmonary edema of the left upper lobe in a patient with TOF and PA after unifocalization</div><div class=\"cntnt\"><img style=\"width:545px; height:267px;\" src=\"images/PEDS/90742_Chest_x_reperfus_ed_TOF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Preoperative angiogram in a three-year-old patient showing a long-segment stenotic collateral vessel to the left upper lobe (arrowhead).<br />(B) Chest radiograph on postoperative day two after unifocalization of the left upper lobe collateral vessel showing reperfusion pulmonary edema in the left upper lobe (arrowhead).</div><div class=\"graphic_footnotes\">TOF: tetralogy of Fallot; PA: pulmonary atresia.</div><div id=\"graphicVersion\">Graphic 90742 Version 1.0</div></div></div>"},"90743":{"type":"graphic_table","displayName":"Computed tomography grading of caustic esophageal injuries","title":"Computed tomography grading of caustic esophageal injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Computed tomography grading of caustic esophageal injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">CT findings</td> </tr> <tr> <td>Grade I</td> <td>No definite swelling of esophageal wall (&#60;3 mm, within normal limits).</td> </tr> <tr> <td>Grade II</td> <td>Edematous, thickened (&#62;3 mm) esophageal wall without periesophageal soft tissue infiltration.</td> </tr> <tr> <td>Grade III</td> <td>Edematous, thickened (&#62;3 mm) esophageal wall with periesophageal soft tissue infiltration and a well-demarcated tissue interface.</td> </tr> <tr> <td>Grade IV</td> <td>Edematous, thickened (&#62;3 mm) esophageal wall with periesophageal soft tissue infiltration and blurring of the tissue interface or localized fluid collection around esophagus or descending aorta.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Ryu HH, Jeung KW, Lee BK, et al. Caustic injury: Can CT grading system enable prediction of esophageal stricture? Clin Toxicol (Phila) 2010; 48:137.</div><div id=\"graphicVersion\">Graphic 90743 Version 1.0</div></div></div>"},"90745":{"type":"graphic_picture","displayName":"Keratosis pilaris histo","title":"Histologic features of keratosis pilaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histologic features of keratosis pilaris</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/90745_Keratosispilarishisto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The follicle is plugged with compact orthokeratin that protrudes above the skin surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioffreda MD. Inflammatory diseases of hair follicles, sweat glands, and cartilage. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=_blank>www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90745 Version 5.0</div></div></div>"},"90746":{"type":"graphic_diagnosticimage","displayName":"Changes interventricular septum RV pressure or volume overload","title":"Changes in interventricular septum with right ventricular (RV) pressure or volume overload","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in interventricular septum with right ventricular (RV) pressure or volume overload</div><div class=\"cntnt\"><img style=\"width:346px; height:618px;\" src=\"images/CARD/90746_Chng_inter_RV_overload.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial stop-frame short-axis two-dimensional echocardiographic images of the left ventricle at the mitral chordal level with diagrams from a patient with isolated right ventricular (RV) pressure overload due to primary pulmonary hypertension (A) and from a patient with isolated RV volume overload due to tricuspid valve resection (B). Whereas the left ventricular (LV) cavity maintains a circular profile throughout the cardiac cycle in normal subjects, in RV pressure overload, there is leftward ventricular septal (VS) shift and reversal of septal curvature present throughout the cardiac cycle with most marked distortion of the left ventricle at end-systole. In the patient with RV volume overload, the septal shift and flattening of VS curvature occurs predominantly in mid to late diastole with relative sparing of LV deformation at end-systole.</div><div class=\"graphic_reference\">Reproduced from: Louie EK, Rich S, Levitsky, et al. Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. J Am Coll Cardiol 1992; 19:84. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90746 Version 1.0</div></div></div>"},"90747":{"type":"graphic_figure","displayName":"BMI curves for girls with severe obesity","title":"BMI curves for girls with severe obesity","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">BMI curves for girls with severe obesity</div><div class=\"cntnt\"><img style=\"width:726px; height:914px;\" src=\"images/PEDS/90747_BMI_curv_girls_sev_obesity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe obesity in pediatric patients is defined as a body mass index (BMI) that is either &ge;120% of the 95<sup>th</sup> percentile curve, or BMI &ge;35 kg/m<sup>2</sup> (whichever is lower). The area defining severe obesity is shaded in red in the figure above. A BMI of 40 kg/m<sup>2</sup> is typically used as a threshold for weight loss surgery in adults and adolescents without major comorbidities. Note that this threshold is well above the curve representing 120% of the 95<sup>th</sup> percentile at all ages.<br />The black curves (50 through 97) represent the standard BMI growth reference from the CDC, published in 2000. The blue curves (110% through 190%) are derived by multiplying the 95<sup>th</sup> percentile values by 1.1 through 1.9, respectively.</div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Source: Kelly AS, Barlow SE, Rao G, Inge TH, et al. Severe obesity in children and adolescents: Identification, associated health risks, and treatment approaches. A scientific statement from the American Heart Association. Circulation 2013; 128:1689.</div><div id=\"graphicVersion\">Graphic 90747 Version 3.0</div></div></div>"},"90750":{"type":"graphic_picture","displayName":"Fluorescence in situ hybridization ","title":"Fluorescence in situ hybridization (FISH) for ALK gene wild type control","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fluorescence in situ hybridization (FISH) for ALK gene wild type control</div><div class=\"cntnt\"><img style=\"width:504px; height:440px;\" src=\"images/ONC/90750_Fluorescence_situ_hybrid.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90750 Version 1.0</div></div></div>"},"90758":{"type":"graphic_table","displayName":"Diagnostic criteria for primary progressive aphasia","title":"Diagnostic criteria for primary progressive aphasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for primary progressive aphasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inclusion: criteria 1-3 must be answered positively</td> </tr> <tr> <td> <ol> <li>Most prominent clinical feature is difficulty with language </li> <li>These deficits are the principal cause of impaired daily living activities </li> <li>Aphasia should be the most prominent deficit at symptom onset and for the initial phases of the disease </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Exclusion: criteria 1-4 must be answered negatively</td> </tr> <tr> <td> <ol> <li>Pattern of deficits is better accounted for by other nondegenerative nervous system or medical disorders </li> <li>Cognitive disturbance is better accounted for by a psychiatric diagnosis </li> <li>Prominent initial episodic memory, visual memory, and visuoperceptual impairments </li> <li>Prominent, initial behavioral disturbance </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPA: primary progressive aphasia.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006. DOI: <a href=\"http://www.neurology.org/content/76/11/1006\" target=_blank>10.1212/WNL.0b013e31821103e6</a>. Copyright © 2011 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90758 Version 6.0</div></div></div>"},"90759":{"type":"graphic_table","displayName":"Diagnostic criteria for nonfluent variant PPA","title":"Diagnostic criteria for nonfluent/agrammatic variant PPA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for nonfluent/agrammatic variant PPA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Clinical diagnosis of nonfluent/agrammatic variant PPA</td> </tr> <tr> <td>At least one of the following core features must be present: <ol> <li>Agrammatism in language production </li> <li>Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech) </li> </ol> At least 2 of 3 of the following other features must be present: <ol> <li>Impaired comprehension of syntactically complex sentences </li> <li>Spared single-word comprehension </li> <li>Spared object knowledge </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Imaging-supported nonfluent/agrammatic variant diagnosis</td> </tr> <tr> <td>Both of the following criteria must be present: <ol> <li>Clinical diagnosis of nonfluent/agrammatic variant PPA </li> <li>Imaging must show one or more of the following results: <p class=\"sublist1\">a. Predominant left posterior fronto-insular atrophy on MRI</p> <p class=\"sublist1\">b. Predominant left posterior fronto-insular hypoperfusion or hypometabolism on SPECT or PET</p> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">III. Nonfluent/agrammatic variant PPA with definite pathology</td> </tr> <tr> <td>Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present: <ol> <li>Clinical diagnosis of nonfluent/agrammatic variant PPA </li> <li>Histopathologic evidence of a specific neurodegenerative pathology (eg, FTLD-tau, FTLD- TDP, AD, other) </li> <li>Presence of a known pathogenic mutation </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: Alzheimer disease; FTLD: frontotemporal lobar degeneration; PPA: primary progressive aphasia.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006. DOI: <a href=\"http://www.neurology.org/content/76/11/1006\" target=_blank>10.1212/WNL.0b013e31821103e6</a>. Copyright © 2011 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90759 Version 7.0</div></div></div>"},"90760":{"type":"graphic_picture","displayName":"Phrynoderma","title":"Phrynoderma (vitamin A deficiency)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Phrynoderma (vitamin A deficiency)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90760_Phrynoderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic papules on the extensor surfaces of the knee in a child with vitamin A deficiency.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90760 Version 1.0</div></div></div>"},"90761":{"type":"graphic_table","displayName":"Diagnostic criteria for semantic variant PPA","title":"Diagnostic criteria for semantic variant PPA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for semantic variant PPA</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Clinical diagnosis of semantic variant PPA</td> </tr> <tr> <td>Both of the following core features must be present: <ol> <li>Impaired confrontation naming </li> <li>Impaired single-word comprehension </li> </ol> At least 3 of the following other diagnostic features must be present: <ol> <li>Impaired object knowledge, particularly for low-frequency or low-familiarity items </li> <li>Surface dyslexia or dysgraphia </li> <li>Spared repetition </li> <li>Spared speech production (grammar and motor speech) </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Imaging-supported semantic variant PPA diagnosis</td> </tr> <tr> <td>Both of the following criteria must be present: <ol> <li>Clinical diagnosis of semantic variant PPA </li> <li>Imaging must show one or more of the following results: <p class=\"sublist1\">a. Predominant anterior temporal lobe atrophy</p> <p class=\"sublist1\">b. Predominant anterior temporal hypoperfusion or hypometabolism on SPECT or PET</p> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">III. Semantic variant PPA with definite pathology</td> </tr> <tr> <td>Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present: <ol> <li>Clinical diagnosis of semantic variant PPA </li> <li>Histopathologic evidence of a specific neurodegenerative pathology (eg, FTLD-tau, FTLD- TDP, AD, other) </li> <li>Presence of a known pathogenic mutation </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: Alzheimer disease; FTLD: frontotemporal lobar degeneration; PPA: primary progressive aphasia.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76:1006. DOI: <a href=\"http://www.neurology.org/content/76/11/1006\" target=\"_blank\">10.1212/WNL.0b013e31821103e6</a>. Copyright &copy; 2011 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 90761 Version 7.0</div></div></div>"},"90762":{"type":"graphic_table","displayName":"Echo estimates of RA pressure","title":"Echocardiographic parameters used to estimate right atrial (RA) pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic parameters used to estimate right atrial (RA) pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Normal (0 to 5 [3] mmHg)</td> <td class=\"subtitle1\" colspan=\"2\">Intermediate (5 to 10 [8] mmHg)</td> <td class=\"subtitle1\">High (15 mmHg)</td> </tr> <tr> <td>IVC diameter</td> <td>&#8804;2.1 cm</td> <td>&#8804;2.1 cm</td> <td>&#62;2.1 cm</td> <td>&#62;2.1 cm</td> </tr> <tr> <td>Collapse with sniff</td> <td>&#62;50 percent</td> <td>&#60;50 percent</td> <td>&#62;50 percent</td> <td>&#60;50 percent</td> </tr> <tr> <td>Secondary indices of elevated RA pressure</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Restrictive filling</p> <p>Tricuspid E/E' &#62;6</p> Diastolic flow predominance in hepatic veins (systolic filling fraction &#60;55 percent) </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Ranges are provided for low and intermediate categories, but for simplicity, midrange values of 3 mmHg for normal and 8 mmHg for intermediate are suggested. Intermediate (8 mmHg) RA pressures may be downgraded to normal (3 mmHg) if no secondary indices of elevated RA pressure are present, upgraded to high if minimal collapse with sniff (&lt;35 percent) and secondary indices of elevated RA pressure are present, or left at 8 mmHg if uncertain.</div><div class=\"graphic_footnotes\">IVC: inferior vena cava; RA: right atrial.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685.&nbsp;Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90762 Version 1.0</div></div></div>"},"90763":{"type":"graphic_table","displayName":"Echo parameters for right heart","title":"Echocardiographic parameters for right heart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic parameters for right heart</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Unit</td> <td class=\"subtitle1\">Normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chamber dimensions</td> </tr> <tr> <td class=\"indent1\">RV basal diameter</td> <td class=\"centered\">cm</td> <td class=\"centered\">&#8804;4.1</td> </tr> <tr> <td class=\"indent1\">RV wall thickness in subcostal view</td> <td class=\"centered\">cm</td> <td class=\"centered\">&#8804;0.5</td> </tr> <tr> <td class=\"indent1\">RVOT diameter in PLAX view</td> <td class=\"centered\">cm</td> <td class=\"centered\">&#8804;3.0<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">RA end-systolic volume index</td> <td class=\"centered\">mL/m<sup>2</sup></td> <td class=\"centered\">&#8804;39 in men / &#8804; 33 in women<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">RA end-systolic area</td> <td class=\"centered\">cm<sup>2</sup></td> <td class=\"centered\">&#8804;18</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Systolic function</td> </tr> <tr> <td class=\"indent1\">TAPSE</td> <td class=\"centered\">cm</td> <td class=\"centered\">&#8805;1.7<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">Pulsed Doppler peak annular velocity (S')</td> <td class=\"centered\">cm/s</td> <td class=\"centered\">&#8805;9.5<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">Pulsed Doppler MPI</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8804;0.43<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">Tissue Doppler MPI</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8804;0.54</td> </tr> <tr> <td class=\"indent1\">FAC</td> <td class=\"centered\">percent</td> <td class=\"centered\">&#8805;35</td> </tr> <tr> <td class=\"indent1\">3D-derived RVEF (percent)</td> <td class=\"centered\">percent</td> <td class=\"centered\">&#8805;45<sup>1</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diastolic function</td> </tr> <tr> <td class=\"indent1\">E/A ratio</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">0.8 to 2.1</td> </tr> <tr> <td class=\"indent1\">E/E' ratio</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#8804;6</td> </tr> <tr> <td class=\"indent1\">IVC diameter in subcostal view</td> <td class=\"centered\">cm</td> <td class=\"centered\">&#8804;2.1<sup>1</sup></td> </tr> <tr> <td class=\"indent1\">IVC collapse during inspiratory sniff</td> <td class=\"centered\">percent&nbsp;</td> <td class=\"centered\">&#8805;50<sup>1</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hepatic vein velocity ratio in subcostal view&nbsp;</td> <td class=\"centered\">&nbsp;&ndash;</td> <td class=\"centered\">Systolic &#62; Diastolic&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FAC: fractional area change; MPI: myocardial performance index; PLAX: parasternal long-axis; PSAX: parasternal short-axis; RA: right atrium; RV: right ventricle; RVD: right ventricular diameter; RVOT: right ventricular outflow tract; TAPSE: tricuspid annular plane systolic excursion.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28:1.</LI></OL>Original figure modified for this publication. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90763 Version 3.0</div></div></div>"},"90765":{"type":"graphic_picture","displayName":"Diaper dermatitis irritant PI","title":"Irritant diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/90765_Diaper_dermatitis_irrit_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intense erythema and scaling with sparing of the skin fold are characteristic of irritant diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 90765 Version 1.0</div></div></div>"},"90767":{"type":"graphic_algorithm","displayName":"Genetic family screening strategies in HCM","title":"Genetic family screening strategies in hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Genetic family screening strategies in hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:612px; height:476px;\" src=\"images/CARD/90767_GenfamscreenstratHCM.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PGD: preimplantation genetic diagnosis; HCM: hypertrophic cardiomyopathy; Dx: diagnosis; VUS: variant of uncertain significance; ICD: implantable cardioverter-defibrillator.<br />* Includes patients with associated cardiovascular diseases (eg, systemic hypertension) or athlete's heart.<br />¶ First option for assessment of family members would be a clinical screening evaluation with imaging tests and ECG; the option of genetic testing is triggered largely for those relatives with negative or indeterminant clinical testing (for the HCM phenotype).<br />Δ Genetic screening often not productive; co-segregation, while an option, has practical obstacles including limited family size or compliance.</div><div class=\"graphic_reference\">Reproduced from: Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy after 20 years. J Am Coll Cardiol 2012; 60:705. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90767 Version 4.0</div></div></div>"},"90768":{"type":"graphic_figure","displayName":"Distribution of HCM sarcomere gene mutations","title":"Distribution of HCM sarcomere gene mutations","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Distribution of HCM sarcomere gene mutations</div><div class=\"cntnt\"><img style=\"width:620px; height:582px;\" src=\"images/CARD/90768_Distrib_HCM_gene_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of genes encoding proteins of cardiac sarcomere in clinical populations. A variety of laboratories report a wide range in mutational yield (24 to 63 percent), leaving a significant proportion of the HCM population genotype-negative. Highest yields are in families with multiple affected relatives, with lower rates in clinically identified HCM probands.</div><div class=\"graphic_reference\">Data from: Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy after 20 years. J Am Coll Cardiol 2012; 60:705.</div><div id=\"graphicVersion\">Graphic 90768 Version 1.0</div></div></div>"},"90769":{"type":"graphic_figure","displayName":"Sarcomeric gene mutation locations in HCM","title":"Sarcomeric gene mutation locations in hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Sarcomeric gene mutation locations in hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:590px; height:418px;\" src=\"images/CARD/90769_Sarco_gene_mut_loc_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence for each of the 11 genes derived from studies in unrelated HCM probands with positive genotyping are shown in parentheses. Not shown are genes previously linked to HCM, but with lesser degrees of evidence for pathogenicity: &alpha;-myosin heavy chain, titin, muscle LIM protein, telethonin, vincalin/metavinculin, junctophilin 2.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Maron BJ, Maron MS, Hypertrophic cardiomyopathy. The Lancet 2013; 381:242. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90769 Version 1.0</div></div></div>"},"90772":{"type":"graphic_picture","displayName":"Erythromelanosis follicularis faciei","title":"Erythromelanosis follicularis faciei et colli","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Erythromelanosis follicularis faciei et colli</div><div class=\"cntnt\"><img style=\"width:590px; height:436px;\" src=\"images/DERM/90772_Erythromel_follicula_faciei.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patches with telangiectasias and follicular papules in a 19-year-old girl with a history of redness and roughness of the cheeks since early childhood.</div><div class=\"graphic_reference\">Reproduced with permission from: Augustine M, Jayaseelan E. Erythromelanosis follicularis faciei et colli: Relationship with keratosis pilaris. Indian J Dermatol Venereol Leprol 2008: 74:47. Copyright &copy; 2008 Medknow. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90772 Version 1.0</div></div></div>"},"90773":{"type":"graphic_diagnosticimage","displayName":"X-ray type III Garden fracture femoral neck","title":"Garden type III femoral neck fracture on x-ray","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Garden type III femoral neck fracture on x-ray</div><div class=\"cntnt\"><img style=\"width:596px; height:604px;\" src=\"images/RADIOL/90773_Xray_III_Gardn_fem_nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An x-ray of the right hip in AP projection (A) shows angulation of the femoral head but minimal cranial translation of the shaft. The arrow shows the fracture line inferiorly. Image B magnifies the fracture line (arrow). Image C is a diagrammatic representation of a Garden type III fracture.</div><div class=\"graphic_reference\">(C) Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 90773 Version 4.0</div></div></div>"},"90774":{"type":"graphic_diagnosticimage","displayName":"3D echo sources of measurement errors chamber volumes","title":"Three-dimensional echocardiography (3D echo) sources of measurement errors in the calculation of chamber volumes","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) sources of measurement errors in the calculation of chamber volumes</div><div class=\"cntnt\"><img style=\"width:519px; height:510px;\" src=\"images/CARD/90774_Src_err_3D_ech_meas_vol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: Cross-sectional views of a water-filled latex balloon with two alternative manually traced boundaries: along the inner interface (left), and in the center of the latex layer (right). Volumes resulting from each tracing session in this balloon are shown to be compared with the true volume of 150 mL. Bottom: Example of short-axis cut-planes extracted from RT3DE datasets: while in one patient (left), trabeculae can be well visualized and clearly differentiated from the myocardium, in another patient (right), the spatial resolution of the RT3DE image is not sufficient to provide this kind of detail.</div><div class=\"graphic_reference\">Original figure modified for this publication. Modified with permission from: Mor-Avi V, Jenkins C, Kuhl HP, et al. Real-time 3D echocardiographic quantification of left ventricular volumes: Multicenter study for validation with magnetic resonance imaging and investigation of sources of error. J Am Coll Cardiol Img 2008; 1:413. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90774 Version 1.0</div></div></div>"},"90775":{"type":"graphic_figure","displayName":"3D parametric models of the mitral valve","title":"Three-dimensional echocardiography (3D echo) parametric models of the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) parametric models of the mitral valve</div><div class=\"cntnt\"><img style=\"width:551px; height:537px;\" src=\"images/CARD/90775_3D_para_mod_mitral_vlv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color-encoded parametric models of the mitral valve obtained from 3D echocardiographic images in four different patients demonstrating (top, from left to right): normal anatomy, P3 flail scallop, P2 and P3 prolapse, and Barlow's disease. Shown below is the improvement in the diagnostic accuracy gained by the addition of the color-encoded models by readers with different levels of experience. Note that the models mostly improved the interpretation by novice readers, bringing them to the level of intermediate experience.</div><div class=\"graphic_reference\">Reproduced from: Tsang W, Weinert L, Sugeng L, et al. The value of three-dimensional echocardiography derived mitral valve parametric maps and the role of experience in the diagnosis of pathology. J Am Soc Echocardiogr 2011; 24:860. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90775 Version 1.0</div></div></div>"},"90784":{"type":"graphic_diagnosticimage","displayName":"CT angiogram TOF_PA_MAPCAs","title":"Computed tomographic angiogram of a patient with tetralogy of Fallot and pulmonary atresia demonstrating four MAPCAs","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Computed tomographic angiogram of a patient with tetralogy of Fallot and pulmonary atresia demonstrating four MAPCAs</div><div class=\"cntnt\"><img style=\"width:573px; height:269px;\" src=\"images/PEDS/90784_CT_angio_TOF_PA_MAPCAs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomographic (CT) angiogram demonstrating four MAPCAs. The largest is MAPCA 2, with three immediate branches, labeled 2a, 2b (which includes 3) to the right, and 2c to the left.<br />(B) The schematic drawing of the CT angiogram displays the four MAPCAs counting from top to bottom off the descending aorta. To the right lung, MAPCAs 1, 2a, 2b including 3, and the right pulmonary artery (PA) are all interconnected and from them all segments of the right lung are connected. To the left lung, MAPCAs 2c, 4, and left PA are all interconnected and from them all segments of the left lung are connected.</div><div class=\"graphic_footnotes\">MAPCA: major aortopulmonary collateral artery; Post: posterior; Lat: lateral; Ant: anterior; Med: medial; Sup: superior; Inf: inferior; RPA: right pulmonary artery; LPA: left pulmonary artery; Ap: anterior-posterior; Ap-post: anterior-posterior.&nbsp;</div><div id=\"graphicVersion\">Graphic 90784 Version 1.0</div></div></div>"},"90785":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical 4 chamber RA linear dimensions and area","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing right atrial (RA) linear dimensions and area","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing right atrial (RA) linear dimensions and area</div><div class=\"cntnt\"><img style=\"width:502px; height:348px;\" src=\"images/CARD/90785_Echo_api_4_RA_dim_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right atrial (RA) area (shown in yellow) is measured by planimetry of the atrial cavity in the apical four chamber view at end-systole (when the atrial cavity is at its largest). RA linear dimensions can also be measured in the apical four chamber view at end-systole. The normal reference limits for RA major-axis dimension (superior-inferior, from the center of the tricuspid annular plane to the uppermost aspect of the RA wall, shown as line 1) and minor-axis dimension (left-right, from the interatrial septum to the rightmost aspect of the RA wall, shown as line 2) are ≤5.3 cm and ≤4.4 cm, respectively.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90785 Version 1.0</div></div></div>"},"90787":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical 4 chamber RV linear dimensions and area","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing right ventricular (RV) linear dimensions and area","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing right ventricular (RV) linear dimensions and area</div><div class=\"cntnt\"><img style=\"width:502px; height:352px;\" src=\"images/CARD/90787_Ec_api_4_ch_RV_dim_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The area of the body and apex of the&nbsp;right ventricle (RV, shown in yellow)&nbsp;is measured by planimetry of the ventricular cavity in the apical four chamber view at end-diastole. RV linear dimensions are also measured in the apical four chamber view, at both the basal (line 1) and mid (line 2) portions of the RV.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90787 Version 1.0</div></div></div>"},"90788":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical 4 chamber errors in RV area tracing","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing errors in right ventricular (RV) area tracing","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing errors in right ventricular (RV) area tracing</div><div class=\"cntnt\"><img style=\"width:513px; height:349px;\" src=\"images/CARD/90788_Ech_api_4chm_err_RV_tr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Proper tracing of the right ventricular (RV) endocardial outline.<BR>B. Underestimation of RV size due to exclusion of noncompacted RV trabeculations.<BR>C. Underestimation of RV size due to exclusion of the RV apex by incorrection tracing along the moderator band.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90788 Version 1.0</div></div></div>"},"90789":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical off axis view erroneous RV dimension and area","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from an off axis apical view showing erroneous RV dimension and area","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from an off axis apical view showing erroneous RV dimension and area</div><div class=\"cntnt\"><img style=\"width:494px; height:342px;\" src=\"images/CARD/90789_Echo_api_axis_RV_dim_ar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracings and measurements of the right ventricle (RV) taken from an off axis apical view lead to overestimation of RV size and volumes.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90789 Version 1.0</div></div></div>"},"90790":{"type":"graphic_diagnosticimage","displayName":"2D TTE and M-mode apical 4 chamber TAPSE measurement","title":"Two-dimensional transthoracic echocardiogram (2D TTE) and M mode from the apical 4 chamber view showing TAPSE measurement","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) and M mode from the apical 4 chamber view showing TAPSE measurement</div><div class=\"cntnt\"><img style=\"width:500px; height:340px;\" src=\"images/CARD/90790_Echo_api_4_TAPSE_meas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tricuspid annular plane systolic excursion (TAPSE) is measured in the apical four-chamber view by placing an M-mode cursor on the lateral tricuspid annulus and measuring the peak distance travelled by this reference point during systole. A greater distance travelled during systole implies greater right ventricular systolic function, with the normal reference limit being a TAPSE of ≥1.7 cm.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90790 Version 2.0</div></div></div>"},"90791":{"type":"graphic_diagnosticimage","displayName":"Echo PW Doppler MPI calculation","title":"Echocardiography using pulsed wave (PW) Doppler to perform myocardial performance index (MPI) calculation","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Echocardiography using pulsed wave (PW) Doppler to perform myocardial performance index (MPI) calculation</div><div class=\"cntnt\"><img style=\"width:601px; height:434px;\" src=\"images/CARD/90791_Echo_PW_Dopp_MPI_calc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calculation of right ventricular myocardial performance index (MPI) by pulsed Doppler.</div><div class=\"graphic_reference\">Reproduced from: Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23:685. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90791 Version 1.0</div></div></div>"},"90792":{"type":"graphic_diagnosticimage","displayName":"Doppler echo estimation TR velocity","title":"Doppler echocardiography showing estimation of pulmonary artery systolic pressure using tricuspid regurgitation (TR) velocity","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Doppler echocardiography showing estimation of pulmonary artery systolic pressure using tricuspid regurgitation (TR) velocity</div><div class=\"cntnt\"><img style=\"width:550px; height:377px;\" src=\"images/CARD/90792_Dop_ech_est_TR_vel_set.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Continuous wave Doppler showing tricuspid regurgitation (TR). Measurement of peak TR velocity should be performed at the modal frequency (point 1) rather than at the point of highest visible signs (point 2).<br />(B) Gain settings which are too low do not allow for appropriate visualization of the TR jet, leading to underestimation of the amount of TR and inability to accurately estimate pulmonary artery systolic pressure (PASP).<br />(C) PASP is estimated using the modified Bernoulli equation; PASP in the absence of&nbsp;right ventricular outflow obstruction is equivalent to&nbsp;right ventricular systolic pressure&nbsp;= right atrial pressure&nbsp;+ [4 *(TR velocity)<SUP innerHtml>2</SUP>].</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90792 Version 3.0</div></div></div>"},"90793":{"type":"graphic_diagnosticimage","displayName":"PW Doppler RVOT notching","title":"Pulsed wave Doppler in the right ventricular outflow tract showing notching with pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Pulsed wave&nbsp;Doppler in the right ventricular outflow tract showing notching with pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:501px; height:350px;\" src=\"images/CARD/90793_PW_Dopp_RVOT_pulm_HTN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systolic notching in the pulsed wave Doppler recording of&nbsp;right ventricular outflow tract flow. Mid-systolic notching strongly suggests elevated pulmonary vascular resistance.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90793 Version 2.0</div></div></div>"},"90794":{"type":"graphic_diagnosticimage","displayName":"Tissue Doppler lateral tricuspid annulus","title":"Tissue Doppler lateral tricuspid annulus","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Tissue Doppler lateral tricuspid annulus</div><div class=\"cntnt\"><img style=\"width:502px; height:348px;\" src=\"images/CARD/90794_Tis_Dop_lat_tricus_ann.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue Doppler of the lateral tricuspid annulus obtained from the apical 4-chamber view.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90794 Version 1.0</div></div></div>"},"90795":{"type":"graphic_movie","displayName":"2D TTE apical 4 chamber normal","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing normal function","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing normal function</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/90795_Echoapical4chnormvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:607px; height:431px;\" src=\"images/CARD/90795_Echoapical4chnormimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical 4 chamber view showing normal left and right ventricular size and systolic function.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90795 Version 1.0</div></div></div>"},"90796":{"type":"graphic_movie","displayName":"2D TTE apical 4 chamber normal RV focused","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view focused on the right ventricle (RV) showing normal RV function","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view focused on the right ventricle (RV) showing normal RV function</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/90796_Echoapical4chRVfocvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:559px; height:430px;\" src=\"images/CARD/90796_Echoapical4chRVfocimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical 4 chamber view focused on the right ventricle (RV) showing normal RV function. By focusing on the RV (decreasing the sector size), the image resolution is increased.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90796 Version 1.0</div></div></div>"},"90797":{"type":"graphic_movie","displayName":"2D TTE apical 4 chamber severe RV dysfunction","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing severe right ventricular (RV) dysfunction","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical 4 chamber view showing severe right ventricular (RV) dysfunction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/90797_Echoap4chsevRVdysvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:596px; height:428px;\" src=\"images/CARD/90797_Echoap4chsevRVdysimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical 4 chamber view showing severe right ventricular enlargement with reduced systolic function.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90797 Version 1.0</div></div></div>"},"90798":{"type":"graphic_movie","displayName":"2D TTE subcostal IVC change with inspiration","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing change in inferior vena cava (IVC) size with inspiration","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing change in inferior vena cava (IVC) size with inspiration</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/90798_EchosubcostIVCinspvideo.mp4\" style=\"width:512px;height:368px\"></div><img style=\"width:541px; height:430px;\" src=\"images/CARD/90798_EchosubcostIVCinspimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal view showing&nbsp;a decrease (normal)&nbsp;in inferior vena cava (IVC) size with inspiration. This change occurs due to the temporary decrease in intrathoracic pressure associated with inspiration, resulting in augmented venous return to the right heart.</div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90798 Version 1.0</div></div></div>"},"90801":{"type":"graphic_diagnosticimage","displayName":"Glomerular thrombotic microangiopathy in HUS","title":"Glomerular thrombotic microangiopathy in hemolytic uremic syndrome","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Glomerular thrombotic microangiopathy in hemolytic uremic syndrome</div><div class=\"cntnt\"><img style=\"width:513px; height:342px;\" src=\"images/PEDS/90801_Glomer_microangio_HUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of a patient with hemolytic uremic syndrome. Panel A demonstrates fibrin deposition in the glomerular capillaries (arrow). Panel B shows narrowing of the glomerular arteriole due to widening of the subendothelial space (arrow). Panel C demonstrates double contour appearance of glomerular capillary wall and widening of the subendothelial space (arrow). Panel D is an electron micrograph showing swollen endothelial cells.</div><div class=\"graphic_footnotes\">HUS: hemolytic uremic syndrome.</div><div class=\"graphic_reference\">Courtesy of MC Gubler, MD.</div><div id=\"graphicVersion\">Graphic 90801 Version 1.0</div></div></div>"},"90802":{"type":"graphic_table","displayName":"Causes of RV dilation and dysfunction","title":"Causes of right ventricular (RV) dilation and/or dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of right ventricular (RV) dilation and/or dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td rowspan=\"11\"><strong>Pressure overload</strong></td> <td>Massive pulmonary embolism (acute)</td> </tr> <tr> <td class=\"sublist1_start\">Pulmonary hypertension (PH)</td> </tr> <tr> <td class=\"indent1\">- Pulmonary arterial hypertension</td> </tr> <tr> <td class=\"indent1\">- PH due to left heart disease</td> </tr> <tr> <td class=\"indent1\">- PH due to lung disease and/or hypoxemia</td> </tr> <tr> <td class=\"indent1\">- PH due to chronic thrombotic and/or embolic disease</td> </tr> <tr> <td class=\"indent1\">- PH due to other causes</td> </tr> <tr> <td>Pulmonary artery stenosis (supravalvular, branch, peripheral)</td> </tr> <tr> <td>Pulmonary valve stenosis</td> </tr> <tr> <td>Infundibular/subvalvular stenosis (including Tetralogy of Fallot)</td> </tr> <tr> <td>Systemic right ventricle</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Volume overload</strong></td> <td>Atrial septal defect</td> </tr> <tr> <td>Tricuspid valve regurgitation (including Ebstein's anomaly)</td> </tr> <tr> <td>Pulmonary valve regurgitation</td> </tr> <tr> <td>Anomalous pulmonary venous connections</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Intrinsic pathology</strong></td> <td>Right ventricular infarction (acute)</td> </tr> <tr> <td>Arrhythmogenic right ventricular cardiomyopathy (ARVC)</td> </tr> <tr> <td>Primary cardiomyopathies</td> </tr> <tr> <td>Secondary cardiomyopathies</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Jonathon Afilalo, MD and Lawrence Rudski, MD.</div><div id=\"graphicVersion\">Graphic 90802 Version 1.0</div></div></div>"},"90803":{"type":"graphic_diagnosticimage","displayName":"Arterial thrombotic microangiopathy in HUS","title":"Arterial thrombotic microangiopathy in hemolytic uremic syndrome","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Arterial thrombotic microangiopathy in hemolytic uremic syndrome</div><div class=\"cntnt\"><img style=\"width:513px; height:347px;\" src=\"images/PEDS/90803_Art_throm_microang_HUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows endothelial swelling, narrowing of the lumen, and intraluminal thrombus of an afferent arteriole. Panel B demonstrates shrunken and ischemic glomeruli. Panel C is an electron micrograph showing splitting of the capillary wall (arrowhead) and wrinkling of the glomerular basement membrane (arrow).</div><div class=\"graphic_footnotes\">HUS: hemolytic uremic syndrome.</div><div class=\"graphic_reference\">Courtesy of MC Gubler, MD.</div><div id=\"graphicVersion\">Graphic 90803 Version 1.0</div></div></div>"},"90835":{"type":"graphic_table","displayName":"Brand-name vs generic drug prices PI","title":"Examples of prices for some common brand-name medicines and their generic versions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of prices for some common brand-name medicines and their generic versions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" colspan=\"2\">Brand-name medicine</td> <td class=\"subtitle1\" colspan=\"2\">Generic or non-prescription version of medicine</td> </tr> <tr> <td class=\"subtitle2\">Name</td> <td class=\"subtitle2\">Cost per month (US dollars)</td> <td class=\"subtitle2\">Name</td> <td class=\"subtitle2\">Cost per month (US dollars)</td> </tr> <tr> <td rowspan=\"3\">Arthritis</td> <td>Celebrex 200 mg</td> <td>$345</td> <td>Celecoxib 200 mg</td> <td>$30 to 45</td> </tr> <tr> <td>Mobic&nbsp;7.5 mg</td> <td>$235</td> <td>Meloxicam&nbsp;7.5 mg</td> <td>$5</td> </tr> <tr> <td>Naprosyn 500 mg </td> <td>$195</td> <td>Naproxen 500 mg</td> <td>$10</td> </tr> <tr> <td rowspan=\"3\">Allergy</td> <td>Claritin 10 mg (no prescription needed)</td> <td>$17 </td> <td>Loratadine 10 mg (no prescription needed)</td> <td>$7</td> </tr> <tr> <td>Flonase 50 mcg nasal spray</td> <td>Not available</td> <td> <p>Fluticasone 50 mcg nose spray&nbsp;(prescription needed)</p> Flonase 50 mcg Allergy Relief nose spray (no prescription needed)</td> <td> <p>$15 to 25</p> <p>&nbsp;</p> <p>$20 to 25</p> </td> </tr> <tr> <td>Nasacort AQ 55 mcg nose spray</td> <td>$125</td> <td> <p>Nasacort Allergy 24 HR nose spray (no prescription needed)</p> </td> <td>$15 to 35</td> </tr> <tr> <td>Asthma</td> <td>Singulair 10 mg</td> <td>$245</td> <td>Montelukast 10 mg</td> <td>$15 to 30</td> </tr> <tr> <td>Bladder control</td> <td>Oxytrol 3.9 mg patch</td> <td>$625</td> <td>Oxytrol for women 3.9 mg patch (no prescription needed)</td> <td>$30</td> </tr> <tr> <td rowspan=\"6\">Depression or pain (Wellbutrin SR/bupropion SR&nbsp;is also used to help stop smoking)</td> <td>Celexa 20 mg</td> <td>$260</td> <td>Citalopram 20 mg</td> <td>$5 to 10</td> </tr> <tr> <td>Effexor XR&nbsp;75 mg</td> <td>$410</td> <td>Venlafaxine ER&nbsp;75 mg</td> <td>$10 to 25</td> </tr> <tr> <td>Pamelor&nbsp;25 mg</td> <td>$3500</td> <td>Nortriptyline&nbsp;25 mg</td> <td>$10 to 30</td> </tr> <tr> <td>Paxil 20 mg</td> <td>$190</td> <td>Paroxetine 20 mg</td> <td>$4 to 20</td> </tr> <tr> <td>Wellbutrin SR 150 mg</td> <td>$430</td> <td>Bupropion SR 150 mg</td> <td>$17 to 40</td> </tr> <tr> <td>Zoloft 100 mg</td> <td>$305</td> <td>Sertraline 100 mg</td> <td>$10 to 15</td> </tr> <tr> <td rowspan=\"2\">Diabetes</td> <td>Glucotrol&nbsp;5 mg</td> <td>$96</td> <td>Glipizide&nbsp;5 mg</td> <td>$7 to 10</td> </tr> <tr> <td>Glucophage XR&nbsp;500 mg</td> <td>$70</td> <td>Metformin 500 mg</td> <td>$4 to 15</td> </tr> <tr> <td>Glaucoma</td> <td>Cosopt eye drops</td> <td>$210</td> <td>Dorzolamide/timolol drops</td> <td>$17 to 40</td> </tr> <tr> <td rowspan=\"3\">Heart disease or high cholesterol</td> <td>Lipitor 20 mg</td> <td>$415</td> <td>Atorvastatin 20 mg</td> <td>$10 to 25</td> </tr> <tr> <td>Pravachol 40 mg</td> <td>$180</td> <td>Pravastatin 40 mg</td> <td>$10 to 20</td> </tr> <tr> <td>Zocor 40 mg</td> <td>$255</td> <td>Simvastatin 40 mg</td> <td>$3 to 15</td> </tr> <tr> <td>Heart failure</td> <td>Coreg 25 mg</td> <td>$290</td> <td>Carvedilol 25 mg</td> <td>$4 to 15</td> </tr> <tr> <td>Heart stents</td> <td>Plavix 75 mg</td> <td>$210</td> <td>Clopidogrel 75 mg </td> <td>$10&nbsp;to 20</td> </tr> <tr> <td rowspan=\"5\">High blood pressure</td> <td>Avapro 150 mg</td> <td>$190</td> <td>Irbesartan 150 mg</td> <td>$10 to 20</td> </tr> <tr> <td>Diovan 160 mg</td> <td>$233</td> <td>Valsartan 160 mg</td> <td>$15 to 20</td> </tr> <tr> <td>Norvasc 5 mg</td> <td>$180</td> <td>Amlodipine 5 mg</td> <td>$3 to 10</td> </tr> <tr> <td>Toprol XL&nbsp;50 mg</td> <td>$79</td> <td>Metoprolol succinate ER 50 mg</td> <td>$20 to 30</td> </tr> <tr> <td>Zestril 40 mg</td> <td>$398</td> <td>Lisinopril 40 mg</td> <td>$4 to 10</td> </tr> <tr> <td rowspan=\"3\">Mental illness</td> <td>Risperdal&nbsp;1 mg</td> <td>$310</td> <td>Risperidone 1 mg</td> <td>$10 to 15</td> </tr> <tr> <td>Seroquel 100 mg</td> <td>$600</td> <td>Quetiapine 100 mg</td> <td>$20</td> </tr> <tr> <td>Zyprexa 10 mg</td> <td>$574</td> <td>Olanzapine 10 mg</td> <td>$13 to 20</td> </tr> <tr> <td rowspan=\"2\">Migraine</td> <td>Amerge 2.5 mg </td> <td>$529 for&nbsp;9 tablets </td> <td>Naratriptan 2.5 mg </td> <td>$36 for&nbsp;9 tablets</td> </tr> <tr> <td>Imitrex 100 mg</td> <td>$536 for 9 tablets</td> <td>Sumatriptan 100 mg</td> <td>$13 to 30&nbsp;for 9 tablets</td> </tr> <tr> <td rowspan=\"2\">Osteoporosis</td> <td>Boniva 150 mg</td> <td>$574 for 3 tablets</td> <td>Ibandronate 150 mg</td> <td>$44 to 100&nbsp;for 3 tablets</td> </tr> <tr> <td>Fosamax 70 mg</td> <td>$134 for 4 tablets</td> <td>Alendronate 70 mg</td> <td>$4 to 15&nbsp;for 4 tablets</td> </tr> <tr> <td rowspan=\"4\">Reflux, heartburn, stomach problems</td> <td> <p>Prilosec 20 mg</p> </td> <td> <p>$231</p> </td> <td> <p>Omeprazole 20 mg <strong>or</strong></p> <p>Prilosec OTC 20 mg&nbsp;(no prescription needed)</p> </td> <td>$4 to 20</td> </tr> <tr> <td>Nexium 20 mg</td> <td>$167 to 274</td> <td> <p>Esomeprazole 20 mg<strong> or</strong></p> <p>Nexium 24HR (no prescription needed)</p> </td> <td> <p>$41 to 100 (prescription)</p> <p>$16 (no prescription needed)</p> </td> </tr> <tr> <td>Prevacid&nbsp;15 mg</td> <td> <p>$432</p> </td> <td> <p>Lansoprazole&nbsp;15 mg <strong>or</strong></p> <p>Prevacid 24HR 15 mg (no prescription needed)</p> </td> <td> <p>$20 to&nbsp;70 (prescription)</p> <p>$20 (no prescription needed)</p> </td> </tr> <tr> <td>Pepcid 20 mg</td> <td>$10 to 115</td> <td> <p>Famotidine 20 mg <strong>or</strong></p> <p>Pepcid AC 20 mg (no prescription needed)</p> </td> <td> <p>$4 to&nbsp;15 (prescription)</p> <p>$7 to 15&nbsp;(no prescription needed)</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Medicine prices vary widely from one pharmacy to another. This list&nbsp;might be useful for comparing prices at different pharmacies&nbsp;to help you find lower prices on your medicines.</LI>&#xD;&#xA;<LI>These prices are from large retail pharmacy chain stores in the United States for prescriptions bought without insurance. Depending on which pharmacy you use, you may need a store club membership or a discount card to get prices like these. </LI>&#xD;&#xA;<LI>Generic versions of medicines can look different (in size, shape, and color) from the brand-name versions. If changing medicines, always learn what the new medicine should look like and which one it is replacing.</LI></UL></div><div class=\"graphic_reference\">Data from:&nbsp;GoodRx&nbsp;website. Available at: http://www.goodrx.com/. Accessed on&nbsp;July 5, 2017.&nbsp;</div><div id=\"graphicVersion\">Graphic 90835 Version 22.0</div></div></div>"},"90836":{"type":"graphic_figure","displayName":"Ligaments of the shoulder - Anterior view","title":"Ligaments of the shoulder: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Ligaments of the shoulder: Anterior view</div><div class=\"cntnt\"><img style=\"width:662px; height:610px;\" src=\"images/EM/90836_Lgmnt_shldr_Anterior_view.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 90836 Version 5.0</div></div></div>"},"90837":{"type":"graphic_figure","displayName":"Ligaments of the shoulder - Posterior view","title":"Ligaments of the shoulder: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Ligaments of the shoulder: Posterior view</div><div class=\"cntnt\"><img style=\"width:556px; height:554px;\" src=\"images/EM/90837_Ligament_shldr_Poster_view.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90837 Version 4.0</div></div></div>"},"90838":{"type":"graphic_figure","displayName":"Superficial muscles of the shoulder - Anterior view","title":"Superficial muscles of the shoulder: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the shoulder: Anterior view</div><div class=\"cntnt\"><img style=\"width:505px; height:690px;\" src=\"images/EM/90838_Sprfic_mscls_shldr_Antr_viw.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90838 Version 4.0</div></div></div>"},"90839":{"type":"graphic_figure","displayName":"Superficial muscles of the shoulder - Posterior view","title":"Superficial muscles of the shoulder: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Superficial muscles of the shoulder: Posterior view</div><div class=\"cntnt\"><img style=\"width:597px; height:686px;\" src=\"images/EM/90839_Sprfc_mscls_shldr_Pstr_view.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90839 Version 5.0</div></div></div>"},"90840":{"type":"graphic_figure","displayName":"Deep muscles of the shoulder - Anterior view","title":"Deep muscles of the shoulder: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Deep muscles of the shoulder: Anterior view</div><div class=\"cntnt\"><img style=\"width:520px; height:588px;\" src=\"images/EM/90840_Deep_muscles_sh_anterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90840 Version 4.0</div></div></div>"},"90841":{"type":"graphic_figure","displayName":"Deep muscles of the shoulder - Posterior view","title":"Deep muscles of the shoulder: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Deep muscles of the shoulder: Posterior view</div><div class=\"cntnt\"><img style=\"width:610px; height:588px;\" src=\"images/EM/90841_Deep_muscles_sh_posterior.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90841 Version 4.0</div></div></div>"},"90842":{"type":"graphic_picture","displayName":"Movements available to the scapulothoracic joint","title":"Movements available: Scapulothoracic joint","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Movements available: Scapulothoracic joint</div><div class=\"cntnt\"><img style=\"width:566px; height:561px;\" src=\"images/EM/90842_Movements_Scapulothoracic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Elevation.<br />(B) Depression.<br />(C) Retraction.<br />(D) Protraction.<br />(E) Upward rotation.<br />(F) Downward rotation.</div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90842 Version 5.0</div></div></div>"},"90843":{"type":"graphic_picture","displayName":"Movements available to the glenohumeral joint","title":"Movements available: Glenohumeral joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Movements available: Glenohumeral joint</div><div class=\"cntnt\"><img style=\"width:438px; height:646px;\" src=\"images/EM/90843_Movement_Glenohumeral_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Flexion.<br />(B) Extension.<br />(C) Abduction.<br />(D) Adduction.<br />(E) Internal rotation.<br />(F) External rotation.<br />(G) Horizontal abduction.<br />(H) Horizontal adduction.</div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90843 Version 4.0</div></div></div>"},"90844":{"type":"graphic_figure","displayName":"Synergists antagonists - Scapula","title":"Synergists/antagonists: Scapula","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">Synergists/antagonists: Scapula</div><div class=\"cntnt\"><img style=\"width:804px; height:637px;\" src=\"images/EM/90844_Synergists_antagon_scapula.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90844 Version 4.0</div></div></div>"},"90845":{"type":"graphic_figure","displayName":"Synergists antagonists - Shoulder","title":"Synergists/antagonists: Shoulder","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Synergists/antagonists: Shoulder</div><div class=\"cntnt\"><img style=\"width:808px; height:844px;\" src=\"images/EM/90845_Synergists_antagon_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90845 Version 4.0</div></div></div>"},"90846":{"type":"graphic_table","displayName":"Gene mutations in nephronophthisis","title":"Gene mutations and affected proteins linked to nephronophthisis and other associated syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gene mutations and affected proteins linked to nephronophthisis and other associated syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein</td> <td class=\"subtitle1\">Clinical features/syndrome</td> </tr> <tr> <td><em>NPHP1</em></td> <td>Nephrocystin-1</td> <td>NPH, SLS, JBTS</td> </tr> <tr> <td><em>NPHP2/INVS</em></td> <td>Inversin</td> <td>NPH, SLS, HF, situs inversus</td> </tr> <tr> <td><em>NPHP3</em></td> <td>Nephrocystin-3</td> <td>NPH, SLS, HF, MKS</td> </tr> <tr> <td><em>NPHP4</em></td> <td>Nephrocystin-4/Nephroretinin</td> <td>NPH, SLS</td> </tr> <tr> <td><em>NPHP5/IQCB1</em></td> <td>Nephrocystin-5/IQ motif containing B1</td> <td>NPH, SLS, LCA</td> </tr> <tr> <td><em>NPHP6/CEP290</em></td> <td>Centrosomal protein 290</td> <td>NPH, SLS, LCA, JBTS, MKS, </td> </tr> <tr> <td><em>NPHP7/GLIS2</em></td> <td>GLI similar 2</td> <td>NPH</td> </tr> <tr> <td><em>NPHP8/RPGRIP1L/MKS5</em></td> <td>RPGRIP1-like</td> <td>NPH, SLS, JBTS, MKS</td> </tr> <tr> <td><em>NPHP9/NEK8</em></td> <td>NIMA-related kinase 8</td> <td>NPH, SLS</td> </tr> <tr> <td><em>NPHP10/SDCCAG8/SLSN7</em></td> <td>Serologically defined colon cancer antigen 8</td> <td>NPH, SLS, BBS-like</td> </tr> <tr> <td><em>NPHP11/TMEM67/MKS3</em></td> <td>Transmembrane protein 67</td> <td>NPH, JBTS, MKS, HF</td> </tr> <tr> <td><em>NPHP12/TTC21B</em></td> <td>Intraflagellar transport protein 139</td> <td>NPH, JBTS, JATD, BBS</td> </tr> <tr> <td><em>NPHP13/WDR19</em></td> <td>WD repear domain 19/IFT protein 144</td> <td>NPH, JATD, SBS</td> </tr> <tr> <td><em>NPHP14/ZNF423</em></td> <td>Zing finger protein 423</td> <td>NPH, JBTS</td> </tr> <tr> <td><em>NPHP15/CEP164</em></td> <td>Centrosomal protein 164</td> <td>NPH, SLS, JBTS, BBS</td> </tr> <tr> <td><em>NPHPL1/XPNPEP3</em></td> <td>X-prolyl aminopeptidase 3</td> <td>NPH</td> </tr> <tr> <td><em>TMEM216/JBTS2/MKS2</em></td> <td>Tranbsmembrane protein 216</td> <td>NPH, JBTS, MKS</td> </tr> <tr> <td><em>AH11/JBTS3</em></td> <td>Jouberin</td> <td>NPH, JBTS</td> </tr> <tr> <td><em>CC2D2A/MKS6</em></td> <td>Coiled coil and C2 domain containing 2A</td> <td>NPH, JBTS, MKS</td> </tr> <tr> <td><em>ATXN10</em></td> <td>Ataxin 10</td> <td>NPH, JBTS, HF</td> </tr> <tr> <td><em>IFT43</em></td> <td>Intraflagellar transport protein 43</td> <td>NPH, SBS</td> </tr> <tr> <td><em>IFT122</em></td> <td>Intraflagellar transport protein 122</td> <td>NPH, SBS</td> </tr> <tr> <td><em>IFT140</em></td> <td>Intraflagellar transport protein 140</td> <td>NPH, JATD, SMS</td> </tr> <tr> <td><em>CEP41</em></td> <td>Centrosomal protein 41</td> <td>NPH, JBTS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPH: nephronophthisis; SLS: Senior-Loken syndrome; LCA: Leber's congenital amaurosis; JBTS: Joubert syndrome; HF: hepatic fibrosis; MKS: Meckel-Gruber syndrome; BBS: Bardet-Biedl syndrome; JATD: Jeune syndrome; SBS: Sensenbrenner syndrome; SMS: Saldino-Mainzer syndrome.</div><div id=\"graphicVersion\">Graphic 90846 Version 1.0</div></div></div>"},"90847":{"type":"graphic_table","displayName":"Trials of novel agents in advanced carcinoid tumors","title":"Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Molecular target(s)</td> <td class=\"subtitle1\">Patients*</td> <td class=\"subtitle1\">Objective tumor response rate (percent)</td> <td class=\"subtitle1\">Median TTP or PFS</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">VEGF pathway inhibitors</td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"><strong>Phase II studies</strong></td> </tr> <tr> <td class=\"indent2\">Bevacizumab</td> <td>VEGF</td> <td>22</td> <td>18<sup>&#182;</sup></td> <td>66 weeks</td> <td>Yao J; 2008<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">Sunitinib</td> <td>VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT; RET; CSF-1R; FLT3</td> <td>41</td> <td>2</td> <td>10.2 months (TTP)</td> <td>Kulke M; 2008<sup>[2]</sup></td> </tr> <tr> <td class=\"indent2\">Sorafenib</td> <td>VEGFR-2, PDGFR, FGFR-1, BRAF</td> <td>50</td> <td>7<sup>&#916;</sup></td> <td>7.8 months</td> <td>Hobday T; 2007<sup>[3]</sup></td> </tr> <tr> <td class=\"indent2\" rowspan=\"3\">Pazopanib</td> <td rowspan=\"3\">VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT</td> <td>22</td> <td>0</td> <td>12.7 months</td> <td>Phan AT; 2015<sup>[4]</sup></td> </tr> <tr> <td>15 (GI tract)</td> <td rowspan=\"2\">9</td> <td>10 months</td> <td rowspan=\"2\">Grande E; 2015<sup>[5]</sup></td> </tr> <tr> <td>7 (lung, thymus)</td> <td>3.4 months</td> </tr> <tr> <td class=\"indent2\">Cabozantinib</td> <td>VEGFR-2, MET, RET, AXL</td> <td>41</td> <td>15</td> <td>31.4 months</td> <td>Chan J; 2017<sup>[6]</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"><strong>Randomized trials</strong></td> </tr> <tr> <td class=\"indent2\">Octreotide + Bevacizumab</td> <td class=\"divider_bottom\" rowspan=\"3\">VEGF</td> <td>214</td> <td>12</td> <td>16.6&nbsp;(PFS)</td> <td class=\"divider_bottom\" rowspan=\"3\">Yao J; 2017 (SWOG S-0518)<sup>[7]</sup></td> </tr> <tr> <td class=\"indent3\">versus</td> <td colspan=\"3\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Octreotide + Interferon</td> <td>213</td> <td>4</td> <td>15.4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">mTOR inhibitors</td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"><strong>Phase II studies</strong></td> </tr> <tr> <td class=\"indent2\">Everolimus</td> <td>mTOR</td> <td>30</td> <td>17</td> <td>63 weeks</td> <td>Yao J; 2008<sup>[8]</sup></td> </tr> <tr> <td class=\"indent2\">Temsirolimus</td> <td>mTOR</td> <td>21</td> <td>5</td> <td>6 months</td> <td>Duran I; 2006<sup>[9]</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"6\"><strong>Randomized trials</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Everolimus + Octreotide LAR</td> <td>216</td> <td>2</td> <td>16.4 months</td> <td rowspan=\"3\">Pavel et al, 2011 (RADIANT2)<sup>[10]</sup></td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">versus</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Placebo + Octreotide LAR</td> <td>213</td> <td>2</td> <td>11.3 months</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Everolimus + BSC</td> <td>205</td> <td>2</td> <td>11.0 months</td> <td rowspan=\"3\">Yao J; 2016 (RADIANT4)<sup>&#9674;</sup><sup>[11]</sup></td> </tr> <tr> <td class=\"indent3\" colspan=\"5\">versus</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Placebo + BSC</td> <td>97</td> <td>1</td> <td>3.9 months</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF-1R: colony-stimulating factor receptor; EGFR: epidermal growth factor receptor; KIT: stem cell factor receptor; mTOR: mammalian target of rapamycin; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection or glial cell-line derived neurotrophic factor; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; PFS: progression-free survival; TTP: time to tumor progression; LAR: long acting release; BSC: best supportive care.<br />* Number of patients evaluable for efficacy endpoints.<br />&para; Patients also received treatment with octreotide.<br />&Delta; Confirmed.<br /><span class=\"lozenge\">&loz;</span> All patients had nonfunctioning neuroendocrine tumors of the lung or gastrointestinal origin.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Yao JC, Phan A, Hoff PM. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316.</LI>&#xD;&#xA;<LI>Kulke MH, Lenz HJ, Meropol NJ, et al, Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403.</LI>&#xD;&#xA;<LI>Hobday TJ, Rubin K, Holen J, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clinl Oncol 2007; 25:ASCO Annual Meeting Proceedings part I, abstract 4504.</LI>&#xD;&#xA;<LI>Phan AT, Halperin DM, Chan JA, et al, Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 2015; 16:695.</LI>&#xD;&#xA;<LI>Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol 2015; 26:1987.</LI>&#xD;&#xA;<LI>Chan J, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; suppl 4S: abstract 228.</LI>&#xD;&#xA;<LI>Yao JC, Guthrie KA, Moran C, et al.&nbsp;Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab&nbsp;in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35:1695.</LI>&#xD;&#xA;<LI>Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.</LI>&#xD;&#xA;<LI>Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148.</LI>&#xD;&#xA;<LI>Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.</LI>&#xD;&#xA;<LI>Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968.</LI></OL></div><div id=\"graphicVersion\">Graphic 90847 Version 11.0</div></div></div>"},"90848":{"type":"graphic_table","displayName":"CARG risk scores for predictive model of chemotherapy toxicity","title":"CARG risk scores for predictive model of chemotherapy toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CARG risk scores for predictive model of chemotherapy toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk factor</td> <td class=\"subtitle1\" colspan=\"2\">Prevalence</td> <td class=\"subtitle1\" colspan=\"2\">Grades 3 to 5 toxicity</td> <td class=\"subtitle1\" rowspan=\"2\">OR</td> <td class=\"subtitle1\" rowspan=\"2\">95% CI</td> <td class=\"subtitle1\" rowspan=\"2\">Score</td> </tr> <tr> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> </tr> <tr> <td>Age &#8805;72 years</td> <td class=\"centered\">270</td> <td class=\"centered\">54</td> <td class=\"centered\">163</td> <td class=\"centered\">60</td> <td class=\"centered\">1.85</td> <td class=\"centered\">1.22 to 2.82</td> <td class=\"centered\">2</td> </tr> <tr> <td>Cancer type GI or GU</td> <td class=\"centered\">185</td> <td class=\"centered\">37</td> <td class=\"centered\">120</td> <td class=\"centered\">65</td> <td class=\"centered\">2.13</td> <td class=\"centered\">1.39 to 3.24</td> <td class=\"centered\">2</td> </tr> <tr> <td>Chemotherapy dosing, standard dose</td> <td class=\"centered\">380</td> <td class=\"centered\">76</td> <td class=\"centered\">204</td> <td class=\"centered\">54</td> <td class=\"centered\">2.13</td> <td class=\"centered\">1.29 to 3.52</td> <td class=\"centered\">2</td> </tr> <tr> <td>No. of chemotherapy drugs, polychemotherapy</td> <td class=\"centered\">351</td> <td class=\"centered\">70</td> <td class=\"centered\">192</td> <td class=\"centered\">55</td> <td class=\"centered\">1.69</td> <td class=\"centered\">1.08 to 2.65</td> <td class=\"centered\">2</td> </tr> <tr> <td>Hemoglobin &#60;11 g/dL (male), &#60;10 g/dL (female)</td> <td class=\"centered\">62</td> <td class=\"centered\">12</td> <td class=\"centered\">46</td> <td class=\"centered\">74</td> <td class=\"centered\">2.31</td> <td class=\"centered\">1.15 to 4.64</td> <td class=\"centered\">3</td> </tr> <tr> <td>Creatinine clearance (Jelliffe, ideal weight) &#60;34 mL/min</td> <td class=\"centered\">44</td> <td class=\"centered\">9</td> <td class=\"centered\">34</td> <td class=\"centered\">77</td> <td class=\"centered\">2.46</td> <td class=\"centered\">1.11 to 5.44</td> <td class=\"centered\">3</td> </tr> <tr> <td>Hearing, fair or worse</td> <td class=\"centered\">123</td> <td class=\"centered\">25</td> <td class=\"centered\">76</td> <td class=\"centered\">62</td> <td class=\"centered\">1.67</td> <td class=\"centered\">1.04 to 2.69</td> <td class=\"centered\">2</td> </tr> <tr> <td>No. of falls in last 6 months, 1 or more</td> <td class=\"centered\">91</td> <td class=\"centered\">18</td> <td class=\"centered\">61</td> <td class=\"centered\">67</td> <td class=\"centered\">2.47</td> <td class=\"centered\">1.43 to 4.27</td> <td class=\"centered\">3</td> </tr> <tr> <td>IADL: Taking medications, with some help/unable</td> <td class=\"centered\">39</td> <td class=\"centered\">8</td> <td class=\"centered\">28</td> <td class=\"centered\">72</td> <td class=\"centered\">1.50</td> <td class=\"centered\">0.66 to 3.38</td> <td class=\"centered\">1</td> </tr> <tr> <td>MOS: Walking 1 block, somewhat limited/limited a lot</td> <td class=\"centered\">109</td> <td class=\"centered\">22</td> <td class=\"centered\">69</td> <td class=\"centered\">63</td> <td class=\"centered\">1.71</td> <td class=\"centered\">1.02 to 2.86</td> <td class=\"centered\">2</td> </tr> <tr> <td>MOS: Decreased social activity because of physical/emotional health, limited at least sometimes</td> <td class=\"centered\">218</td> <td class=\"centered\">44</td> <td class=\"centered\">126</td> <td class=\"centered\">58</td> <td class=\"centered\">1.36</td> <td class=\"centered\">0.90 to 2.06</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CARG: Cancer and Aging Research Group; GU: genitourinary; IADL: instrumental activities of daily living; MOS: Medical Outcomes Study; OR: odds ratio.</div><div class=\"graphic_reference\">From: Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29(25):3457-65. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90848 Version 1.0</div></div></div>"},"90849":{"type":"graphic_figure","displayName":"Ability of CARG risk score predict chemo tox","title":"Ability of CARG risk score to predict grade 3-5 chemotherapy toxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ability of CARG risk score to predict grade 3-5 chemotherapy toxicity</div><div class=\"cntnt\"><img style=\"width:314px; height:385px;\" src=\"images/ONC/90849_Ability_CARG_risk_score.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CARG: Cancer and Aging Research Group; %: percent.</div><div class=\"graphic_reference\">From: Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29(25):3457-65. Reprinted with permission. Copyright © 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 90849 Version 1.0</div></div></div>"},"90851":{"type":"graphic_picture","displayName":"Molluscum contagiosum PI","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:432px; height:269px;\" src=\"images/DERM/90851_Molluscum_contagiosum_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with molluscum contagiosum develop small, dome-shaped bumps with a dimple in the center.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 90851 Version 1.0</div></div></div>"},"90853":{"type":"graphic_diagnosticimage","displayName":"Echo 3D right ventricle","title":"Echo 3D right ventricle","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Echo 3D right ventricle</div><div class=\"cntnt\"><img style=\"width:551px; height:514px;\" src=\"images/CARD/90853_Echo_3d_right_ventricl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Starting from a full-volume acquisition, the RV endocardial border is semi-automatically contoured in orthogonal planes (panels A, B, and C) and, using a surface modelling algorithm, a 3-dimensional volumetric representation of the RV is generated (panel D). Global and regional RV-end diastolic and end-systolic volumes are reported, along with RV ejection fraction.</div><div class=\"graphic_footnotes\">RV: right ventricular.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2013 TomTec Imaging Systems Corp.</div><div id=\"graphicVersion\">Graphic 90853 Version 3.0</div></div></div>"},"90862":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation of a thyroid nodule","title":"Initial evaluation of a patient with a thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial evaluation of a patient with a thyroid nodule</div><div class=\"cntnt\"><img style=\"width:405px; height:423px;\" src=\"images/ENDO/90862_Algoevalthyroidnodule.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to be used in conjunction with additional UpToDate content on thyroid nodules.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; FT4: free thyroxine; T3: triiodothyronine; FNA: fine-needle aspiration.<br />* Patients with TSH above the normal range require an evaluation for hypothyroidism. Refer to UpToDate content on hypothyroidism.<br />¶ Patients with TSH below the normal range require an evaluation for hyperthyroidism. Refer to UpToDate content on hyperthyroidism.<br />Δ Thyroid nodules that do not meet sonographic criteria for FNA should be monitored with periodic ultrasonography. The frequency of evaluation (ranging from 6 to 24 months) depends upon the sonographic features of the nodules.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate content on subclinical hyperthyroidism and toxic adenoma.</div><div id=\"graphicVersion\">Graphic 90862 Version 3.0</div></div></div>"},"90863":{"type":"graphic_algorithm","displayName":"Management of thyroid nodules based on FNA results","title":"Management of thyroid nodules based upon results of fine-needle aspiration","html":"<div class=\"graphic\"><div style=\"width: 876px\" class=\"figure\"><div class=\"ttl\">Management of thyroid nodules based upon results of fine-needle aspiration</div><div class=\"cntnt\"><img style=\"width:856px; height:780px;\" src=\"images/ENDO/90863_AlgmgmtthyndbsFNAEdt1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FNA: fine needle aspiration; AUS: atypical cells of undetermined significance; FLUS: follicular lesion of undetermined significance; TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 90863 Version 7.0</div></div></div>"},"90873":{"type":"graphic_figure","displayName":"Coagulation cascade overview","title":"Coagulation cascade overview","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coagulation cascade overview</div><div class=\"cntnt\"><img style=\"width:255px; height:411px;\" src=\"images/HEME/90873_Coagulation_cascade_revised.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic shows a revised version of the coagulation cascade that emphasizes the importance of pathways for hemostasis in vivo. Tissue factor exposed at a wound interacts with factor VIIa and initiates clotting by two pathways: (1) activaton of factor X to Xa (ie, the extrinsic ten-ase complex) and (2) conversion of factor IX to IXa, which activates factor X to Xa (ie, the intrinsic ten-ase complex). Pathways 1 and 2 are equally important.<br />In a third pathway (3), thrombin also activates factor XI to XIa, which can lead to further generation of factor IXa;&nbsp;it serves as an amplification pathway&nbsp;is required during severe hemostatic challenges.<br />Coagulation factors are shown as Roman numerals. Only the activated forms (with the suffix \"a\") are shown in this diagram for simplicity. Thrombin is also known as factor IIa.</div><div id=\"graphicVersion\">Graphic 90873 Version 6.0</div></div></div>"},"90878":{"type":"graphic_figure","displayName":"Criteria for squamous cell carcinoma","title":"Dermoscopic criteria for squamous cell carcinoma: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup>","html":"<div class=\"graphic\"><div style=\"width: 641px\" class=\"figure\"><div class=\"ttl\">Dermoscopic criteria for squamous cell carcinoma: Dermoscopic structures and histopathologic correlation<sup>[1-4]</sup></div><div class=\"cntnt\"><img style=\"width:621px; height:621px;\" src=\"images/DERM/90878_Crit_squamous_cell_carcinom.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cameron A, Rosendahl C, Tschandl P, et al. Dermatoscopy of pigmented Bowen's disease. J Am Acad Dermatol 2010; 62:597.</li>&#xD;&#xA;    <li>Jaimes N, Zalaudek I, Braun RP, et al. Pearls of keratinizing tumors. Arch Dermatol 2012; 148:976.</li>&#xD;&#xA;    <li>Rosendahl C, Cameron A, Argenziano G, et al. Dermoscopy of squamous cell carcinoma and keratoacanthoma. Arch Dermatol 2012; 148:1386.</li>&#xD;&#xA;    <li>Zalaudek I, Giacomel J, Schmid K, et al. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol 2012; 66:589.</li>&#xD;&#xA;    <li>Cuellar F, Vilalta A, Puig S, et al. New dermoscopic pattern in actinic keratosis and related conditions. Arch Dermatol 2009; 145:732.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 90878 Version 2.0</div></div></div>"},"90879":{"type":"graphic_picture","displayName":"Lymphocytic cytologic atypia","title":"Mycosis fungoides: Lymphocytic cytologic atypia","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides: Lymphocytic cytologic atypia</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/90879_Lymphocytic_cytologic_atypi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In mycosis fungoides, numerous enlarged lymphocytes with hyperchromatic, cerebriform nuclei invade the epidermis. The yellow arrow highlights a normal, reactive lymphocyte for comparison.</div><div id=\"graphicVersion\">Graphic 90879 Version 1.0</div></div></div>"},"90880":{"type":"graphic_picture","displayName":"Allergic contact dermatitis histo","title":"Histologic features of allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histologic features of allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:585px; height:438px;\" src=\"images/DERM/90880_Allergic_contact_derm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In contrast with mycosis fungoides, this biopsy of allergic contact dermatitis demonstrates extensive spongiosis and lymphocytic exocytosis. The lymphocytes lack cytologic atypia and there are scattered eosinophils within the dermal infiltrate.</div><div id=\"graphicVersion\">Graphic 90880 Version 1.0</div></div></div>"},"90881":{"type":"graphic_picture","displayName":"Mycosis fungoides histo","title":"Histologic features of mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Histologic features of mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:573px; height:429px;\" src=\"images/DERM/90881_Mycosis_fungoides_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mycosis fungoides. Hyperchromatic lymphocytes with irregular nuclear contours and surrounding haloes align along the dermal-epidermal junction and invade the epidermis with minimal associated spongiosis. Focally, the intraepidermal lymphocytes form small clusters called \"Pautrier's microabscesses.\"</div><div id=\"graphicVersion\">Graphic 90881 Version 1.0</div></div></div>"},"90882":{"type":"graphic_picture","displayName":"Cutaneous B cell lymphoma histo","title":"Histologic features of cutaneous B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Histologic features of cutaneous B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:572px; height:530px;\" src=\"images/DERM/90882_Cutan_B_cell_lymphoma_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this primary cutaneous follicle center lymphoma, the lymphocytic infiltrate is poorly circumscribed and \"bottom heavy.\"</div><div id=\"graphicVersion\">Graphic 90882 Version 1.0</div></div></div>"},"90883":{"type":"graphic_picture","displayName":"B cell pseudolymphoma","title":"B cell pseudolymphoma (cutaneous lymphoid hyperplasia)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">B cell pseudolymphoma (cutaneous lymphoid hyperplasia)</div><div class=\"cntnt\"><img style=\"width:408px; height:306px;\" src=\"images/DERM/90883_Allergic_contact_derm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">B cell pseudolymphoma. This thick bite reaction demonstrates a dense, relatively well-circumscribed, and \"top-heavy\" infiltrate with numerous reactive germinal centers.</div><div id=\"graphicVersion\">Graphic 90883 Version 1.0</div></div></div>"},"90884":{"type":"graphic_diagnosticimage","displayName":"US nonpalpable recurrent papillary thyroid carcinoma","title":"Thyroid ultrasound of a nonpalpable recurrent papillary thyroid carcinoma","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound of a nonpalpable recurrent papillary thyroid carcinoma</div><div class=\"cntnt\"><img style=\"width:549px; height:221px;\" src=\"images/ENDO/90884_US_nonpalp_rec_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) An example of an abnormal lymph node demonstrating a round, heterogeneous appearance with no fatty hilum.<br />(Panel B) An example of an abnormal lymph node demonstrating a rounded structure with peripheral vascularity.</div><div class=\"graphic_reference\">Courtesy of Dr. Stephanie Fish, Endocrinology Service, Memorial Sloan-Kettering Cancer Center, New York.</div><div id=\"graphicVersion\">Graphic 90884 Version 1.0</div></div></div>"},"90887":{"type":"graphic_figure","displayName":"Anatomy of the cornea","title":"Anatomy of the cornea","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Anatomy of the cornea</div><div class=\"cntnt\"><img style=\"width:474px; height:618px;\" src=\"images/EM/90887_Anatomy_of_the_cornea.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90887 Version 2.0</div></div></div>"},"90888":{"type":"graphic_waveform","displayName":"EPS tracing atrial tachycardia onset and termination","title":"Electrophysiology study (EPS) tracing showing atrial tachycardia onset and termination","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracing showing atrial tachycardia onset and termination</div><div class=\"cntnt\"><img style=\"width:585px; height:506px;\" src=\"images/CARD/90888_EPS_trac_onset_termination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From top to bottom, surface ECG leads I, II, III, and VI and intracardiac recordings in the high right atrium (2 leads) and His bundle, obtained during electrophysiologic study performed in a 79-year-old with an incessant atrial tachycardia with a rate of 130 beats per minute. This figure shows that a tachychycardia similar to the spontaneous tachycardia could be induced using programmed electrical stimulation with one stimulus (St) and terminated with one stimulus, which favors a reentrant mechanism. This tachycardia was successfully ablated by detecting the earliest atrial activation in reference to the onset or the P wave on the surface ECG. Note during the tachycardia that the QRS complexes are preceded (lead II) by a P wave with a configuration different of that of the sinus P wave (last beat).</div><div id=\"graphicVersion\">Graphic 90888 Version 1.0</div></div></div>"},"90889":{"type":"graphic_figure","displayName":"3D echo automated segmentation heart chambers","title":"Three-dimensional echocardiography (3D echo) showing automated segmentation of the heart chambers","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) showing automated segmentation of the heart chambers</div><div class=\"cntnt\"><img style=\"width:503px; height:523px;\" src=\"images/CARD/90889_Automated_3D_segment_heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The technique for fully-automated segmentation of the 3D echocardiographic images allows identification of the boundaries of the four cardiac chambers, resulting in accurate volume measurements.</div><div id=\"graphicVersion\">Graphic 90889 Version 1.0</div></div></div>"},"90890":{"type":"graphic_figure","displayName":"3D echo MV","title":"Three-dimensional echocardiography (3D echo) of the mitral valve (MV) and analysis of its shape and function","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) of the mitral valve (MV) and analysis of its shape and function</div><div class=\"cntnt\"><img style=\"width:622px; height:449px;\" src=\"images/CARD/90890_3D_view_mitral_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mitral valve as viewed from the atrial perspective in a patient with mitral prolapse due to a flail posterior leaflet (top, center). A parametric model of the valve with the height of the leaflets relative to the annular plane encoded in color (bottom, center) clearly depicts the prolapsing P2 scallop. A variety of parameters of valvular geometry can be obtained automatically, including annular area and dimensions, annular height, mitral-aortic angle, and the coaptation zone.</div><div id=\"graphicVersion\">Graphic 90890 Version 1.0</div></div></div>"},"90891":{"type":"graphic_diagnosticimage","displayName":"3D echo tricuspid valve","title":"Three-dimensional echocardiography (3D echo) of the tricuspid valve","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Three-dimensional echocardiography (3D echo) of the tricuspid valve</div><div class=\"cntnt\"><img style=\"width:585px; height:302px;\" src=\"images/CARD/90891_3D_echocardiogr_tricusp_val.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic transthoracic 3D echocardiographic images of the tricuspid valve from the right ventricular (left) and right atrial (right) perspectives.</div><div class=\"graphic_footnotes\">A: anterior leaflet; P: posterior leaflet; S: septal leaflet.</div><div id=\"graphicVersion\">Graphic 90891 Version 1.0</div></div></div>"},"90894":{"type":"graphic_diagnosticimage","displayName":"3D TEE transcatheter closure paravalvular leak","title":"Three-dimensional transesophageal echocardiography (3D TEE) performed during transcatheter closure of a paravalvular leak","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Three-dimensional transesophageal echocardiography (3D TEE) performed during transcatheter closure of a paravalvular leak</div><div class=\"cntnt\"><img style=\"width:508px; height:669px;\" src=\"images/CARD/90894_Transcath_clos_paraval_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">3D TEE images obtained during transcatheter closure of a paravalvular leak in a patient with a prosthetic mitral valve, highlighting the value of real-time imaging-based guidance of interventional procedures. After identification of the position and size of the leak (top panels), 3D images were used to guide the placement of the catheter wire (middle panels) to allow successful closure using an Amplatzer device (bottom panels).</div><div id=\"graphicVersion\">Graphic 90894 Version 1.0</div></div></div>"},"90898":{"type":"graphic_picture","displayName":"Buruli ulcer axilla","title":"Buruli ulcer - Axilla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buruli ulcer - Axilla</div><div class=\"cntnt\"><img style=\"width:245px; height:200px;\" src=\"images/ID/90898_Buruli_ulcer_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eight-year-old boy from Ghana with healed Buruli ulcer located near axilla, after surgery; mild limitation in mobility of right shoulder joint.</div><div class=\"graphic_reference\">Courtesy of Tjip S van der Werf, MD, PhD, and Ymkje Stienstra, MD, PhD.</div><div id=\"graphicVersion\">Graphic 90898 Version 1.0</div></div></div>"},"90899":{"type":"graphic_picture","displayName":"Buruli ulcer hand","title":"Buruli ulcer - Hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buruli ulcer - Hand</div><div class=\"cntnt\"><img style=\"width:345px; height:257px;\" src=\"images/ID/90899_Buruli_ulcer_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ten-year-old girl from Democratic Republic of Congo with healed Buruli ulcer on dorsum of the left hand; contracture resulted in functional limitation.</div><div class=\"graphic_reference\">Courtesy of Tjip S van der Werf, MD, PhD, and Ymkje Stienstra, MD, PhD.</div><div id=\"graphicVersion\">Graphic 90899 Version 1.0</div></div></div>"},"90900":{"type":"graphic_table","displayName":"Anal cancer populations","title":"Populations at increased risk of anal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Populations at increased risk of anal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>HIV-positive men and women</td> </tr> <tr> <td>Men who have sex with men</td> </tr> <tr> <td>Iatrogenic immunosuppression (eg, solid organ transplant recipients, long term oral corticosteroids)</td> </tr> <tr> <td>Women with a history of high-grade cervical, vulvar, vaginal dysplasia or cancer</td> </tr> <tr> <td>Individuals with a history of anal warts</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90900 Version 1.0</div></div></div>"},"90901":{"type":"graphic_table","displayName":"Preparative regimens HCT","title":"Common preparative regimens for hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common preparative regimens for hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"33%\" colspan=\"3\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Myeloablative regimens</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">A myeloablative regimen is expected to destroy the hematopoietic cells in the bone marrow and result in profound pancytopenia within one to three weeks from the time of administration. Suppression of the host's immune system is also important to prevent graft rejection. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells.</td> </tr> <tr> <td class=\"indent1\">BEAM</td> <td>The BEAM regimen combines carmustine (BCNU, 300 mg/m<sup>2</sup>) over one day, etoposide (400 to 800 mg/m<sup>2</sup>) over four days, cytosine arabinoside (800 to 1600 mg/m<sup>2</sup>) over four days, and melphalan (140 mg/m<sup>2</sup>) over one day</td> <td>BEAM is the most commonly employed myeloablative preparative regimen for patients with non-Hodgkin or Hodgkin lymphoma.</td> </tr> <tr> <td class=\"indent1\">Cy/TBI</td> <td>The Cy/TBI regimen combines cyclophosphamide 120 mg/kg total dose administered over two days with total body irradiation (TBI, 12 to 14 Gy) administered over four days</td> <td>TBI/Cy is an alternative where the TBI is given first, followed by cyclophosphamide. Other regimens include etoposide (60 mg/kg) instead of cyclophosphamide or in addition to cyclophosphamide for patients with advanced disease not in remission.</td> </tr> <tr> <td class=\"indent1\">Bu4/Cy</td> <td>The Bu4/Cy regimen combines intravenous busulfan 12.8 mg/kg total dose administered over four days with cyclophosphamide 120 mg/kg administered over two days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;Flu/Bu4</td> <td>The Flu/Bu4 regimen combines intravenous busulfan 12.8 mg/kg total dose with fludarabine 120 to 180 mg/m<sup><span style=\"font-size: 13px;\">2</span></sup>, each administered over four days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">High dose melphalan</td> <td>Melphalan (200 mg/m<sup>2</sup>)</td> <td>Commonly employed as the preparative regimen prior to autologous HCT for multiple myeloma. A lower dose is used in older patients (ie, &#62;70 years), those with renal dysfunction, or patients with multiple comorbidities.</td> </tr> <tr> <td class=\"indent1\">CVP</td> <td>The CVP regimen combines a single dose of carmustine (300 to 500 mg/m<sup>2</sup>) followed by both etoposide (600 to 2400 mg/m<sup>2</sup>) and cyclophosphamide (4.8 to 7.2 g/m<sup>2</sup>) administered over four days</td> <td>Commonly employed as a preparative regimen for patients with lymphoma undergoing autologous transplant.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Reduced intensity regimens</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Reduced intensity conditioning regimens are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenias, which may be prolonged and result in significant morbidity and mortality, and require hematopoietic stem cell support. These regimens are tailored to suppress the host's immune system to allow engraftment.</td> </tr> <tr> <td class=\"indent1\">Flu/Mel</td> <td>Fludarabine (125 to150 mg/m<sup>2</sup> total dose) administered over five days with melphalan (140 mg/m<sup>2</sup>) administered over two days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Flu/Bu2 and Flu/Bu3</td> <td>Fludarabine (150 to 160 mg/m<sup>2</sup> total dose) administered over four to five days with oral busulfan (8 to 10 mg/kg) administered over two to three days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Flu/Cy</td> <td>Fludarabine (150 to 180 mg/m<sup>2</sup> total dose) administered over five to six days with cyclophosphamide (120 to 140 mg/kg) administered over two days</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Flu/Bu3/TT</td> <td>Fludarabine 150 mg/m<sup>2</sup> total dose administered over three days with busulfan (8 mg/kg) administered over three days and thiotepa (5 to 10 mg/m<sup>2</sup>) over&nbsp;one to&nbsp;two days, respectively</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nonmyeloablative regimens</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">A nonmyeloablative regimen is one that will cause minimal cytopenia (but significant lymphopenia) by itself and does not require stem cell support. However, the transplant, when given in this setting, usually becomes myeloablative because the engrafting donor T cells will eventually eliminate host hematopoietic cells, allowing the establishment of donor hematopoiesis.</td> </tr> <tr> <td class=\"indent1\">Flu/TBI</td> <td>Fludarabine 90 mg/m<sup>2</sup> total dose administered over three days with low dose total body irradiation (TBI, 2 Gy) administered on the day of graft infusion</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">TLI/ATG</td> <td>Total lymphoid irradiation (TLI, 8 to 12 cGy) administered over 11 days with anti-thymocyte globulin (ATG; 1.25 mg/kg) administered over five days</td> <td>TLI and anti-thymocyte globulin appear to alter the host immune profile to favor regulatory natural killer T cells that suppress GVHD but retain graft antitumor activity.</td> </tr> <tr> <td class=\"indent1\">Low dose TBI</td> <td>Low dose TBI can be administered at a dose of 1 to 2 Gy on the day of graft infusion</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation; GVHD: graft-versus-host disease.</div><div id=\"graphicVersion\">Graphic 90901 Version 4.0</div></div></div>"},"90907":{"type":"graphic_picture","displayName":"Classic PCMZL","title":"Classic primary cutaneous marginal zone lymphoma","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Classic primary cutaneous marginal zone lymphoma</div><div class=\"cntnt\"><img style=\"width:514px; height:432px;\" src=\"images/HEME/90907_Classic_PCMZL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A superficial and deep, perivascular and periadnexal, dermal lymphoplasmacytic infiltrate is present with scattered follicles sometimes with CD10&ndash;, BCL6+ germinal centers and IgM+, IgD+ (not shown) mantle zones and a more polymorphous-appearing interfollicular proliferation.<br />(B) The more polymorphous-appearing interfollicular proliferation includes plasma cells at the periphery.<br />(C) Immunohistochemical stains demonstrated CD20+ B cells concentrated in the follicles.<br />(D) Immunohistochemical stains demonstrated numerous CD3+ T cells, clearly predominating in the interfollicular regions.</div><div class=\"graphic_reference\">Reproduced with permission from: Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-Cell Lymphoproliferative Disorders: Report of the 2011 Society for Hematopathology/European Association for Haematopathology Workshop. Am J Clin Pathol 2013; 139:515. Copyright © 2013 American Society for Clinical Pathology, American Journal of Clinical Pathology.</div><div id=\"graphicVersion\">Graphic 90907 Version 1.0</div></div></div>"},"90908":{"type":"graphic_table","displayName":"DDx primary cutaneous B cell lymphomas","title":"Differential diagnosis of primary cutaneous B cell lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of primary cutaneous B cell lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Entity</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Immunophenotype</td> <td class=\"subtitle1\">Genetic features/other</td> </tr> <tr> <td>Primary cutaneous marginal zone lymphoma</td> <td>Red to violaceous papules, plaques, or nodules localized preferentially on the trunk, upper extremities, or head/neck. Multifocal lesions are common. Ulceration is rare. No evidence of internal or nodal involvement at the time of diagnosis.</td> <td>Nodular to diffuse infiltrates with sparing of the epidermis. Infiltrate comprised of small to medium sized lymphocytes, often with a plasmacytoid appearance.</td> <td>Monotypic cytoplasmic immunoglobin (Ig). The neoplastic cells express CD20, CD22, CD79a, and BCL2 and are typically negative for CD3, CD5, CD10, and BCL6.</td> <td>No single cytogenetic change is typical or diagnostic</td> </tr> <tr> <td>Primary cutaneous follicle center lymphoma</td> <td>Solitary or grouped firm erythematous, painless, nonpruritic papules, plaques, or tumors with a predilection for the head, neck, and trunk. Ulceration is rare. No evidence of internal or nodal involvement at the time of diagnosis.</td> <td>The lesions are composed of predominantly medium-sized and large centrocytes (large cleaved follicle center cells) and variable proportions of centroblasts (large follicle center cells with prominent nucleoli). Growth can be in a follicular, follicular and diffuse, or diffuse pattern.</td> <td>All cases express pan B cell antigens (CD19, CD20, CD79a), but are usually&nbsp;Ig negative&nbsp;and always CD5 negative. All cases express BCL-6 and most do not express BCL-2. Monotypic surface Ig or surface Ig negative.</td> <td>No single cytogenetic change is typical or diagnostic</td> </tr> <tr> <td>Primary cutaneous diffuse large B cell lymphoma, leg type</td> <td>Red or bluish nodules or tumors on one or both legs, preferentially the lower legs. No evidence of internal or nodal involvement at the time of diagnosis.</td> <td>Skin biopsy specimens are characterized by a diffuse non-epidermotropic infiltrate, which often extends into the subcutaneous tissue. These infiltrates generally show a monotonous population or large confluent sheets of centroblasts (large follicle center cells with round nuclei and prominent nucleoli) and immunoblasts that spare the epidermis. Frequent mitoses are seen.</td> <td>The neoplastic cells express B cell markers (eg, CD19, CD20, CD22, and CD79a) and may express cytoplasmic IgM (and IgD) and monotypic Ig light chains. Expression of Bcl-2, Mum1, FOXP1, and MYC proteins are common.&nbsp;Bcl-6 is frequently positive. </td> <td>No single cytogenetic change is typical or diagnostic</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90908 Version 3.0</div></div></div>"},"90913":{"type":"graphic_picture","displayName":"PCFCL","title":"Primary cutaneous follicle center lymphoma","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous follicle center lymphoma</div><div class=\"cntnt\"><img style=\"width:491px; height:325px;\" src=\"images/HEME/90913_PCFCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clustered plum-colored nodules covered by thinned, glistening epidermal layer.<br />(B) Scanning magnification showing coalescent nodules forming follicle-like architecture.<br />(C) Higher magnification of malignant centrocytes and centroblasts.<br />(D) One-micron, toluidine blue-stained section showing cytologic features of centrocytes and centroblasts.</div><div class=\"graphic_reference\">Reproduced with permission from: Hsu M, Murphy GF. Cutaneous lymphomas and leukemias. In: Lever's Histopathology of the Skin, 10th ed, Elder DE (Ed). Lippincott, Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90913 Version 5.0</div></div></div>"},"90914":{"type":"graphic_picture","displayName":"PCFCL diffuse growth pattern","title":"Primary cutaneous follicle center lymphoma (PCFCL) with a diffuse growth pattern","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous follicle center lymphoma (PCFCL) with a diffuse growth pattern</div><div class=\"cntnt\"><img style=\"width:513px; height:433px;\" src=\"images/HEME/90914_PCFCL_diff_grw_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">PCFCL with a diffuse growth pattern in a 62-year-old woman with a 5 mm pearly scalp papule of 3 months' duration.<br />(A) A large mass of lymphocytes extends diffusely from the upper reticular dermis to the subcutaneous tissue.<br />(B) The lymphocytes are predominantly large centrocytes with some centroblasts. Some of the cells appear spindled.<br />(C) They express BCL6 and lack CD10 (not shown).<br />(D) Immunostaining for CD21 revealed very focal small remnants of follicular dendritic cell meshworks.</div><div class=\"graphic_reference\">Reproduced with permission from: Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-Cell Lymphoproliferative Disorders: Report of the 2011 Society for Hematopathology/European Association for Haematopathology Workshop. Am J Clin Pathol 2013; 139:515. Copyright © 2013 American Society for Clinical Pathology, American Journal of Clinical Pathology.</div><div id=\"graphicVersion\">Graphic 90914 Version 1.0</div></div></div>"},"90915":{"type":"graphic_picture","displayName":"DLBCL leg type subcutaneous mass","title":"Primary cutaneous diffuse large B cell lymphoma (DLBCL), leg type, subcutaneous mass","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous diffuse large B cell lymphoma (DLBCL), leg type, subcutaneous mass</div><div class=\"cntnt\"><img style=\"width:513px; height:432px;\" src=\"images/HEME/90915_DLBCL_leg_typ_sbct_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">DLBCL, leg type, occurring predominantly as a subcutaneous mass at a non-leg site in an 89-year-old woman with history of diffuse large B cell lymphoma (DLBCL) involving the dermis/subcutaneous tissue of the left shoulder two years earlier, presented with a slow growing 6 cm subcutaneous mass.<BR>(A) Localized on positron emission tomography/computed tomography scan to the right lower abdominal wall.<BR>(B) A diffuse monotonous proliferation of large lymphocytes with a centroblast-like or rarely immunoblastic appearance.<BR>(C) The tumor cells strongly express BCL2.<BR>(D) The tumor cells strongly express IRF4/ MUM1.<BR>The tumor cells only focally express BCL6 and lack CD10 (not shown). This immunophenotype was the same as the earlier DLBCL; fluorescence in situ hybridization demonstrated a complex karyotype (not shown) with multiple MYC signals (also present in the earlier DLBCL). The patient was treated with rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin (vincristine), and prednisone or prednisolone (R-CHOP) and was in complete remission at 15 months' follow-up.</div><div class=\"graphic_reference\">Reproduced with permission from: Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-Cell Lymphoproliferative Disorders: Report of the 2011 Society for Hematopathology/European Association for Haematopathology Workshop. Am J Clin Pathol 2013; 139:515. Copyright © 2013 American Society for Clinical Pathology, American Journal of Clinical Pathology.</div><div id=\"graphicVersion\">Graphic 90915 Version 1.0</div></div></div>"},"90916":{"type":"graphic_table","displayName":"Hemodynamic measurements portal hypertension","title":"Hemodynamic measurements in patients with intrahepatic causes of portal hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic measurements in patients with intrahepatic causes of portal hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Hemodynamic measurement</td> <td class=\"subtitle1\" colspan=\"3\">Site of resistance to portal blood flow</td> </tr> <tr> <td class=\"subtitle2\">Pre-sinusoidal</td> <td class=\"subtitle2\">Sinusoidal</td> <td class=\"subtitle2\">Post-sinusoidal</td> </tr> <tr> <td>FHVP</td> <td>Normal</td> <td>Normal</td> <td>Increased</td> </tr> <tr> <td>WHVP</td> <td>Normal or slightly increased</td> <td>Increased</td> <td>Increased</td> </tr> <tr> <td>HVPG* (WHVP &ndash; FHVP)</td> <td>Normal or slightly increased</td> <td>Increased</td> <td>Normal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FHVP: free hepatic venous pressure; HVPG: hepatic venous pressure gradient; WHVP: wedged hepatic venous pressure.<br />* Normally, the HVPG is &le;5 mmHg. Values between 6 and 9 mmHg are associated with \"subclinical\" portal hypertension, whereas values &ge;10 mmHg are associated with the complications of portal hypertension (eg, varices, ascites).</div><div id=\"graphicVersion\">Graphic 90916 Version 2.0</div></div></div>"},"90917":{"type":"graphic_figure","displayName":"Muscles of the face - Lateral view of oral and buccal regions","title":"Muscles of the face: Lateral view of oral and buccal regions","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Muscles of the face: Lateral view of oral and buccal regions</div><div class=\"cntnt\"><img style=\"width:626px; height:334px;\" src=\"images/EM/90917_Facelatervieworalbuccal.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Not muscles of facial expression.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90917 Version 5.0</div></div></div>"},"90918":{"type":"graphic_figure","displayName":"Muscles of the face - Anterior view","title":"Muscles of the face: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Muscles of the face: Anterior view</div><div class=\"cntnt\"><img style=\"width:620px; height:624px;\" src=\"images/EM/90918_Musclesfaceanteriorview.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Not muscles of facial expression.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90918 Version 5.0</div></div></div>"},"90919":{"type":"graphic_figure","displayName":"Muscles of the face - Lateral view","title":"Muscles of the face: Lateral view","html":"<div class=\"graphic\"><div style=\"width: 658px\" class=\"figure\"><div class=\"ttl\">Muscles of the face: Lateral view</div><div class=\"cntnt\"><img style=\"width:638px; height:506px;\" src=\"images/EM/90919_Musclesfacelateralview.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Not muscles of facial expression.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 90919 Version 6.0</div></div></div>"},"90920":{"type":"graphic_table","displayName":"Topical ophthalmologic medications for corneal abrasion","title":"Topical ophthalmologic medications for corneal abrasion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical ophthalmologic medications for corneal abrasion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Brand&nbsp;name(s)</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical antibiotics*</td> </tr> <tr> <td class=\"indent1\">Erythromycin 0.5% ophthalmic ointment</td> <td>Ilotycin, Romycin, Diomycin </td> <td>0.5 inch (1.25 cm) ribbon, four times per day for three to five days</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-polymyxin B 0.1%-10,000 units/mL ophthalmic solution</td> <td>Polytrim, PMS-Polytrimethoprim</td> <td>1 drop, four times per day for three to five days</td> </tr> <tr> <td class=\"indent1\">Sulfacetamide 10% ophthalmic ointment<sup>&#182;</sup></td> <td>Generic only</td> <td>0.5 inch (1.25 cm) ribbon, four times per day for three to five days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sulfacetamide 10% ophthalmic solution<sup>&#182;</sup></td> <td>Bleph-10, Diasulf, Sulamyd</td> <td>1 to 2 drops, four times per day for three to five days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipseudomonal topical antibiotics* (preferred in contact lens wearers)</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 0.3% ophthalmic ointment</td> <td>Ciloxan, Ciprodar&nbsp;ointment</td> <td>0.5 inch (1.25 cm) ribbon, four times per day for three to five days</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 0.3% ophthalmic solution</td> <td>Ciloxan, Ciprodar&nbsp;solution</td> <td>1 to 2 drops, four times per day for three to five days</td> </tr> <tr> <td class=\"indent1\">Ofloxacin 0.3% ophthalmic solution</td> <td>Ocufloxm Exocin</td> <td>1 to 2 drops, four times per day for three to five days</td> </tr> <tr> <td class=\"indent1\">Tobramycin 0.3% ophthalmic ointment</td> <td>Tobrex, Tobral&nbsp;</td> <td>0.5 inch (1.25 cm) ribbon, two to three times per day for three to five days&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tobramycin 0.3% ophthalmic solution&nbsp;</td> <td>Tobrex, Tobral</td> <td>1 to 2 drops, four times per day for three to five days&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gentamicin 0.3% ophthalmic ointment<sup>&#916;</sup></td> <td>Gentak, Garamycin ointment</td> <td>0.5 inch (1.25 cm) ribbon, two to three times per day for three to five days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gentamicin 0.3% ophthalmic solution<sup>&#916;</sup></td> <td>Garamycin, Gentocin</td> <td>1 to 2 drops, four times per day for three to five days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical NSAIDs</td> </tr> <tr> <td class=\"indent1\">Bromfenac 0.07 or 0.09% once-daily ophthalmic solution</td> <td>Bromday, Prolensa</td> <td>1 drop, once per day for two to three days</td> </tr> <tr> <td class=\"indent1\">Diclofenac 0.1% ophthalmic solution</td> <td>Voltaren Ophtha</td> <td>1 drop, four times per day for two to three days</td> </tr> <tr> <td class=\"indent1\">Ketorolac 0.4 or 0.5% ophthalmic solution </td> <td>Acular LS (0.4%), Acular (0.5%)</td> <td>1 drop, four times per day for two to three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ketorolac 0.45% ophthalmic solution (preservative free)</td> <td>Acuvail</td> <td>1 drop, four times per day for two to three days</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Topical cycloplegics (for office use only in patients with ciliary spasm)</td> </tr> <tr> <td class=\"indent1\">Cyclopentolate 1% ophthalmic solution</td> <td>Cyclogyl, AK Pentolate </td> <td>1 drop, may repeat in five minutes if needed</td> </tr> <tr> <td class=\"indent1\">Homatropine 2 or 5% ophthalmic solution</td> <td>Isopto Homatropine, Homatropaire</td> <td>1 drop, may repeat in five minutes if needed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Brand (trade)&nbsp;names&nbsp;listed&nbsp;above are for preparations available in United States, Canada,&nbsp;and some other countries. Some brand versions may not be available.<br />* Topical antibiotics are prescribed to prevent bacterial superinfection. Ointments rather than drops may be preferred due to their lubricant and protective functions. Topical antibiotic dosing frequency provided above&nbsp;reflects mild to moderate infection; more frequent administration as advised by an ophthalmologist is indicated for more severe infections. Dosing frequency may be decreased to twice per day if there is no foreign body sensation, and may be discontinued when the patient is asymptomatic for 24 hours. Topical preparations containing steroids should not be used (refer to accompanying text).<br />¶ Rarely, sulfacetamide is associated with serious allergic reactions, including Stevens-Johnson syndrome.<br />Δ Aminoglycosides can be toxic to the corneal epithelium and should be avoided, <STRONG>except </STRONG>as an alternative&nbsp;in abrasions associated with recent contact lens wear and&nbsp;if a topical fluoroquinolone is not available or cannot be used.</div><div class=\"graphic_reference\">Adapted with permission from Evaluation and Management of Corneal Abrasions, January 15, 2013, Vol 87, No 2, American Family Physician. Copyright © 2013 American Academy of Family Physicians. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 90920 Version 8.0</div></div></div>"},"90923":{"type":"graphic_figure","displayName":"Video bronchoscopy","title":"Patient undergoing video bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Patient undergoing video bronchoscopy</div><div class=\"cntnt\"><img style=\"width:540px; height:665px;\" src=\"images/PULM/90923_Video_bronchoscopy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90923 Version 1.0</div></div></div>"},"90924":{"type":"graphic_table","displayName":"Dose comparison of different formulations of desmopressin","title":"Dose comparison of different formulations of desmopressin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose comparison of different formulations of desmopressin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Melt</td> <td class=\"subtitle1\">Tablets</td> <td class=\"subtitle1\">Spray</td> <td class=\"subtitle1\">Solution for injection</td> </tr> <tr> <td rowspan=\"3\"><strong>Dose comparison</strong></td> <td>60 mcg</td> <td>100 mcg</td> <td>2.5 mcg</td> <td>N/A</td> </tr> <tr> <td>120 mcg</td> <td>200 mcg</td> <td>5 mcg</td> <td>Less than 0.5 mcg</td> </tr> <tr> <td>240 mcg</td> <td>400 mcg</td> <td>10 mcg</td> <td>Less than 1 mcg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: The indication of desmopressin is varying between countries and regions, not all desmopressin formulations are approved for the treatment of neurohypophyseal diabetes insipidus in all countries. Based on unpublished BA studies (CS004, RG84063-102, 45A02/48).</div><div class=\"graphic_reference\">Reproduced with permission from: Oiso Y, Robertson GL, N&oslash;rgaard JP, Juul KV. Clinical review: Treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 2013; 98:3958-67. <a href=\"http://press.endocrine.org/journal/jcem\" target=\"_blank\">http://press.endocrine.org/journal/jcem</a>. Copyright &copy; 2013 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 90924 Version 3.0</div></div></div>"},"90927":{"type":"graphic_figure","displayName":"Post-travel infections by region","title":"Infections in returning travelers by region of exposure, 1996 to 2011","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Infections in returning travelers by region of exposure, 1996 to 2011</div><div class=\"cntnt\"><img style=\"width:720px; height:458px;\" src=\"images/ID/90927_Infections_by_region.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This map indicates the number of cases of selected acute and potentially life-threatening diseases region reported among 82,825 travelers from resource-rich countries to various tropical regions between 1996 to 2011. Data are from the GeoSentinel surveillance network.</div><div class=\"graphic_reference\">Reproduced with permission of American Society of Tropical Medicine and Hygiene, Jensenius M, Han PV, Schlagenhauf P, et al. Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011. Am J Trop Med Hyg 2013; 88:397. Copyright &copy; 2013; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 90927 Version 3.0</div></div></div>"},"90929":{"type":"graphic_table","displayName":"Serratia species distribution - Environment and human infection","title":"Environmental distribution and associated human infections of pathogenic Serratia species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Environmental distribution and associated human infections of pathogenic Serratia species</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Species</td> <td class=\"subtitle1\">Habitat</td> <td class=\"subtitle1\">Relative frequency of disease in humans</td> <td class=\"subtitle1\">Clinical manifestations in humans</td> </tr> <tr> <td><em>S. marcescens</em></td> <td>Animals, insects, plants, water, soil</td> <td>Common</td> <td> <p>Wound infections</p> <p>Ocular infections</p> <p>Urinary tract infections</p> <p>Central nervous system infections</p> <p>Respiratory tract infections</p> <p>Bacteremia</p> Endocarditis</td> </tr> <tr> <td><em>S. liquefaciens</em></td> <td>Animals, insects, plants, water, soil</td> <td>Uncommon</td> <td> <p>Wound infections</p> <p>Urinary tract infections</p> <p>Central nervous system infections</p> <p>Respiratory tract infections</p> Bacteremia</td> </tr> <tr> <td><em>S. rubidaea</em></td> <td>Plants, water</td> <td>Rare</td> <td> <p>Wound infections</p> <p>Urinary tract infections</p> Bacteremia</td> </tr> <tr> <td><em>S. ficaria</em></td> <td>Insects, plants</td> <td>Rare</td> <td> <p>Cutaneous abscesses</p> <p>Wound infections</p> <p>Upper respiratory tract infections</p> <p>Endophthalmitis</p> Bacteremia</td> </tr> <tr> <td><em>S. fonticola</em></td> <td>Water</td> <td>Rare</td> <td>Wound infections</td> </tr> <tr> <td><em>S. odorifera</em></td> <td>Plants</td> <td>Rare</td> <td> <p>Urinary tract infections</p> <p>Respiratory tract infections</p> <p>Wound infections</p> Bacteremia</td> </tr> <tr> <td><em>S. plymuthica</em></td> <td>Animals, insects, plants, water</td> <td>Rare</td> <td> <p>Wound infections</p> Bacteremia</td> </tr> <tr> <td><em>S. quinivorans</em></td> <td>Animals, insects, plants, water, soil</td> <td>Rare</td> <td>Respiratory tract infections</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 90929 Version 2.0</div></div></div>"},"90930":{"type":"graphic_table","displayName":"Risk factors - Acquisition of Serratia during hospital outbreak","title":"Selected risk factors associated with acquisition of Serratia infection during hospital outbreaks","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected risk factors associated with acquisition of Serratia infection during hospital outbreaks</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Adult outbreaks<sup>[1-3]</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Receipt of contaminated medication</td> </tr> <tr> <td class=\"indent1\">Indwelling device (central venous catheter, urinary catheter)</td> </tr> <tr> <td class=\"indent1\">Endotracheal intubation</td> </tr> <tr> <td class=\"indent1\">Longer hospital or intensive care unit stay</td> </tr> <tr> <td class=\"indent1\">Antibiotic exposure prior to infection</td> </tr> <tr> <td class=\"indent1\">Tube feeding</td> </tr> <tr> <td class=\"indent1\">Parenteral nutrition</td> </tr> <tr> <td class=\"indent1\">Medical comorbidities</td> </tr> <tr> <td class=\"indent1\">Immune compromise</td> </tr> <tr> <td class=\"subtitle1_single\">Neonatal outbreaks<sup>[4,5]</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Low birth weight</td> </tr> <tr> <td class=\"indent1\">Maternal infection prior to delivery (eg, chorioamnionitis)</td> </tr> <tr> <td class=\"indent1\">Longer hospital or intensive care unit stay</td> </tr> <tr> <td class=\"indent1\">Antibiotic exposure prior to infection</td> </tr> <tr> <td class=\"indent1\">Central venous catheter</td> </tr> <tr> <td class=\"indent1\">Endotracheal intubation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev. 2011; 24(4):755-91.</li>&#xD;&#xA;    <li>De Boer MG, Brunsveld-Reinders AH, Salomons EM, Dijkshoorn L, Bernards AT, van den Berg PC, et al. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics. J Infect. 2008; 56(6):446-53.</li>&#xD;&#xA;    <li>Van der Sar-van der Brugge S, Arend SM, Bernards AT, Berbee GAM, Westendorp RGJ, Feuth JDM, et al. Risk factors for acquisition of Serratia marcescens in a surgical Intensive Care Unit. Journal of Hospital Infection. 1999; 41(4):291-9.</li>&#xD;&#xA;    <li>Buffet-Bataillon S, Rabier V, Betremieux P, Beuchee A, Bauer M, Pladys P, et al. Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors. J Hosp Infect. 2009; 72(1):17-22.</li>&#xD;&#xA;    <li>Voelz A, Muller A, Gillen J, Le C, Dresbach T, Engelhart S, et al. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health. 2010; 213(2):79-87.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 90930 Version 3.0</div></div></div>"},"90931":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray pneumomediastinum cocaine abuse","title":"Pneumomediastinum from cocaine abuse on x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pneumomediastinum from cocaine abuse on x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:367px;\" src=\"images/RADIOL/90931_Chst_x_pneu_cocai_abus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray (A) shows pneumomediastinum on both sides of the trachea (arrows). A magnified view of the chest x-ray (B) highlights the pneumomediastinum in the upper chest and neck.</div><div id=\"graphicVersion\">Graphic 90931 Version 1.0</div></div></div>"},"90932":{"type":"graphic_diagnosticimage","displayName":"CT pneumomediastinum cocaine abuse","title":"Pneumomediastinum from cocaine abuse on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pneumomediastinum from cocaine abuse on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:195px;\" src=\"images/RADIOL/90932_CT_pneum_cocaine_abuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the neck in the axial plane (A) shows air in the prevertebral space (arrows) posterior to the trachea (T). A CT scan of the lung apices (B) using lung windows shows air bubbles in the superior mediastinum (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90932 Version 1.0</div></div></div>"},"90933":{"type":"graphic_diagnosticimage","displayName":"Imaging ground glass changes following cocaine abuse","title":"Ground glass opacification following cocaine abuse on CT scan and chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ground glass opacification following cocaine abuse on CT scan and chest x-ray</div><div class=\"cntnt\"><img style=\"width:598px; height:329px;\" src=\"images/RADIOL/90933_Img_grnd_glass_cocaine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest x-ray in the PA projection (A) shows vague basilar opacities (arrows). A CT scan in the axial projection through the mid chest shows bilateral ground glass opacities (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 90933 Version 2.0</div></div></div>"},"90934":{"type":"graphic_picture","displayName":"Red-pigmented colonies of Serratia marcescens on MacConkey agar","title":"Red-pigmented colonies of Serratia marcescens on MacConkey agar","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Red-pigmented colonies of Serratia marcescens on MacConkey agar</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/ID/90934_Serrat_marce_MacConkey_agar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical red-pigmented, environmental colonies of S. marcescens from a patient with endophthalmitis. The patient acquired S. marcescens after swimming in a lake. Hospital-acquired strains of S. marcescens typically produce creamy-white to grayish-colored colonies.</div><div class=\"graphic_reference\">Courtesy of Dr. Steven Mahlen</div><div id=\"graphicVersion\">Graphic 90934 Version 1.0</div></div></div>"},"90935":{"type":"graphic_picture","displayName":"Serratia marcescens on Gram stain of sputum","title":"Serratia marcescens on Gram stain of sputum","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Serratia marcescens on Gram stain of sputum</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/ID/90935_Serrat_marce_Gram_sputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Steven Mahlen</div><div id=\"graphicVersion\">Graphic 90935 Version 1.0</div></div></div>"},"90936":{"type":"graphic_picture","displayName":"Squamous cell carcinoma dermoscopy 1","title":"Dermoscopic features of squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:590px; height:591px;\" src=\"images/DERM/90936_Squam_cell_carcinoma_derm_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Squamous cell carcinoma in situ. Dermoscopy reveals yellow scale, focal glomerular, and dotted vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 90936 Version 1.0</div></div></div>"},"90937":{"type":"graphic_picture","displayName":"Squamous cell carcinoma dermoscopy 2","title":"Dermoscopic features of squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:575px; height:590px;\" src=\"images/DERM/90937_Squam_cell_carcinoma_derm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented squamous cell carcinoma in situ. Dermoscopy reveals focal dotted vessels and brown-gray dots aligned radially.</div><div class=\"graphic_reference\">Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 90937 Version 3.0</div></div></div>"},"90938":{"type":"graphic_picture","displayName":"Mast cell structure on electron microscopy","title":"Mast cell structure on electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Mast cell structure on electron microscopy</div><div class=\"cntnt\"><img style=\"width:612px; height:603px;\" src=\"images/ALLRG/90938_Mastcellultrastructure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Micrograph A shows a mast cell from human lung tissue in which there are granules containing scroll-like structures. It is unclear precisely what these structures are composed of, although the granules contain predominantly tryptase. A higher power image of these scroll-like structures (yellow arrows) is shown in micrograph C. The black arrows point to granules with an amorphous structure, which likely represent developing (as opposed to mature) granules.<br />Micrograph B shows a mast cell from the skin with granules that display a lattice-like grating pattern on electron microscopy. The granules in this type of mast cell contain carboxypeptidase A, chymase, and tryptase. A higher power image of these granules (yellow arrows) is shown in micrograph D.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Journal of Investigative Dermatology. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol 1991; 96:26S. Copyright &copy; 1991. <a href=\"http://www.nature.com/jid\" target=\"_blank\">www.nature.com/jid</a>.</div><div id=\"graphicVersion\">Graphic 90938 Version 3.0</div></div></div>"},"90939":{"type":"graphic_diagnosticimage","displayName":"Aneurysm 7 years after balloon dilation","title":"Angiogram of large aneurysm after balloon dilation","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Angiogram of large aneurysm after balloon dilation</div><div class=\"cntnt\"><img style=\"width:590px; height:543px;\" src=\"images/PEDS/90939_Aneury_aft_balloon_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ascending aorta angiogram in a 20-year-old female who underwent balloon angioplasty of native coarctation seven years prior to this study. This angiogram reveals a large aneurysm (arrow).</div><div id=\"graphicVersion\">Graphic 90939 Version 1.0</div></div></div>"},"90940":{"type":"graphic_diagnosticimage","displayName":"Aneurysm and residual coarctation post balloon dilation","title":"Aneurysm formation and residual coarctation after balloon dilation for coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Aneurysm formation and residual coarctation after balloon dilation for coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:594px; height:306px;\" src=\"images/PEDS/90940_Aneurys_coarct_post_balloon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ascending aorta angiogram demonstrating a severe coarctation of the aorta involving the origin of the subclavian artery (arrow) before balloon dilation.<br />(B) Repeat angiogram after balloon dilation of the coarctation showing acute aneurysm formation (arrow) and residual coarctation.</div><div id=\"graphicVersion\">Graphic 90940 Version 1.0</div></div></div>"},"90942":{"type":"graphic_table","displayName":"Signal to cut-off ratios for anti-HCV immunoassays","title":"Signal to cut-off ratios suggestive of true positive anti-HCV antibody tests, by assay","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signal to cut-off ratios suggestive of true positive anti-HCV antibody tests, by assay</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Screening test kit name</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Assay format</td> <td class=\"subtitle1\">Signal-to-cut-off ratio predictive of a true positive &#8805;95 percent of the time</td> </tr> <tr> <td>Ortho HCV Version 3.0 ELISA Test System</td> <td>Ortho</td> <td>EIA (enzyme immunoassay)</td> <td>&#8805;3.8</td> </tr> <tr> <td>Abbott HCV EIA 2.0</td> <td>Abbott</td> <td>EIA (enzyme immunoassay)</td> <td>&#8805;3.8</td> </tr> <tr> <td>VITROS Anti-HCV</td> <td>Ortho</td> <td>CIA (chemiluminescennt immunoassay)</td> <td>&#8805;8.0</td> </tr> <tr> <td>AxSYM Anti-HCV</td> <td>Abbott</td> <td>MEIA (microparticle immunoassay)</td> <td>&#8805;10.0</td> </tr> <tr> <td>Architect Anti-HCV</td> <td>Abbott</td> <td>CMIA (chemiluminescent microparticle immunoassay)</td> <td>&#8805;5.0</td> </tr> <tr> <td>Advia Centaur HCV</td> <td>Bayer</td> <td>CIA (chemiluminescennt immunoassay)</td> <td>&#8805;11.0</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: US Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals. Available at: <a href=\"http://www.cdc.gov/hepatitis/hcv/labtesting.htm\" target=\"_blank\">http://www.cdc.gov/hepatitis/hcv/labtesting.htm</a> (Accessed on September 27, 2013).</div><div id=\"graphicVersion\">Graphic 90942 Version 1.0</div></div></div>"},"90943":{"type":"graphic_table","displayName":"Manifestations of cirrhosis","title":"Clinical manifestations of cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td class=\"indent1\">Anorexia</td> </tr> <tr> <td class=\"indent1\">Weight loss</td> </tr> <tr> <td class=\"indent1\">Weakness</td> </tr> <tr> <td class=\"indent1\">Fatigue</td> </tr> <tr> <td class=\"indent1\">Muscle cramps</td> </tr> <tr> <td class=\"indent1\">Easy bruising</td> </tr> <tr> <td class=\"indent1\">Amenorrhea/oligomenorrhea/metrorrhagia (women)</td> </tr> <tr> <td class=\"indent1\">Impotence (men)</td> </tr> <tr> <td class=\"indent1\">Infertility</td> </tr> <tr> <td class=\"indent1\">Decreased libido (men)</td> </tr> <tr> <td class=\"indent1\">Jaundice*</td> </tr> <tr> <td class=\"indent1\">Dark or \"cola-colored\" urine*</td> </tr> <tr> <td class=\"indent1\">Pruritus*</td> </tr> <tr> <td class=\"indent1\">Hematemesis/melena/hematochezia*</td> </tr> <tr> <td class=\"indent1\">Abdominal distension*</td> </tr> <tr> <td class=\"indent1\">Lower extremity edema*</td> </tr> <tr> <td class=\"indent1\">Confusion or sleep disturbances*</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> </tr> <tr> <td class=\"indent1\">Splenomegaly</td> </tr> <tr> <td class=\"indent1\">Spider angiomata/spider telangiectasias</td> </tr> <tr> <td class=\"indent1\">Palmar erythema</td> </tr> <tr> <td class=\"indent1\">Digital clubbing</td> </tr> <tr> <td class=\"indent1\">Hypertrophic osteoarthropathy</td> </tr> <tr> <td class=\"indent1\">Dupuytren's contracture</td> </tr> <tr> <td class=\"indent1\">Muehrcke nails</td> </tr> <tr> <td class=\"indent1\">Terry nails</td> </tr> <tr> <td class=\"indent1\">Parotid gland enlargement (likely due to alcohol use and not cirrhosis per se)</td> </tr> <tr> <td class=\"indent1\">Gynecomastia (men)</td> </tr> <tr> <td class=\"indent1\">Loss of chest or axillary hair (men)</td> </tr> <tr> <td class=\"indent1\">Testicular atrophy (men)</td> </tr> <tr> <td class=\"indent1\">Caput medusa</td> </tr> <tr> <td class=\"indent1\">Cruveilhier-Baumgarten murmur (venous hum heard best with the stethoscope over the epigastrium)</td> </tr> <tr> <td class=\"indent1\">Jaundice*</td> </tr> <tr> <td class=\"indent1\">Ascites (abdominal distension, shifting dullness, fluid wave)*</td> </tr> <tr> <td class=\"indent1\">Asterixis*</td> </tr> <tr> <td class=\"indent1\">Fetor hepaticus*</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory tests</td> </tr> <tr> <td class=\"indent1\">Moderately elevated aminotransferases (often with an AST:ALT ratio &#62;1)</td> </tr> <tr> <td class=\"indent1\">Elevated alkaline phosphatase (2 to 3 times the ULN)</td> </tr> <tr> <td class=\"indent1\">Elevated gamma-glutamyl transpeptidase</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Leukopenia/neutropenia</td> </tr> <tr> <td class=\"indent1\">Anemia</td> </tr> <tr> <td class=\"indent1\">Low serum albumin*</td> </tr> <tr> <td class=\"indent1\">Prolonged prothrombin time/elevated INR*</td> </tr> <tr> <td class=\"indent1\">Hyperbilirubinemia*</td> </tr> <tr> <td class=\"indent1\">Hyponatremia*</td> </tr> <tr> <td class=\"indent1\">Elevated serum creatinine*</td> </tr> <tr> <td class=\"subtitle1_single\">Imaging tests</td> </tr> <tr> <td class=\"indent1\">Surface nodularity</td> </tr> <tr> <td class=\"indent1\">Increased echogenicity (ultrasound)</td> </tr> <tr> <td class=\"indent1\">Atrophy of the right lobe</td> </tr> <tr> <td class=\"indent1\">Hypertrophy of the caudate or left lobes</td> </tr> <tr> <td class=\"indent1\">Small, nodular liver*</td> </tr> <tr> <td class=\"indent1\">Ascites*</td> </tr> <tr> <td class=\"indent1\">Hepatocellular carcinoma*</td> </tr> <tr> <td class=\"indent1\">Portal/splenic/superior mesenteric vein thrombosis*</td> </tr> <tr> <td class=\"indent1\">Portosystemic collaterals*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; INR: international normalized ratio; ULN: upper limit of normal.<br />* Suggests advanced disease or the development of a major complication.</div><div id=\"graphicVersion\">Graphic 90943 Version 2.0</div></div></div>"},"90944":{"type":"graphic_table","displayName":"Therapies for Rx SS","title":"Therapies used for the treatment of Sézary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapies used for the treatment of Sézary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Comment</td> <td class=\"subtitle1\">Combination therapy</td> <td class=\"subtitle1\">US FDA status</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Primary treatment (Group \"A\" therapies)</td> </tr> <tr> <td class=\"indent1\">Extracorporeal photopheresis (ECP)</td> <td>Only available at specialized centers; does not cause generalized immunosuppression</td> <td>Can be combined with other systemic (retinoid, low dose methotrexate, HDAC inhibitor, interferon) or skin-directed (topicals, phototherapy, TSEBT) therapy</td> <td>Approved</td> </tr> <tr> <td class=\"indent1\">Retinoids (bexarotene, acitretin, isotretinoin, all-trans retinoic acid)</td> <td>Teratogenic; common side effects include hyperlipidemia and central hypothyroidism (bexarotene)</td> <td>Can be combined with other systemic (ECP, interferon) or skin directed (PUVA, TSEBT) therapy</td> <td>Bexarotene approved for refractory disease</td> </tr> <tr> <td class=\"indent1\">Interferons (interferon alpha, interferon gamma)</td> <td>Use with caution in patients with concomitant autoimmune conditions (ie, rheumatoid arthritis) or solid organ transplant patients</td> <td>Can be combined with other systemic (ECP, bexarotene) or skin directed (topicals, PUVA, TSEBT) therapy</td> <td>Off label (interferon alpha is US FDA approved for non-Hodgkin lymphoma, which includes mycosis fungoides/S&#233;zary syndrome)</td> </tr> <tr> <td class=\"indent1\">Histone deacetylase (HDAC) inhibitors (vorinostat, romidepsin)</td> <td>Fatigue, nausea, diarrhea, thrombocytopenia, nonspecific electrocardiogram effects</td> <td>Can be combined with other systemic (ECP, interferon) or skin-directed (TSEBT) therapy</td> <td>Romidepsin approved for the treatment of progressive, persistent, or recurrent disease on or following at least one prior systemic therapy; vorinostat approved following two systemic therapies</td> </tr> <tr> <td class=\"indent1\">Low-dose methotrexate</td> <td>Teratogenic; mild generalized immunosuppression; liver toxicity</td> <td>Can be combined with other systemic (ECP, interferon, HDAC inhibitor) or skin directed therapy</td> <td>Approved</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Secondary treatment (Group \"B\" therapies): to be used after inadequate response, refractory disease, or progression despite primary treatments</td> </tr> <tr> <td class=\"indent1\">Pegylated liposomal doxorubicin</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Alemtuzumab</td> <td>Not commercially available</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Fludarabine</td> <td>Myelosuppressive</td> <td>Can be combined with cyclophosphamide</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Cladribine</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Pentostatin</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Intermediate dose methotrexate</td> <td>Myelosuppressive</td> <td>&nbsp;</td> <td>Approved</td> </tr> <tr> <td class=\"indent1\">Pralatrexate (low dose)</td> <td>Stomatitis, skin toxicity</td> <td>&nbsp;</td> <td>Approved for refractory disease</td> </tr> <tr> <td class=\"indent1\">Brentuximab vedotin</td> <td>&nbsp;Peripheral neuropathy</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"indent1\">Pembrolizumab&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Off label</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Allogeneic hematopoietic cell transplantation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US FDA: US Food and Drug Administration; ECP: extracorporeal photopheresis; HDAC: histone deacetylase; TSEBT: total skin electron beam therapy; PUVA: psoralen plus ultraviolet A (UVA).</div><div class=\"graphic_reference\">Adapted&nbsp;from: Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2013; 64:352.</div><div id=\"graphicVersion\">Graphic 90944 Version 4.0</div></div></div>"},"90950":{"type":"graphic_table","displayName":"Causes and key features of acute traumatic knee pain in adults","title":"Acute traumatic knee pain in active adults: Causes and distinguishing features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute traumatic knee pain in active adults: Causes and distinguishing features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Mechanism &#38; historical features</td> <td class=\"subtitle1\">Common symptoms</td> <td class=\"subtitle1\">Key examination findings</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Significant knee swelling</td> </tr> <tr> <td class=\"indent1\">Anterior cruciate ligament (ACL)&nbsp;tear</td> <td> <p>Sudden change in direction or landing from a jump (non-contact injury most common)</p> <p>Audible \"pop\" at time of injury</p> Rapid swelling</td> <td> <p>Knee feels unstable</p> Pain variable</td> <td> <p>Substantial effusion</p> Positive Lachman, anterior drawer, &#38; pivot shift tests</td> <td>Female athletes at higher risk</td> </tr> <tr> <td class=\"indent1\">Large meniscus tear</td> <td> <p>Sudden, forceful twisting of the knee with foot planted</p> Tearing or popping sensation at time of injury</td> <td> <p>Knee pain and swelling</p> <p>Knee is popping, locking, catching, not moving properly, or feels unstable</p> <p>Knee may not fully extend &#38; may give way with rotation</p> Pain increases with squatting or pivoting</td> <td> <p>Substantial effusion</p> <p>Joint line tenderness</p> <p>Loss of smooth passive flexion &#38; extension</p> <p>May not be able to achieve full active flexion or extension</p> <p>Positive McMurray test</p> <p>Positive bounce home test</p> Pain with compression and twisting of knee (eg, positive Thessaly test)</td> <td>Severity of symptoms &#38; signs varies with extent and location of tear</td> </tr> <tr> <td class=\"indent1\">Intra-articular fracture</td> <td> <p>Large valgus stress on knee, possibly during landing from jump or fall</p> <p>Trauma may be minor in osteoporotic women or elder men</p> Rapid swelling</td> <td>Knee pain and swelling</td> <td> <p>Joint line tenderness (usually lateral)</p> Ligamentous instability absent</td> <td> <p>Lateral tibial plateau most often affected</p> <p>Imaging studies (eg, CT) needed for diagnosis</p> Aspiration fluid may be bloody and contain fat globules</td> </tr> <tr> <td class=\"indent1\">Osteochondral defect</td> <td> <p>Vigorous activity involving sudden change in direction and/or jumping</p> Immediate pain and rapid swelling</td> <td>Knee pain and swelling (effusion varies with size of defect)</td> <td>Ligamentous instability absent (distinguishes from ACL injury)</td> <td> <p>Medial femoral condyle at greatest risk</p> <p>Can occur from direct trauma or overuse</p> </td> </tr> <tr> <td class=\"indent1\">Patellar dislocation</td> <td>Pivoting or sudden change in direction</td> <td> <p>Knee \"out of place\" (typically lateral)</p> Many reduce spontaneously prior to presentation</td> <td> <p>Effusion</p> <p>Patella may be dislocated or subluxed</p> Tenderness often present along medial patellar border</td> <td> <p>Patients with hypermobility may have recurrent dislocation with milder symptoms and physical findings</p> <p>More common among young females</p> </td> </tr> <tr> <td class=\"indent1\">Posterior lateral corner tear</td> <td> <p>Patients may not recall trauma</p> If recalled, trauma may involve blow to proximal anterior tibia</td> <td> <p>Posterior knee pain and instability</p> Pain at posterior knee with pivoting</td> <td> <p>Focal tenderness at posterior lateral corner of knee</p> Positive dial test</td> <td>May occur with ACL or LCL injury</td> </tr> <tr> <td class=\"indent1\">Posterior cruciate ligament&nbsp;(PCL)&nbsp;tear</td> <td>Direct blow to proximal anterior tibia</td> <td> <p>Posterior knee pain</p> Instability (may not be present): knee feels like it may hyperextend</td> <td> <p>Positive sag sign</p> Positive posterior drawer test</td> <td>History may be unclear: Patient may not&nbsp;associate current symptoms&nbsp;with past trauma&nbsp;</td> </tr> <tr> <td class=\"indent1\">Patellar tendon tear</td> <td>Sudden forceful flexion of a knee already flexed 60 degrees or more</td> <td> <p>Knee pain and swelling</p> Cannot extend knee&nbsp;</td> <td> <p>Infrapatellar swelling &#38; ecchymosis</p> <p>Tenderness (and possible tendon defect) at inferior patellar border</p> <p>Painful knee extension with partial tear</p> Unable to extend knee with complete tear</td> <td>Anabolic steroid use and quinolone antibiotics increase risk</td> </tr> <tr> <td class=\"indent1\">Quadriceps tendon tear</td> <td>Sudden fall backward while foot is fixed and knee flexed; athlete tackled while in this position (American football; rugby)</td> <td> <p>Anterior knee pain and swelling</p> <p>Cannot extend knee</p> <p>Difficulty bearing weight</p> </td> <td> <p>Suprapatellar swelling &#38; ecchymosis</p> <p>Tenderness (and possible tendon defect) at superior patellar border</p> <p>Painful knee extension with partial tear</p> Unable to extend knee with complete tear</td> <td>Uncommon but can occur spontaneously in athletes over 40</td> </tr> <tr> <td class=\"indent1\">Knee (tibiofemoral) dislocation</td> <td> <p>Typically high energy trauma involving direct blow to anterior knee causing hyperextension</p> Can occur in obese individuals who fall</td> <td> <p>Knee pain, swelling, and instability</p> May reduce spontaneously prior to presentation</td> <td> <p>Substantial effusion</p> Ligamentous instability in multiple planes</td> <td>Dangerous injury that can compromise blood flow to leg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Limited knee swelling</td> </tr> <tr> <td class=\"indent1\">Small or moderate meniscus tear</td> <td> <p>Sudden forceful twisting of the knee with foot planted</p> Tearing or popping sensation at time of injury</td> <td> <p>Knee is popping, locking, catching, not moving properly, or feels unstable</p> Pain increases with squatting or pivoting</td> <td> <p>Joint line tenderness</p> <p>Positive McMurray test</p> Pain with compression and twisting of knee (eg, positive Thessaly test)</td> <td>Severity of symptoms &#38; signs varies with extent and location of tear</td> </tr> <tr> <td class=\"indent1\">Medial collateral ligament (MCL) strain</td> <td>Twisting of leg or direct blow to lateral knee creating valgus force</td> <td> <p>Medial knee pain</p> Medial knee feels unstable with \"cutting\" or lateral movements</td> <td> <p>Focal tenderness over MCL</p> Positive valgus stress test</td> <td>Medial meniscal tear often accompanies MCL tear</td> </tr> <tr> <td class=\"indent1\">Lateral collateral ligament (LCL) strain</td> <td>Twisting of leg or direct blow to medial knee creating varus force</td> <td> <p>Lateral knee pain</p> Lateral knee feels unstable with \"cutting\" or lateral movements</td> <td> <p>Focal tenderness over LCL</p> Positive varus stress test</td> <td>LCL tear requires greater force than MCL so injuries to cruciate ligaments (ACL, PCL)&nbsp;can occur</td> </tr> <tr> <td class=\"indent1\">Patellar subluxation</td> <td>History as above for patellar dislocation</td> <td> <p>Anterior knee pain</p> Crepitation along superior lateral corner of patella</td> <td> <p>Effusion mild or absent</p> <p>Hypermobile patella</p> Apprehension test may be positive</td> <td> <p>Increased risk with hypermobility syndromes</p> More common with shallow patellar groove</td> </tr> <tr> <td class=\"indent1\">Partial ACL tear</td> <td>History as above for ACL tear</td> <td>Symptoms as above but generally milder</td> <td>Ligamentous instability may be mild or absent</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Partial PCL tear</td> <td>History as above for PCL tear</td> <td>Symptoms as above but generally milder</td> <td>Ligamentous instability may be mild or absent</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Patella fracture&nbsp;</td> <td>Direct trauma to anterior knee</td> <td>Anterior knee pain, ecchymosis, and swelling&nbsp;</td> <td>Focal patella tenderness</td> <td> <p>Perform plain radiographs including sunrise view</p> <p>Must assess integrity of knee extensor mechanism and PCL</p> </td> </tr> <tr> <td class=\"indent1\">Fibular neck or head fracture&nbsp;</td> <td>Direct trauma to lateral knee, or associated with severe ankle sprain or fracture&nbsp;</td> <td>&nbsp;Lateral knee pain</td> <td>Focal tenderness over&nbsp; proximal fibula </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">History of forceful collision, landing, or abrupt change in movement. Abrupt onset of pain, swelling, and possibly instability.</div><div id=\"graphicVersion\">Graphic 90950 Version 5.0</div></div></div>"},"90954":{"type":"graphic_table","displayName":"Management of dyslipidemia in adolescents with type 2 diabetes","title":"Screening and management of dyslipidemia in adolescents with type 2 diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening and management of dyslipidemia in adolescents with type 2 diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Screening</td> </tr> <tr> <td class=\"indent1\">Obtain a lipid profile at diagnosis (after glycemic control is well established). If abnormal, obtain a fasting lipid profile.</td> </tr> <tr> <td class=\"sublist2_start\">Monitoring</td> </tr> <tr> <td class=\"sublist2\">If LDL cholesterol values are within the accepted risk levels (&#60;100 mg/dL [2.6 mmoL/L]), a lipid profile should be repeated every two years</td> </tr> <tr> <td class=\"sublist2\">If lipids are abnormal, more frequent monitoring is recommended</td> </tr> <tr> <td class=\"subtitle1_single\">Goals</td> </tr> <tr> <td class=\"indent1\">LDL &#60;100 mg/dL</td> </tr> <tr> <td class=\"indent1\">HDL &#62;35 mg/dL</td> </tr> <tr> <td class=\"indent1\">Triglycerides &#60;150 mg/dL</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment strategies</td> </tr> <tr> <td class=\"indent1\">Diet: Step 2 AHA diet, aimed to decrease intake of saturated fat and cholesterol</td> </tr> <tr> <td class=\"indent1\">Maximize glycemic control</td> </tr> <tr> <td class=\"indent1\">Weight reduction</td> </tr> <tr> <td class=\"indent1\">Increase physical activity</td> </tr> <tr> <td class=\"sublist2_start\">Medications: Begin after six months of dietary intervention if lipid goals are not met</td> </tr> <tr> <td class=\"sublist2\">Indications: Age &#62;10 years and LDL &#8805;130 mg/dL</td> </tr> <tr> <td class=\"sublist2\">Statins</td> </tr> <tr> <td class=\"sublist2\">Fibric acid derivatives or niacin if triglycerides &#62;1000 mg/dL</td> </tr> <tr> <td class=\"sublist2_start\">Manage other cardiovascular disease risk factors</td> </tr> <tr> <td class=\"sublist2\">Blood pressure</td> </tr> <tr> <td class=\"sublist2\">Tobacco</td> </tr> <tr> <td class=\"sublist2\">Obesity</td> </tr> <tr> <td class=\"sublist2\">Inactivity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein; AHA: American Heart Association.</div><div class=\"graphic_reference\">Modified with permission from: The American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26:2194. Copyright &copy; 2003. Updated based on 2013 ADA guidelines: Springer SC, Silverstein J, Copeland K, et al. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics 2013; 131:e648.</div><div id=\"graphicVersion\">Graphic 90954 Version 2.0</div></div></div>"},"90965":{"type":"graphic_picture","displayName":"Scleredema","title":"Scleredema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleredema</div><div class=\"cntnt\"><img style=\"width:504px; height:320px;\" src=\"images/DERM/90965_Scleredema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Woody induration on the upper back in a patient with scleredema associated with diabetes mellitus.</div><div id=\"graphicVersion\">Graphic 90965 Version 1.0</div></div></div>"},"90966":{"type":"graphic_table","displayName":"Cycling for parenteral nutrition","title":"Example of a step-wise approach to cycling parenteral nutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of a step-wise approach to cycling parenteral nutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Continuous</td> <td class=\"subtitle1\">Continuous 24 hour PN</td> <td class=\"subtitle1\">1000 mL infusing at 42 mL/hr for 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Start of cycling</td> <td>22 hours on, 2 hours off</td> <td> <p>48 mL/hr x 20 hours</p> <p>24 mL/hr x 1 hour <em>(Cycle down)</em></p> <p>12 mL/hr x 1 hour <em>(Cycle down)</em></p> Off 2 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Step 2</td> <td>20 hours on, 4 hours off</td> <td> <p>25 mL/hr x 1 hour <em>(Cycle up)</em></p> <p>55 mL/hr x 17 hours</p> <p>25 mL/hr x 1 hour <em>(Cycle down)</em></p> <p>15 mL/hr x 1 hour <em>(Cycle down)</em></p> Off 4 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Step 3</td> <td>18 hours on, 6 hours off</td> <td> <p>35 mL/hr x 1 hour <em>(Cycle up)</em></p> <p>61 mL/hr x 15 hours</p> <p>35 mL/hr x 1 hour <em>(Cycle down)</em></p> <p>15 mL/hr x 1 hour <em>(Cycle down)</em></p> Off 6 hours</td> </tr> <tr> <td>Step 4</td> <td>16 hours on, 8 hours off</td> <td> <p>36 mL/hr x 1 hour <em>(Cycle up)</em></p> <p>70 mL/hr x 13 hours</p> <p>36 mL/hr x 1 hour <em>(Cycle down)</em></p> <p>18 mL/hr x 1 hour <em>(Cycle down)</em></p> Off 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Example of a step-wise approach to cycling parenteral nutrition. The cycle length achieved will be dependent on the glucose infusion rate (GIR) and the glucose tolerance of the individual patient.</div><div class=\"graphic_reference\">Courtesy of Susan Baker, MD, Robert Baker, MD, Jessica Briggs, RD, and Georgina Bojczuk, RD, CSP.</div><div id=\"graphicVersion\">Graphic 90966 Version 2.0</div></div></div>"},"90967":{"type":"graphic_picture","displayName":"Scleredema on back","title":"Scleredema","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Scleredema</div><div class=\"cntnt\"><img style=\"width:504px; height:310px;\" src=\"images/DERM/90967_Scleredema_on_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse induration and mild erythema involving the skin of the posterior neck and trunk in a patient with scleredema associated with diabetes mellitus.</div><div id=\"graphicVersion\">Graphic 90967 Version 1.0</div></div></div>"},"90968":{"type":"graphic_picture","displayName":"Scleredema neck","title":"Scleredema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scleredema</div><div class=\"cntnt\"><img style=\"width:391px; height:295px;\" src=\"images/DERM/90968_Scleredema_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin induration and erythema on the posterior neck in a patient with scleredema associated with monoclonal gammopathy.</div><div id=\"graphicVersion\">Graphic 90968 Version 1.0</div></div></div>"},"90969":{"type":"graphic_table","displayName":"Management of dyslipidemia in children with type 1 diabetes","title":"Screening and management of dyslipidemia in children and adolescents with type 1 diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening and management of dyslipidemia in children and adolescents with type 1 diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Screening</td> </tr> <tr> <td class=\"sublist2_start\">Obtain a lipid profile at diagnosis (after glycemic control is well established). If abnormal, obtain a fasting lipid profile.</td> </tr> <tr> <td class=\"sublist2\">Begin at age 10 years (or onset of puberty, if earlier)</td> </tr> <tr> <td class=\"sublist2\">Begin before to age 10 years if there is a family history of hypercholesterolemia or early cardiovascular disease (before age 55 years)</td> </tr> <tr> <td class=\"sublist2_start\">Monitoring</td> </tr> <tr> <td class=\"sublist2\">If LDL cholesterol values are within the accepted risk levels (&#60;100 mg/dL [2.6 mmoL/L]), a lipid profile should be repeated every&nbsp;five years*</td> </tr> <tr> <td class=\"sublist2\">If lipids are abnormal, annual monitoring is recommended</td> </tr> <tr> <td class=\"subtitle1_single\">Goals</td> </tr> <tr> <td class=\"indent1\">LDL &#60;100 mg/dL</td> </tr> <tr> <td class=\"indent1\">HDL &#62;35 mg/dL</td> </tr> <tr> <td class=\"indent1\">Triglycerides &#60;150 mg/dL</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment strategies</td> </tr> <tr> <td class=\"indent1\">Diet: Step 2 American Heart Association diet, aimed to decrease intake of saturated fat and cholesterol</td> </tr> <tr> <td class=\"indent1\">Maximize glycemic control</td> </tr> <tr> <td class=\"indent1\">Weight reduction, if indicated</td> </tr> <tr> <td class=\"sublist2_start\">Pharmacotherapy: Begin after six months of dietary intervention if lipid goals are not met</td> </tr> <tr> <td class=\"sublist2\">Indications: Age &#62;10 years and LDL &#8805;160 mg/dL, or LDL 130 to 159 mg/dL and one or more other risk factors for cardiovascular disease<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Medications:&nbsp;</td> </tr> <tr> <td class=\"sublist3\">Statins </td> </tr> <tr> <td class=\"sublist3\">Fibric acid derivatives or niacin if triglycerides &#62;1000 mg/dL</td> </tr> <tr> <td class=\"sublist2_start\"><span>Borderline patients (LDL 100 to 130, or LDL 130 to 159 without risk factors):&nbsp;Intensify dietary intervention and monitor closely.</span>&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\">Manage other cardiovascular disease risk factors</td> </tr> <tr> <td class=\"sublist2\">Blood pressure</td> </tr> <tr> <td class=\"sublist2\">Tobacco</td> </tr> <tr> <td class=\"sublist2\">Obesity</td> </tr> <tr> <td class=\"sublist2\">Inactivity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein; A1C: hemoglobin A1C.<br />* If the initial screen is normal but the child's diabetes is in poor control (eg, A1C &gt;9 percent), we suggest screening at least every two years.<br /><SUP>¶</SUP>&nbsp;Cardiovascular disease risk factors include hypertension, obesity (body mass index [BMI] &gt;95th percentile), tobacco use, or a family history of early cardiovascular disease.</div><div class=\"graphic_reference\">Modified with permission from: The American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26:2194. Copyright © 2003. Updated with information from: American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 Suppl 1:S14.</div><div id=\"graphicVersion\">Graphic 90969 Version 5.0</div></div></div>"},"90984":{"type":"graphic_diagnosticimage","displayName":"Neuroendocrine cell hyperplasia of infancy","title":"Neuroendocrine cell hyperplasia of infancy (NEHI)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Neuroendocrine cell hyperplasia of infancy (NEHI)</div><div class=\"cntnt\"><img style=\"width:513px; height:198px;\" src=\"images/PEDS/90984_Neur_hyperplasia_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of chest computerized tomography (CT) pattern consistent with NEHI. The presence of relatively homogeneous ground glass opacities in the perihilar regions (panel A) and right middle lobe and lingula (panel B), without other abnormalities, demonstrates a pattern consistent with NEHI.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90984 Version 2.0</div></div></div>"},"90985":{"type":"graphic_diagnosticimage","displayName":"Bronchiolitis obliterans","title":"Bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:513px; height:196px;\" src=\"images/PEDS/90985_Bronchioliti_obliteran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of chest computerized tomography (CT) findings consistent with bronchiolitis obliterans. Variable mosaic attenuation is present, with irregular areas of relative ground-glass opacity and hyperlucency. Bronchiectasis is also a significant finding.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90985 Version 1.0</div></div></div>"},"90987":{"type":"graphic_table","displayName":"Clinical pathologic classification of DLD in children","title":"Clinical-pathologic classification of interstitial and diffuse lung disease in childhood","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical-pathologic classification of interstitial and diffuse lung disease in childhood</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Specific entities</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders more prevalent in infancy</td> </tr> <tr> <td class=\"indent1\">Diffuse developmental disorders</td> <td> <ul> <li>Acinar/alveolar dysgenesis </li> <li>Congenital alveolar dysplasia </li> <li>Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD-MPV) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Lung growth abnormalities</td> <td> <ul> <li>Pulmonary hypoplasia&nbsp;&#8212; eg, due to oligohydramnios, congenital diaphragmatic hernia, thoracic mass lesion </li> <li>Chronic neonatal lung disease (BPD)&nbsp;&#8212; eg, due to prematurity </li> <li>Structural changes due to chromosomal abnormalities &nbsp;&#8212; eg, trisomy 21 </li> <li>Associated with congenital&nbsp;heart disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Specific conditions of unknown or poorly understood etiology</td> <td> <ul> <li>Neuroendocrine cell hyperplasia of infancy (NEHI) </li> <li>Pulmonary interstitial glycogenosis (P.I.G.) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Surfactant dysfunction disorders and related abnormalities</td> <td><em>SFTPB</em>, <em>SFTPC</em>, <em>ABCA3</em>, <em>NKX2.1/TTF1</em>, lysinuric protein intolerance; pulmonary alveolar proteinosis due to <em>CSF2RA</em> and<em>&nbsp;CSF2RB</em> mutations;&nbsp;other genetic mutations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders not specific to infancy</td> </tr> <tr> <td class=\"indent1\">Disorders of the normal host (immunocompetent)</td> <td> <ul> <li>Infectious/post-infectious processes&nbsp;&#8212; chronic airway changes,&nbsp;organizing pneumonia, or specific infections </li> <li>Related to environmental agents (hypersensitivity pneumonitis or toxic inhalation) </li> <li>Aspiration syndromes&nbsp; </li> <li>Eosinophilic pneumonia </li> <li>Acute interstitial pneumonia (AIP) </li> <li>Nonspecific interstitial pneumonia (NSIP) </li> <li>Idiopathic pulmonary hemosiderosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Disorders of the immunocompromised host</td> <td> <ul> <li>Opportunistic infections </li> <li>Related to therapeutic intervention&nbsp;&#8212; eg, chemotherapy and/or radiation injury; drug reaction&nbsp; </li> <li>Related to transplantation or rejection syndromes </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Disorders related to systemic disease processes</td> <td> <ul> <li>Immune-mediated&nbsp; </li> </ul> <p>&nbsp; - Anti-GBM antibody (Goodpasture); acquired pulmonary alveolar proteinosis/antibody to GMCSF; pulmonary&nbsp;vasculitis syndromes&nbsp;&nbsp;&nbsp;</p> <p>&nbsp; - Nonspecific pulmonary manifestations &#8212; NSIP, pulmonary hemorrhage syndromes, organizing pneumonia, nonspecific airway changes</p> <p>&nbsp; - Collagen-vascular disease&nbsp;&#8212;&nbsp;eg, SLE, polymyositis/dermatomyositis, and systemic sclerosis</p> <ul> <li>Storage diseases </li> <li>Sarcoidosis </li> <li>Langerhans cell histiocytosis </li> <li>Malignant infiltrates </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Vascular disorders masquerading as ILD</td> <td> <ul> <li>Arterial hypertensive vasculopathy </li> <li>Congestive vasculopathy and veno-occlusive disease </li> <li>Lymphatic&nbsp;disorders&nbsp;&#8212;&nbsp;eg, lymphangiectasia, lymphangiomatosis&nbsp; </li> <li>Pulmonary edema </li> <li>Thromboembolic disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Unclassified</td> <td>Captures cases of&nbsp;diffuse lung disease&nbsp;that cannot be classified for any reason. Common reasons include end-stage disease, non-diagnostic biopsies, or inadequate biopsy material.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACD-MPV: alveolar capillary dysplasia with misalignment of pulmonary veins; BPD: bronchopulmonary dysplasia; NEHI: neuroendocrine cell hyperplasia of infancy; P.I.G: pulmonary interstitial glycogenosis; <EM>SFTPB</EM>: gene encoding the surfactant protein B; <EM>SFTPC</EM>: gene encoding surfactant protein C; <EM>ABCA3</EM>: member A3 of the ATP Binding Cassette family of proteins; <EM>NKX2.1/TTF1</EM>: gene encoding the thyroid transcription factor 1; CSF2RA: colony-stimulating factor 2 receptor alpha; CSF2RB: colony-stimulating factor 2 receptor beta; AIP: acute interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; GBM: glomerular basement membrane; GMCSF: granulocyte-macrophage colony stimulating factor; NSIP: nonspecific interstitial pneumonia; SLE: systemic lupus erythematosus.</div><div class=\"graphic_reference\">Adapted from: Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: Application of a novel classification scheme. Am J Respir Crit Care Med 2007; 176:1122.&nbsp; Updated with Fan LL, Dishop MK, Galambos C, et al. Diffuse Lung Disease in Biopsied Children 2 to 18 Years of Age. Application of the chILD Classification Scheme. Ann Am Thorac Soc 2015; 12:1498.</div><div id=\"graphicVersion\">Graphic 90987 Version 7.0</div></div></div>"},"90991":{"type":"graphic_picture","displayName":"Reactive skin decontamination lotion","title":"Reactive skin decontamination lotion (RSDL)","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Reactive skin decontamination lotion (RSDL)</div><div class=\"cntnt\"><img style=\"width:651px; height:428px;\" src=\"images/EM/90991_React_skin_decontam_lotion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">RSDL lotion is packaged on a foam applicator inside a single use pouch. The lotion is applied within three minutes of contamination, and the non-toxic residue is washed away at a later time. Application of RSDL to wounds or the eyes is considered off label use.</div><div class=\"graphic_reference\">Photo of RSDL® (KBDO individual use decontamination packet) reproduced with permission from Emergent BioSolutions. Originally published in: Braue EH, Boardman CH, Hurst CG. Decontamination of chemical casualties. In: Medical Aspects of Chemical Warfare, 2nd edition, Tuorinsky SD (Ed), United States Department of the Army, Office of the Surgeon General at TMM Publications, Borden Institute, Washington, DC, 2008. Copyright © 2014 Emergent BioSolutions.</div><div id=\"graphicVersion\">Graphic 90991 Version 1.0</div></div></div>"},"90992":{"type":"graphic_table","displayName":"Types of interstitial and diffuse lung diseases in infancy","title":"Types of interstitial and diffuse lung diseases most commonly presenting in infancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of interstitial and diffuse lung diseases most commonly presenting in infancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diffuse developmental disorders</td> </tr> <tr> <td class=\"indent1\">Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD-MPV)</td> </tr> <tr> <td class=\"indent1\">Acinar dysplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of lung growth and development</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypoplasia</td> </tr> <tr> <td class=\"indent1\">Chronic neonatal lung disease or bronchopulmonary dysplasia (BPD)</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary interstitial glycogenosis (P.I.G.)*&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Neuroendocrine cell hyperplasia of infancy (NEHI)</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic disorders of surfactant production and metabolism<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Surfactant protein B gene mutations (<em>SFTPB</em>)</td> </tr> <tr> <td class=\"indent1\">Surfactant protein C gene mutations (<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\"><em>SFTPC </em></span>)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">ATP-binding cassette member A-3 gene mutations (<em>ABCA3</em>)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Lung disease due to <em>NKX2.1/TTF1</em> gene mutations<sup>&#916;&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Others<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Often occurs in conjunction with disorder of lung growth and development.<br />¶ Refer to UpToDate topic on genetic disorders of surfactant dysfunction.<br />Δ Deletions in <EM>SFTPC</EM>, <EM>ABCA3,</EM> and <EM>NKX2.1</EM> also have been reported.<br /><FONT class=lozenge>◊</FONT> <EM>NKX2.1</EM> mutations may result in reduced expression of the genes responsible for surfactant production and metabolism. In addition, a spectrum of lung disease phenotypes, including abnormal lung development, has been reported in association with <EM>NKX2.1/TTF1</EM> mutations.<br />§ A subset of cases have radiographic and histologic features consistent with a surfactant dysfunction disorder, but no mutations in <EM>SFTPB</EM>, <EM>SFTPC</EM>, <EM>ABCA3,</EM> or <EM>NKX2.1/TTF1</EM> are identified.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90992 Version 11.0</div></div></div>"},"90993":{"type":"graphic_table","displayName":"Types of childhood interstitial and diffuse lung diseases","title":"Types of childhood interstitial and diffuse lung diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of childhood interstitial and diffuse lung diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders with primary pulmonary involvement</td> </tr> <tr> <td class=\"indent1\">Alveolar hemorrhage syndromes (eg, idiopathic pulmonary capillaritis)</td> </tr> <tr> <td class=\"indent1\">Aspiration syndromes</td> </tr> <tr> <td class=\"indent1\">Disorders of lung growth and development</td> </tr> <tr> <td class=\"indent1\">Drug or radiation induced lung disease</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"indent1\">Infectious or post-infectious chronic lung disease</td> </tr> <tr> <td class=\"indent1\">Neuroendocrine cell hyperplasia of infancy (NEHI)</td> </tr> <tr> <td class=\"indent1\">Pulmonary alveolar proteinosis (PAP)</td> </tr> <tr> <td class=\"indent1\">Chronic eosinophilic pneumonia</td> </tr> <tr> <td class=\"indent1\">Pulmonary interstitial glycogenosis (P.I.G.)</td> </tr> <tr> <td class=\"indent1\">Pulmonary vascular disorders (proliferative and congenital)</td> </tr> <tr> <td class=\"indent1\">Pulmonary alveolar microlithiasis</td> </tr> <tr> <td class=\"indent1\">Genetic disorders of surfactant production and metabolism (mutations in <em>SFTPB</em>, <em>SFTPC</em>, <em>ABCA3</em>, or <em>NKX2.1</em>/<em>TTF1*</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic disorders with associated pulmonary involvement</td> </tr> <tr> <td class=\"indent1\">Brain-lung-thyroid syndrome with interstitial lung disease (ILD) due to <em>NKX2.1</em>/<em>TTF1</em> gene mutations</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease (eg, SLE, polymyositis/dermatomyositis, systemic sclerosis, mixed connective tissue disease, or systemic JIA)</td> </tr> <tr> <td class=\"indent1\">Dyskeratosis congenita (bone marrow hypoplasia, often with skin, nail and mucosal changes)</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency and lymphoproliferative disorders (usually with histologic patterns of lymphocytic interstitial pneumonia [LIP] or follicular bronchiolitis)</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Lymphatic disorders</td> </tr> <tr> <td class=\"indent1\">Storage diseases (Niemann-Pick, mucopolysaccharidosis, others)</td> </tr> <tr> <td class=\"indent1\">Malignancies</td> </tr> <tr> <td class=\"indent1\">Neurocutaneous syndromes</td> </tr> <tr> <td class=\"indent1\">Other inborn errors of metabolism (lysinuric protein intolerance)</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><em>SFTPB</em>: surfactant protein B gene; <em>SFTPC</em>: surfactant protein C gene; <em>ABCA3</em>: member A3 of the ATP binding cassette family; <em>NKX2.1</em>/<em>TTF1</em>: gene encoding thyroid transcription factor 1; SLE: systemic lupus erythematosus; JIA: juvenile idiopathic arthritis.<br />* Note that a spectrum of lung disease phenotypes, including abnormal lung development, has been reported in association with <em>NKX2.1</em>/<em>TTF1</em> mutations.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90993 Version 10.0</div></div></div>"},"90994":{"type":"graphic_table","displayName":"Histologic patterns for childhood interstitial and diffuse lung","title":"Histologic patterns and considerations for childhood interstitial and diffuse lung diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic patterns and considerations for childhood interstitial and diffuse lung diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Histologic pattern</td> <td class=\"subtitle1\">Specific types of&nbsp;diffuse lung disease&nbsp;that may display this histologic pattern</td> </tr> <tr> <td>Pulmonary alveolar proteinosis (PAP)</td> <td> <p>Disorders of surfactant dysfunction* or of GM-CSF signaling (eg, mutations in <em>CSF2RA</em>, <em>CSF2RB</em>)</p> <p>Lysinuric protein intolerance</p> Autoimmune mechanisms, including GM-CSF autoantibodies</td> </tr> <tr> <td>Cellular interstitial pneumonitis</td> <td>Pulmonary interstitial glycogenosis (P.I.G.)</td> </tr> <tr> <td>Chronic pneumonitis of infancy (CPI)</td> <td>Disorders of surfactant dysfunction*</td> </tr> <tr> <td>Desquamative interstitial pneumonia (DIP)</td> <td>Disorders of surfactant dysfunction* or chronic pulmonary hemorrhage syndrome</td> </tr> <tr> <td>Diffuse alveolar damage/acute interstitial pneumonia (DAD/AIP)</td> <td>The findings of AIP are identical to the organizing or proliferative state of DAD, which is the histological lesion of acute respiratory distress syndrome (ARDS)</td> </tr> <tr> <td>Lymphocytic interstitial pneumonia (LIP), follicular bronchiolitis, and related disorders</td> <td>Immunodeficiency disorders; connective tissue disease</td> </tr> <tr> <td>Nonspecific interstitial pneumonia (NSIP)</td> <td>Connective tissue disease; rarely <em>SFTPC</em> mutations</td> </tr> <tr> <td>Organizing pneumonitis</td> <td> <p>Cryptogenic organizing pneumonitis (COP)<sup>&#182;</sup></p> This finding also may accompany other histologic patterns, and may be seen as a complication of HIV infection, chemotherapy, or bone marrow transplantation</td> </tr> <tr> <td>Usual interstitial pneumonitis (UIP)<sup>&#916;</sup></td> <td>One case of UIP was reported in an adolescent with an <em>ABCA3</em> mutation. Otherwise, UIP has not been reported in children.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SFTPB: surfactant protein B gene; SFTPC: surfactant protein C gene; ABCA3: member A3 of the ATP Binding Cassette family of proteins; GM-CSF: granulocyte-macrophage colony-stimulating factor; CSF2RA: colony-stimulating factor 2 receptor, alpha (GM-CSF receptor alpha); CSF2RB: colony-stimulating factor 2 receptor, beta (GM-CSF receptor beta).<br />* Disorders of surfactant dysfunction may be caused by mutations in <EM>SFTPB</EM>, <EM>SFTPC</EM>, <EM>ABCA3</EM>, or <EM>NKX2.1/TTF1</EM>.<br />¶ Cryptogenic organizing pneumonitis was previously called bronchiolitis obliterans with organizing pneumonia (BOOP).<br />Δ Usual interstitial pneumonitis (UIP) is associated with idiopathic pulmonary fibrosis (IPF) in adults, but IPF does not occur in children. In adults, the UIP pattern may also be seen in individuals with connective tissue disease and hypersensitivity pneumonitis.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90994 Version 5.0</div></div></div>"},"90995":{"type":"graphic_table","displayName":"Diagnostic studies children with DLD","title":"Diagnostic studies in children with suspected diffuse lung disease (interstitial lung disease)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic studies in children with suspected diffuse lung disease (interstitial lung disease)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">To exclude more common causes of chronic respiratory symptoms:<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Sweat chloride testing</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Evaluation for gastroesophageal reflux and recurrent aspiration (such as barium swallow, pH/impedance probe and others)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Bronchoscopy</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Cultures and testing for infectious etiologies</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Echocardiogram</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Testing for HIV and other immunodeficiencies</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">To assess extent and severity of disease:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Radiographic studies:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Chest radiographs</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Chest computed tomography (CT) scan</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Cardiac studies:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Electrocardiogram</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Echocardiogram</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Cardiac catheterization (in selected cases)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Pulmonary function studies:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Spirometry</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Lung volumes by plethysmography</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Diffusion</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\"> <p>Pulse oximetry (resting, sleeping, and with exercise)</p> - Arterial blood gases in selected cases</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\">Six minute walk test</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\" colspan=\"2\">Infant pulmonary function testing</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Laboratory studies to identify systemic disorders predisposing to&nbsp;diffuse lung disease:</td> </tr> <tr> <td class=\"subtitle2\">Studies</td> <td class=\"subtitle2\">Rationale/potential diagnosis</td> </tr> <tr> <td class=\"sublist1_start\">Immune studies<sup>&#9674;</sup></td> <td class=\"sublist1_start\">Immunodeficiency/immune dysfunction</td> </tr> <tr> <td class=\"sublist1\">HIV</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Immunoglobulins</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Response to immunizations</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Lymphocyte subsets</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Complement</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Others as indicated</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Studies for connective tissue disease</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Antinuclear antibody</td> <td class=\"sublist_other\">Autoimmune disease</td> </tr> <tr> <td class=\"sublist1\">Angiotensin converting enzyme</td> <td class=\"sublist_other\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist1\">Antineutrophil cytoplasmic antibody</td> <td class=\"sublist_other\">Vasculitis syndromes including granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"sublist1\">Anti-glomerular basement membrane antibody</td> <td class=\"sublist_other\">Anti-glomerular basement membrane disease</td> </tr> <tr> <td class=\"sublist1_start\">Others</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hypersensitivity pneumonitis panel</td> <td class=\"sublist_other\">Hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"sublist1\">Serum and urine amino acids</td> <td class=\"sublist_other\">Lysosomal storage diseases and lysinuric protein intolerance</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Genetic studies for surfactant dysfunction</td> <td class=\"sublist_other\">Disorders of surfactant production and metabolism</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Diagnoses established by invasive studies:</td> </tr> <tr> <td class=\"indent1\">Bronchoscopy</td> <td>Infection, aspiration, pulmonary hemorrhage,<sup>&#167;</sup> pulmonary alveolar proteinosis,<sup>&#167;</sup> Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Lung biopsy</td> <td>Many forms of childhood diffuse lung disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">Diffuse lung disease (DLD) is traditionally known as interstitial lung disease (ILD). Because many of these disorders are associated with extensive alteration of alveolar and airway architecture, in addition to changes in the interstitial compartment, we prefer the term DLD rather than ILD. </SPAN></div><div class=\"graphic_footnotes\">* Not all of these studies are needed. The choice of testing should be determined based on clinical context and urgency.<br />¶ Note that identification of one of these underlying disorders does not preclude a diagnosis of DLD. Consider further DLD evaluations if the respiratory symptoms persist or if the findings are out of proportion to comorbidities.<br />Δ It is important to recognize that gastroesophageal reflux may be a secondary finding in some children with DLD, but may be the primary caues of symptoms in others. For a discussion of this evaluation, refer to the UpToDate topic review on aspiration and swallowing dysfunction in children.<br /><FONT class=lozenge>◊</FONT> For a discussion of the evaluation for immunodeficiency/immune dysfunction, refer to UpToDate topic review on the approach to the child with recurrent infections.<br />§ If pulmonary hemorrhage or pulmonary alveolar proteinosis (PAP) are discovered at bronchoscopy, additional evaluation for the cause of these findings will be needed.</div><div class=\"graphic_reference\">Courtesy of Lisa R Young, MD.</div><div id=\"graphicVersion\">Graphic 90995 Version 6.0</div></div></div>"},"90996":{"type":"graphic_figure","displayName":"West Nile Virus neuroinvasive cases by week of onset 1999-2014","title":"West Nile Virus neuroinvasive cases by week of onset, 1999-2014","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">West Nile Virus neuroinvasive cases by week of onset, 1999-2014</div><div class=\"cntnt\"><img style=\"width:644px; height:399px;\" src=\"images/ID/90996_Wst_nl_vrs_nrnvsv_wk_99_14.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention. Provided by Lyle R. Petersen, MD, MPH.</div><div id=\"graphicVersion\">Graphic 90996 Version 2.0</div></div></div>"},"90997":{"type":"graphic_figure","displayName":"Average annual incidence of WNND by county for 1999 to 2015","title":"Average annual incidence of West Nile virus neuroinvasive disease, by county, 1999 to 2015","html":"<div class=\"graphic\"><div style=\"width: 897px\" class=\"figure\"><div class=\"ttl\">Average annual incidence of West Nile virus neuroinvasive disease, by county, 1999 to 2015</div><div class=\"cntnt\"><img style=\"width:877px; height:569px;\" src=\"images/ID/90997_Av_annl_inc_WNND_cntry_99_14.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 90997 Version 3.0</div></div></div>"},"90998":{"type":"graphic_figure","displayName":"Popliteal artery aneurysm","title":"Popliteal artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Popliteal artery aneurysm</div><div class=\"cntnt\"><img style=\"width:516px; height:696px;\" src=\"images/SURG/90998_Popliteal_artery_aneurysm.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 90998 Version 3.0</div></div></div>"},"90999":{"type":"graphic_diagnosticimage","displayName":"Aneurysm post coarctation repair with prosthetic patch","title":"Echocardiography demonstrating an aneurysm at the site of surgical repair for coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Echocardiography demonstrating an aneurysm at the site of surgical repair for coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:600px; height:447px;\" src=\"images/PEDS/90999_Aneur_post_coarct_pro_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiographic image demonstrating a large aneurysm of the descending thoracic aorta in a 19-year-old patient who underwent surgical repair with a Gore-Tex patch at two years of age.</div><div class=\"graphic_footnotes\">%: percent; DAO: descending (thoracic) aorta.</div><div id=\"graphicVersion\">Graphic 90999 Version 1.0</div></div></div>"}};